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Summary 
Background  
International best practice endorses the use of a standardised approach 
in the management of analgesic and sedative drugs in the Paediatric 
Intensive Care Unit (PICU). In adult intensive care settings incorporating 
analgesia and sedation guidelines has been associated with significant 
patient benefits including a reduction in the amounts of analgesia and 
sedative drugs used and a decrease in the duration of mechanical 
ventilation.  
 
In contrast, the evidence to support this change in practice in the 
paediatric setting is limited and inconsistent. Also the administration of 
analgesia and sedation has predominantly been based on personal 
preferences and ritualistic practice, without the support of an evidence 
base. The key role that PICU staff play in analgesia and sedation 
management, their perceptions around introducing  changes in the 
management of analgesia and sedation  has not been fully addressed. In 
an Irish context this study was seminal, as no previous studies had 
reported on current and alternate analgesia and sedation management 
practices within the PICU and the staff perception of a change of 
practice.   
 
Research Hypotheses 
Given the lack of evidence in this area for PICU practice, this study 
aimed to address the following primary and secondary hypotheses: 
Primary Hypothesis:  
“Standardised pain and sedation management did not cause a reduction 
in the dosage of morphine administered to patients in PICU” 
ix 
 
 
Secondary Hypothesis:  
“The implementation of standardised pain and sedation was not 
associated with a change in duration of mechanical ventilation and PICU 
stay.” 
 
Methods  
Ethical approval was obtained for the study. A quasi-experimental 
approach was used employing a before/after design. Kotter’s model of 
change was chosen to guide the change intervention, which comprised 
the introduction of multidisciplinary developed analgesia and sedation 
guidelines in the PICU and standardised pain and distress assessment 
using the validated COMFORT-B instrument. Patient census data were 
retrieved from the PICU census database for 12 month time period 
before and after the change in practice. P1-The before group; consisted 
of all patients admitted to the PICU between 1st March 2009 and 28th 
February 2010, treated according to standard analgesia and sedation 
management practices. P2-The after group comprised all patients 
admitted to the PICU between 1st August 2010 and 31st July 2011. This 
patient group were managed according to the changed approach to 
analgesia and sedation management. 
  
As census data are not conducive to deeper analysis, a subset of P1 and 
P2 was selected to facilitate more in-depth analysis. Strict inclusion and 
exclusion criteria were used to obtain 2 comparable groups. Using an 
instrument exclusively developed and validated for this purpose, the 
PASQ (Patient Analgesia and Sedation Questionnaire); data from these 
cardiac non-equivalent control (PASQ 1; n=61) and intervention (PASQ 
2; n=64) patient groups were collected for the first 72h (3x 24hour 
x 
 
Epochs) post-operatively. In addition, staff surveys were conducted 
before and after guideline introduction using the SASQ (Staff Analgesia 
and Sedation Questionnaire) instrument. Chi-square analysis, t-tests and 
the Mann-Whitney-U test were used for group comparisons.  
 
Results 
The CIPP model of evaluation was employed to determine the impact of 
the change intervention, on both patients and staff. Before and after 
comparisons of study groups determined that: 
 
Patient Census Data:  
There was no statistically significant difference in the median duration of 
mechanical ventilation (3 days [2:7]) (p=0.44) or median length of PICU 
stay (4 days [2:8]) (p= p=0.47) between the before and after intervention 
groups P1 and P2.  However, patients with Down Syndrome (Trisomy 
21or T21) were noted to have a longer median duration of mechanical 
ventilation than non-T21 patients, which proved to be statistically 
significant (4 [2:9]) vs (3[2:7]), (p=0.017) and a significantly longer 
duration of PICU stay (6 [3:12]) vs 4 [2:8]), (p<0.001) than that of non-
T21 patients before the standardisation of analgesia and sedation 
practice.  
 
After the intervention, the duration of mechanical ventilation for patients 
with T21 was reduced by one day (P1 4[2:9] vs P2 3[2:6], p=0.04). No 
statistically significant reduction in length of PICU stay emerged for this 
group (P1 6 [3:12] vs P2 5 [3:9], p=0.09). After the intervention, the 
duration of mechanical ventilation between T21 and non-T21 patients 
was comparable 3[2:7] and 3[2:6] (p=0.36) respectively, as was the 
duration of PICU stay for both T21 and non-T21 patient groups (5[3:9] vs 
4[2:8]) (p=0.28) respectively.  
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PASQ Data: 
No statistically significant reduction in morphine administration by 
continuous intravenous infusion emerged after the intervention in either 
of the 3 Epochs (Epoch 1 PASQ 1 median 36mcg/kg/hr [27.7:43.9] vs 
PASQ 2 median 27.4mcg/kg/hr [29.0:37.1] (p=0.13)). However, after the 
change in practice a statistically significant reduction the mean rate of 
morphine infusion on return to PICU from the operating theatre was 
noted (PASQ 1 69.5mkg/kg/hr vs PASQ 2 55.38mkg/kg/hr (p=<0.001). 
Furthermore, patients received significantly more morphine boluses in 
the first 24 hours after the intervention, and this reached statistical 
significance (PASQ 1 mean 2.26mcg/kg/day, vs PASQ 2 26.35 
mcg/kg/day, p=<0.001). Further changes in the pattern of analgesia and 
sedation management after the intervention were observed, including a 
statistically significant increase in the amount co-analgesic and adjuvant 
agents used such as paracetamol and clonidine, and an increase in the 
use of non-opioid analgesia in line with best international practice. 
 
SASQ Data 
A statistically significant increase in PICU staff satisfaction with analgesia 
and sedation practice after the intervention emerged (p<0.001). Although 
there was a slight reduction in the number of individuals who felt the 
COMFORT-B assessment tool combined with guidelines was valuable in 
patient management in PICU from 92.5%, (n=97) to 81% (n=76), 
suggesting the intervention may not have met all expectations; there was 
a mean reduction of 2.8 items which respondents felt merited concern 
after the intervention (p<0.001). Good compliance with the change in 
practice was observed, consistent with a 70.3% compliance rate. 
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Conclusion 
This study reports how a change in analgesia and sedation management 
in line with best international practice has been successfully 
implemented. There are considerable potential patient benefits of basing 
analgesia and sedation management on robust assessment using 
validated tools. The resulting statistically significant reduction in duration 
of mechanical ventilation in the T21 population has the potential to 
reduce exposure to the complications of mechanical ventilation and 
hospital acquired infections, as well as decreasing interruptions to 
cognitive and social development and the parental bonding process. 
Reduced resource usage has significant cost implications and can 
facilitate increased patient turnover at a time when hospital resources are 
limited and inpatient waiting lists exist.  
An observed change in the pattern of analgesia and sedatives 
administered to patients in line with emerging evidence is welcome; 
acknowledging the risks associated with prolonged use of analgesia and 
sedation including withdrawal syndrome, and emerging evidence 
associating neuroapoptosis with use of certain sedatives. Using validated 
methods of assessing pain and distress leads to improved management 
which fulfils our humanitarian obligations and may increase job 
satisfaction. The neighbouring PICU has adopted the same approach to 
pain and sedation as it is seen best practice, moving towards 
standardisation at a National level.  Valuable research collaborations 
have also evolved from the writers’ study and an important 
pharmacokinetic and pharmacodynamic study has been possible at the 
study site as a result of the implementation of validated pain assessment. 
High level dialogue about pain and sedation now occurs between 
clinicians and nurses, where previously uncertainty and a lack of 
direction prevented this from occurring. 
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Chapter 1: Background to the Study 
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1.0 Introduction 
Research questions often develop from patient centred questions in 
routine clinical practice. The writer had 15 years of bedside nursing 
experience in both adult and paediatric intensive care settings, and had 
worked as the Clinical Audit and Research Nurse in the Paediatric 
Intensive Care Unit (PICU) with Clinical Nurse Manager level 2 (CNM 2) 
status since February 2009. This role required the writer to have a strong 
clinical presence in the unit. The writer visited each patient’s bedside on 
a daily basis, to monitor study protocol compliance and collect research 
data. This clinical presence together with daily collaboration with nursing, 
medical and allied health professional (AHP) colleagues ensured that the 
writer was well placed to identify aspects of practice that required a 
research focus. The area of analgesia and sedation management 
emerged as an area that required an urgent research focus in the PICU.   
The aim of this chapter is to provide an insight into the significance of this 
study in the context of contemporary clinical practice in the PICU. The 
importance of analgesia and sedation in this setting will be provided, and 
the unique challenge of managing analgesic and sedative agents 
appropriately will be elucidated. The aims and objectives of this study will 
then be presented, and the research hypotheses introduced. Finally a 
thorough description of the layout of the thesis will be provided.   
 
1.1 Analgesia and Sedation in PICU 
The provision of optimum comfort to critically ill children admitted to the 
unfamiliar and unpredictable PICU environment requires a great degree 
of skill and planning. It is imperative that the patient’s exposure to 
excessive auditory, visual and tactile stimuli is limited. Control of 
excessive motor activity which might interfere with intensive therapies, 
including invasive lines and the endotracheal tube, is also necessary 
(Nair et al. 2004). It is well known that failure to provide adequate 
sedation and analgesia to control the stress response is associated with 
4 
 
increased complications and mortality (Tobias, 2000a); reinforcing the 
key role analgesic and sedative drugs play in the PICU. 
 
However there is a concern that some agents used for sedation 
administered during synaptogenesis may adversely affect cerebral 
development (Jevtovic-Todorovic et al. 2003). Moreover, despite routine 
use and years of experience with intravenous opioids, Anand et al. 
(2004) have reported a connection between morphine and adverse 
outcomes in premature neonates. The association between morphine 
and haemodynamic instability as well as prolonged reliance on 
mechanical ventilation is not new (Osterman et al. 2000; Jacobi et al. 
2002). This has contributed to current best practice in adult ICU settings 
recommending titration of sedatives to a goal using a validated 
assessment tool to improve the quality of sedation therapy (DeGrado et 
al. 2011). A systematic review by Jackson et al. (2010) concluded that 
optimisation of analgesia and sedation management in this way was 
associated with reduced duration of mechanical ventilation and ICU stay. 
Among other benefits reported, including a reduction in mortality, 
significant reductions in the drugs used for sedation were reported in the 
majority of studies addressing this issue.  
 
Applicability of these findings in adults to the paediatric population is not 
straightforward, as certain pharmacotherapies such as propofol are not 
approved for prolonged continuous sedation in children (Thomas et al. 
2010). It is important to acknowledge that the pharmacokinetics and 
pharmacodynamics of analgesics for children and adults are not the 
same (Berde and Sethna, 2002). In the paediatric critical care context, 
there is a lack of high quality evidence to guide practice regarding 
analgesia and sedation management (Zuppa et al. 2005; Hartman et al. 
2009). Several authors and societies have endorsed the assessment of 
pain and sedation levels using validated tools, and the titration of 
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analgesics and sedatives using guidelines, protocols or algorithms 
(Gordon et al. 2005; Playfor et al. 2006; Jenkins et al. 2007). There is a 
dearth of paediatric research studies to guide practice; while the studies 
that exist in this area have returned inconsistent findings (Alexander et 
al. 2002; Ista et al. 2009a; Jin et al. 2007). It has long been 
acknowledged that studies are required to guide standardisation of 
analgesic and sedative use in critically ill children (Statler, 2004). 
Therefore the aim of this research study was to examine the impact of 
standardised analgesia and sedation management in an Irish PICU.  
 
1.2 Aims and Objectives of the Study 
The primary focus of this research was determining whether 
standardisation of analgesia and sedation practice affected the dosages 
of the primary analgesic and sedative; morphine administered to PICU 
patients. Furthermore, reflecting the findings of studies in adult ICU 
settings in relation to morphine; it was established whether this change in 
practice impacted PICU patients’ duration of mechanical ventilation and 
PICU stay. As key personnel in the prescription, administration, weaning 
and bolusing of the agents used for analgesia and sedation in the PICU; 
this study also aimed to determine whether PICU staff welcomed this 
change in practice and perceived it as clinically valuable one year after 
its implementation. The specific aims and objectives of the study were: 
Aim 
 To determine the impact of introducing evidence based analgesia 
and sedation guidelines and a validated pain and distress 
assessment instrument on patients and staff in an Irish PICU.  
Objectives 
 To identify if this change in practice resulted in an alteration in the 
dosages of the primary analgesics and sedatives administered to 
PICU patients. 
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 To investigate if this intervention was associated with a decrease 
in the duration of mechanical ventilation and PICU stay of these 
patients. 
 To determine the importance of pain and distress measurement in 
conjunction with analgesia and sedation guidelines. 
 To describe the attitudes and perceptions of PICU nurses and 
doctors towards this change in practice. 
 To make recommendations to the hospital and PICU community 
generally on the use of analgesia and sedation guidelines and 
related issues of pain and distress in PICU. 
 
The null hypotheses and additional research question were framed as 
follows: 
 
Primary Hypothesis: 
Standardised pain and sedation management did not cause a reduction 
in the dosage of morphine administered to patients in PICU. 
Secondary Hypothesis:  
The implementation of standardised pain and sedation was not 
associated with a change in duration of mechanical ventilation and PICU 
stay.  
 
Additional Research Question: 
Did PICU staff welcome this change in practice and perceive it as 
clinically valuable one year after its implementation?  
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1.3 Thesis layout 
The thesis is laid out as follows. Having provided a background and 
introduction to the study in chapter 1; chapter 2 will present the 
theoretical basis for the study. With an appreciation for the rationale and 
the context for this research, the physiology of pain including 
developmental neurobiology will be provided. A closely related 
phenomenon; anxiety will be discussed, and the significance of poorly 
managed pain and anxiety will be highlighted. The agents used for 
analgesia and sedation will be outlined, and complications including 
neuroapoptosis and withdrawal syndrome discussed. Non-
pharmacological methods of managing distress and minimising anxiety 
will also be explored.  
 
Chapter 3 will address the challenging task of assessing pain and 
distress in PICU and the development of validated methods of 
assessment. The benefits and limitations of each instrument will be 
investigated. A full rationale for the final selection of the COMFORT-B 
pain and distress assessment instrument will be presented. In Chapter 4, 
a systematic account of the findings of studies performed to examine the 
impact of analgesia and sedation guidelines in intensive care units will be 
provided. A thorough search of the literature will enable presentation of a 
comprehensive report, facilitating the evaluation of the methodological 
approaches adopted in these studies. 
 
Chapter 5 will describe the application of an established change 
management model to guide the process of engagement of over 160 
nurses and doctors in implementing the new approach to this 
fundamental aspect of PICU care. The strategies involved in 
implementing and sustaining the change will be presented, as well as the 
challenges encountered. Chapter 6 will focus on the process of selecting 
the research methodology to evaluate the impact of this changed 
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approach to analgesia and sedation management in the PICU. For this 
purpose, the main research paradigms will be critiqued. The strengths 
and limitations of various methodologies will be examined, and 
justification for the final selection provided. An appropriate research 
design will be selected, and the variables of interest for the study 
documented. The study setting will be described, and poplulation and 
sampling explored as well as study inclusion and exclusion criteria. Data 
collection will be examined, and the development and validation of data 
collection instruments presented. The statistical tests used in analysing 
the data will be described and negotiation of access and ethical 
considerations will be discussed. 
 
For clarity, the study findings will be divided into in 3 separate chapters. 
The PICU patient will first be focussed on, and findings from analysis of 
PICANet patient census data including duration of mechanical ventilation 
and PICU stay will be presented in Chapter 7. Following this, in Chapter 
8 findings from analysis of PASQ (Patient Analgesia and Sedation 
Questionnaire) data will reveal the impact of the intervention on selected 
subgroups of the census data meeting established inclusion and 
exclusion criteria. More detailed information, such as dosages of 
analgesia and sedation received by patients, and precise calculation of 
duration of mechanical ventilation and PICU stay will be focussed on. 
The focus will then shift to the PICU staff, where the results of the before 
and after SASQ (Staff Sedation and Analgesia Questionnaire) surveys 
will be presented in Chapter 9, and these data will be supported with 
material from PICU analgesia and sedation committee meetings. A 
model of evaluation will aid the appraisal of the change intervention.  
 
A discussion will ensue in Chapter 10, where the study findings will be 
evaluated in the context of appropriate literature, and the statistical and 
clinical significance of these findings critically analysed.  Finally, Chapter 
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11 will provide recommendations for practice, education research and 
dissemination. The wider impact of the findings will be presented, and in 
conclusion, a reflection on the study will close the thesis. The chapters 
are divided into four sections within the thesis entitled ‘1: Introduction and 
Background, 2: Study Design and Methodology, 3: Study Findings, and 
4: Discussion and Conclusion’. 
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Chapter 2:  Theoretical Basis for the Study 
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2.0 Introduction 
The primary aim of the study was to determine whether the introduction 
of standardised analgesia and sedation management impacted dosages 
of morphine administered to PICU patients and whether duration of 
mechanical duration and PICU stay were impacted as a result. It follows 
that the main objective of this chapter was therefore to present the 
background and contextual issues related to the current status of pain, 
anxiety, analgesia and sedation in the PICU. These topics will be 
discussed in the context of contemporary nursing and medical literature, 
however where appropriate; landmark research will also be referred to, 
e.g. Anand et al. (1987a).  A good understanding of the physiology of 
pain; including neurobiology and pain perception is vital in 
comprehending the implications of untreated or poorly managed pain. 
These will be addressed in this chapter. Pain and anxiety are closely 
associated; therefore anxiety will be examined, and the concepts of 
anxiolysis, sedation, anaesthesia and analgesia clarified.  
The agents most commonly used for analgesia and sedation in the PICU 
and their modes of action will be presented. Acknowledging that children 
admitted to the PICU ranged in age from 0-18 years, and included 
premature neonates; this section is not intended to address any 
particular age group exhaustively. Although care of the critically ill 
neonate is a speciality in itself, this group will only be discussed in the 
context of their presence in the PICU. To facilitate consistency, age 
stratification was in accordance with the International Conference on 
Harmonisation methodology (2000): 
 Preterm neonates: <36 weeks gestation 0-7 days 
 Full term neonates: >36 weeks gestation 0-27 days 
 Infants and toddlers: 28 days to 23 months 
 Children: 2-11 years 
 Adolescents: 12-17 years 
The primary focus of this research was on the PICU patient; 
acknowledging that patient-centred health outcomes are an important 
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aspect of health care quality (Murray and Frank, 2000). The theoretical 
basis of this study centred around the interplay between the approach of 
PICU staff to analgesia and sedation management, particularly on the 
amounts of analgesics and sedatives administered to patients, and the 
influence of  these drugs on duration of mechanical ventilation and PICU 
length of stay. These will be discussed in turn.  
 
2.1 Analgesics and Sedatives in PICU 
There is increasing awareness of the risk of prolonged duration of 
mechanical ventilation as a consequence of morphine use leading to 
ventilator associated pneumonia (VAP), extended PICU and hospital 
length of stay and increased morbidity and mortality. Accordingly a 
fundamental outcome measure of this study was to determine whether 
raising awareness of these issues and the introduction of analgesia and 
sedation guidelines led to a reduction in the amount of analgesics and 
sedatives administered to PICU patients, while not exposing them to pain 
and distress.  
 
Importantly, there is an increasing awareness that agents used in PICU 
for sedation and anaesthesia have considerable side effects. Mellon et 
al. (2007) have described the significance of neuroapoptosis with 
detrimental cognitive, social and neurological sequelae in developing 
animal brains exposed to ketamine. More recent studies in non-human 
primates have extended these findings, however additional research is 
necessary to determine the implications of these data for children 
exposed to anaesthetic and sedative drugs (Rappaport et al. 2011). 
 
2.2 Duration of Mechanical Ventilation in PICU 
Mechanical ventilation is a prevalent supportive therapy in PICU. A US 
study by Khemani et al. (2007) confirmed that 30% (range 20-64%) of 
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patients admitted to the average PICU received mechanical ventilation 
for a mean duration of 5-6 days. An Italian multicentre study by Wolfler et 
al. (2011) revealed that almost half of their annual admissions to PICU 
(49%, n=468) received mechanical ventilation, and that severity of illness 
on admission, associated chronic disease, length of stay and PICU 
mortality were significantly higher in children who received mechanical 
ventilation compared with those who did not. 
 
While mechanical ventilation in PICU is often life saving, this therapy is 
associated with many adverse effects including airway lesions and dental 
injury due to intubation, sinusitis, volutrauma, barotrauma, biotrauma and 
atelectrauma induced by positive pressure ventilation as well as a 
predisposition to nosocomial pneumonia (Gattinoni et al. 2003). In their 
US study of paediatric healthcare associated infections Richards et al. 
(1999) confirmed 95% of pneumonia cases were in patients undergoing 
mechanical ventilation. Endotracheal tubes (ETT) are uncomfortable for 
patients and increase the need for sedatives, which can lead to a vicious 
cycle of drug induced respiratory depression necessitating prolonged 
mechanical ventilation. An ETT in the upper airway can lead to an airway 
injury, particularly in mobile young patients. Moreover, positive pressure 
ventilation may compromise cardiovascular stability by increasing 
thoracic pressure (Newth et al. 2009). Respiratory muscle atrophy as 
well as polyneuropathy have also been reported as a consequence of 
mechanical ventilation, (Miranda, 2001). It is therefore paramount that 
prolonged ventilator dependence is avoided and mechanical ventilation 
be discontinued as soon as the patient is capable of sustaining 
spontaneous breathing. 
 
2.3 Length of PICU stay 
Paediatric intensive care beds are a valuable resource, costing from 
€2,000 to €5,000 per night. Demand runs consistently high and peaks 
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over the winter months (> 85% occupancy, see appendix 1 for PICU 
occupancy). While median length of stay in PICU is 3 days (IQR 2-7) 
(see appendix 2 for demographics and summary indicators of PICU 
activity), there are occasions where the issues that required admission to 
PICU cannot be resolved in this timeframe. Furthermore, there is a 
population group often with complex needs and/or co-morbid illness who 
require prolonged PICU stay.  
 
The largest study to date focussing on the ‘long-stay’ patient in PICU was 
conducted by Wood et al. (2011). While ‘long-stay’ was defined as 
patients with a PICU length of stay of more than 28 consecutive days 
(above the 97th centile); these patients accounted for 21.7% of total bed 
days delivered between the years of 2005 to 2009 inclusive in UK PICUs. 
Observed mortality increased significantly with duration of stay (3.8%, 
7.1% and 18.6% respectively for children admitted for <7, 7-28 and >28 
days). This finding is consistent with other studies (Marcin et al. 2001; 
Naghib et al. 2010). 
  
A significant risk of any prolonged PICU and hospital stay is a 
predisposition to hospital acquired infections (Richards et al. 1999; Mizra 
et al. 2011) leading to increased mortality and healthcare costs. In 2002, 
an estimated 1.7 million healthcare associated infections occurred in the 
United States, resulting in 99,000 deaths (Klevens et al. 2007). In 
addition, the associated costs are significant and are estimated at 
between $28-45 billion in the USA annually, Scott (2008). The substantial 
financial implications of a prolonged PICU stay are generated by the 
nature of critical illness necessitating complex and multiple treatments 
(investigations and drug therapies) and high numbers of skilled staff, 
(Woodrow, 2000). Advanced supportive measures include ECMO (Extra 
Corporeal Membrane Oxygenation), haemofiltration and plasma 
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exchange. (See appendix 3 for PICU specific interventions offered to 
patients in PICU).  
 
In addition to the physiological and economic implications of a prolonged 
PICU stay, there are also significant psychological implications for the 
patient and their family. It is recognised that parents experience 
significant post-traumatic stress after a child has been admitted to the 
PICU. Acknowledging this issue, the Paediatric Intensive Care Audit 
Network (PICANet) has recognised that gaining an insight into the impact 
of admission to PICU on children and their families as an urgent research 
priority (PICANet Annual Report, 2011). Prolonged anxiety, limited 
contact with their child and disruption of the bonding process can have 
long-term consequences (Colville, 2008). In addition, depending on the 
age of the child; admission to PICU can adversely influence cognitive 
and social development and delay acquisition of psychomotor skills. Any 
initiative that can potentially limit such adverse incidents is very welcome. 
 
2.4 Staff Perceptions of Analgesia and Sedation Practice 
PICU staff are closely involved in the prescribing, administering and 
evaluation of analgesia and sedation therapy in PICU. Thomas et al. 
(2010) argue that this complex role mandates a collaborative team 
approach to promote the use of evidence-based practices, as institutional 
customs and individual preferences often guide the practice of individuals 
in this area. It was imperative therefore to gain an insight into existing 
staff attitudes and beliefs in order to plan an effective intervention. 
Gaining the support and involving key stakeholders in the intervention 
was vital.  This was reinforced by Ploeg et al.’s (2007) assertion that any 
attempt to change clinical practice will not be successful without the 
support of those most affected by it.  
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Acknowledging these issues; appropriate management of patient pain 
and sedation in the PICU was a priority. Furthermore; Mancuso (2009), 
proposes that the challenge of this era is to integrate the advances in 
diagnosis and treatment with ongoing adaptation of clinical practice as 
dictated by research advances in the field. Accordingly, analgesic and 
sedative administration practice in the PICU could not continue to be 
based on unit culture and traditions and baseless rituals. The use of 
evidence based practice in this area was hugely lacking. As the current 
literature emphatically endorsed an individual approach to analgesia and 
sedation using an appropriate validated assessment tool; it was 
imperative that current practice be reviewed, and the best available 
evidence to inform an analgesic and sedation management strategy that 
best served the PICU patient population be implemented. The first step 
in promoting the effective management of pain was having a good 
understanding of it; hence an explanation of pain is now provided.   
 
2.5 Defining Pain 
The most widely accepted definition of pain remains that provided by 
Merskey and Bogduk (1994, p209-14) “Pain is an unpleasant sensory 
and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage.” This definition 
acknowledges the multiple components of pain which impact an 
individual’s psychosocial and physical functioning. The highly subjective 
and personal nature of pain is reflected in McCaffery’s (1968, p8) 
definition “Pain is whatever the experiencing person says it is, existing 
whenever he says it does.” Inherent in this definition is the implication 
that the patient’s self report of pain is the single most reliable indicator of 
pain.  Evaluation of pain in the neonate, preverbal child and notably the 
critically ill intubated paediatric patient poses a significant challenge.  
Acknowledging that pain has strong emotional associations,  Anand et al. 
(1987a) advised discussing “nociceptive activity” rather than “pain” with 
regard to the neonate as it is now well established that perceptual 
17 
 
mechanisms of pain and physiologic responses to nociceptive activity 
exist in preterm and full term neonates. Defining pain, distinguishing 
between the different types of pain and understanding the way in which 
noxious stimuli are transmitted from the periphery to the area of pain 
perception in the brain are crucial in assessing pain and providing 
adequate pain relief. 
 
2.6 Physiological Basis of Pain 
Pain perception is a function of the sensory nervous system. Pain 
pathways comprise nerve fibres connecting peripheral or visceral pain 
receptors to interpretation centres in the brain via the spinal cord (see 
appendix 4 for further clarification). Pain pathways can be divided into 5 
regions;   
 Nociceptors or pain receptors are situated at the distal end of 
sensory neurons and are widely distributed in the superficial 
layers of the skin, in periosteum, joint surfaces, arterial walls and 
areas of the dura mater. A less extensive supply serves the 
deeper tissues, particularly the walls of internal organs (Guyton, 
1991). Two types of nociceptor exist- Aδ or Type C fibres. Type 
Aδ fibres are myelinated, small in diameter and capable of 
conduction speeds up to 25 metres/second. They respond only to 
mechanical stimuli and produce sharp, prickling, protective and 
well localised pain sensations. Type C fibres are unmyelinated, 
smaller in diameter and conduct at a slower rate of up to 2 
metres/second. These fibres can respond to all three types of pain 
stimuli; mechanical, thermal or chemical, hence they are 
polymodal. The pain sensations elicited are burning, aching and 
poorly localised (Kittelberger and Borsook, 1996). 
 First connecting nerve fibres- primary afferent neurones. These 
neurones terminate in the dorsal horns of the spinal cord where 
they synapse with second order neurones. The grey matter of the 
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spinal cord is divided into laminae numbered from I-X. Aδ fibres 
synapse in laminae I, II and V whilst C fibres synapse only in I and 
II. Dobson (1997) explains how there are two major types of 
second order neurone in the spinal cord which respond to 
nociceptive stimuli. Nociceptive specific (NS) have small receptive 
fields as they respond only to one or two primary afferent 
neurones and they are mainly found in lamina I. In contrast, wide 
dynamic range (WDR) neurones are nociceptive non specific 
responding not only to noxious stimuli but also light touch or low 
heat. Their large receptive fields synapse with a greater number of 
primary afferent neurones, they are the most prevalent second 
order neurones in the dorsal horn and are found in all laminae, 
particularly lamina V.   
 Transmission of pain- Because the nociceptors carrying the 
impulse from the periphery terminate in the dorsal horn of the 
spinal cord, another method of transmission is required to 
continue the pain impulse across the synaptic cleft from the 
nociceptors to the dorsal horn neurons. Neurotransmitters 
including adenosine triphosphate, glutamine and substance P fulfil 
this role. It is at this point that exogenous and endogenous opioids 
have a function in pain control as they bind to opioid receptors and 
prevent the release of these neurotransmitters; particularly 
substance P, (McCaffery and Pasero, 1999).  From the dorsal 
horn, pain transmission is achieved by various different ascending 
nociceptive tracts within the spinothalmic tract, terminating in the 
brain stem and thalamic regions. The thalamus then acts as a 
relay station, sending the pain impulse to central structures where 
it can be interpreted (Wallace, 1992).   
 Areas of interpretation in the brain- higher centres. Aδ and C 
fibres are carried to the brain via ascending tracts. Second order 
Aδ fibres mainly terminate in the thalamus, synapsing with further 
neurones which transmit the signals to other basal areas of the 
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brain and to the somatosensory cortex (Dobson, 1997). In 
contrast, type C fibres terminate in three distinct areas of the 
brainstem and only one tenth to one quarter reach the thalamus. It 
is believed that the reticular system controls the autonomic 
response to pain while the somatosensory cortex localises and 
characterises pain. Finally the limbic system is considered 
responsible for the emotional and behavioural response to pain 
(Fields, 1987).  Acknowledging that pain perception occurs in the 
cortical structures; cognitive–behavioural strategies can be used 
to ameliorate the sensory and affective components of pain as the 
brain can accommodate only a limited number of incoming signals 
(McCaffery and Pasero, 1999). This supports the use of 
techniques such as distraction, relaxation and imagery to modify 
pain perception. 
 Systems involved in modulating pain- descending systems. The 
presence of a descending inhibitory control mechanism was 
originally proposed by Melzack and Wall (1965) in the “gate 
control theory” of pain. The existence of nerve tracts descending 
from the brain and terminating in the spinal cord which modulate 
pain intensity has since been proven by Basbaum and Fields 
(1978). The periacqueductal grey area of the midbrain, the raphae 
magnus nucleus in the pons and a pain inhibitory complex in the 
dorsal horn of the spinal cord are involved (Stamford, 1995). The 
mechanism of action of this inhibitory mechanism involves the 
release of substances such as endogenous opioids, particularly 
endorphins and dynorphin, serotonin (5HT), norepinephrine, γ-
aminobutyric acid (GABA), and neurotensin that have the 
capability of blocking the circulation of neurotransmitters at 
synapses between primary afferent and second order neurones, 
thereby interrupting the ascending pain pathway; producing 
analgesia. 
20 
 
 Pain physiology and pain experience interface. An intense noxious 
stimulus such as stepping on a drawing pin stimulates Aδ fibre 
nociception and pain signals are transmitted to the somatosensory 
cortex. The pain can be localised, enhanced by simultaneous 
stimulation of touch receptors in the corresponding area. Pain 
perception is normally accompanied by a corresponding 
withdrawal reflex, activated by flexor motor neurones in the ventral 
horns of the spinal cord (Woolf, 1995). This withdrawal reflex is a 
protective mechanism, however such mechanisms are 
congenitally absent in some individuals, can be suppressed during 
general anaesthesia and altered by disease processes such as 
diabetic neuropathy (Melzack and Wall, 1996).  
 
Tissue damage is usually followed by adaptive pain, where inflammatory 
changes occur. Inflammation is associated with chemical release by 
nerve endings and immune system cells resulting in the customary signs 
of redness, swelling, heat and pain. While some of these chemicals are 
responsible for causing pain; others enhance responses to painful 
stimuli. Around the site of tissue damage, hyperalgesia and peripheral 
sensitisation occur. Nociceptors become increasingly responsive to low 
intensity stimuli; even light pressure can cause severe pain. Such a 
change is triggered by the presence of prostanoids, kinins and histamine 
(Dobson, 1997).  
 
Prostanoids such as prostaglandins and leukotrienes are among the 
most significant mediators of primary hyperalgesia. Created by a 
naturally occurring form of cyclo-oxygenase (COX1) acting on 
arachidonic acid, prostaglandins usually sensitise nociceptors. Their 
usual function includes protection of the stomach lining, supporting renal 
function, bronchiolar tone and platelet aggregation.  However, during 
inflammation; an alternative from of cyclo-oxygenase is produced; COX2.  
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Prostaglandin production at the site of tissue damage is enhanced by 
COX2. 
 
Kinins; As part of the clotting cascade activated during tissue damage; 
enzyme activity transforms kininogens to either bradykinin or kallidin.  
Kinins activate B1 and B2 receptors, producing pain by stimulating 
nociceptors and sensitising them to heat and mechanical stimuli. 
Bradykinin also increases the effects of other pain inducing substances 
such as prostaglandins and 5-hydroxytriptamine. It has been 
demonstrated that by preventing the ability of bradykinin to bind with B1 
and B2 receptors, pain can be substantially attenuated (Dray, 1995). 
 
Histamine is circulated after degranulation of mast cells by numerous 
chemical mediators including substance P, interleukin 1 and nerve 
growth factor. Histamine acts on sensory neurones to induce itch at low 
concentrations and pain at high concentrations. An increase in 
excitability within the spinal cord known as central sensitisation has been 
described as the reason why there is increased sensitivity to even light 
touch around the area following tissue damage (Woolf, 1995).   
 
2.7 Effects of Unrelieved Pain in Children 
The experience of pain triggers several physiologic stress responses in 
the human body. The sympathetic nervous system is activated to prevent 
further damage to the body by means of maintaining perfusion to vital 
organs, minimising blood loss, promoting healing and preventing and 
fighting infection. If this response is prolonged, its effects can become 
deleterious. The adverse physical and psychological consequences of 
unrelieved pain induce a stress response characterised by tachycardia, 
hypercoagulability, immunosuppression and the persistence of a 
catabolic state (Middleton, 2003). The presence of pain in postoperative 
22 
 
patients may lead to pulmonary complications due to reduced movement 
of the chest wall and diaphragm. Maladaptive pain is described by 
Dobson (1997) which may be the result of nerve damage, or may have 
no obvious cause, continuing long after the original injury is resolved. 
Characteristics of persistent maladaptive pain are anxiety, tension, 
sleeplessness and irritability. Ongoing failure to control the pain 
underlying these behavioural responses may lead to the ‘vicious cycle of 
chronic pain’ described by Latham (1993). This occurs when these states 
subconsciously and insidiously adjust pain perception, reducing 
tolerance and augmenting the pain response. It is clear that there are 
lifetime consequences for children whose pain is untreated or poorly 
managed. This will have significant implications on their physical and 
psychological wellbeing in the future. However despite this knowledge, 
Playfor (2000b) report that 44% of children who remembered details of a 
PICU admission recalled being in pain. This prompted a review of pain 
and sedation management practices at the study site to determine how 
this could be brought into line with best evidence based practice. A shift 
in the approach to pain management in neonates revealed how research 
evidence can positively impact the morbidity and mortality of critically ill 
infants.    
 
2.8 Pain and the Neonate 
Three decades ago, medical literature reflected a reluctance to prescribe 
inhaled anaesthetics and analgesic drugs to alleviate operative and post 
operative or other pain in neonates because of the potentially harmful 
effects of analgesics particularly on the respiratory system, and because 
of doubts about whether neonates felt pain to the same extent as adults 
(Rackow et al. 1961; Lippmann et al. 1976). It was not uncommon that 
newborns were not given analgesic or anaesthetic agents during invasive 
procedures, including surgery (Shearer 1987; Hatch 1987). In addition, 
during this period newborns and infants were regularly denied adequate 
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analgesia for painful procedures outside of the operating room (Truog et 
al. 1991).  
 
The 1980s heralded a change in this practice through a number of key 
findings. Research undertaken in the 1980s demonstrated that the foetus 
had developed the necessary anatomic, neurophysiological, and 
hormonal components to perceive pain (Anand et al. 1987a). This 
landmark discovery was complemented by important clinical 
investigations that demonstrated poorer outcomes for neonates and 
infants not adequately analgesed during painful procedures as well as 
reduced morbidity and mortality in infants receiving high doses of opioids 
intra-operatively during cardiac surgery (Anand et al. 1987b, 1990). This 
seminal work, together with the development of safer anaesthetic agents 
and improved monitoring techniques, prompted a worldwide shift towards 
what is referred to today as adequate anaesthetic care for the neonate. 
An insight into the developmental neurobiology of pain highlights the 
importance of appropriate pain management in this vulnerable 
population.    
 
2.9 Developmental Neurobiology of Pain 
Even the most premature neonate possesses the neural pathways 
required for nociception and demonstrates cortical responses to noxious 
stimuli such as heel lances (Slater et al. 2006). It has been established 
that sensory neurons cover all foetal cutaneous and mucosal surfaces by 
20 weeks gestation and at full term the density of cutaneous neurons in 
neonatal skin is similar to or greater than that of the adult (Rakie et al. 
1982; Gleiss et al. 1970). Organisation of the dorsal horn cells and 
myelination of nerve tracts up to the level of the thalamus is complete by 
30 weeks gestation and synaptic connection between the thalamus and 
cortex occurs at 24 weeks gestation (Gilles et al. 1983; Kostovic 1984). 
Early incomplete myelination of nerve fibres is negated by the shorter 
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interneuron and neuromuscular distances required by the impulse 
(Anand et al. 1987a). The neuromediators including substance P and 
endogenous opioids as well as their receptors have been confirmed in 
foetuses, endogenous opioids being released in the foetus at birth and in 
response to distress. (See appendix 5 for a schematic diagram of the 
development of the functional requirements for pain perception in the 
human foetus and neonate). 
 
During the postnatal period however, significant functional and structural 
changes occur in nociceptive pathways, consequently there are distinct 
variations in the patterns of activity evoked by pain in the infant and adult 
central nervous system (Fitzgerald et al. 2009). While it is accepted that 
C-fibre polymodal nociceptors are mature in their ability to be stimulated 
by exogenous stimuli at birth, their central synaptic connections in the 
dorsal horn are initially immature. Initial ‘wind-up’ can be triggered by A-
fibre rather than C-fibre stimulation, as A-beta fibres initially extend into 
laminae I and II and only recede once C fibres have matured. This 
overlap is highly significant as there is less discrimination between 
noxious and non-noxious stimuli. In addition the receptive fields of the 
dorsal horn neurones being extensive- peripheral stimuli can trigger an 
increased number of central neurones. Furthermore, descending 
inhibitory pathways are not fully mature in early development, hence 
more generalised and exaggerated reflex responses are elicited by lower 
intensity stimuli (Fitzgerald, 2005). Despite the differences in underlying 
mechanisms, nociceptive pathways can be sensitised by painful stimuli in 
early life, as evidenced by a reduction in reflex thresholds in neonates 
following repeated heel lance (Fitzgerald et al. 1988) and infants 
following abdominal surgery (Andrews et al. 2002). It is therefore clear 
that poor pain management in the neonatal period can predispose the 
infant to lower pain thresholds and exaggerated pain responses in the 
future.  
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2.10 Effects of Unrelieved Pain in Neonates 
The specific behavioural changes that develop after painful experiences 
in neonates which disrupt the adaptation of the infant to its postnatal 
environment were first described by Anand et al. (1987a). Changes in the 
biochemical, physiologic, and behavioural responses to noxious 
stimulation may produce acute and long term responses to pain. These 
changes increase the breakdown of fat and carbohydrate stores, prolong 
hyperglycaemia, and increase serum lactate, pyruvate, total ketone 
bodies, and non-esterified fatty acids. Furthermore, it is known that 
exposure to frequent painful procedures associated with neonatal illness 
can result in hypoxia, ischaemia and insufficient energy for metabolism, 
contributing to higher neonatal morbidity and mortality, Brazy et al. 
(1993). It was reported by Taddio et al. (1995) that male infants 
circumcised without analgesia had increased pain from immunisation at 2 
months compared with uncircumcised infants. The interruption of parent-
infant bonding and feeding routines are short term manifestations of pain, 
in the long term painful experiences in the neonate include reduced 
ability to perform neurobehavioural functions, (Brazy et al. 1993). This 
may later present with increased prevalence of neurologic deficits, 
cognitive defects, learning disabilities, psychosocial problems and 
behavioural disorders (Anand et al. 2000).  
 
A phenomenon called ‘wind-up’ has been described; where repeated, 
prolonged noxious stimuli cause hypersensitivity at the spinal cord level, 
which can lead to chronic neuropathic pain states (Eide et al. 1995; 
Portenoy et al. 1996).  In both adults and neonates; it is the experiences 
associated with pain rather than pain itself that is remembered 
(McCaffery et al. 1999). Memory therefore is highly important in the recall 
of pain. The structures required for long-term memory, namely the limbic 
system and diencephalon are well developed and functioning in the 
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newborn. In addition, the brain plasticity required for cellular, synaptic 
and molecular changes that facilitate memory and learning is at its 
highest in the late prenatal and neonatal periods (Prechtl, 1984).  
 
It is therefore apparent that neonates, particularly preterm neonates, are 
particularly vulnerable to pain and its consequences. However pain is 
less adequately controlled in this group than any other (McCaffery et al. 
1999). A survey among English anaesthesiologists in 1988 illustrated 
that while 80% of the respondents considered neonates capable of 
experiencing pain, only 52% gave them opioids after surgery (Purcell-
Jones et al. 1988). Contemporary research further highlights 
inadequacies in recognising and treating infants in pain (Anand et al. 
2001) and supports the need for the development of increased 
educational programmes to improve the knowledge of junior doctors 
regarding neonatal pain (Schultz et al. 2010). The standardisation of pain 
management strategies is advocated for this patient group, which have 
associated benefits such as decreased length of time to extubation, 
shorter hospital stay, improved fluid balance, reduced side effects from 
opioids, decreased overall cost and more efficient use of nursing time 
(Furdon et al. 1999).  
 
2.11 The Issue of Neuroapoptosis 
Compelling evidence by Anand et al. (1992) established that deep 
anaesthesia in neonatal surgery and post-operative analgesia with high 
doses of opioids was beneficial as it reduced vulnerability to 
complications such as sepsis, metabolic acidosis and disseminated 
intravascular coagulation. However, in 1999 Ikononomidou et al. reported 
that certain anaesthetic agents and analgesics which generated 
prolonged reductions in synaptic activity, produced evidence of 
neurotoxicity in infant rats. These findings were substantiated by further 
animal studies affirming that neurodegeneration, with possible cognitive 
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sequelae, as a potential long term risk of anaesthetics in neonatal and 
young paediatric patients (Mellon et al. 2007). Evidence confirms that the 
entire classes of barbiturates, benzodiazepines and inhaled anaesthetics 
as well as chloral hydrate, propofol, ketamine and nitrous oxide, which 
are widely used in the paediatric population, induce neuronal injury and 
death in the brains of juvenile rodents. Primate studies are currently 
underway with a view to generating more clinically relevant information 
regarding these drugs.   
 
Acknowledging such findings, it is imperative that patient tailored regimes 
be endorsed, and an attempt made to minimise exposure to potentially 
harmful drugs and consider alternative therapies, (Mellon et al. 2007). 
Strong justification for the writers’ research study was therefore provided; 
current pain management strategies were reviewed and brought into line 
with current evidence. While it was important to heed this advice in the 
context of pain management; in PICU pain is seldom addressed in 
isolation. There is a strong association between pain and anxiety in the 
PICU setting, therefore the concept of anxiety will now be discussed. 
 
2.12 Anxiety in the PICU Patient 
It is confirmed that relatively little is known about children’s 
understanding of what happens to them during critical illness or their 
longer-term psychologic recovery (Colville, 2008). This is despite more 
than 200,000 children in the U.S. receiving critical care annually (Odetola 
et al. 2005). In the Irish context; the study site was the largest PICU in 
the country, and saw 1,050 PICU admissions in 2012 (PICANet, 2013). 
In the past, cortisol levels in hospitalised infants were observed to 
exceed those seen in response to surgery, a feature indicative of 
initiation of the stress response (Hughes et al. 1987). Furthermore, it was 
demonstrated that increased stress hormone concentrations in sick 
infants are associated with an increased risk of mortality (Barker et al. 
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1996). There is evidence of the persistence of distress in a significant 
minority of children admitted to PICU, (Colville, 2008).  
 
While a study conducted by Playfor et al. (2000b) into children’s recall 
following PICU stay found that two thirds of children were able to 
remember PICU. The children interviewed had essentially neutral 
recollections, with any negative recollections focusing on uncomfortable 
aspects of medical care or environmental factors. Indeed 55% had 
specific recollections of the PICU nursing staff which were mainly neutral 
and positive.  Accordingly, nurses should never underestimate the effect 
of their behaviour and responsiveness on children. Conversely, an 
observational study by Jones and Fisher (1992) found PICU patients 
exhibited higher levels of distress than other paediatric patients following 
extubation. In contrast, a cross-sectional study by Board (2005) reported 
an average level of anxiety in school aged children post PICU stay. 
However, this author acknowledged that their repertoire of coping 
strategies were limited in the PICU, especially while intubated. A 
retrospective cohort study by Rees et al. (2004) reported that PICU 
children exhibited considerable features of post traumatic stress disorder 
(PTSD) after discharge from PICU, including irritability and persistent 
avoidance of reminders of the admission.  
 
A worrying finding by Rennick et al. (2004) confirmed that most children, 
who had significant levels of post traumatic stress at 6 weeks post PICU 
admission, were still reporting high levels at 6 months. The impact of this 
on the child and their family should not be underestimated. With this in 
mind, in order to make good clinical decisions about analgesia and 
sedation, it is first necessary to be clear about the purpose of the 
pharmacological intervention. Sedation, anxiolysis and analgesia will 
therefore be elucidated, and research evidence regarding the use of 
these agents clinically will then be presented.  
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2.13 Distinguishing Between Sedation, Anxiolysis and Analgesia 
When choosing an analgesic or sedative in the PICU, it must first be 
identified what is required; sedation, anxiolysis or analgesia. The ideal 
approach should be a sedative/hypnotic for sedation, an anxiolytic for 
anxiety, and an analgesic for pain (Nair et al. 2004). Therefore, it is 
essential to provide the right drug for the problem at the right time in the 
right dosage. Elucidation of analgesia, sedation and anaesthesia is now 
provided, followed by a review of influencing factors regarding their use 
in PICU. 
 
2.13.1 Analgesia 
Analgesia is defined by Playfor et al. (2006) as the “blunting or 
eradication of the sensation of pain or other noxious stimuli.” In clinical 
practice analgesics are divided into 3 groups; non-opioids, opioids and 
adjuvants. Opioids will be discussed shortly, non-opioids refer to the 
“non-narcotics” acetaminophen and non-steroidal anti-inflammatory 
drugs (NSAIDS). Adjuvants or co-analgesics are drugs that have a 
primary indication other than pain (e.g. antidepressant or anticonvulsant) 
but also have analgesic properties in some painful conditions (McCaffery 
et al. 1999).  
 
2.13.2 Anxiolysis 
The emotion anxiety comes from the appraisal of a situation as causing 
uncertain, existential threat, Board (2005). It is appropriate that a child 
admitted to the unfamiliar and unpredictable environment of PICU would 
experience this emotion. Such an unpleasant state of tension is 
associated with apprehension or uneasiness causing sympathetic 
activation such as tachycardia, diaphoresis, trembling and palpitations. 
All medications used for anxiolysis also cause some sedation; the same 
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drugs in many cases function clinically as both anxiolytics and sedatives 
(Mycek et al. 2000).  
 
2.13.3 Sedation 
Sedation is the administration of agents to depress the level of 
consciousness (Nair et al. 2004). It is known that children who are deeply 
sedated or unconscious may perceive painful stimuli (Ewen et al. 1995). 
Therefore all painful procedures require analgesia or a nerve block as 
sedation alone does not address pain. Situations that require the use of 
sedation and analgesia in the PICU are broadly grouped in the following 
way by Nair et al. (2004): 
 
(a) Short term procedural sedation and analgesia 
(b) Long term sedation and analgesia as an adjunct to PICU 
(c) Off site procedural sedation and analgesia e.g. for MRI, CT 
scan etc.  
 
2.13.4 Anaesthesia 
There is no clear definition of anaesthesia. Weber (2010) proposes that 
the aim of anaesthesia be it procedural, general, regional or a 
combination is to reduce the humoral stress response, pain and 
emotional distress. The objective of general anaesthesia as opposed to 
regional techniques is to produce unconsciousness, the total absence of 
perception of any experience and amnesia.  
 
2.14 Desired Level of Sedation 
Current literature reflects a desire for a target end point of light sedation 
that allows patients to be calm and interactive (Guldbrand et al. 2004; 
Mehta et al. 2006; Devlin et al. 2004; Martin et al. 2007). A trend in 
critical care has been the reversal from sedation-analgesia to analgo-
sedation, with the primary goal of addressing pain and discomfort, and 
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then if necessary, adding sedation (Egerod et al. 2010). Daily sedation 
interruption has been used as a way of reducing escalation of medication 
doses and indeed a new study has demonstrated the feasibility of a 
protocol of ‘no sedation’ (Strøm et al. 2010). Using less sedation in 
patients receiving mechanical ventilation has merits including minimising 
exposure to agents that may cause withdrawal syndromes as well as 
neuroapoptosis in developing brains.  
 
Despite the majority of clinicians surveyed preferring their patients to be 
calm but capable of interacting with caregivers, in reality patients are 
usually more heavily sedated and respond only to verbal or painful 
stimuli (O’Connor et al. 2010). Several interpretations are offered for the 
discrepancy between the ideal and actual level of sedation, such as the 
implications of critical illness on decreasing the clearance of analgo-
sedatives and their active metabolites (i.e. morphine-6-glucuronide and 
hydroxymidazolam). Given the high level of autonomy bedside nurses 
have with analgo-sedative dosing and titration, an unwillingness to allow 
the patient to be exposed to the noxious stimuli of an endotracheal tube 
and invasive procedures may influence the nurse towards deep rather 
than light sedation (Egerod, 2006). In addition, high workloads 
associated with complicated monitoring and management of multiple 
supportive therapies may transpire to prevent clinicians from maintaining 
their patient in a calm and co-operative state, prompting the use of 
heavier sedation regimes (O’Connor et al. 2010).  
 
2.15 Influencing Factors on Analgesia and Sedation in PICU  
During the first few weeks of life, factors affecting the pharmacokinetic 
profile of analgesic drugs such as body water, fat composition, plasma 
protein binding, hepatic metabolism and renal function change rapidly. 
Neonates may have reduced clearance of many agents because of 
hepatic enzyme system immaturity, and children between 2 and 6 years 
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of age may have greater weight-indexed clearance of many agents than 
adults due to their higher relative liver mass (Berde et al. 2002). 
Recently, overwhelming evidence suggests morphine requirements for 
the neonate aged 7 days or younger are significantly less than those 
required in the older post operative neonate.  Furthermore, mechanical 
ventilation significantly reduces morphine metabolism and clearance in 
this population (Bouwmeester et al. 2003; Nandi and Fitzgerald 2005; 
Anand et al. 2013).  
 
This had a major impact on the development of appropriate dosing 
regimens for individual patients in the PICU. Particularly in the context of 
studies such as that by Mickell et al. (1990) which demonstrated that 
older infants and toddlers in the PICU had an increased requirement for 
morphine, benzodiazepines and neuromuscular blocking agents (NMBs). 
Several factors may influence this requirement; developmental 
differences in the expression of separation anxiety, developmental 
differences in benzodiazepine and opioid receptors as well as the 
pharmacokinetics of these drugs, paradoxical stimulation from the 
benzodiazepines and benzodiazepine-opioid antagonism. An acute 
awareness of this phenomenon was essential when addressing the 
analgesic and sedation needs of the PICU patient. Taddio et al. (2002). 
Endorse a comprehensive patient assessment and individualised 
approach. The drugs that were used for analgesia and sedation in the 
PICU and their clinically relevant characteristics will now be discussed. 
Non-pharmacological methods of pain relief and relaxation had a major 
role in the PICU; therefore these will be included. In addition; withdrawal 
syndromes were an ever present challenge as part of pain and sedation 
management, therefore this phenomenon also merits focus.  
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2.16 Agents Used for Analgesia and Sedation in PICU 
The role of pharmacological therapy is to deliver an effective 
concentration of the chosen drug to its target site where it produces the 
desired clinical effects. The ideal agents used for analgesia in the PICU 
would be rapidly metabolised, facilitate varying levels of sedation at 
different doses, compromise neither haemodynamic nor respiratory 
function, be effective via a variety of routes and have no associated 
withdrawal phenomena (Birchley, 2009). Unfortunately at present no 
drug fulfils all these functions (Rosen, 2005).  
 
The literature concerning analgesic and sedative agents used in PICUs 
worldwide show remarkable similarities. In the USA, Zuppa et al. (2005) 
confirmed that almost one third of the 25 most commonly prescribed 
agents in the PICU were analgo-sedatives; analgesics possessing 
sedative properties and utilised for both characteristics. More specifically, 
a multicentre study by Martin et al. (2001) found almost universal use of 
benzodiazepine (≥94%) and opioid (≥99%) combinations in long-term 
PICU patients. This is echoed in a multicentre survey by Rhoney and 
Murray (2002) indicating midazolam, fentanyl, lorazepam and morphine 
are the most commonly used agents. In the UK, Playfor et al. (2003) 
indicated that combinations of midazolam and morphine were the most 
commonly used choices for sedation in PICU settings.  
 
More recently Jenkins et al. (2007) reported the use of 14 different 
intravenous and 10 different enteral sedatives and analgesics. Of these, 
intravenous opioids (morphine and fentanyl) were used in 88% of cases, 
while intravenous benzodiazepines were used in 63%. Of particular 
significance is that despite such similarity in choices of analgesic and 
sedative agents used; there is widespread variation between centres 
regarding analgesic and sedation practices. These included the use of 
intravenous bolus rather than infusions, intermittently suspending 
infusions to allow metabolic clearance, the use of NMBs, and use of 
other sedating agents such as propofol medications (Martin et al. 2001; 
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Rhoney and Murray, 2002; Jenkins et al. 2007). It appears that 
notwithstanding pharmacological advances in the development of newer 
medications such as dexmedetomidine and remifentanyl; traditional 
analgesics and sedatives continue to be used most often (O’Connor et 
al. 2010). Despite this, data supporting appropriate dosing, safety and 
efficacy of combination therapies, and evidence for optimal drug choices 
for sedation during mechanical ventilation in PICU is hugely lacking 
(Hartman et al. 2009). Of particular concern is that less than half of UK 
units surveyed perform standardised titration of these agents and formal 
sedation assessments (Jenkins et al. 2007). An outline of the most 
commonly used drugs used for analgesia and sedation is now provided, 
commencing with opioids.  
    
 
2.16.1 Opioids 
Opioid analgesics have increasingly been used for sedation and 
analgesia in the PICU to improve clinical outcome. A number of opioids 
are available for clinical use including morphine; the archetypal opioid, 
hydromorphone, oxycodone, fentanyl and remifentanyl. Opioids are 
believed to exert their analgesic effect in the central nervous system 
through binding to opioid receptor sites, usually mu, kappa and delta in 
the brain and spinal cord (McCaffery et al. 1999). The majority of the 
clinically relevant opioids have their primary activity at mu receptor sites 
which are primarily found in the brainstem and medial thalamus. Mu 
receptors are responsible for supraspinal analgesia, sedation, respiratory 
depression, euphoria, decreased gastrointestinal motility and physical 
dependence (Trescot et al. 2008). Opioid metabolism occurs mainly in 
the liver, and the kidney is an important site of excretion. Many of the 
side effects of the opioids as well as therapeutic effects are related to 
their metabolites.  
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2.16.1(i) Morphine 
Morphine is the most widely used of all the opioids and relieves visceral, 
somatic and neuropathic pain with peak analgesic effect occurring 20 
minutes post intravenous administration. Its low lipid solubility accounts 
for its slow entry into the brain and delayed onset of clinical effect. 
Morphine undergoes extensive hepatic and extra-hepatic glucuronidation 
and metabolites are excreted renally. An active metabolite, morphine-6 
glucuronride delays drug elimination in renal disease, while morphine-3 
glucuronide fails to bind to opioid receptors and is considered an anti-
analgesic. Because analgesia occurs at low doses and sedation and 
hypnosis at higher doses, morphine is a mainstay in maintenance 
sedation and analgesia (Nair et al. 2004). 
 
Morphine clearance in the newborn is slow and quantitatively dissimilar, 
however adult values are reached in the first few months of life 
(Bouwmeester et al. 2003). Morphine stimulates the release of histamine 
and inhibits compensatory sympathetic responses. The vasodilation 
caused by morphine can cause hypotension, particularly with bolus 
administration. As a result its use has become controversial in recent 
times. The NEOPAIN trial (Neurologic Outcomes and Pre-emptive 
Analgesia in Neonates) was a double-blind, placebo controlled trial 
involving 898 ventilated neonates between 23 and 32 weeks gestation 
randomised to receive masked morphine or placebo infusions. This trial 
investigated whether pre-emptive morphine analgesia decreased the rate 
of composite primary outcome of neonatal death, severe intraventricular 
haemorrhage and periventricular leucomalacia in preterm neonates 
(Anand et al. 2004).  
 
Findings suggest pre-emptive morphine infusions may be a safer mode 
of delivery than intermittent boluses of open-label morphine. However, 
ventilated premature neonates were at significant risk of the adverse 
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effects of this drug, therefore morphine should be used judiciously and 
cautiously when indicated for severe pain in this group (Anand et al. 
2004). Particular care is advised when using morphine in the 23 to 26 
week gestation neonates, and those with pre-existing hypotension (Hall 
et al. 2005). Secondary results of this trial confirmed that although 
morphine use delayed the attainment of full enteral feeds and in preterm 
infants, it did not increase gastrointestinal complications. Nevertheless, 
data collected from the NEOPAIN trial have provided a powerful cohort to 
examine the long-term effects of opioid therapy on brain development 
and behaviour.  
 
2.16.1(ii) Fentanyl 
Fentanyl is a synthetic opioid phenylpiperidine one hundred times more 
analgesically potent than morphine. It has a rapid onset of action due to 
its high lipid solubility, and causes less histamine release than morphine. 
Consequently there is less incidence of hypotension associated with 
fentanyl administration (Mycek et al. 2000). A characteristic of fentanyl is 
that it reduces cardiac output by decreasing heart rate; an advantage in 
situations where ablation of the stress and/or stressor response is 
sought. Intravenous fentanyl has a relatively short half-life of 30-60 
minutes because of rapid redistribution to peripheral compartments, this 
characteristic increases the context specific half time with prolonged 
administration. Indeed, prolonged IV infusion of fentanyl in the neonatal 
intensive care has been associated with more rapid dose escalation than 
morphine (Simons and Anand, 2006).  
 
In addition tolerance can rapidly develop (Arnold et al. 1990), and 
withdrawal syndromes can present following rapid cessation (Simons 
and Anand, 2006). Fentanyl is almost exclusively metabolised in the 
liver, producing no active metabolites, although clearance is only 70-80% 
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of adult levels in neonates but rapidly matures (Tibboel et al. 2005). 
Cross reaction does not occur in patients with morphine allergy.  
 
2.16.1(iii) Remifentanyl 
Remifentanyl is equipotent to fentanyl, and is a synthetic opioid 
phenylpiperidine derivative that acts as a pure mu receptor agonist. It 
has cardiorespiratory effects similar to other opioids. It has a 3 minute 
half-life in all age groups as it is metabolised by plasma and tissue 
esterases and has a very small volume of distribution. Given its short 
lived therapeutic effects; its clinical utility may lie in procedural analgesia 
although it has been used to effectively provide ongoing analgesia in the 
PICU (Tobias, 1998). Safety concerns were cited in 11.5% of a 
pharmacokinetic study cohort evaluating sedation with remifentanyl in a 
PICU post cardiac surgery (Rigby-Jones et al. 2007), due to developing 
hypotension. In contrast, effective sedation was provided for 5-7 days in 
two medical intubated PICU patients, (German et al. 2000). According to 
the BNF for children (2010-2011) there is little evidence to support the 
use of remifentanyl in neonates.  
 
2.16.2 NSAIDS and Paracetamol 
Non-steroidal anti-inflammatory drugs (NSAIDS) are effective analgesics 
for mild to moderate pain. Using NSAIDS as part of multimodal analgesic 
therapy to decrease opioid consumption is well endorsed (Korpela et al. 
1999; Antila et al. 2006; Rugyte and Kokki 2007), while combining 
NSAIDS and paracetamol is strongly promoted (Hiller et al. 2006; Riad 
and Moussa 2007). NSAIDS have been studied and used in all age 
groups including infants (Eustace and O’Hare, 2007), they exert their 
analgesic effect via the non-selective, competitive inhibition of cyclo-
oxygenase (COX). They thus reduce the production of prostaglandins 
and the consequent sensitisation of peripheral nociceptors.  
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However, the prostaglandins produced by COX-1 activity have a number 
of maintenance functions; on the gastric mucosa, renal function, 
bronchiolar tone and platelet aggregation (Dobson, 1997). These 
maintenance functions are impeded by non-selective action of NSAID 
drugs, leading to undesirable side effects including gastrointestinal 
erosion, prolonged coagulation time, renal insufficiency and potentiation 
of asthma. The risks associated with NSAIDS in children with conditions 
such as asthma, renal compromise and at risk of bleeding e.g. post-
tonsillectomy have been identified (Allegaert et al. 2005; Cardwell et al. 
2005; Palmer 2005).  This has stimulated efforts to develop a more 
selective NSAID analgesic that inhibits COX-2 and not COX-1. However 
as the degree of COX-2 selectivity, pharmacokinetic profile adverse 
effects and use of parenteral forms have as yet not been adequately 
studied in children, they remain currently unlicensed for use in this 
population (Macintyre et al. 2010).  
 
Paracetamol is an analgesic used to treat mild to moderate pain (Playfor 
et al. 2006). While exerting analgesic and anti-pyretic properties, 
paracetamol has no anti-inflammatory effects. It is well tolerated without 
causing respiratory depression and is less irritant to the stomach than 
NSAIDS. In combination with an opioid, paracetamol provides a greater 
analgesic effect than higher doses of the opioid alone (Berde et al. 
2002). A variety of routes of administration are available; oral, rectal and 
intravenous and the route used affects the biovailability of the drug. Oral 
doses are subject to first pass hepatic metabolism of 10% to 40% (Arana 
et al. 2001) while rectal administration is associated with slower and 
more erratic absorption (Howell and Patel, 2003). Paracetamol is 
metabolised in the liver, and hepatoxicity is a significant risk factor, in 
particular where fasting, vomiting, dehydration, systemic sepsis, pre-
existing liver disease and prior paracetamol intake are present 
(Kaplowitz, 2004).    
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2.16.3 Midazolam  
Midazolam is a member of the benzodiazepine family. Benzodiazepines 
bind to specific benzodiazepine receptor sites in the central nervous 
system in a complex with GABA (Gamma-aminobutyric acid) receptors 
triggering an opening of the chloride channel. The resultant influx of 
chloride ions causes hyperpolarisation that inhibits action potentials 
(Mycek et al. 2000). This action results in their anxiolytic, sedative, 
hypnotic, anticonvulsant and muscle relaxation effects. Midazolam is 
considered an excellent agent for inducing antegrade amnesia without 
impairing the ability to retrieve previously learned information (Randolph 
et al. 2002). This characteristic feature may play an important role in the 
infrequency of unpleasant experiences recalled by PICU survivors 
treated with this agent (Playfor et al. 2000b).  
 
Benzodiazepines do not have an antipsychotic or analgesic effect and do 
not affect the autonomic nervous system. However, benzodiazepines are 
often used in combination with opioid analgesics for procedural and post-
operative pain management. Despite limited use regarding the safety 
and efficacy of combining these drugs in the neonatal population, this 
combination is also used in neonates to manage stress (McCaffery et al. 
1999), (See appendix 6 for a complete list of anxiolytic and hypnotic 
drugs).   
 
2.16.4 Propofol   
Propofol is described as a sedative/hypnotic used in the induction or 
maintenance of anaesthesia (Mycek et al. 2000). Propofol has never 
been licensed for the provision of sedation in critically ill children. The 
longer term infusion of propofol for sedation by infusion is associated 
with the phenomenon “propofol infusion syndrome”, a rare but frequently 
fatal complication characterised by acidosis, bradyarrythmia and 
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rhabdomyolosis (Bray, 1999). This has been reported in at least 21 
children and 14 adults (Vasile et al. 2003). The Irish Medicines Board 
(2008) has advised that propofol is contraindicated for ICU sedation in 
patients of 16 years of age or younger. This is congruent with the 
approach taken by the UK Medicines and Healthcare Products 
Regulation Agency (2010) and the US Food and Drug Administration 
(2011).  
 
2.16.5 Neuromuscular Blocking Agents (NMBs) 
Non-depolarizing neuromuscular blocking drugs are structural analogues 
of acetylcholine and prevent cholinergic transmission between motor 
nerve endings and the nicotinic receptor on the neuromuscular end-plate 
of skeletal muscle (Mycek et al. 2000). These drugs are used 
therapeutically to provide complete muscle relaxation, a useful state 
during surgery. Indeed, to facilitate tracheal intubation, induction of 
anaesthesia is usually followed by a neuromuscular blocking drug or a 
short acting opioid (BNF for Children, 2010). In the past NMBs or muscle 
relaxants were used to achieve ventilator synchrony and reduce 
intraventricular haemorrhage in unsedated infants (Perlman et al. 1985), 
a practice which is untenable today (Aranda et al. 2005), as these agents 
do not have analgesic or sedative properties. Although effective methods 
of assessing depth of sedation in patients using neurophysiological 
methods such as BIS (Bispectral Index Monitoring) during the 
administration of neuromuscular blocking agents had been anticipated; 
insufficient evidence to support this technique in the PICU exists (Playfor 
et al. 2006).  
 
2.17 Non-Pharmacological Interventions 
The requirement for analgesic and sedative therapy can be attenuated 
by sympathetic nursing and attention to simple environmental factors to 
promote comfort in the critically ill patient (Playfor et al. 2006). One of the 
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major causes of sleep disruption in the critically ill is excessive noise 
(Meyer et al. 1994; Aaron et al. 1996). Although maintaining hospital 
noise levels below 45 decibels during the day and below 35 decibels at 
night is endorsed by the United States Environmental Protection Agency 
(Agency UEP, 1974); it has been established that environmental noise in 
critical care units ranges from 60 to 84 decibels (Freedman et al. 1999). 
Prioritising sleep in critical care environments is crucial as it is known that 
sleep deprivation can deleteriously affect pulmonary function, protein 
synthesis, healing and immune function (Krachman et al. 1995). 
 
Other non-pharmacological interventions which soothe the patient and 
may reduce the requirement for analgesia and sedation include massage 
and relaxation techniques. Effective methods of distracting children 
during echocardiography include watching videos (Stevenson et al. 
1990); while music therapy, guided imagery and relaxation techniques 
have proved highly effective tools in enhancing cooperation and 
relaxation in children in the interventional cardiology laboratory (Bullock 
et al. 1993). Simple measures such as communication, reassurance, 
family presence,  orientation to time and place, ensuring clocks are 
visible, providing adequate warmth and nutrition are factors PICU 
survivors cite as positive recollections (Playfor et al. 2000b). In addition, 
oral glucose when administered to neonates and small infants orally in 
the concentration of 25-50% has been shown to produce analgesia 
adequate for short procedures like heel lancing (Skogsdal et al. 1997; 
Bless et al. 1991). 
 
2.18 Withdrawal Symptoms 
Withdrawal symptoms may manifest in the PICU when sedative agents, 
particularly benzodiazepines and opioids, are abruptly discontinued in a 
patient who is physiologically dependent. There are limited studies 
examining the prevalence of withdrawal symptoms in general PICU 
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populations. The reported incidence ranges between 10% of patients in a 
multicentre study (Jenkins et al. 2007) and 57% of children in a 
prospective study by Katz et al. (1994). The main body systems affected 
in opioid withdrawal are the central nervous system, autonomic system 
and gastrointestinal system. Diagnosis is through the display of a range 
of symptoms, including tremors, agitation, sleeplessness, inconsolable 
crying, diarrhoea and sweating (Ista et al. 2007 & 2008). No single 
symptom is sufficient to diagnose withdrawal, usually other causes are 
ruled out first (Zapantis and Leung, 2005). Withdrawal syndromes are a 
significant problem, producing a number of negative consequences 
including increased morbidity (Biswas et al. 2005), increased 
hospitalisation costs (Sorce, 2005) and psychological distress (Nichols, 
2004).  
 
Tapering regimes have been forwarded as a method of discontinuing 
opioids, however experimental data supporting any tapering method over 
another is lacking (Taddio et al. 2004). In addition, a UK study found no 
standardised practice in weaning regimens exists between different 
PICUs (Jenkins et al. 2007). In general, more aggressive weaning 
schedules are endorsed for shorter regimes such as a reduction of 25-
50% of the dose per day, while for long-term therapy; a decrease in 
original dose of 10-20% per day and switching infusions to intermittent 
dosages before discontinuation is advised (Taddio et al. 2004). 
 
Only one double-blinded RCT to evaluate this approach in a PICU 
population was identified. Berens et al. (2005) randomised 37 PICU 
patients to a 5 day and 10 day weaning programme, both groups 
receiving enteral methadone. No significant difference was found 
between groups; however the study was limited by its small sample size 
and the use of an inappropriate scoring tool. An approach to weaning 
opioids that includes using the same opioid that was used therapeutically 
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is endorsed by Anand et al. (2010). Continuous evaluation of withdrawal 
symptoms is required throughout the tapering period. Unfortunately 
however, withdrawal syndrome is frequently under-recognised and 
under-treated, and a lack of validated PICU assessment tools confounds 
this problem (Playfor et al. 2006; Fisher 2010). A validated paediatric 
withdrawal tool which has good interrater reliability, construct validity and 
shows sensitivity to change is needed as a matter of urgency (Ista et al. 
2008).   
  
2.19 Context of the Research Study 
The administration of sedation and analgesia is a routine part of 
paediatric intensive care; in order to relieve pain and anxiety, induce 
cooperation, decrease metabolic demands, and when used 
appropriately; reduce mortality. The paediatric critically ill population are 
a high risk group in whom appropriate pharmacotherapy can be either life 
saving or life threatening. It is therefore unacceptable that high quality 
evidence to guide practice regarding these drugs is still lacking. In the 
US, the FDA through a combination of legislation, particularly the Best 
Pharmaceuticals for Children Act (BPCA) (2007) and the Pediatric 
Research Equity Act (PREA) (2007), is striving to address this issue 
through advancing paediatric studies. Similarly, under European Union 
directives, manufacturers of drugs marketed for children in Ireland must 
ensure that such medicines are the subject of high quality research and 
that they are appropriately authorised. The Paediatric Regulation came 
into force in the EU on 26 January 2007, and is directly applicable in 
Member States. It is imperative that newly developed drugs that may 
offer significant benefits to critically ill children, such as selective 
NSAIDS, and the sedative dexmedotomidine, reach this population with 
established dosing guidance to complement the existing selection of 
available agents, or possibly offer an alternative to these traditional 
agents with their associated risks and side-effects.  
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One significant limiting factor in conducting these much needed 
analgesia and sedation studies in the paediatric population has been the 
absence of a robust outcome measure in this population; a validated and 
reliable measure of pain and distress (Ambuel et al. 1992).  The gold 
standard of verbal self report of pain is not feasible in pre-verbal, 
ventilated children (Twycross et al. 2009). Despite the multitude of 
published pain and sedation assessment scales, in the past the available 
scales had limitations that made accurate assessment hugely 
challenging (Brinker, 2004). According to van Dijk et al. (2004), in 
neonates and preverbal children, behaviour can be used as a substitute 
for self-report of pain. Recent developments in the refinement of 
behavioural observation distress assessment scales have offered huge 
potential in overcoming the obstacle of accurate distress measurement 
(Bear 2006; Caljouw et al. 2007; Ista et al. 2009; Jin et al. 2009).  This 
places researchers in a better position to conduct much needed 
analgesic and sedative studies; but also for clinicians to analyse current 
analgesia and sedation practice and determine the impact of 
implementing best analgesia and sedation practice.  
 
2.20 Conclusion   
This chapter provided the background and contextual issues related to 
the current status of pain, anxiety, analgesia and sedation in the PICU. 
The common pharmacological approaches used to manage pain and 
anxiety in the PICU setting have been described, as well as the 
undesirable phenomena of withdrawal syndrome and neuroapoptosis. 
The next section will include a comprehensive literature review regarding 
the current methods available to assess distress in PICU patients. Each 
instrument will be evaluated in terms of its clinical utility and suitability to 
the patient profile of the research setting.  
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3.0 Introduction 
Competent pain assessment is the first step towards pain management, 
and this is of particular significance in PICU where patients are often 
admitted postoperatively and many invasive procedures are carried out 
(van Dijk et al. 2005). Accurate assessment of children’s pain is needed 
to diagnose conditions and guide pain management interventions. 
Accumulating evidence indicates that untreated pain may have long-term 
negative and permanent repercussions on pain sensitivity, immune 
functioning, neurophysiology, attitudes and health care behaviour (Young 
et al. 2006). This chapter aims to provide a critical analysis of 
instruments that have been developed to assess pain and sedation in 
children. The rationale for choosing a particular instrument for use in the 
study setting will be presented.  
 
3.1 Paediatric Pain Assessment  
Since the mid 1990’s, significant research attention has been devoted to 
developing instruments to quantify children’s pain (Cohen et al. 2008). 
Franck et al. (2000) advocate that a pain assessment tool must be 
reliable and valid for the population it is to be used to assess, have 
clinical utility and be feasible to use. While the IASP considers verbal 
pain report  to be the gold standard of pain measurement; 68% of the 
PICU patient population received invasive ventilation and 42% were 
under the age of 1 year at admission to the study setting (PICANet local 
database, 2012), making self report impossible for the majority of the 
patients. Such patient characteristics rendered observation pain 
assessment tools the most suitable approach to measuring pain in this 
setting.  Observation tools can either comprise behavioural cues only 
(unidimensional) or both physiological and behavioural 
(multidimensional) indicators. Specific behavioural indicators of pain in 
infants and young children include: 
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 Individual behaviours, e.g. crying and facial expression. 
 Large movements, e.g. withdrawal of affected limb, movement or 
tensing of limbs and torso. 
 Alterations in sleep/wake state or cognitive functions. 
 Changes in appetite or social behaviour. 
(Twycross et al. 2009). 
 
Although behavioural observation pain measures are particularly 
applicable for pre-verbal children, those with cognitive impairment, or 
when the child is too distressed to indicate their level of pain (von Baeyer 
et al. 2007); Cohen et al. (2008) argues that like self-report, behavioural 
manifestations are also subject to the effects of minimisation, 
exaggeration and the influence of social and other contextual variables. 
Cohen et al. (2008) therefore proposes using a combination of 
behavioural observation and self-report methods when appropriate. 
  
The creation of an assessment tool to examine a construct such as pain 
is a complex, time consuming process (Duhn et al. 2004). It was 
therefore decided to critically analyse existing tools and employ what was 
available and most suitable. This stance is supported by Ceelie et al. 
(2008) who contend that development of additional pain assessment 
tools is unnecessary, except for the fields that are not addressed such as 
prolonged pain in profound cognitive impairment. Pain assessment 
literature is ever-growing; therefore an evidence based approach in 
evaluating popular pain measures was employed. A comprehensive 
literature review, as well as consultation with the Pediatric Initiative on 
Methods, Measurement, and Pain Assessment in Clinical Trials (Ped-
IMMPACT, American Pain Society, 2008) review informed the 
construction of a list of 5 paediatric observational measures that were 
considered ‘well established’ (See table 3.1). 
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Table 3.1: Validated Behavioural Tools for Assessing Paediatric Pain 
Validated Paediatric Pain Assessment Tools 
Measure Brief Description Age 
Group   
Psychometrics Considerations 
Children’s 
Hospital of 
Eastern 
Ontario Pain 
Scale 
(CHEOPS; 
McGrath et al. 
1985). 
Observation 
measure of pain 
based on crying, 
facial expression, 
verbalisations, 
torso activity, 
whether and how 
child touches 
wound, leg position 
(McGrath et al. 
1985). 
1-12 years  
(Cohen et 
al. 2008). 
Inter-rater 
reliability=95% 
Concurrent 
validity= 0.35-
0.85 
(Based on 
DBRCT 
involving 161 
children 
undergoing 
intramuscular 
injection, 
Cassidy et al. 
2001). 
Cannot be used 
in intubated 
patients. 
Lengthy and 
confusing 
scoring system 
makes it 
complicated to 
use (Twycross 
et al. 2009). 
Child Facial 
Coding 
System 
(CFCS; 
Chambers et 
al. 1996). 
Measure of facial 
expressions. 
Thirteen facial 
actions coded for 
frequency or 
intensity 
(Chambers et al. 
1996).  
2-5 years 
(Cohen et 
al. 2008). 
Inter-rater 
reliability 0.75-
0.83 
Concurrent 
validity 0.28-
0.73  
(Based on 
assessment of 
161 children 
undergoing 
intramuscular 
injection, 
Cassidy et al. 
2001).  
Due to the 
detailed coding 
system, 
videotapes are 
recommended 
to capture child 
facial actions 
(Cohen et al. 
2008). 
Premature 
Infant Pain 
Profile (PIPP; 
Observational 
measure of acute 
pain in premature 
Premature 
Infants 
Internal 
consistency = 
Developed for 
use in 
premature 
infants. Not 
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Stevens et al. 
1996). 
infants. Includes 
seven indicators of 
pain (Stevens et al. 
1996). 
(Stevens 
et al. 
1996). 
0.59-0.76 
Inter-rater 
reliability = 
0.95-0.97. 
(Based on 124 
infants 
undergoing 
painful 
procedures, 
Stevens et al. 
1996). 
validated for 
full-term 
neonates and 
older infants 
and children. 
(Cohen et al. 
2008). 
FLACC 
(Merkel et al. 
1997). 
Procedural and 
post-operative pain 
observation tool 
based on facial 
expression, leg 
movement, activity, 
cry and 
consolability 
(Merkel et al. 
1997). 
0-7 years 
(Merkel et 
al. 1997). 
4-18 years 
of age with 
cognitive 
impairment 
(Voepel-
Lewis et 
al. 2002).  
Interobserver 
reliability 0.63 
(Based on pain 
assessment in 
40 post-
operative 
children, 
Johansson et 
al. 2009). 
Cannot be used 
in intubated 
patients 
(Twycross et al. 
2009). 
To assess 
‘consolability’ an 
attempt must be 
made to 
console and 
rating of such 
may be 
subjective 
(Twycross et al. 
2009). 
COMFORT-B 
(van Dijk et al. 
2000). 
Distress 
assessment tool 
based on 
observation of 
alertness, 
calmness, 
agitation, 
respiratory 
response or crying, 
Premature 
neonates 
from 28 
weeks 
gestation 
to children 
of 18 years 
(Wielenga 
et al. 2004; 
Inter-observer 
reliability 0.71-
0.84 (Based on 
pain 
assessment in 
40 post-
operative 
children 
Johansson et 
Validated for 
use in ventilated 
and non-
ventilated 
patients as well 
as patients with 
Down’s 
Syndrome 
(Valkenburg et 
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muscle tone, 
physical movement 
and facial tension. 
Altered from 
original format; 
physiological 
indicators of HR 
and BP removed 
as artificially 
controlled in PICU. 
VAS included (van 
Dijk et al. 2000). 
Ista et al. 
2009; 
Johansson 
et al. 
2009).  
al. 2009; Based 
on assessment 
of 78 PICU 
patients, Ista et 
al. 2005). 
al. 2011). 
Administration 
time is over 2 
minutes, staff 
require 2 hours 
training to use 
tool (van Dijk et 
al. 2000). 
 
 
3.2 Pain Assessment Tool Selection 
As evident in table 3.1, a number of procedural of observational pain 
assessment scales have been developed to measure children’s pain 
during painful procedures. These include the Procedural Behavioural 
Rating Scale (PBRS; Katz et al. 1980), the Observational Scale of 
Behavioural Distress-Revised version (OSBD-R; Elliott et al. 1987), the 
Child-Adult Medical Procedure Interaction Scale (CAMPIS; Blount et al. 
1989), the Procedure Behavior Checklist (PBCL; LeBaron et al. 1984). 
Although each of these measures has been used successfully with 
paediatric patients undergoing various medical procedures, attesting to 
their broad applicability (Cohen et al. 2008); they are unsuitable for use 
as an instrument to measure post-operative pain, or the discomfort 
associated with disease progression in the PICU patient. Observational 
pain assessment instruments which have been designed to measure 
distress in PICU patients and which have been validated will now be 
discussed. 
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(i) The Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS; 
McGrath et al. 1985) is a measure of post-operative pain in 
children which can be used as real-time, live coding tool. It 
includes operational definitions for 6 domains: cry, facial, child 
verbal, torso, touch and legs. Each domain is scored on a scale of 
1-3. Inter-rater reliability following surgical procedures for children 
aged 1-5 years ranges from 90% to 99.2% for the different 
behavioural domains (McGrath et al. 1985). CHEOPS scores 
correlate with child self-report of pain during injections, and it has 
been found to be sensitive to the effects of pharmacological 
interventions to reduce pain (Cassidy et al. 2001). However, no 
differences were detected on the CHEOPS between children 
receiving behavioural intervention and those who did not during 
immunisations (Cassidy et al. 2001). For our purposes; as the 
primary indication for CHEOPS is as a post-operative pain 
assessment tool, and as it is untested in the under 1 year old 
population; it was ruled out for use in our PICU. 
(ii) The Child Facial Coding System (CFCS; Chambers et al. 1996) 
rates children’ facial expressions during painful experiences. It 
was designed for use in pre-school children aged between 2 and 5 
years. It includes 13 facial actions, 10 of which are coded for 
intensity (e.g. eye squeeze, nasolabial furrow), and 3 items (blink, 
flared nostril and open lips) are coded as absent or present. Inter-
rater reliability ranged from 0.75 (Cassidy et al. 2002) to 0.83 
(Gilbert et al. 1999). CFCS scores differed depending on whether 
or not a patient was receiving an injection (Breau et al. 2001). In 
addition, the CFCS was sensitive to group differences in pain 
expressions for children receiving injections with or without topical 
anaesthesia (Cassidy et al. 2001), and for those receiving 
behavioural intervention or not (Cassidy et al. 2002). According to 
Cohen et al. (2008), the CFCS has been used effectively with 
healthy children; however due to the detailed coding system, 
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videotapes are recommended to capture child facial actions. This 
reduced the clinical utility of this tool for the study setting due to 
resource and time constraints, use of video would not be 
practicable. In addition, it has not undergone testing in critically ill 
children, nor in those under 2 years of age (Cohen et al. 2008), 
making it an unsuitable tool for the PICU patient population at the 
study site.  
(iii) The Premature Infant Pain Profile (PIPP; Stevens et al. 1996) is a 
7 item observational, multidimensional measure of acute pain in 
premature infants (gestational age between 28 to 36 weeks). Each 
item is scored on a 4 point scale. The items include physiological 
(heart rate, oxygenation) and behavioural dimensions (e.g. facial 
expression, brow bulge, crying).  Scores are summed across the 7 
items. A high inter-rater reliability of 0.95 has been reported for the 
PIPP (Ballantyne et al. 1999), as well as good sensitivity to 
change (Johnston et al. 1999). However, the inclusion of 
physiological parameters in a pain assessment tool is debated 
(Ista et al. 2005).  Ramelet et al. (2004) and von Baeyer et al. 
(2007) argue that in the critical care environment; heart rate and 
blood pressure can vary due to medical condition and 
interventions such as inotropic drugs and therefore may not be 
specific for pain.  For this reason, and because of the limited age 
range that this tool was designed for, it was deemed unsuitable for 
use in the majority of the PICU patient population at the study site, 
and therefore ruled out. 
(iv) Facial expression, leg movement, activity, cry and consolability 
(FLACC; Merkel et al. 1997). This tool was designed to measure 
procedural and post-operative pain in patients aged from 2 
months to 8 years of age, where each category is scored on a 0-2 
scale resulting in an overall score of 0-10. While a well established 
evidence of reliability is confirmed (Twycross et al. 2009), it is 
argued that there is inconsistent ability to detect change (von 
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Baeyer et al. 2007). Despite its high clinical utility; it is unsuitable 
for intubated patients (Twycross et al. 2009), deeming it inapt for 
the purposes of the study. 
(v) COMFORT-B (original version Ambuel et al. 1992; revised version 
van Dijk et al. 2000). A non-intrusive method originally designed to 
measure distress in mechanically ventilated PICU patients, in 
which eight factors (2 physiologic and 6 behavioural) were 
assessed. This tool was modified to include ‘crying’ for non-
ventilated children, and the physiologic variables were removed 
without jeopardising the quality of the assessment (van Dijk et al. 
2000). Because pain assessment based solely on observable 
behaviour is limited; addition of the VAS (visual analogue scale) 
(from 0-10) an estimation of pain intensity reflects the nurses 
expert opinion well as her knowledge of the patient, reflecting if 
the patient is distressed because of pain or perhaps due to 
hunger. Validated in children aged from 28 weeks gestation 
(Caljouw et al. 2007); COMFORT-B has a reported inter-rater 
reliability of kappa 0.71 (Johansson et al. (2009).  
 
 
Neonatal patients were routinely admitted to the PICU in the study 
setting for surgical management of conditions such as necrotising 
enterocolitis, patent ductus arteriosus ligation and congenital 
diaphragmatic hernia repair. Data showed that the number of neonatal 
admissions to the PICU at the study site had progressively increased 
over the last decade and in 2010; 31% (n=313) of all PICU admissions 
were neonates (corrected age at admission less than 29 days) (Healy et 
al. 2011). It was vital that the chosen tool was valid for use in the 
neonatal population- but not exclusive to this patient group as the age 
range of inpatients in the PICU extended to 18 years. In order to 
rationalise the approach to patient assessment; a pain assessment tool 
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that was valid for most, if not all of the PICU patient groups was required. 
The CFCS scale was validated only for the 2-5 year old age group 
(Cohen et al. 2008), thus was ruled out. Over two thirds of the PICU 
inpatients received mechanical ventilation during their PICU stay. The 
COMFORT-B scale was the only tool that had been validated for use in 
ventilated children (Twycross et al. 2009). CHEOPS could not be used in 
intubated patients (Twycross et al. 2009). This was also the case for the 
FLACC scale, although the modified FLACC had proven superior to any 
other pain assessment tool for measuring distress in the child with 
developmental delay (Twycross et al. 2009). Selection of the COMFORT-
B tool for assessment of pain in the PICU was therefore justified.  
 
3.3 Assessing Sedation in PICU 
Aside from physical discomfort, children admitted to PICU experience 
stress and anxiety (Johnson et al. 1990; Ambuel et al. 1992). Stress is a 
well acknowledged factor in delaying recovery in children (Kidder, 1989). 
Notwithstanding the clinical judgement of trained PICU staff; the use of a 
validated system for formally assessing sedation is vital to assess the 
efficacy of sedatives and therapeutic interventions, and facilitate inter-
institutional comparisons (Ista et al. 2005). Adult ICU settings primarily 
use the Ramsay scale for measuring sedation (Ramsay et al. 1974). No 
gold standard for assessing sedation exists in PICU (de Jonghe et al. 
2000); tools such as the Ramsay scale are inappropriate in young 
children as the assessor must rate the patient’s response to commands. 
This called for other, more specific observations in the PICU setting. 
Table 3.3 presents 6 validated sedation scoring scales which were 
considered for the PICU. 
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Table 3.3 Paediatric Sedation Scoring Scales 
Name Conditions 
Measured 
Population Validated for 
use in & Psychometric 
Measurements 
Considerations 
Hartwig 
Sedation 
Scale  
(Hartwig et al. 
1991). 
Consciousness, 
agitation, ventilation, 
pain, reaction to 
endotracheal suction 
(Hartwig et al. 1991). 
Paediatric (Hartwig et al. 
1991). 
Compared favourably with 
COMFORT scale in 30 
observations of 18 PICU 
patients, no significant 
difference in mean scores 
(p=0.006) (de Cervalho et al. 
1999). 
Not validated in 
non-ventilated 
patients, 
response to 
suction 
assessed (de 
Cervalho et al. 
1999). 
COMFORT-B 
(Van Dijk et 
al. 2000). 
Observation of 
alertness, calmness, 
agitation, respiratory 
response or crying, 
muscle tone, 
physical movement 
and facial tension 
(van Dijk et al. 
2000). 
Paediatric and neonatal 
patients from 28 weeks 
gestation (Johansson et al. 
2009; Ista et al. 2009). 
Inter-observer reliability 0.71-
0.84 (Based on pain 
assessment in 40 post-
operative children Johansson 
et al. 2009; Based on 
assessment of 78 PICU 
patients, Ista et al. 2005). 
Validated for 
both ventilated 
and non-
ventilated 
patients (Cohen 
et al. 2008). 
Children’s 
Hospital of 
Wisconsin 
Sedation 
Scale 
(Soetenga et 
al. 1991). 
Consciousness and 
agitation (Soetenga 
et al. 199). 
Paediatric. 
Based on 124 observations 
of 74 children an internal 
consistency of 0.93, and an 
inter-rater reliability of 0.92 
were reported (Soetenga et 
al. 1991). 
Element of 
intrusiveness as 
response to 
verbal and 
noxious stimuli 
measured 
(Jeleazcov et al. 
2007). 
University of Depth of sedation in 4 months to 5 years (Razmus Restricted to 
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Michigan 
Sedation 
Scale 
(Malviya et al. 
2002). 
Children (Maviya et 
al. 2002). 
et al. 2006). 
Based on 4 nurses assessing 
32 patients sedated for CT 
scan, criterion validity was 
0.95, did not discriminate 
depth of sedation well , 
significant difference between 
blinded observers and CT 
nurses ratings 40 min from 
baseline (p=0.02) (Malviya et 
al. 2002)  
level of 
consciousness, 
validated only 
for short 
procedural 
observations 
(Ista et al. 
2005). 
Vancouver 
Sedative 
Recovery 
Scale 
(Macnab et 
al. 1991). 
Recovery from 
sedation (Macnab et 
al. 1991). 
Paediatric. 
Inter-observer agreement 
0.97, internal consistency 
0.85 based on 16 patients 
observed by novice and 
expert raters (Macnab et al. 
1991). 
Designed to 
measure 
recovery from 
sedation 
(Macnab et al. 
1991).  
NISS (Nurse 
Interpretation 
of Sedation 
Scale) 
(Marx et al. 
1994). 
3 response 
categories: 
1. Insufficient 
sedation. 
2. Adequate 
sedation. 
3. Oversedation
. 
Neonatal, paediatric and 
adult. 
Based on 96 observations 
COMFORT and NISS 
correlated in 66.1% of 
physician observations (Marx 
et al. 1994). 
 
Highly 
subjective, 
numeric value 
allocated to 
patient’s 
sedation status 
based on nurses 
opinion (Ista et 
al. 2005).  
 
NPASS 
(Neonatal 
Pain, 
Agitation and 
A measure of level 
of consciousness, 
pain and agitation in 
the neonatal 
Neonatal. 
Inter-rater reliability 0.95 for 
pain and 0.9 for sedation 
based on paired 
Restricted to 
neonates, not 
validated in 
ventilated 
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Sedation 
Scale)  
(Hummell et 
al. 2003). 
population (Ista et al. 
2005). 
assessments of 72 neonatal 
subjects. High inter-rater 
reliability for high pain scores 
(0.82) but low inter-rater 
reliability for low pain scores 
(0.31) was reported 
(Hummell et al. 2003). 
patients (Ista et 
al. 2005).  
 
Patient assessment using the COMFORT-B did not require stimulation of 
the subject through rousing or suctioning, as did the Hartwig and 
Children’s Hospital of Wisconsin Sedation Scale. In addition it was not 
restricted for use in the neonatal population as was the NPASS. While 
many sedation assessment tools were developed to evaluate a patient’s 
sedation level after general anaesthesia or procedural sedation in 
determining readiness for discharge (University of Michigan Sedation 
Scale, Vancouver Sedative Recovery Scale), the scope of an 
assessment tool in PICU goes beyond this function to encompass 
evaluation of patient distress. While research by Razmus et al. (2003) 
and Wielenga et al. (2004) has determined that the COMFORT-B tool is 
indeed capable of determining if a child was optimally sedated; the 
original remit of this tool was to measure distress in PICU patients.  
 
The Oxford English Dictionary (1989) defines distress as mental 
suffering, e.g. that caused by grief, anxiety or unhappiness. There is no 
mention of pain which is often synonymous with “tissue damage, actual 
or potential” (IASP). Stressors in the PICU include endotracheal suction 
and ventilator asynchrony (Wielenga et al. 2004). While clinically; 
distress has been defined by Ambuel et al. (1992) as behaviours of 
negative effect associated with pain, anxiety and fear. Ambuel et al. 
(1992) adds that distress can occur in the absence of pain and often 
occurs in PICU patients where signs of acute pain are aggressively 
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managed. The overlap between pain and distress is evident, and the 
most rational approach according to Ceelie et al. (2008) is careful 
observation of the effects of pain reducing or distress reducing 
interventions and consideration of other factors contributing to the level 
of pain and distress of the patient. Refinement and subsequent validation 
of the original COMFORT scale by the Dutch team led to its increased 
utility as a means of measuring pain and distress, but also in 
distinguishing between the two. It was therefore the logical choice as an 
instrument for measuring pain and distress in the PICU patients at the 
study site. 
 
3.4 The COMFORT-B Pain and Distress Assessment Tool 
The COMFORT-B scale (see appendix 7) is a non-intrusive measure of 
behaviour designed to assess distress in PICU patients. The observer 
must consider the intensity of 6 behavioural manifestations over a 2 
minute observation period while not disturbing the patient; alertness, 
agitation, respiratory response (in ventilated patients) crying (in self-
ventilating patients), physical movement, muscle tone and facial tension. 
After the two minute observation period the assessor should lift a non-
instrumented limb to check muscle tone by gently extending the limb and 
assessing resistance to this movement. For each of these items 5 
descriptions rating from 1 to 5 are provided reflecting the increasing 
intensity of the behaviour in question. Summing the ratings of the 6 
behavioural manifestations leads to a score ranging from 6 to 30 (van 
Dijk et al. 2000). Clinical cut-off levels for the COMFORT-B scale have 
been developed (see appendix 8). 
 
3.4.1 ‘COMFORT-B’; Establishing Cut-Off Values  
The original COMFORT scale incorporated the daily adjusted 
physiological variables heart rate and blood pressure. These variables 
are often manipulated artificially in PICU by inotropic and other drugs. 
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Their inclusion in the tool was therefore questioned and it was found 
these two variables had a low interrater agreement (Ambuel et al. 1992). 
Poor correlation between the physiologic and behavioural items of the 
COMFORT scale were identified by van Dijk et al. (2000) and Carnevale 
et al. (2002). A study by Ista et al. (2005) demonstrated an increased 
Cronbach’s alpha (from 0.79 to 0.84) when blood pressure and heart rate 
were excluded during 843 paired observations, confirming a more 
reliable COMFORT score when these items were omitted. The original 8 
item COMFORT scale became a more refined and reliable 6 item scale 
and it became known as COMFORT-B, or the COMFORT Behaviour 
scale, as the physiological items had been removed. However testing of 
this refined version by Ista et al. (2005) revealed a definite ‘grey area’ 
where COMFORT-B scores fell into the range of ≥11 and ≤22; evaluation 
of patient distress could not be based on COMFORT-B scores alone. 
The implications of this finding were that an additional measure was 
required to supplement this score. 
 
Ista et al. (2005) confirm an observation tool alone cannot be relied upon 
to determine pain and anxiety without prior knowledge or expertise. As 
the “gold standard” of verbal self-report is not feasible; the “silver 
standard” of nurses’ clinical judgement is valuable. PICU Nurses are 
experienced in pain assessment and trained to perform the COMFORT 
assessment. They are also uniquely positioned in a 1:1 nurse to patient 
ratio and have an in depth knowledge of their patient and the patient’s 
circumstances. Ista et al. (2005) further acknowledge the nurses’ opinion 
based on time attending to the child, familiarity with their illness and 
circumstances, medication administered, idiosyncratic behaviour, 
synchronisation with ventilation and other PICU aspects of their care 
increases the validity of the opinion of the allocated nurse. Ista et al. 
(2005) therefore endorsed a proxy self report through application of the 
visual analogue scale (VAS). 
60 
 
 
The VAS is a 10cm continuous horizontal line with the anchors ‘no pain’ 
at the left side and ‘extreme pain’ at the right side. In pain research the 
VAS is frequently used as an observational instrument and has been 
found to have good interrater reliability (Varni et al. 1987; Lawrence et al. 
1993). Furthermore the VAS has demonstrated a strong correlation with 
other pain instruments (McGrath et al. 1985; Tarbell et al. 1992). When 
the 10cm horizontal line is not visualised to measure pain; the pain 
intensity rating between 0-10 is referred to as the Numeric Rating Scale, 
or NRS. The nurse is acting as a proxy to report pain based on her 
knowledge of the patient (van Dijk et al. 2000).   
 
The target range for COMFORT was 17-26 in the original scale with 8 
items, this required revision when the physiological variables of heart 
rate and blood pressure were removed and VAS added. Much research 
was undertaken by Ista et al. (2005) in developing cut-off points for 
COMFORT-B. In their study in 29 of 843 of all patient observations; the 
risk of undersedation was 95% when COMFORT-B scores were ≥23 and 
the risk of undersedation was 0% with a COMFORT-B score of ≤10, 
while if the COMFORT-B score ranged between 11-22; patients were 
only considered under or over-sedated in 15.4% and 0.4% of 
observations respectively. It is now universally agreed that a COMFORT-
B score of ≤ 10 is synonymous with oversedation (Ista et al. 2005; Ceelie 
et al. 2008), and an upper cut-off score of 17 for COMFORT-B indicating 
pain or distress is well supported in the literature (van Dijk et al. 2000; 
Caljouw et al. 2007; Johansson et al. 2009; Valkenburg et al. 2012a).    
 
A COMFORT-B score of ≥17 is highly significant indicating patient 
distress. To distinguish whether the source of distress is pain or 
sedation;  administration of the VAS is required. A COMFORT-B score of 
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≥17 accompanied by a VAS score <4 indicates pain is not the source of 
distress; anxiety, hunger and separation anxiety should be investigated. 
A COMFORT-B score ≥ 17 coinciding with a VAS ≥4 indicates pain, and 
interventions such as analgesia, comfort measures or non-
pharmacological methods of pain relief, if appropriate, must be 
implemented. The treatment algorithm developed by the Analgesia and 
Sedation Committee (see appendix 9) demonstrates the application of 
these cut-off scores in the study site. Extensive work on validating the 
COMFORT-B scale its refined form has been undertaken by van Dijk et 
al. (2000); the tool in its current format (see appendix 7) is what is 
predominantly used in clinical practice. 
 
3.4.2 Validity and Reliability of COMFORT-B 
The reliability and validity of the COMFORT-B scale as a post-operative 
pain instrument for 158 children aged 0-3 years was investigated by van 
Dijk et al. (2000). COMFORT-B variables displayed good interrater 
reliability (Kappa 0.63-0.93) with the exception of the item “Respiratory 
response” which was moderate (Kappa 0.54). COMFORT-B has been 
validated in all patients undergoing mechanical ventilation (Ambuel et al. 
1992; van Dijk et al. 2000). Self ventilating children over the age of 3 in 
many cases will be able to verbalise their pain. The scale has criterion 
validity (r =0.75), and good internal consistency (r =0.84) (de Jonghe et 
al. 2000). Bair et al. (2000) concluded COMFORT-B data displayed good 
consistency obtaining a Cronbach coefficient of 0.85, while t-test analysis 
confirmed no significant differences between scores obtained by staff 
nurses compared with an expert. In addition Marx et al. (1994) reported 
less interrater variability between measurements using the COMFORT-B 
scale than between physicians’ subjective assessments.  
Caljouw et al. (2007) evaluated COMFORT-B in premature neonates in a 
NICU before and after painful heel stick tests and capillary blood 
sampling. No significant correlation was found between gestational age 
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and COMFORT-B and VAS scores. Furthermore COMFORT-B was 
found to have good interrater agreement and to be a valid and reliable 
instrument to measure distress in premature neonates from 28 weeks 
gestation. Sensitivity to change was calculated at a satisfactory 93%. 
Good correlation between COMFORT-B and VAS scores indicated 
accurate assessment of distress in this patient group using these 
instruments.  
 
A study assessing the clinometric properties and diagnostic quality of 
COMFORT-B in 19 ventilated premature infants by Wielenga et al. 
(2004) found the tool had excellent criterion validity (Pearson’s r =0.84), 
very good inter observer reliability (weighted kappa =0.84) and the 
weighted kappa of each item was very good (mean >0.64). The 
diagnostic quality of the COMFORT-B score was found to be excellent, 
further supporting its validity and reliability in assessing distress in 
ventilated prematurely born babies.  
 
Concern for using this tool in the T21 (Trisomy 21 or Down’s Syndrome) 
population centred around reports that these children have a weaker 
muscle tone (Weijerman et al. 2010) thereby influencing response to the 
item “muscle tone” in the COMFORT-B tool. In addition, Lind et al. (1970) 
observed that children with T21 have a low pitched, hoarse cry, which 
could contribute to inaccuracy in assessing the variable “cry” in this tool. 
Valkenburg et al. (2011) undertook testing of COMFORT-B in 0-3 year 
old children with T21in a level III PICU at a University Hospital. Recorded 
COMFORT-B scores from a defined time period were retrieved from the 
PICU clinical data management system. Twenty six patients with T21 
and 466 without T21 were included. Findings indicated no significant 
difference in mean COMFORT-B scores between the two groups. 
Psychometric properties of the scale were comparable between patients 
with and without T21. As COMFORT-B evaluates the intensity of the item 
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‘crying’ and not its characteristics, the hoarseness of the cry did not 
affect the accuracy of the score. In addition, the mean item score for 
‘muscle tone’ was lower in the T21 group (0.21). This small but not 
significant difference was possibly due to many assessing nurses 
anticipating hypotonia when assessing muscle tone in children withT21. 
The validity of COMFORT-B in children with T21 was of great importance 
in the study site PICU as up to 10% of the patient population had this 
syndrome.   
 
3.4.3 COMFORT-B and BIS 
BIS (bispectral index monitoring) is a processed electroencephalographic 
parameter which non-intrusively measures depth of sedation in PICU 
patients using probes placed on the patients’ forehead. Several studies 
have compared BIS and COMFORT-B to determine sedation levels in 
PICU patients with varying results. Froom et al. (2008) used an 
observational study with 19 intubated and sedated PICU patients 
undergoing physiotherapy and tracheal suction. Correlation between BIS 
and COMFORT-B was highly significant (p<0.001) during light and 
moderate sedation. Similar results were obtained from a prospective 
observational trial by Triltsch et al. (2005). 40 PICU patients were 
studied, and results indicated good correlation (Spearman’s rho 0.651, 
p= 0.001) between BIS and COMFORT-B. While evidence of moderate 
correlation was established by Courtman et al. (2003); BIS was not found 
to discriminate between deep and very deep levels of sedation in their 
study of 43 PICU patients. This evidence of moderate correlation is 
supported by Crain et al. (2002).  Conversely, research findings from 
Amigoni et al. (2012) confirmed a weak correlation between COMFORT-
B and BIS in a study containing 46 subjects. Additionally; a prospective 
study by Twite et al. (2005) found that as both indices measured different 
variables; correlation was not significant. As COMFORT-B is not 
validated in patients receiving neuromuscular blockade; BIS was found to 
be a reliable objective monitor for assessing sedation in these patients. 
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However, the use of neuromuscular blockade infusions is not 
commonplace in the study setting; therefore use of BIS for this purpose 
was rarely required. In addition; as light sedation is commonly the goal in 
PICU, evidence of the reliability of COMFORT-B at this level of sedation 
was important. 
 
3.4.4 Achieving Competence in Using COMFORT-B 
All PICU nurses and doctors required training to use COMFORT-B by 
using both videotaped instruction and by performing 10 bedside 
assessments with an “expert”. Scores were recorded and Cohen’s kappa 
calculated. This coefficient corrects for chance agreement (Fleiss et al. 
1969). When the linearly weighted Cohen’s Kappa was satisfactory 
(>0.65) then competency in using COMFORT-B was confirmed.  
 
Using COMFORT-B in clinical practice was in line with best practice as 
the American Academy of Paediatrics (2000) advocate the ongoing 
assessment of the presence and severity of pain as well as the child’s 
response to treatment of pain as essential for adequate pain 
management. The presence of a treatment algorithm which allowed for 
re-assessment and re-evaluation is strongly endorsed. The algorithm 
developed to manage distress in the PICU at the study site is contained 
in appendix 9. 
 
3.5 The Limitations/Criticisms of COMFORT-B 
While it is acknowledged that in isolation, physiological indicators do not 
constitute a valid clinical pain measure for children, Franck et al. (2000) 
and von Von Baeyer and Spagrud (2007) argue that a multidimensional 
or composite measure that incorporates physiological or behavioural 
indicators, as well as self-report is preferred whenever possible. 
However, in an environment where self-report is not feasible and 
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physiological variables are manipulated artificially, such arguments 
become moot points.  In addition criticisms of COMFORT-B citing a lack 
of reliability due to the inclusion of the physiological items heart rate and 
blood pressure (Popernack et al. 2004; Baeyer and Spagrud 2007) have 
little relevance since these items were omitted and subsequent reliability 
testing successfully completed. 
 
Ramelet et al. (2004) cited a major limitation of this tool was its failure to 
differentiate between pain and sedation. It can be argued that the 
addition of the VAS (Visual Analogue Scale) allows differentiation 
between pain and other sources of distress such as anxiety. Valkenburg 
et al. (2012b) confirms the combined use of COMFORT-B with a 
Numerical Rating Scale (NRS) or VAS which refers to pain score applied 
by proxy raters, serves to differentiate between pain and distress. For 
example a high COMFORT-B score coinciding with a low VAS indicating 
the child requires sedation rather than analgesia. Conversely when both 
COMFORT-B scores and VAS scores are high- pain is indicated. 
 
Despite being strong advocates of this assessment tool; Ista et al. (2005) 
acknowledge the COMFORT-B scale as a single measure of patient 
sedation has its drawbacks. It limits observation of distress to a single 
point in time, where prior knowledge of the patient may not be included. 
This stance was reinforced by an observation study by Grap et al. (2006) 
where 20 children aged 1 month to 14 years were observed for a 2 hour 
period. It was found that COMFORT-B did not detect subtle changes in a 
state that may have reflected less than optimal levels of sedation. These 
researchers reason that until more definitive measures are developed, 
use of a combination of measures may provide the most effective means 
of ensuring safe outcomes. In reality; as long as there is an absence of 
methods to assess distress as a continuous variable, the use of a scale 
such as COMFORT-B in the PICU remains necessary. 
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The administration time of the COMFORT-B tool is 2 minutes, and there 
is a 2 hour training period required in order to become proficient in its 
use. These factors contributed to a rating by Twycross et al. (2009) of 
low to medium clinical utility. Research by Boerlage et al. (2012) 
confirmed that an administration time of less than the recommended time 
of 2 minutes resulted in consistent underestimation of children’s pain. 
Investing the time to carefully observe the child for 2 minutes may pay 
dividends in more accurate assessment and management of their 
distress leading to improved outcomes. 
 
The COMFORT-B scale is not validated for children with severe 
developmental delay, neither is it suitable for use in children with severe 
hypotonia as muscle tone is assessed in the scale (Twycross et al. 
2009). Children receiving neuromuscular blockade by infusion will be 
unable to display any behavioural signs where movement is assessed; 
therefore COMFORT-B cannot be used in these patients.  
 
While within the hospital setting it may be necessary to employ more 
than one pain assessment tool to address all patient groups. It is 
advocated by Twycross et al. (2009) that each pain assessment tool, 
whenever possible, should use a common metric, so that a pain score of 
5 will mean the same whichever pain assessment tool is being used. 
Such practice serves to facilitate effective communication about each 
child’s pain. The COMFORT-B scale with a score range of 6 to 30 does 
not fulfil this criterion, and as a PICU specific tool; on transfer to the ward 
these distress scores would be incomprehensible to ward staff familiar 
with a pain scale of 0 to 10. Comprehensive patient handover and 
thorough explanation were a means of overcoming this. 
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3.6 Conclusion 
It is well established that use of written guidelines incorporating a 
validated assessment tool for pain management improves both 
assessment and management of pain in neonates and children (Falanga 
et al. 2006; Gharavi et al. 2007). Furthermore, the use of validated tools 
combined with the clinical judgement of trained PICU nurses and 
physicians is vital in improving the management of children’s pain and 
sedation (Voepel-Lewis et al. 2002). The COMFORT-B scale for 
measuring distress in PICU patients fulfils the criteria of a reliable 
instrument validated for use in the majority of the PICU patient 
population. Incorporated with multidisciplinary developed guidelines; we 
hoped to elevate this neglected area of PICU care to universally 
acceptable standards, ensuring children whose journey took them 
through the PICU would meet the best possible pain and sedation care 
available to them. The next chapter will address the development of 
these guidelines incorporating the COMFORT-B scale and implementing 
the changed approach to analgesia and sedation management in the 
PICU. 
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Chapter 4: The Impact of Analgesia and 
Sedation Guidelines in Critical Care 
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4.0 Introduction 
The purpose of this chapter is to provide a systematic account of the 
findings of studies performed to examine the impact of the introduction of 
analgesia and/or sedation protocols in intensive care units. A thorough 
search of the literature enabled presentation of a comprehensive report. 
Sedation and analgesia guidelines have been included in a diversity of 
hospital settings; including the emergency department, MRI and CT 
scanning departments as well as day surgery facilities. For the purposes 
of this review only studies which concerned intensive care units were 
included. Acknowledging the use of analgesia and sedation guidelines 
within the PICU was the focus of this project; the age profile of patients in 
the study setting ranged from premature neonates to 18 year old 
individuals. Therefore adult ICU literature was included as according to 
Playfor et al. (2006); findings from adult literature about the use of 
algorithms and goal-directed therapy have some relevance to the 
paediatric population. Similarly evidence from the neonatal critical care 
discipline was also alluded to, but not exhaustively analysed. 
 
4.1 The Analgesia and Sedation Overlap 
The close relationship between sedation and analgesia has been 
acknowledged in Chapter 2. Anxiety reduces the pain threshold and 
effective pain control can reduce anxiety (Shapiro et al. 2007).  In 
addition, Wildschut et al. (2010) confirm the opioid morphine is more 
likely to be used for its sedative rather than analgesic properties, 
particularly in neonatal ICUs. There is a well recognised difficulty in 
discriminating between the sedative effects of morphine and midazolam. 
Literature concerning sedation and/or analgesia guidelines was therefore 
considered as sedation guidelines may well concern the use of drugs 
used for sedation as well as analgesia. The literature comparing the 
efficacy of one agent with another was not included, as this falls outside 
the remit of this study.  
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4.2 Policies, Guidelines, Protocols and SOPs in Clinical Practice 
The terms “protocols” and “guidelines” although different in meaning, 
appear to be used interchangeably in the literature. The study setting 
used the following definitions for guidelines, protocols, policies and 
standard operating procedures: 
 
4.2.1 A Policy – is a course or principle adopted and proposed by our 
institution which must be adhered to by all staff during their course of 
work. A breach of a policy could lead to disciplinary action. 
 
4.2.2 A Guideline – is a series of documented evidence based actions to 
assist and guide staff of our institution in carrying out care for patients 
and their families. 
 
4.2.3 A Protocol – is a prescribed series of actions to be undertaken when 
carrying out a procedure or treatment for the care of children in our 
institution. A protocol may only be altered on a named patient basis by a 
senior member of the medical and nursing team caring for the child. Any 
changes to the protocol must be clearly documented in the child’s case 
notes. 
4.2.4 A Standard Operating Procedure (SOP) – a written step by step 
process of an action/activity decided by the organisation/department to 
ensure best practice.  
(Nurse Practice Committee, 2011, p.6). 
Because the analgesic and sedative needs of each patient were 
determined in an individual manner; rigid policy could be applied to this 
area of practice. Hence guidelines were the appropriate means of 
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providing support and facilitating decision making in analgesia and 
sedation management. Clinical practice guidelines are further described 
as “systematically developed statements designed to assist practitioner 
and patient decisions about appropriate health care for specific clinical 
circumstances” (Davis et al. 1997 p410). While according to Thomas 
(1999), clinical guidelines should arise from a systematic evaluation of 
the current best evidence and be presented in a manner that makes the 
application of evidence to practice clear.   
 
According to Francke et al. (2008); the greatest benefit to be achieved by 
guidelines is to improve health outcomes by promoting interventions of 
scientifically proven benefit and discouraging ineffective ones. In the past 
the frequency with which procedures were performed varied enormously 
among doctors, specialties and geographical regions, even after casemix 
was controlled for (Chassin et al. 1986). Woolf et al. (1999) argue that 
guidelines can offer consistency of care, so that patients with identical 
problems will be cared for in the same manner regardless of by whom or 
where they are treated. Further benefits of guidelines include the 
elimination of uncertainty in practice, and the provision of authoritative 
recommendations for appropriate treatment (Hewitt-Taylor, 2003). 
Furthermore, quality improvement initiatives can be introduced based on 
evidence based guidelines, which offer a common point of reference for 
prospective or retrospective evaluations of hospital practices (Woolf et al. 
1999). 
 
The most important limitation of guidelines is that the recommendations 
may be incorrect.  The promotion of flawed guidelines can encourage, if 
not institutionalise the delivery of harmful, ineffective or wasteful 
interventions (Woolf et al. 1999). Furthermore, Hewitt-Taylor (2003) 
contends that guidelines present practitioners with a potential tension 
between standardisation of service, client choice and the use of clinical 
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expertise in decision making.  Effective guidelines must be sufficiently 
evidence based and flexible to allow for non-uniform clinical problems. 
Discerning use and a familiarity with the limitations and potential hazards 
of guidelines is endorsed, together with an appreciation that guidelines 
may not result in a significant change in behaviour (Feder et al. 1999). 
The National Institute of Clinical Excellence (NICE) (2003) promotes the 
use of clinical judgement in applying guidelines, to make the most 
appropriate decision in each individual circumstance. Acknowledging 
this, (Hewitt-Taylor, 2003) proposes that following clinical guidelines is 
part of, not the entirety of the provision if high quality patient care. The 
role of analgesia and sedation guidelines as a tool to guide decisions in 
the proposed context was thus justified.   
 
4.3 The Origin of Analgesia and/or Sedation Guidelines  
The impetus for analgesia and sedation guidelines in intensive care 
stemmed from the critical nature of the environment.  The need for 
effective communication from the bedside caregiver to the physician 
usually results in a time delay, while guidelines can potentially reduce 
these delays and ensure that interventions are executed in a 
standardised and efficient manner (Quigley et al. 1997). One of the first 
studies to evaluate systematic and evidenced-based approaches to 
sedation was by Ramsay et al. (1974) in which sedation was titrated to a 
scale, a subset of patients was monitored with electroencephalography, 
sedation medication was interrupted and a relatively light level of 
sedation was targeted. The success of this approach to sedation 
triggered a departure from deep sedation practices due to concerns that 
it prolonged weaning from mechanical ventilation and length of stay in 
intensive care and potentially increased morbidity (Schweickert et al. 
2004; Brook et al. 1999).  
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It is now advocated that analgesics and sedatives are titrated to the 
individual patient’s needs, that a sedation goal or endpoint is established 
and regularly redefined for each patient and validated tools are used to 
regularly assess pain and sedation levels (Jacobi et al. 2002). Playfor et 
al. (2006) further support the use of guidelines or algorithms to facilitate 
the titration of pharmacological interventions to targeted sedation goals. 
Research in managing sedation and analgesia in the adult intensive care 
setting has led to best practice standards enhancing patient care (Jacobi 
et al. 2002; Chanques et al. 2006; Mehta et al. 2006). However similar 
research in the paediatric setting has proved more challenging.  
 
Notwithstanding that there are no differences in the selection of available 
agents for analgesia and sedation in adult and paediatric intensive care 
units (Nolent et al. 2008); the pharmacokinetics and pharmacodynamics 
of analgesics and sedatives for adults and children are different (Berde et 
al. 2002). First line agents for analgesia and sedation in adult settings 
may therefore not be used widely in PICU. The most notable example of 
this perhaps relates to the anaesthetic agent propofol. Although widely 
used in adult settings; incidence of ‘propofol infusion syndrome’ is 
reported where ventilated children receiving this anaesthetic agent 
experienced serious adverse effects. In addition there is concern that γ-
aminobutyric agonists and/or N-methyl-D-aspartate antagonists 
administered during synaptogenesis may adversely affect cerebral 
development (Jevtovic-Todorovic et al. 2003). Similar findings by Mellon 
et al. (2007) and Rappaport et al. (2011) continue to emerge.  
 
Such occurrences have highlighted the importance of paediatric specific 
data on the safety of drugs in critically ill children (Bray 1999), and 
deterred indiscriminate extrapolation of adult derived evidence to 
paediatric populations. Similarly; engaging in practices such as “drug 
holidays” are not broadly endorsed in PICU due to fears of self-
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extubation. However, the growing body of evidence endorsing a 
structured approach to sedation and/or analgesia management in adult 
intensive care settings cannot be overlooked (Jackson et al. 2010). This 
research required careful evaluation if effective changes in the approach 
to analgesia and sedation in the PICU setting were to be made.  
 
4.4 Impact of Sedation and Analgesia Guidelines in Adult ICUs 
The studies addressing the impact of sedation and analgesia guidelines 
in adult intensive care units will now be considered. The Cinahl, Medline 
and Embase online literature databases were searched. English 
language studies done in the last 15 years in the ICU setting which 
reported the impact of sedation practice on patient outcomes and 
resource cost were considered. Research studies comparing specified 
analgesic or sedative agents were not assessed. The keywords used 
were ‘sedation’, ‘analgesia’, ‘pain’, ‘anxiety’, ‘distress’, ‘guidelines’, 
‘protocols’, ‘intensive care’, ‘critical care’, ‘PICU’, ‘adult ICU’, ‘NICU’, 
‘paediatric’, ‘neonatal’. Study aim, design and methodology as well as 
population size were extracted, and findings including duration of 
mechanical ventilation, ICU and hospital stay and also costs and 
mortality were reported. Appendix 10 contains a synopsis of studies 
examining the impact of analgesia and sedation guidelines in paediatric 
settings, appendix 11 considers the impact of such interventions in adult 
ICU settings, while appendix 12 relates to studies examining sedation 
interruption in critical care. 
 
4.4.1 Methodologies of Studies Undertaken in Adult ICUs  
There was some variation in the design, patient populations and aims of 
studies assessing the impact of a structured approach to analgesia 
and/or sedation management in adult ICUs. However researchers 
predominantly used the before/after method. Using this technique; 
specific patient data were collected from before the introduction of the 
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changed approach to analgesia and sedation management – in most 
cases in a retrospective manner.  This was compared with data collected 
once the new approach was in place. The impact of the intervention was 
then determined by comparison. While the protocols and guidelines 
themselves differed in each study; the manner in which the structured 
approaches were implemented were also different i.e. nurse driven 
(Brook et al. 1999; Quenot et al. 2007; Arias-Rivera et al. 2008) versus 
pharmacist driven (Devlin et al. 1997; Marshall et al. 2008).  
 
The outcome measures used also varied; while the majority of studies 
reviewed used the effect of the intervention on the duration of patient 
mechanical ventilation (10 studies out of 16), some focussed on the 
impact on drug costs (Mascia et al. 2000), while others sought to 
determine the effect on patient’s pain and/or distress levels (MacLaren et 
al. 2000). Adherence to guidelines was the focus of three studies (Bair et 
al. 2000; Elliott et al. 2006; Hoffman et al. 2008). In some cases RCTs 
were the chosen methodology (Brook et al. 1999; Bucknall et al. 2008), 
while observation studies were also a methodology used (Brattebo et al. 
2002; Jakob et al. 2007). The impact of multiple quality improvement 
protocols including ventilation weaning protocols were addressed in two 
studies (Afessa et al. 2007; Jakob et al. 2007); a major limitation 
associated with this strategy was identifying which intervention was 
responsible for changes in outcome measure.  
  
4.4.2 Critical Analysis of Findings from Adult ICU Studies 
Where duration of ventilation, length of ICU and hospital stay were used 
as outcome measures; 11 researchers (Brook et al. 1999; Mascia et al. 
2000; Brattebo et al. 2002; De Jonghe et al. 2005; Chanques et al. 2006; 
Arabi et al. 2007; Jakob et al. 2007; Quenot et al. 2007; Hoffman et al. 
2008; Marshall et al. 2008; Robinson et al. 2008) noted a significant 
reduction in these dependent variables after the intervention. A reduction 
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in tracheostomy rate was also detected after protocol introduction (Brook 
et al. 1999; Arabi et al. 2007), and a decrease in mortality after protocol 
introduction was reported in 2 studies (Brattebo et al. 2002; Jakob et al. 
2007). A reduction in drug costs post protocol introduction was reported 
in 5 cases (Devlin et al. 1997; Gupta et al. 1999; Mascia et al. 2000; 
Adam et al. 2008; Robinson et al. 2008).  
 
Arias-Rivera et al. (2008) revealed that their baseline practice of sedation 
had been inadequate; after the changed approach patients were more 
awake and had increased likelihood of successful extubation. An 
increase in successful extubations post protocol implementation was also 
reported by Quenot et al. (2007). Additionally a decrease in the incidence 
of ventilator associated pneumonia in patients treated according to a 
sedation algorithm was identified by two researchers (De Jonghe et al. 
2005; Chanques et al. 2006), while De Jonghe et al. (2005) further 
identified a decrease in the number of pressure sores after protocol 
implementation.  
 
In contrast to these reported patient benefits associated with introducing 
a structured approach to analgesia and/or sedation management in adult 
ICUs; MacLaren (2000) found patients had a longer duration of sedation 
and had a more extended dependence on mechanical ventilation after 
protocol based sedation and analgesia was introduced. The patients 
studied had less discomfort and lower hourly sedation costs, however the 
financial savings made on hourly drug costs were likely to have been 
negated by longer duration of ventilation and exposure to the associated 
risks of this such as ventilator associated pneumonia. A blinded RCT 
carried out by Bennett (2008) in a single study setting compared usual 
sedation practice to protocolised sedation where specified medications 
were administered to achieve a Sedation Agitation Scale (SAS) target. 
The results indicated that the sedation protocol and usual care groups 
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did not differ for mortality or duration of mechanical ventilation and ICU 
stay.  
 
Similarly Arias-Rivera (2008) revealed that a nurse-driven sedation 
protocol had no impact on the duration of mechanical ventilation, nor was 
there any impact on the total doses of analgesics and sedatives 
administered. However the probability of successful extubation was 
higher in the protocolised group and patients were more awake with no 
significant difference in nursing workload. Similarly Devlin et al. (1997) 
demonstrated that ICU sedation guidelines and pharmacist interventions 
resulted in no difference in ventilator weaning time, although the pre and 
post-intervention groups were not appropriately matched in terms of 
acuity- reported mean APACHE (Acute Patient and Chronic Health 
Evaluation) scores. The mean APACHE scores in post-intervention 
patients were significantly higher indicating this group were likely to be 
more acutely ill and had a lower probability of survival. Similar findings 
were reported by Duane et al. (2002) who investigated the impact of 
weaning and sedation protocols on self-extubation rates, duration of 
ventilator dependence and length of stay in a trauma ICU. No difference 
was found in these main outcome measures; this finding was attributed 
to the possibility of difficulties inherent in the protocols or their utilisation.  
 
The findings of a monosite RCT by Bucknall et al. (2008) provided no 
evidence of a reduction in the duration of mechanical ventilation or ICU 
and hospital length of stay after the introduction of protocolised sedation. 
The incidence of unplanned extubations and tracheostomies were 
unchanged, while there was a 22% decrease in successful weaning from 
mechanical ventilation in the protocolised group. This study involved 
protocol and control group subjects being cared for concurrently in the 
same study setting. Data contamination may therefore have been a 
possibility. An acknowledged limitation of the study was that it was 
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unblinded; non-compliance with the protocol was cited as a threat to the 
integrity of the research findings. While evidence of an association 
between choice of agent used for sedation and duration of mechanical 
ventilation was established; the median dose rate of propofol was 
somewhat lower in the protocol compared with the control group, and 
greater use of propofol was independently associated on multivariate 
analysis with a shorter duration of mechanical ventilation.  
 
The acknowledgement of possible noncompliance with the research 
protocol calls into question the overarching key findings of Bucknall et 
al.’s (2008) study. Furthermore, propofol use was found to be 
synonymous with shorter ventilation times. Had this drug been included 
in the sedation guidelines used with the protocolised patients, one has to 
question whether the study findings would be significantly different. 
Finally, the author does not acknowledge the possibility that through 
raising awareness of sedation and ventilatory weaning among all staff, 
data contamination was inadvertently occurring. Had a division of staff 
been possible where half of the staff would only care for protocolised 
patients and the other half only care for patients in the traditional non-
protocolised way and receive no education on the protocol, a truer 
picture may well have emerged.   
 
Bucknall et al. (2008) highlighted the dissimilarities between North 
American and Australian ICUs. For example, Australian ICU nurses, in 
consultation with medical staff, routinely and frequently assessed, titrated 
and weaned mechanical ventilation and sedation and analgesic 
requirements without the input of a respiratory therapist. Ventilatory 
weaning in Australia was mainly individualised and not protocol directed, 
while patients receiving mechanical ventilation were cared for in a 1:1 
ratio by a registered nurse. Respiratory therapists did not exist, and 
Australian ICU nurses managed both the ventilation and sedation of a 
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single patient in consultation with the ICU medical staff. This 
arrangement may decrease the number of people involved expediting the 
decision making process. Such an arrangement also existed in the study 
site, although the study design in determining the impact of sedation and 
analgesia guidelines in the study site was vastly different to that of 
Bucknall et al.’s (2008) RCT and the retrospective before/after approach 
used in this study. Such methodological differences may have resulted in 
significantly diverse research outcomes.  
 
A possible limitation of studies such as those described is that most have 
been carried out in a single ICU thereby limiting the generalisabilty of 
their findings. Ibrahim et al. (2001) point out that many of these studies 
were not blinded, introducing the potential for bias on the part of the 
treating clinicians to alter their practices. There are acknowledged 
challenges associated with blinding in such studies, particularly if there is 
only one study site involved. In addition, outcome measures ofen focus 
on length of stay and medical care costs, while other clinically relevant 
outcomes such as the occurence of unplanned extubation, nosocomial 
pneumonia, and subsequent patient functional status also need to be 
evaluated to assess the overall effect of sedation protocols on 
mechanically ventilated patients. Lastly, many of the studies mentioned 
do not measure the level of compliance of critical care staff with the 
protocols being examined. Therefore it was difficult to determine the level 
of compliance necessary to achieve the desired clinical outcomes 
described in these investigations. Cognisance that the implementation of 
the guidelines themselves may have impacted the weaning time and 
amount of drugs administered in the post guideline group through the 
Hawthorne effect was vital (Streiner et al. 1989). 
 
In summary, evidence supporting the use of analgesia and sedation 
protocols vastly outweighted that against their use in adult ICUs. There 
80 
 
was evidence of acceptance of their use clinically by healthcare 
professionals (Mehta et al. 2006). It was also important to consider the 
use of analgesia and sedation guidelines in neonatal ICUs.  
 
4.5 The Neonatal Perspective 
The studies of Anand et al. (1985, 1987, 1992) have provided evidence 
that neonates have the neurological capacity to perceive pain and are 
more sensitive to pain than older infants and adults.  Despite the 
increasing number of instruments being developed for pain assessment 
in neonates, guidelines for managing analgesia and sedation in the NICU 
are not widely available (van Dijk et al. 2004). This was confirmed by 
McKechnie et al. (2008) who undertook a postal audit of UK NICUs.  A 
79% response rate was achieved (192 responded from 244 units 
targeted). Most NICUs (≥70%), reported the existence of guidelines for 
elective intubation, sedation for ventilation and post-operative pain where 
appropriate. Less prevalent were guidelines for painful minor procedures 
(35%). These findings represent only a modest improvement since these 
researchers originally undertook the survey in 2000.  
 
This is of huge concern given that Simons et al.’s (2001) prospective 
study of procedural pain and analgesia in neonates showed that despite 
critically ill neonates undergoing 2-14 invasive procedures per day, less 
than one third received analgesic therapy. Worryingly the younger these 
neonates were in terms of gestational age; the increased number of 
invasive procedures they underwent. There are increasing concerns for 
the long-term and possibly permanent effects of pain on the immature 
brain. Evidence shows that recurrent pain in infancy alters the 
behavioural responses to pain in adulthood (Anand, 2000). The adequate 
treatment of pain in early life is fundamental in preventing this cascade of 
events. Of major significance was whether analgesia and sedation 
guidelines might be a means of facilitating this.  
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In summary; Ista et al. (2009a) confirmed that the effects of the 
implementation of analgesia and sedation guidelines in adult ICU 
settings was different to paediatric settings and was therefore not 
generalisable to this area of practice. There remains a dearth of reliable 
evidence from NICU settings. Therefore the current knowledge status 
regarding a structured approach to analgesia and/or sedation in PICU 
will be addressed. 
 
4.6 Analgesia and/or Sedation Guidelines in PICUs 
It is acknowledged that the evidence on PICU outcomes regarding the 
use of analgesia and sedation guidelines is lacking (Statler et al. 2004). 
A number of surveys have been undertaken internationally to establish 
the status of analgesia and sedation practices. In their US National 
survey in 2002, Rhoney et al. verified that only 13.4% of 145 paediatric 
institutions reported using written protocols for sedatives. It was then 
acknowledged that development and implementation of protocols for the 
selection, use and monitoring of sedatives and neuromuscular blocking 
agents to provide safe and cost-effective therapy to critically ill PICU 
patients was a priority. Two years later (Twite et al. 2004) confirmed 
progress in this area; of 35 US centres responding to an analgesia and 
sedation use survey, two thirds reported using written sedation protocols.  
 
In Australia and New Zealand, Long et al. (2004) determined that only 4 
out of a total of 8 PICUs had written guidelines for sedation mangement, 
and a quarter (n=2) used designated tools for sedation and withdrawal 
assessment.  While a survey of 19 Italian PICUs by Benini et al. (2010) 
revealed that although the majority of PICUs claimed to possess a 
protocol for dealing with sedation and analgesia; in reality this protocol 
was implemented with difficulty or not at all in routine clinical practice. In 
the UK it was revealed by Jenkins et al. (2007) that as little as 45% of 
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units possessed sedation guidelines for critically ill children. While a 
more recent audit of sedation and analgesia practices in the UK and 
Ireland prompted by the Paediatric Intensive Care Society (PICS) nursing 
subgroup on analgesia and sedation presented a better picture with 60% 
(n=22) of contributing PICUs possessing such guidelines (Harris et al. 
2011).   
 
It was therefore worth investigating the current status of literature in 
relation to the impact of a structured approach to analgesia and/or 
sedation management in PICUs. Although there was a dearth of such 
literature compared to adult ICUs; all available evidence was included 
that related to this topic. Twycross et al. (2009) advocated developing 
and using algorithms to facilitate the administration of regular multi-modal 
analgesia in paediatric patients. Such an initiative was evaluated by 
Falanga et al. (2006) in a paediatric ward to support decision making 
related to the administration of analgesia. When the algorithm was used, 
children received more analgesia and had lower pain intensity scores. 
 
Paediatric ward settings aside; an analysis of sedation guidelines using a 
pre-test post-test intervention study was performed in convenience 
samples of PICU patients by Ista et al. (2009a). Administered sedatives 
and analgesics were documented before (n=27) and after (n=29) 
implementation of a sedation protocol incorporating a tool to assess 
distress in children.  Findings indicated that although infants in the post-
test period received significantly more morphine and midazolam, the 
proportion of patients adequately sedated had increased from 63% in the 
pre-test to 72% in the post-test and 75% in the long run. Although the 
majority of staff considered the sedation protocol comprehensible and 
useful, the researchers claimed insufficient evidence to surmise whether 
implementation of a sedation treatment protocol indeed improved 
sedation treatment for this population.  
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A similar study by Jin et al. (2007) evaluated the efficacy of a distress 
scale in assessing sedation in mechanically ventilated patients in a 22 
bedded Korean PICU. A total of 21 patients were prospectively selected 
to assess the impact of a newly introduced sedation protocol which 
incorporated a validated distress scale. This group was compared to a 
retrospectively selected pre-protocol sample of 20 patients who served 
as the control group. Findings suggested the use of protocol-directed 
sedation incorporating the distress scale was associated with significant 
decreases in the mean duration of mechanical ventilation in the 
intervention group compared to the control group (12.5 vs 11.0 days, 
p=0.04), the protocol was also synonymous with a reduction in the 
median length of PICU stay. The duration of sedation tended to be lower 
in the intervention group than in the control group (8.0 days vs 11.5 days, 
p=0.053). In addition the overall incidence of withdrawal symptoms was 
significantly lower in the intervention than in the control group (1 vs 7 
patients, p=0.02).  
 
Notwithstanding the validity of these findings, two key issues emerged 
from Jin et al.’s (2007) study. There were significant differences in unit 
practices in this research setting as demonstrated by use of continuous 
neuromuscular blockade agent (NMBA) infusions for 9 patients in the 
intervention group and 8 patients in the control group. Such a divergence 
in practice brought into question the generalisability of the findings to 
PICUs where NMBA infusions are not administered to patients. 
Furthermore, the distress scale used in this study has not been validated 
for children receiving NMBAs (Ista et al. 2005). In addition, the authors 
cited adjusting infusion rates of sedatives to attain an “optimal score of 
between 17 and 26 points”, but did provide justification of how these cut-
off points were arrived at.  
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A study by Alexander et al. (2002) evaluated a sedation protocol as a 
means of providing safe and effective sedation in a Canadian PICU. The 
study population comprised 10 patients admitted to the PICU during a 
five month period. Using retrospective chart review, time intervals when 
patients were on the sedation protocol were compared with clinically 
comparable time intervals in terms of clinical acuity, when the same 
patient received conventional management. The sedation protocol used 
incorporated a scale to evaluate patient distress, and a standard 
prescription that allowed adjustment of analgesic and sedative dosages 
to maintain a specified target level of comfort.  
 
In parallel with the study by Ista et al. (2009a), analysis of Alexander et 
al.’s (2002) findings revealed that patients received more sedation while 
on the sedation protocol. Interestingly, the periods when patients were on 
the sedation protocol were characterised by a moderate number of 
incidents of under-sedation, while severe under-sedation incidents were 
more likely to occur when the patient was off the protocol. These 
researchers evaluated staff opinion on the use of the protocol. There was 
general consensus among nurses that the use of the sedation protocol 
facilitated more effective management of patient comfort and more 
efficient and rapid intervention. The medical staff responded favourably 
to the questions relating to the protocol, alluding to more effective and 
efficient patient management.  
 
However, the small study population, together with retrospective data 
collection and purposive sampling strategy incorporating the risk of 
selection bias, served to view the findings of this research with great 
caution. In addition, the same patients were used in the control as well as 
in the intervention group. This represented a major design flaw as 
bedside nurses may have been influenced by awareness of the protocol, 
and data contamination may have resulted. The authors acknowledged 
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the limitations imposed by the study design and proposed a prospective 
study using a control group and a protocolised group, employing a larger, 
more representative sample to enable a more controlled evaluation of the 
study variables and enhance the generalisability of its findings.      
 
A US study by Popernack et al. (2004) examined whether the 
incorporation of a standardised algorithm of goal-directed sedation 
impacted the incidence of unplanned extubations in a PICU. The Penn 
State Children’s Hospital Sedation Algorithm (PSCHSA) was developed, 
incorporating six levels of sedation, each level focussing on target goals 
for objective patient behaviours. Every ventilated PICU patient was 
required to have a written physician order for a sedation level goal and 
the appropriate medications written to allow the bedside nurse to achieve 
that goal as part of formal hospital policy. Unplanned extubation rates 
were subsequently tracked for five years following adoption of this policy. 
Comparisons were made between the pre-PSCHSA and post-PSCHSA 
data.  
 
Unplanned extubations rates pre-PSCHSA ranged between 0.44 and 
0.63 per 100 intubated patient days. In the 4 years after mandatory use 
of the PSCHSA, rates of unplanned extubation were between 0 and 0.19 
(p<0.01) demonstrating a statistically significant decrease. The findings 
of this study must be viewed in light of its protracted duration, 
encompassing a ten year period prior to PSCHSA introduction and 5 
years after its implementation. It was therefore impossible to deduce 
whether improvements in standards of care and increased vigilance 
around endotracheal tube safety were responsible for the decrease in 
unplanned extubations. In addressing potential claims that oversedation 
of patients may have been responsible for a fall in unplanned extubation 
rate, Popernack et al. (2004) countered that if this were the case length 
of PICU stay would have been longer post PSCHSA introduction. In fact, 
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no statistical difference was found in length of stay before and after 
introduction of this algorithm. Again, improvements in PICU care could 
not be out ruled as justification for PICU stay not being prolonged. 
Finally, both pre and post-PSCHSA patient groups were not matched in 
terms of demographics, diagnosis and severity of illness by inclusion of a 
severity of illness score such as PRISM (Paediatric Risk of Mortality) or 
PIM (Paediatric Index of Mortality).     
 
4.7 Conclusion 
A comprehensive account of literature alluding to the impact of a 
strategic approach to analgesia and sedation management in ICU; both 
adult and paediatric settings, has been presented. A dearth of research 
into the impact of such an approach in the neonatal setting has been 
highlighted. On balance, the burden of evidence supported the 
implementation of multidisciplinary guidelines to guide the management 
of analgesia and sedation in ICU. The patient benefits were many and 
included a reduction in the duration of ventilator dependence, a 
shortened ICU and hospital stay, significant savings in drug costs and a 
decreased incidence in the requirement for tracheostomy and in the 
development of ventilator associated pneumonia and even pressure 
sores. Improved pain control and less oversedation as well as reduced 
incidence of delirium and withdrawal syndromes were cited as outcomes 
of a changed approach to analgesia and sedation management. Such 
humanitarian, financial and resource benefits could not be ignored.  
 
The evidence from paediatric settings was at best inconclusive and 
limited, and at worst contradictory. It therefore rested with individual units 
to determine whether such a change in their routine enhanced practice 
and outcomes. The extrapolation of evidence from the adult settings and 
assumption of similar results in the paediatric setting was simply not 
appropriate. The limitations of RCTs in providing the answers to these 
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questions were identified. It was therefore crucial to determine by means 
of a well designed before/after study whether the implementation of 
nurse-driven evidence based multidisciplinary guidelines to manage 
analgesia and sedation in an Irish PICU would result in reduced amounts 
of analgesics and sedatives administered, a shortened dependence on 
mechanical ventilation and a decreased length of PICU and hospital stay. 
Adherence to the guidelines would be measured as would attitudes of 
PICU nurses and doctors before and after guideline introduction to gain 
an appreciation of the receptiveness and satisfaction with the changed 
approach. 
 
The next chapter will present the process undertaken to implement a 
changed approach to analgesia and sedation management in the PICU. 
The process of changing practice using an established change 
management model will be examined.   
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Chapter 5: Changing Clinical Practice in Managing 
Analgesia and Sedation in the PICU 
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5.0 Introduction 
In its Scope of Nursing and Midwifery Practice, The Irish Nursing and Midwifery 
Board as the regulating body for nursing states that nurses and midwives ‘must 
deliver care based on the best available evidence’ (ABA, 2000, p1). 
Furthermore, nurses are urged to respond to the changing needs of the service 
and patients in a ‘dynamic way’, suggesting there is a continuous need to 
update and change practice. Change encompasses numerous variations and 
complexities, and an experience of change can be seen as opportunistic, 
exciting and threatening at the same time. For this reason, it is recommended 
that any attempt to understand and manage change must take this complexity 
into account (Hardiman, 2010). 
 
Various forces drive change in healthcare, including the increasing financial 
constraints, advances in science and the promotion of better patient outcomes. 
Using clinical guidelines to manage analgesia and sedation incorporating 
validated assessment tools to measure pain and distress has been proven to 
significantly improve patient care in adult settings; reducing duration of 
dependence on mechanical ventilation, length of stay in intensive care and 
associated drug costs (Jacobi et al. 2002; Chanques et al. 2006; Mehta et al. 
2006). Studies have confirmed that such an approach offers the bedside nurse 
more autonomy in managing their patient’s condition; minimising the 
inefficiencies contributing to morbidity and the knock on effects including 
prolonged PICU stay and patient care costs (Thomas et al.  2010). Significant 
economic benefits are a well recognised result of effective pain management, 
with Brodner et al. (2000) citing an annual saving of €91,620 after an acute pain 
management service was introduced for post-operative patients (n=6,349) in 
their hospital. In Ireland the health budget provision for 2013 included a cost 
reduction target of €666 million. This presented a major challenge to the Health 
Service Executive and came at a time of significant reform of the public health 
system (HSE, 2013). The timing of this initiative focussing on the quality 
effectiveness of patient analgesia and sedation management therefore occurred 
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during a period where and efficiency in patient care was a major focus of 
attention. 
 
5.1 Changing Practice in the Critical Care Setting 
Despite clinical practice guidelines offering a promising solution for closing the 
gap between research evidence and clinical practice; the implementation of 
guidelines within clinical environments presents a considerable challenge and is 
often inconsistent and fragmented (Grol, 2001). This is consistent with reported 
challenges in organisational settings where 75% of change efforts are reported 
to fail (Kotter, 2007). Such change failures contribute to a delay and reluctance 
in embedding best evidence into practice (Kahn et al. 2005; Schultz et al. 2005). 
Importantly, the setting where change is to occur is hugely relevant to the 
success or otherwise of the change initiative; Murray et al. (1998, p69) describe 
the intensive care unit as a “highly charged” clinical environment where nurses 
day-to-day clinical duties already place considerable demands upon them.    
 
It is reported that staff in intensive care settings are frequently subjected to the 
influence of change as new practices are pioneered in this environment, and 
advances in knowledge in medicine, nursing and technology are at the forefront 
of intensive care practice (Stephenson, 1987). Stephenson, (1987) argues that 
this places a heavy burden on those that are required to provide the service. 
Changes in working practices, in procedures and associated technologies 
ensure that clinical staff in intensive care face a situation where their own role is 
subject to a host of internal and external pressures for change.  Stephenson 
(1987) advises that rather than simply being reactive when change is thrust 
upon an organisation; actively initiating change is a more prudent strategy. 
Adopting a planned approach to change is therefore endorsed. 
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5.2 Choosing a Model of Change 
There were a number of factors to consider when choosing a change model to 
guide this project. The timeline for the intervention was limited. There was 
growing unrest regarding the inconsistencies in analgesia and sedation practice 
among clinical staff, and the Paediatric Intensive Care Society (PICS) had 
strongly advocated the use of a validated distress assessment tool in all PICU 
settings. The writer had embarked on an academic programme with this project 
at its core, and a specific timelines had been developed. In addition the writer 
was a novice to undertaking a change project in a clinical setting.  An 
exploration of some renowned models of change was necessary to underpin 
and inform the decisions made. 
 
The pioneer of planned change is perhaps Kurt Lewin. Lewin (1951) identified 
three stages through which change agents must proceed before change 
becomes part of a system, unfreezing, moving and refreezing. Critics of Lewin’s 
3 stage approach such as Burnes (2004) argued that this model was only 
suitable for small change projects, that it ignored organisational powers and 
politics, and that it assumed organisations operated in stable states. This led 
the way for behavioural approaches to change in organisations (Azjen 1991, 
Prochaska and Di Clemente 1984) which were evident in the 1980’s and early 
1990’s, as were social cognitive theory approaches (Bandura 1988). Emergent 
approaches (Pettigrew 1990) and prescriptive approaches (Kotter 1996) then 
appeared while more recently bottom-up or top-down approaches became 
evident in the literature (Shanley, 2007). Recognition that change often 
occurred in clinical settings as a series of interventions led the Medical 
Research Council to develop a framework for the design and evaluation of 
complex interventions to improve health (Campbell et al. 2000), and similar 
guidance has been published by the Health Service Executive (HSE, 2008).    
 
In selecting the most appropriate model to guide this project, the social 
cognitive and behavioural models were first considered. Although much of the 
92 
 
content of these models including competency development, enhancing self-
motivation and strengthening individuals’ beliefs was viewed as inherently 
valuable; these models were discounted as unfeasible considering the 
intervention involved almost 200 PICU staff with alternating shift patterns.  
Focus shifted to a bottom-up approach, which was rejected as it relied on the 
self-efficacy of staff, and could be subjected to time delays (Shanley, 2007). 
While a top-down approach was not congruent with the non-hierarchical ethos 
of the PICU. Writers from Peters et al. (1982) onwards have argued that 
managers need to abandon top-down, command-and-control styles, that 
organisational structures need to be flatter and more flexible, and that greater 
employee involvement is essential for success (Handy 1989; Kanter 1989 & 
1997; Peters 1989; Kotter 1996; Kanter et al. 1997).  
 
The MRC framework was considered. The process of the development of the 
guideline and its implementation into clinical practice was a central element of 
the project, and bore the hallmarks of a complex intervention. Craig et al. (2000) 
describe complex interventions as those which contain several interacting 
components, where there are a number of groups targeted by the intervention, 
and a number and variability of outcomes are anticipated. The MRC framework 
was originally designed based on the phases of drug development with a “focus 
on randomised designs” (Campbell et al.  2000 p695). The framework has been 
revised to include quasi-experimental and non-experimental designs (Craig et 
al.  2008).  
 
The MRC framework had many appealing attributes, however at its time of 
publication in October 2008, this project was at concept stage and the revised 
MRC framework had not been widely adopted. A paucity of paediatric based 
literature in this area hindered the utilisation of existing evidence and theory, 
and time limitations rendered modelling of process and outcomes; advocated 
when using this model (Craig et al.  2000) unachievable. For these reasons a 
linear, prescriptive model of change which was inclusive and participatory was 
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favoured. Kotter’s model of change was therefore chosen for this project. This 
framework offered a common-sense framework grounded on simple tenets: 
create and communicate a vision and garner organisational support. This 
approach had the required focus of the process of change that the writer had to 
engage. Kotter’s eight step model for successful change is outlined below in 
figure 5.2. 
 
 
Figure 5.2: Kotter’s (1995) Eight Step Model for Successful Change 
  
 
5.3 The Choice of Change Model for this Project 
John Kotter (1995) is recognised as a world renowned expert on 
transformational change. This model of change developed by Kotter was 
successfully used to determine readiness for change in respiratory therapy 
departments by Stoller et al. (2008), while Kinney et al. (1978) highlighted the 
dynamic and highly pressured nature of critical care environments to be an 
appropriate fit for prescriptive models of change. Such evidence reinforced the 
applicability of Kotter’s model of change to this project. The steps within Kotter’s 
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model for successful change have been synthesised into 3 phases; creating a 
climate for change, engaging and enabling the organisation and implementing 
and sustaining the change. See figure 5.3.  
 
Figure 5.3: Kotter’s Eight Step Model for Successful Change (Campbell, 2008) 
 
5.4 Creating a climate for change  
Establishing that change was required was the major first step in the process. 
According to Coghlan et al. (2003) the impetus for initiating change may be 
internal or external. In the case of this research project; both internal and 
external forces were at play. External forces such as a growing body of 
literature endorsing the use of analgesia and sedation guidelines in practice 
could not be ignored. The influential Paediatric Intensive Care Society (PICS), 
whose standards of care for PICU required compliance with, issued consensus 
guidelines on sedation and analgesia in critically ill children to address the 
uncertainty and variability in this area of practice (Playfor et al. 2006). The 
presence of strong internal influences also prompted a review of analgesia and 
sedation practices. The inaugural meeeting of the Analgesia and Sedation 
Committee on 6th April 2010 highlighted the level of disatisfaction with analgesia 
and sedation practice from a nursing and medical perspectice, and this was 
echoed in subsequent committee meetings. PICU staff concerns over the lack 
of consistency in the approach to analgesia and sedation management was 
•Increase urgency 
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change 
•Communicate for buy-in 
•Enable action 
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further confirmed in the SASQ (Staff Analgesia and Sedation Questionnaire) 
survey. This exercise also guaged the readiness and attitudes of the staff 
(Gifford et al.  2006). An account of this research is contained in Chapter 9. In 
addition, the medical director of PICU highlighted that absence of a validated 
tool for measuring distress in our PICU was detrimental to patients, prevented 
inclusion in benchmarking exercises and analgesia and sedation research, and 
clear guidelines were needed to aid new members of staff and doctors on their 
6 month PICU rotation.  
 
Interested parties were invited to form a key stakeholder multidisciplinary 
analgesia and sedation committee. A significant reason for change failure 
identified by Kotter (1995) is the failure to create effective coalitions, formation 
of this stakeholder committee was therefore key factor in the success of this 
change process. Consistent with a co-construction approach; the final 
membership of the committee comprised the PICU Nursing Manager, the Acute 
Pain Clinical Nurse Specialist, 2 consultant intensivists, a consultant 
anaesthesiologist, the PICU pharmacist, members of the clinical nurse 
facilitation team, senior and junior nurses and the writer as the PICU research 
nurse. The involvement of representative individuals from each major discipline 
in the PICU for the successful integration of clinical changes is well recognised 
(Ista et al. 2009a; Stevens et al. 2007). Hardiman (2010) acknowledges that a 
dominant caolition comprising infleuntial personnel is crucial, as without visible 
buy-in from management; staff will not be convinced. The presence of a 
dedicated project lead, such as a change agent or research nurse who can 
influence individuals in their practice settings is also recognised as crucial 
(Thompson et al. 2001; Dopson et al. 2002; Rycroft-Malone et al. 2004). As the 
PICU Research Nurse with Clinical Nurse Manager level 2 status; the writer 
assumed the role of chairperson being best placed to monitor and drive the 
project. 
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5.5 Engaging and Enabling the Organisation 
Kotter (1995) reiterates the importance of broad, clear communication at this 
point, to convince people of the need for change and to motivate them to leave 
their comfort zones and help with the process. Clear communication of the goal 
and desired end point of the initiative was conveyed. This message was 
reiterated in staff meetings and memoranda. Nadler (1988) asserts the 
importance of ‘developing a shared direction’, where the post-change status of 
the organisation is defined. Kotter (1995) warns against a lack of vision, 
highlighting it as a key reason for change failure. A shared vision provides the 
necessary focus and facilitates multi-disciplinary input into what people want to 
see as a result of the change. Hardiman (2010) endorses this process as it 
counters the preoccupation with the negative factors that necessitated the 
change in the first place.  
 
Inviting input from PICU staff extended a sense of ownership over the changed 
approach to analgesia and sedation management and helped shape the 
guidelines to meet the requirements of those who would be using them in 
practice. Involvement of the multidisciplinary committee was essential in 
developing the analgesia and sedation guidelines for PICU; as the assessment, 
prescription and administration of agents used for analgesia and sedation in the 
PICU involved PICU intensivists and anaesthesiologists, bedside nurses and 
the unit pharmacist. Participation and input from these individuals at committee 
meetings was crucial, discussion about effective analgesia and sedation 
dosages and finding solutions to clinical problems were discussed; such as 
maintaining the profile of patient distress assessment, and gaining compliance 
from consultant staff (see Analgesia and Sedation Committee meeting minutes 
from 9th December 2010).  
 
The goal of using validated assessment tools to measure pain and sedation in 
order to reduce subjectivity was recognised by the interprofessional team. 
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Relevant literature was presented to all participants outlining the pain and 
sedation assessment tools available for use in PICU, and the strengths and 
limitations of each (6th April 2010 Analgesia and Sedation Committee meeting). 
After analysing the literature and networking with international experts; the 
COMFORT-B scale was chosen as the ideal tool to measure patient distress in 
our PICU. This instrument had been heavily tested, and was validated to 
measure distress in ventilated PICU patients, in premature neonates from 28 
weeks gestation, and importantly it was also validated for use in children with 
T21 (Valkenburg et al.  2011). It was therefore appropriate to use this 
instrument in the majority of our patient population.  
 
Once agreement was reached on the final format of the guidelines, it was 
decided that a more comprehensive guidance document would be developed 
for the PICU pain resource folder, while more concise A4 summary sheets 
would be laminated and placed in each bedside folder. A stepwise approach to 
managing analgesia and sedation using an algorithm was universally endorsed 
(5th May 2010 Analgesia and Sedation Committee meeting). This complied with 
best practice evidence which recommended the assessment of pain and 
sedation levels using validated tools and the titration of pharmacologic 
interventions to achieve goals using protocols, guidelines or algorithms (Playfor 
et al.  2006). 
 
As the PICU patient profile was unique and a gold standard approach to 
analgesia and sedation management in PICU did not exist; an approach 
specific to the PICU at the study site was devised. While the analgesia and 
sedation guidelines were available to facilitate goal-directed, evidence-based 
care for patients in the PICU; it was acknowledged that each patient and 
disease process is different and no single approach could ensure optimal 
outcomes for every patient. The guidelines were suitable for the majority of the 
patient population, however a patient-centred flexible approach was endorsed.  
98 
 
 
5.6 Implementing and Sustaining the Change 
This period has been described as the process of change itself, where the 
present moves towards the projected desired future (Hardiman, 2010). Between 
these two states is the transition period which is well acknowledged as a difficult 
phase. Therefore Coghlan et al. (2003) proposes a strategic operational plan 
and commitment from the key stakeholders to see the project through (See 
figure 5.6 for strategy for implementation of the guidelines). Such a plan sets 
out the goals, activities, structures and projects needed to reach the end of the 
process, and also serves as a reminder that the transition period is temporary 
and should not be taken for the culmination of the change. The defining element 
of this phase involved teaching the PICU staff how to competently assess PICU 
patient distress using the COMFORT-B assessment tool, which will shortly be 
outlined; and incorporating the analgesia and sedation guidelines into practice.  
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Timeframe Activity Individuals 
Responsible  
Jan 14-31
st
 
2009 
Establish baseline views through audit; administer SASQ (Staff 
Analgesia and Sedation Questionnaire).  
CM. 
Feb 1st -28
th
 
2009 
Hold Annual Pain and Sedation Awareness Month in the 
hospital with a particular focus in PICU. Facilitate staff 
attendance at workshops and lectures. 
GOC, JMG, ET, 
BMM, CM 
Feb 15-16
th
 
2009 
Host Internationally renowned expert MvD. Facilitate open 
lectures, bedside visit and consultations with Analgesia and 
Sedation Committee. 
CM, MH, GOC, 
JMG. 
Feb 01-Mar 
31
st
 2009 
Development of Analgesia and Sedation Guidelines and 
Algorithm. 
EB, GOC and CM 
with input from 
all.  
Feb 01-Apr 
30
th
 2009 
COMFORT training for all PICU staff. CM, CK and PICU 
Education Team. 
June 01 2009 Rollout of Analgesia and Sedation Guidelines. Communicate 
clear message to staff regarding the guidelines and promote 
adherence.  
Every member of 
Analgesia and 
Sedation 
Committee.  
Daily Request COMFORT and VAS scores at bedside during ward 
round to raise profile and enhance adherence to guidelines. 
CMM, CB, MH, 
JMG, BOH, DM, 
BC. 
Daily Check compliance with guidelines, request feedback and clarify 
ambiguities at bedside. 
EB and CM. 
2 weekly 2 weekly teaching rounds to increase awareness and improve 
knowledge levels. 
CMM, CB, GOC, 
CM. 
1-2 monthly 1-2 monthly Analgesia and Sedation Committee meetings to 
address any issues, present scenarios and set plans for 
progression.  
Every member of 
Analgesia and 
Sedation 
Committee. 
Feb 1st -28
th
 
2010 
Hold Annual Pain and Sedation Awareness Month in the 
hospital with a particular focus in PICU. Facilitate staff 
attendance at workshops and lectures. 
GOC, JMG, ET, 
BMM, CM 
1
st
 August 
2010 
Perform any required amendments to guidelines and raise 
awareness to all staff of adjustments. 
CM, GOC, EB and 
every member of 
Committee. 
1
st
 June 2011. Re-audit staff using SASQ to determine any changes in attitudes 
and level of satisfaction with approach to analgesia and sedation 
practices in PICU following introduction of guidelines. 
CM. 
Figure 5.6: Strategy for Changing the Approach to Analgesia and Sedation Management in 
PICU 
 
5.7(i) COMFORT-B Training Strategy 
In order to gain proficiency in using this tool, an international expert in this area 
Associate Professor Monique van Dijk was invited to the PICU. Professor van 
Dijk had been instrumental in refining this tool and validating it in specific patient 
groups, and was therefore well placed to raise the profile of pain related issues 
among staff and instruct individuals on how to use COMFORT-B. After 
Professor Van Dijk’s well received visit there were several COMFORT-B 
‘experts’ who would undertake teaching of the entire PICU staff. 
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Gaining proficiency in assessing patient distress using COMFORT-B was an 
enormous undertaking. Each trainee was obliged to view video footage of PICU 
patients displaying all the behaviours associated with distress contained in the 
tool. Participants then assessed 2 children over a two minute time period from 
videotaped material and determine the COMFORT-B score of each. Open 
discussion elucidated the rationale for each individual’s score aiding consensus 
on determining the COMFORT-B score. Participants then assessed 10 ‘real’ 
PICU patients at the bedside and discussed the scores and provided rationales 
for choices. All COMFORT-B and VAS scores were retained to determine the 
interrater reliability of the clinical judgement of observers and expert. A 
weighted Kappa was calculated for each VAS score by assigning a weight (1-
[1/number of categories -1]) to the frequencies in each cell of a table of 
agreement, with the distance to the diagonal representing optimal agreement. In 
general a Kappa of 1 represents perfect agreement, 0.8-1 as almost perfect, 
0.6-0.8 as substantial, 0.4-0.6 as moderate, 0.2-0.4 as fair and 0.0-0.2 as slight 
agreement (Altman, 1991).  
 
The interobserver reliability over the total COMFORT-B score was calculated by 
an intraclass correlation coefficient (ICC). The ICC determines the conformity of 
measurements made by multiple observers measuring the same quantity 
(Shrout et al.  1979). The ICC was interpreted the same way as a weighted 
measure (Fleis, 1981). 
 
To support implementation 147 PICU staff were trained mainly by the research 
nurse, aided by 6 nurse educators and 1 pain nurse. This was followed by 10 
COMFORT-B and VAS (visual analogue scale) assessments at bedside of 
PICU patients below 3 years of age.  Assessments were done simultaneously 
but independently from the pain nurse. The assessments were done in groups 
ranging from 2 to 12 nurses. The linearly weighed Cohen’s kappa was 
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calculated over all 60 items that were scored in 10 patients (Fleis et al.  1969).  
Flexibility with rostering and utilising all resources such as the education team 
ensured that the training of existing staff was complete within an 8 week period. 
A high level of institutional support was instrumental in achieving the training 
objective.  Newly recruited staff continue to undertake the training and refresher 
sessions made available to anyone wishing to avail of them. 
 
5.7(ii) Results of Staff Training 
The interrater reliability of the VAS scores was estimated with the single 
measure intraclass correlation coefficient (Shrout et al.  1979) (See appendix 
13). The intraclass correlation coefficient for the VAS pain varied from 0.85 to 
0.99 for the different groups of raters indicating an excellent level of agreement 
between raters. Overall VAS scores were low with 53.4% of VAS values 0, and 
38.9% were between 1 and 3 (minor pain). 7.2% of the scores were between 4 
and 7 (moderate pain). Only eight scores were 8 or higher indicating severe 
pain, hence the deduction that pain was well controlled in the PICU.  
 
Results indicated the linearly weighted kappa of trainee’s COMFORT-B scores 
ranged from 0.64 to 1.00 with a median of 0.92 (IQR 0.88 to 0.96) indicating 
substantial to almost perfect agreement (See appendix 14). One nurse had a 
score that was one point higher than the expert on eleven occasions and a 
score that was one point lower than the expert on five occasions. This nurse 
requested to undertake the training again as English was her second language; 
she felt that her understanding of the video clips and instructions was hindered. 
This was facilitated and she was more satisfied with her assessments after 
repeating the training.   
 
5.7.1 Introduction of the Guidelines into Practice 
The guidelines were introduced into practice on June 1st 2010 in tandem with an 
awareness campaign informing staff of the new change in practice. Laminated 
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copies of the algorithm and distress assessment tool as well as instructions on 
utilisation and cut-off points were inserted into bedside folders. As there was no 
computerised clinical information system in operation at that time; other point of 
care cues were used to serve as reminders to nurses such as computer 
screensavers at the nurses station and notices displayed prominently in the 
PICU. Following minor revisions prompted by feedback at the bedside during 
teaching rounds and at analgesia and sedation meetings, the revised guidelines 
were implemented into practice on PICU on 1st August 2010.  
 
Consolidation of the change intervention is often identified as the key to its 
success (Hardiman, 2010). The change required monitoring, refinement and 
assessment if it was to become fully accepted. The medical staff routinely 
requested COMFORT-B scores at the bedside during rounds to promote 
compliance and raise the profile of the initiative. During daily prescription 
checks the unit pharmacist verified analgesia and sedation practices conformed 
to the guidelines. The patient observation flowsheet and patient safety shift 
check sheet were altered by the PICU education team to incorporate the 
analgesia and sedation guidelines. Informal feedback was welcomed and case 
scenarios were chosen from significant situations or issues which had evolved 
which merited a special focus (see meeting inutes from 8th June 2011 for 
example). This formed the basis for discussion at the analgesia and sedation 
meetings and ensured staff concerns were acknowledged and learning from 
real incidents occured. The following three key features promoting the 
successful incorporation of the changed approach to analgesia and sedation in 
the PICU are now described.  
 
5.7.1(i) Analgesia and Sedation Meetings 
One to two monthly open meetings with the Analgesia and Sedation Committee 
occured. The remit of these meetings was wide and included the initial 
development and refinement of the analgesia and sedation guidelines. There 
was ongoing networking with invited guest speakers and engaging attendees 
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through reviewing case scenarios (See appendix 15 for minutes of meetings). 
There was always a rich mixture of expertise present including medical 
consultant staff, the Acute Pain Clinical Nurse Specialist, the unit pharmacist as 
well as senior nurses and members of the PICU education team. There was 
generally vigorous discussion on analgesia and sedation related topics, lively 
debate around contentious or unusual cases and this provided a rich learning 
opportunity for all present. The writer acted as moderator, setting the agenda in 
advance and notifying relevant personnel.  
 
5.7.1(ii) Teaching Rounds 
Ongoing education has been identified as a key enabler to continued guideline 
use in clinical practice (Gifford et al.  2006). Informing and advising rather than 
deskilling nurses is advocated by Twycross et al. (2009). The use of teaching 
rounds as a method of devolving pain management skills among nursing staff 
has been endorsed by Segal et al. (1998), and senior nurses are considered 
well placed to facilitate this practice. In the PICU, bedside nurses were invited to 
present an overview of the patient’s history in relation to pain and discussion 
regarding the challenges, contextual factors and the plan of care. Practical 
demonstrations were valued as a means of developing nurses’ critical thinking 
skills. The success of these rounds depended on the support of the medical 
consultant in charge on the day and the ward manager. Twycross (2002) 
advocated a weekly basis for these teaching rounds. This was not thought to be 
feasible in our PICU, hence we aimed to undertake teaching round every 2 
weeks.  
 
5.7.1(iii) PICU Analgesia and Sedation Champion 
Champions have been endorsed as vital in the implementation and 
sustainability of guidelines. Champions are defined as local opinion leaders who 
informally model and influence practice behaviour (Gifford et al.  2006). Such 
individuals drive and facilitate implementation of guidelines and optimise the 
success of the initiative (Dopson et al. 2002; Rycroft-Malone et al. 2004). It is 
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well recognised that behaviours such as support and role-modelling play a 
major role in the adoption of evidence-based recommendations (Hatcher et al. 
1997; Kajermo et al. 2001; McGaughan et al. 2002; Parahoo 2000; Retsas 
2000). As the PICU research nurse; the writer fulfilled this role. An openess to 
receiving feedback and answering any queries about the guidelines was 
ensured. During daily bedside visits; the guidelines could be observed in action, 
and engagement with staff addressed challenges and criticisms that arose. 
Issues that could not be successfully resolved at the bedside were placed on 
the agenda for discussion at the next scheduled analgesia and sedation 
meeting. It was important that the concerns of staff were acknowledged and 
addressed. Successful implementation of the analgesia and sedation guidelines 
would not have occurred without support from the management team and an 
organisational culture supportive of implementation of evidence based practice.  
 
5.8 Evaluation 
It is well acknowledged that evaluating change is challenging (Craig et al.  
2008). To determine the effectiveness in improving analgesia and sedation 
management in the PICU, a framework sensitive to the context of the 
intervention was selected. The CIPP model (context, input, process and 
product) developed by Stufflebeam (1971) was selected for this purpose. 
Prioritisation was required to determine which outcomes of the intervention 
were most important, which were secondary and  how to deal with multiple 
outcomes in the analysis. Craig et al. (2008) proposes finding the best use of 
the data to provide an adequate assessment of the impact of the intervention 
that has effects across a range of domains. Evaluation of the intervention 
therefore focussed on three perspectives; the PICU patient group as a whole, 
post-operative cardiac patients who were directly affected by the change in 
practice due to their specific analgesic and sedation requirements; and finally 
PICU doctors and nurses whose practice was targeted by the intervention. The 
timing of this evaluation was crucial. An acute awareness of Kotter’s (1995) 
assertion, that declaring victory too soon was recognised as a significant pitfall. 
Changes can take a long period of time to assimilate into the culture of an 
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organisation. In Section 3 of this thesis, the findings of this evaluation are 
presented, and evaluation of the intervention using the CIPP framework is 
undertaken.   
 
5.9 Conclusion 
The development, dissemination and implementation of the analgesia and 
sedation guidelines required a huge level of energy and commitment from all 
those involved. Ongoing input was required to ensure utilisation and adherence 
to the guidelines was sustained. Organisational support and a leadership 
approach that endorsed and promoted the guidelines was vital. Regular open-
access meetings with well publicised guest speakers helped to maintain the 
profile of the guidelines. Habitual practice audits fostered adherence to the 
guidelines, while teaching rounds helped to educate and empower bedside 
nurses. The collaboration and interdisciplinary teamwork required of this 
initiative augmented working relations in a very positive way and inspired the 
subsequent quality improvement initiative which was the development of 
weaning guidelines for analgesia and sedation. 
 
The next chapter will focus on the process of selecting the research 
methodology to evaluate the impact of this changed approach to analgesia and 
sedation management in the PICU. The strengths and limitations of various 
methodologies will be examined, and justification for the final selection 
provided.  
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Section 2: Research Design and 
Methodology 
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Chapter 6: Methodology 
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6.0 Introduction 
Engaging with research to advance knowledge and provide an evidence 
base for care has assumed heightened importance in recent years. 
Nursing research is increasingly being carried out in clinical areas with a 
focus on improving patient outcomes. Research methods are the 
techniques researchers use to structure a study and to gather and 
analyse information relevant to the research question (Polit and Beck, 
2008). Methodological approaches in nursing studies are relying less on 
either exclusively scientific or naturalistic enquiry due to the holistic 
nature of the human experience (Walker, 2005). Complex or multi-
faceted research questions require a methodological approach that will 
accommodate the rich variety of data to be gathered.  Analgesia and 
sedation was an issue that significantly affected patients and staff in the 
PICU. Understanding the impact of a changed approach to the 
management of this area of practice required a fusion of methods which 
were complementary in their strengths and limitations.  
 
6.1 Statement of the Problem  
A departure from deep sedation practices occurred internationally after 
1974 due to concerns that it prolonged weaning from mechanical 
ventilation and length of stay in intensive care and potentially increased 
morbidity (Brook et al. 1999; Schweickert et al. 2004). Best practice now 
advocates that validated tools are used to regularly assess pain and 
sedation levels, that analgesics and sedatives are titrated to the 
individual patients’ needs, and that a sedation goal or endpoint is 
established and regularly redefined for each patient (Jacobi et al. 2002). 
Such an approach to analgesia and sedation in adult ICU settings has 
been associated with significant patient benefits including a reduction in 
the amounts of analgesics and sedatives administered to patients and in 
the associated drug costs, a decreased length of ventilator dependence 
and critical care stay, and reduced incidences of ventilator associated 
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pneumonia, pressure sores, withdrawal symptoms and short term 
mortality (Jackson et al. 2010).  
 
In the paediatric setting the evidence to support this change in practice is 
inconclusive (Alexander et al. 2002; Popernack et al. 2004; Jin et al. 
2007; Ista et al. 2009a). Nevertheless the Paediatric Intensive Care 
Society (PICS) endorse the use of guidelines to facilitate the titration of 
pharmacological interventions to targeted sedation goals (PICS 
Standards 2010). There is evidence to suggest the use of analgesia and 
sedation guidelines combined with a validated distress assessment tool 
is becoming more common. In 2007 40% of PICUs surveyed in the 
United Kingdom UK 2007 used guidelines (Jenkins et al. 2007), while 
this number had increased to 60% in 2011(Harris et al. 2011).  
 
Recognising the increasing utilisation of analgesia and sedation 
guidelines in PICU settings in the absence of conclusive supporting 
research; the primary aim of this study was to investigate the impact of 
introducing analgesia and sedation guidelines combined with a validated 
distress assessment tool on patients in an Irish PICU. It is acknowledged 
by Getliffe (1998) that in order for results to be meaningful; reliable and 
validated outcome measures must be used. For this research study the 
amount of morphine, the main PICU analgesic and anxiolytic, 
administered to PICU patients was chosen to be the primary research 
outcome measure.  
 
6.2 Research Aims and Objectives 
Measuring clinical outcomes and linking them to nursing actions is critical 
in developing an evidence based practice and in launching high quality 
care improvement initiatives (Polit and Beck, 2008). In the short term this 
study sought to determine whether the implementation of analgesia and 
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sedation guidelines combined with a validated distress assessment tool 
was associated with a reduction in the amount of analgesia and sedation 
administered to PICU patients whilst ensuring they were not exposed to 
pain or distress. In the medium term, decreasing the incidence of 
excessive amounts of agents used for analgesia and sedation to patients 
may have been associated with significant clinical outcomes; namely 
reduced reliance on mechanical ventilation and subsequently a shorter 
length of PICU stay.  
 
The benefits of administering sufficient but not excessive amounts of 
analgesics and sedatives have significant long-term benefits including 
reduced exposure to the deleterious effects some of these agents have 
on the developing brain such as neuroapoptosis. Investigation of such 
phenomena were beyond the scope of this study but are well described 
in the literature (Mellon et al. 2007; Rappaport et al. 2011). Earlier 
liberation from mechanical ventilation assumes reduced exposure to 
ventilator induced lung injury as well as ventilator associated pneumonia. 
The long-term benefits of earlier discharge from PICU are many, 
including the likelihood of earlier hospital discharge. This is synonymous 
with less exposure to hospital acquired infections, less disruption to 
cognitive and social development as well as to the parental bonding 
process (Colville, 2008). A higher patient turnover is more cost-effective, 
reduces patient waiting lists and is generally associated with improved 
job satisfaction of staff (Brady, 2010).   
 
Conversely, it is widely acknowledged that implementing evidence based 
research into practice is often fragmented and inconsistent (Grol et al. 
2003). Implementation science highlights the role of individuals most 
closely affected by the change in practice; without their involvement 
interventions are likely to be a poor fit, met with resistance and require an 
active process of engagement to accomplish uptake (Damschroder et al. 
2009). However, in most research exploring the impact of the 
implementation of analgesia and sedation guidelines, the perceptions of 
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intensive care nurses and doctors were not taken into account. 
Acknowledging the significant role of PICU staff in analgesia and 
sedation management; an important aim of this study was to establish 
whether the intervention was welcomed by PICU staff and whether the 
guidelines and distress assessment tool were viewed as being clinically 
effective, and valuable for patient management.  Evaluation of 
compliance with the guidelines would reflect the extent of their adoption 
into practice. The primary and secondary research hypothesis for this 
study will now be clarified; and an additional study aim elucidated.  
 
6.3 Research Hypotheses 
It was appropriate to use a research hypothesis in this study. A 
hypothesis is an assumption which the study is designed to test and it is 
a characteristic of scientific methods of enquiry (Bowling, 2009). The null 
hypothesis states that no relationship exists between the variables under 
study, inferring that there will be no observed effect of the experiment. 
Statistical hypothesis testing therefore is a process of rejection (Polit and 
Beck, 2008). Based on appropriate testing, it can be determined whether 
standardising analgesia and sedation management resulted in a change 
in the dosage of morphine administered to PICU patients.  Nickerson 
(2000) argues that when applied with good judgement, testing the null 
hypothesis can effectively aid the interpretation of experimental data.  
 
In contrast, the alternate hypothesis proposes that there is a relationship 
between the variables, and the intervention did result in a change in the 
dosage of morphine delivered to PICU patients. This is change can be 
bidirectional, as morphine dosages may have increased or decreased 
after the intervention. 
 
In this research study, the primary null hypothesis stated that the 
independent variable; the changed approach to analgesia and sedation 
management, did not cause a reduction in the dependent variable, 
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morphine administered to PICU patients. Following on from this the 
secondary null hypothesis states that the independent variable did not 
cause a reduction in the duration of mechanical ventilation and PICU 
stay of study patients.   
 
The following null hypotheses were posed: 
Primary Hypothesis: 
Standardised pain and sedation management dod not cause a reduction 
in the dosage of morphine administered to patients in PICU. 
Secondary Hypothesis:  
The implementation of standardised pain and sedation was not 
associated with a change in duration of mechanical ventilation and PICU 
stay.  
 
6.3.1 Additional Research Question 
Acknowledging the significant role staff play in prescribing and 
administering analgesic and sedative agents; exploring their views 
around this change in practice was crucial.  The impact of the 
intervention on PICU staff was not framed as a research hypothesis, as 
there was a lack of theory relating to the issue of how standardising 
analgesia and sedation practice impacted PICU staff to base a 
prediction.  It was instead posed as an additional research question  with 
the intention of exploring staff attitudes and approaches to analgesia and 
sedation practices in the context of the planned change in practice. 
The following research question was posed: 
Did PICU staff welcome the standardisation of analgesia and sedation 
management and perceive it as clinically valuable one year after its 
implementation?  
113 
 
 
6.4 Research Paradigms 
To address the primary and secondary research hypotheses effectively; 
it was necessary to choose a suitable methodological approach. In the 
past, theories generated and tested through randomised controlled trials 
(RCTs) were seen as the ‘gold standard’ and actively endorsed as the 
evidence base most suited to advance healthcare and underpin clinical 
decision-making. The RCT typifies true positivism; emphasising the 
rational and the specific, using an orderly and disciplined scientific 
approach with rigid controls to test hypotheses, (Polit and  Beck, 2008).  
In contrast; qualitative research focuses on qualities of a process or 
entity and meanings that are not experimentally measured in terms of 
amount, frequency or intensity (LoBiondo-Wood and Haber, 2006). 
 
In recent times it is the very disciplined and rigid methods of strict 
positivism that it’s critics have challenged. It is felt strict objectivity and 
tight control are not natural bedfellows with the study of humans and their 
world, as the researcher’s influence is pervasive (Koch and Harrington 
1998; Payne et al. 2003). Acknowledgement of this gave rise to post-
positivism; where it is accepted that one truth can never be reached, but 
one can attempt to capture as much of reality as possible, using multiple 
methods to do so (Racher and Robinson, 2002).  
 
The quantitative versus qualitative debate is ongoing, as evidenced by a 
provocative editorial by Watson (2003) entitled “Scientific methods are 
the only way forward for nursing research”, and by the published 
resonses generated by this article. There were those which strongly 
refuted such a stance and highlighted the valuable contributions 
phenomenology, grounded theory and ethnography have made to 
nursing research (Draper and Draper 2003; Payne et al. 2003). While 
Watson acclaimed the objectivity of positivism; Payne et al. (2003) 
argued all research is inherently value laden and, therefore, to some 
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degree subjective. Supporters of Watson’s argument criticise the 
qualitative school for failure to recognise and eliminate error (Paley, 
2004).  
 
Despite such contentious arguments provoking entertaining academic 
debate; the value of arguing the merits of one discipline over another is 
questionable (Closs & Cheater, 1999). An appreciation of the breadth of 
different research methodologies is endorsed, to allow researchers to 
choose the right tools for the job, rather than be constrained to a specific 
research design (King’s Fund 2000, p.192). Different approaches to 
research can generate different but equally valuable forms of evidence 
and different forms of evidence are required to answer different 
questions (Draper et al. 2003). Accordingly, research which achieves the 
research purpose within the research situation is considered good 
research. 
  
6.5 Selection of Research Methodology 
It was pivotal that the research question drove the methodology selected. 
The research methodology for this study had to be problem focused and 
context specific in order to be effective. Qualitative research 
methodologies use techniques such as surveys, interviews and focus 
groups to acquire and analyse rich data from individuals and groups 
(Bowling, 2009). Such methodologies have merit in exploring individual’s 
views and beliefs, but were limited in their focus with regards to PICU 
patients. There were significant practical challenges in acquiring data 
from mainly pre-verbal critically ill PICU patients. In order to gain a 
complete picture of the impact of the intervention on all those affected by 
the change in practice; patients and staff alike, a quantitative 
methodology was required.  
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An action research approach was considered to have merit, as the 
necessary attributes of action research undoubtedly captured the 
essence of the project we were embarking on. However, the cycles of the 
action research process proved restrictive and overly complex for this 
initiative. Similarly an RCT was rejected as this was a monosite study, 
and randomisation was not possible for logistical reasons. 
Randomisation of patients to a control and treatment group being cared 
for in the PICU simultaneously was not practicable. Effective 
randomisation would also require that PICU staff were also randomised 
to the control and treatment arm of the study. This process would require 
a clear division of study patients and the work practices of nurses and 
doctors. The logistics of allocating staff to patients while balancing 
workload and supervision, as well as planning meal break relief would be 
particularly challenging, given the workforce challenges including skill 
mix and staff shortages as well as a high patient turnover in the PICU 
and occupancy levels consistently in excess of 85% (see appendix 1).  
 
Changing analgesia and sedation practice involved comprehensive 
awareness raising strategies as well as education initiatives and open 
analgesia and sedation meetings. The activities associated with raising 
awareness of the intervention including staff teaching sessions, ‘ward 
walk arounds’ and open access analgesia and sedation meetings would 
be restricted to staff in the intervention group if staff were randomised. 
Controlling for crossover effects of these awareness raising strategies 
would be significant, as would encouraging compliance with the 
guidelines with selected staff only. For these reasons, randomisation was 
not considered feasible. 
 
As randomisation was not possible; collection of data from another 
hospital was considered.  The strength of this design relied on a similarity 
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between the comparison and experimental groups at baseline. In reality, 
there were significant differences in the specialties offered in the PICU in 
the neighbouring childrens’ hospital which is a tertiary referral centre for 
neurology and metabolic disorders. The main patient diagnostic groups 
in the PICU of the study hospital were cardiovascular, respiratory and 
gastrointestinal, as seen in appendix 16. These fundamental differences 
in patient population rendered this hospital unfeasible as a comparator 
site. In addition, it is widely known that analgesic and sedation practices 
differ greatly among PICUs and hospitals, and not least among 
physicians (Playfor et al. 2003).  
 
On balance, the quantitative approach held strong appeal when 
considering a suitable research methodology to investigate the research 
hypotheses. According to Mulhall et al. (1998), emphasis on 
effectiveness and efficiency within healthcare including discussions on the 
implementation of guidelines, give the highest regard to research designs 
that are less susceptible to bias. The quantitative approach to research is 
therefore likely to be embraced by those who support this point of view; 
being founded on the belief that the social world lends itself to objective 
forms of measurement (Cowman, 1993) and characterised by a set of 
orderly and disciplined procedures (Polit and Beck, 2008). A true 
experimental design comprises three key features; manipulation- there is 
an intervention, there is a control group that does not receive the 
intervention, and lastly randomisation (Polit and Beck, 2008). This 
research study fulfilled the criteria of both manipulation and use of a 
control group. Although randomisation was not feasible, the use of non-
equivalent control groups was possible to implement. This brought the 
research initiative under the umbrella of quasi-experimental research, the 
signature of which involves an intervention in the absence of 
randomisation, (Polit and Beck, 2008). To overcome the risk of bias and 
satisfy the criteria for establishing causality- control groups were used for 
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the patients and the staff. The control group was a basis of comparison 
and represented a proxy for the ideal counterfactual.  
 
6.6 Quasi-Experimental Design  
Quasi-experiments, like true experiments involve an intervention, 
however quasi-experimental designs lack randomisation (Polit and Beck, 
2008). Where randomisation is not possible because of logistic, ethical or 
other reasons, a quasi-experimental design is acceptable (Norman and 
Humphrey, 2008). Where this design is used, experimental and control 
communities are selected so as to be as similar as possible. If the 
expected change occurs in experimental but not the control condition, 
and there are no unwanted side effects associated with the experimental 
group, then it can be concuded that the intervention is effective and there 
are grounds for its more general application.  
 
In single group quasi-experimental design, only one group is used, where 
the independent variable is manipulated and the changes in the 
dependent variable are measured. The main disadvantage of this design 
relates to the lack of measurement of the dependent variable prior to the 
manipulation; making the detection of changes and inferring causal effect 
impossible. The before/after design is a means of overcoming this 
limitation as it includes a measurement of the dependent variable before 
and after the intervention (Smith, 2008).  
 
6.7 Before/After Approach 
In order to emulate control conditions; the before/after design was 
employed. This approach is endorsed as a means of achieving control 
conditions without encountering the risk of bias. This design is also 
referred to as a pre-test post-test design and is the most frequently used 
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quasi-experimental design. Such a design allows measurement of a 
change in a situation, problem or attitude, and is considered the most 
appropriate design for measuring the impact or effectiveness of an 
intervention (Kumar, 2011). A before/after study can be described as two 
sets of cross-sectional data collection points on the same population to 
find out the extent of the change in the phenomenon or variables 
between two points in time. The change is measured by comparing the 
difference in the phenomenon or variables before and after the 
intervention.  
 
A further strength of the before/after design is that participants do not 
undergo the hawthorne effect. This occurs when subjects change their 
behaviour or respond in a specific manner simply because of awareness 
of being observed (Haughey 1994; Clifford 1997). Data relating to 
analgesia and sedation management of PICU patients was retrieved 
retrospectively, before this area received a research focus to eliminate 
this risk.  
 
In addition a before/after questionnaire survey collected quantitative data 
prospectively from PICU nurses and doctors before the intervention, thus 
eliminating the risk of recall bias and documenting satisfaction with 
analgesia and sedation practice before the intervention and 
receptiveness towards a changed approach. The survey was repeated 
12 months after the intervention to determine if the change in practice 
was considered clinically valuable. In this case, staff who responded 
acted as their own control, enhancing the validity of findings. 
 
The before/after design was used successfully by Wielenga et al. (2008) 
to explore the effect of introduction of major changes in nursing care 
practice by means of NIDCAP (Newborn Individualized Developmental 
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Care and Assessment Program) on nursing staff job satisfaction in a 
neonatal intensive care unit in the Netherlands (NICU).  A survey was 
performed before, and 6 months after the introduction of NIDCAP as the 
new model of care. Job satisfaction was measured by means of the 
Index of Work Satisfaction (IWS) instrument. The results on the IWS 
demonstrated no change in the overall satisfaction rate, 14.4 and 14.5 
respectively. Only in 1 component, organisational policies, the mean 
score increased significantly (3.68 and 4.13, respectively, p = .008). The 
other component scores did not increase significantly and persistent job 
satisfaction, despite this major change in practice, was effectively 
demonstrated.  
 
Similarly McLellan (2004) conducted a before/after study to evaluate a 
nurse-led intervention to improve pain management following surgery. 
The intervention (independent variable) included education for nurses 
and implementation of regular pain assessment and profiling of pain at 
hospital level. The dependent variable (pain) was recorded using a visual 
analogue scale at defined time points post-operatively, and changes over 
time were explored. The before/after design provided the researcher with 
two snapshot measurements of the dependent variable which were 
compared. 
 
6.8 Design Limitations 
A major limitation of the before/after design is the extent to which any 
changes to the dependent variable can be attributed to the independent 
variable. Other factors, such as subject variables, natural changes, pre-
test sensitisation, as well as researcher expectancy may account for 
changes (Smith, 2008). The importance of acknowledging the possibility 
of something other than the intervention accounting for any observed 
differences in outcomes was also noted by Polit and Beck (2008). It was 
necessary to acknowledge this and execute vigilance in identifying and 
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controlling for any extraneous or confounding variables. A further 
criticism of this type of design is that it involves a long time period as the 
after-stage of the study cannot take place until the intervention is 
complete. Indeed Kurt Lewin (1946) acknowledged that changes in 
practice take time to become established. Therefore baseline data were 
collected before the intervention and outcome data were collected one 
year after the change in practice had occurred to detect changes.  
 
6.9 Design Selection Summary 
 A null hypothesis was used in this study and was focused on the 
impact of an intervention: a changed approach to analgesia and 
sedation management on the dosage of morphine administered to 
PICU patients.  
 The impact of the intervention on duration of mechanical 
ventilation and PICU stay was a secondary study outcome. 
 A quasi-experimental design was selected for the study, for 
logistical reasons, an RCT with randomisation was not feasible.   
 The most appropriate approach in this study was a before/after 
approach.  
 An important aspect of this research was whether the change in 
practice was welcomed and valued by PICU staff. Therefore the 
views of PICU nurses and doctors were sought prospectively 
before and after the intervention by questionnaire survey.  
 
A distinguishing feature of experimental research is the collection of 
numerical data (Jack and Clarke, 1998) that, in turn can be subjected to 
statistical analysis (Carter, 2000). Advocates of the quantitative approach 
are therefore described as objective scientists (Duffy, 1986) committed to 
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the discovery of quantifiable information (Carr, 1994). The research 
variables of interest in the study are now outlined. 
 
6.10 Research Variables of the Study 
Aside from patient demographic information, information to describe the 
severity of illness of patients on admission to PICU (PIM and SMR), their 
risk of organ dysfunction (PELOD) and surgical risk (RACHS) were 
collected in order to facilitate comparison of patient groups. In addition 
the amounts of selected, commonly used analgesic and sedative agents 
in post-operative PICU patients were gathered. Determining whether the 
intervention resulted in a reduction in the amounts of these agents 
administered was thus facilitated. Recording the COMFORT-B and NRS 
scores of study patients investigated whether their pain and analgesic 
needs were being met. Collection of each participants’ length of 
dependence of mechanical ventilation and PICU stay were crucial in 
order to explore the association between the amount of analgesics and 
sedatives administered to patients in PICU and their dependence on 
mechanical ventilation. In addition, the perceptions of PICU staff 
regarding analgesia and sedation management were of interest in order 
to establish receptiveness towards the change in practice and gauge its 
utility in practice. The research variables of interest in this study are listed 
in Table 6.10. 
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Table 6.10: Research Variables of Interest for the Study 
Patient 
Charateristics 
 
Severity of 
Illness and 
Mortality Risk 
Prediction Tools  
Analgesics and Sedatives 
Administered to Patient 
Participants 
PICU Staff 
Age in Weeks 
(Corrected for 
Gestation). 
PIM (Paediatric 
Index of Mortality). 
Level and frequency of scores 
of patient’s level of distress 
(COMFORT scale) recorded in 
patient healthcare record. 
Participant 
Demographics. 
Gestation in 
Weeks. 
SMR 
(Standardised 
Mortality Ratio). 
Level and frequency of 
measurement of pain using 
Nurse Rating Scale (NRS). 
Profession: Nurse 
or Doctor. 
Weight in Kg. PELOD 
(Paediatric 
Logistic Organ 
Dysfunction 
score). 
Rate of morphine infusion on 
return from operating theatre 
(mcg/kg/hr). 
Length of PICU 
Experience. 
Length of PICU 
Stay in Hours. 
RACHS (Risk 
Adjustment for 
Congenital Heart 
Surgery). 
Morphine Administered 
mcg/kg/day. 
Education 
regarding 
analgesia and 
sedation. 
Duration of 
Dependence on 
Mechanical 
Ventilation in 
Hours. 
 Midazolam Administered 
mcg/kg/day. 
Satisfaction with 
Management of 
Analgesia and 
Sedation. 
Ventilator free 
days. 
Paracetamol 
Administered mg/kg/day. 
No. of clinical 
items participants 
feel warrant 
concern. 
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Supportive 
therapies 
required. 
Chloral Hydrate 
Administered mg/kg/day. 
Knowledge level 
regarding 
analgesia and 
sedation. 
Status at 
discharge from 
PICU. 
Oramorph 
Administered mcg/kg/day. 
 
30 day follow up 
status. 
Clonidine 
Administered mcg/kg/day. 
 
6.11 Study Setting 
A Paediatric Intensive Care Unit in the Republic of Ireland was the 
setting for this study. As a national tertiary referral centre, a number of 
specialist treatments were offered to children at this hospital including 
cardiac surgery, haematology, oncology, general surgery and 
orthopaedic surgery. The hospital comprised two PICUs with a combined 
bed complement of 23 beds with 18 designated PICU and 5 high 
dependency (HDU). A range of advanced life support therapies were 
offered to PICU patients aside from mechanical ventilation and inotropic 
support, including CVVH (continuous veno-venous haemofiltration), 
ECLS (extra-corporeal life support) and HFOV (high frequency oscillatory 
ventilation). 
 
The PICU/HDU was one of the busiest in Europe (Healy, 2011), with 
annual admissions over 1,000 patients (1,050 admissions in 2012). Data 
collected in 2009 and 2010 confirmed that patient outcomes were 
comparable with institutions that provide quaternary levels of paediatric 
intensive care (PICANet, 2011).  
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The medical and nursing staff complements in the PICU endeavoured to 
meet the requirements of the Paediatric Intensive Care Society 
standards for PICU staffing levels (PICS, 2010).  
 
6.12 Population and Sampling 
The research population refers to the entire aggregation of individuals of 
interest for the study. In order to facilitate valid conclusions about the 
effect of the intervention, an appropriate sample of the population was 
needed. Ideally a sample of participants will be representative of the 
population from which they are drawn. Random sampling gives each of 
the units in the population targeted a calculable (and non-zero) 
probability of being selected (Bowling, 2009). Most investigators using 
experimental and analytic methods recruit participants, including 
patients, consecutively from known, easily accessible populations. Ease 
of recruitment, monitoring and follow up in this research study was 
advantageous, as was the likelihood of higher recruitment rates and 
retention of sample members. However, the external validity of the 
findings may have been compromised as the sample may not have been 
representative of the general population. It was therefore important that 
the study findings were viewed in the context of the population from 
which the samples were drawn.   
 
Two populations of significance were identified for this study, PICU 
patients and PICU staff. A patient sample was required that was 
sufficiently large to allow statistical conclusion validity and generalisability 
of results, while simultaneously facilitating a detailed exploration of 
variables such as analgesia and sedation received. In addition, 
recruitment of a large group of PICU nurses and doctors was needed to 
develop an understanding of the perceptions of analgesia and sedation 
management. For the purposes of gaining a complete view of the impact 
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of the intervention, 3 distinct population sources were identified which will 
be discussed in turn:  
1. PICU patient census data derived from the Paediatric Intensive 
Care Audit Network (PICANet) database. 
2. A cohort of PICU patients meeting strict inclusion and exclusion 
criteria were selected for deeper analysis using the Patient 
Analgesia and Sedation Questionnaire (PASQ). 
3. All PICU nurses and doctors who had a role in prescribing and 
administering analgesia and sedation.  
 
6.12.1 PICU Patient Census Population; PICANet 
Census research covers an entire population. From February 11th 2009 
onwards, the researcher collected, validated and prospectively uploaded 
data on consecutive PICU admissions into the PICANet database in a 
structured and objective manner (See appendix 17 for data collection 
instrument). This ensured a robust database containing census data was 
developing from that date onwards to provide a repository of patient data 
for this and other studies.  The risk of recall bias was therefore not 
considered significant.  
 
There was some constancy regarding age groups of patients admitted to 
the PICU, reasons for admission and male to female ratio (Draper et al. 
2011). If the groups were to differ on some other variable, then this may 
have explained associations between independent and dependent 
variables. If the groups were equivalent on these other variables, then 
these could not explain the association (Bowling, 2009). No significant 
variations in the characteristics of P1 and P2 which could have 
influenced results were expected (Burns and Grove, 2001). A thorough 
comparison of the characteristics of both groups was carried out.   
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6.12.2 Sample Size; PICANet 
As acknowledged by Polit and Beck (2008); quantitative researchers are 
generally advised to use the largest sample possible. Bigger sample 
sizes ensure increased representativeness. Percentages and averages 
calculated from sample data to estimate population values incur smaller 
sampling error incidences when larger sample sizes are used. Statistical 
power is hugely influenced by sample size. Power has been defined as 
the probability of accepting a null hypothesis that is false (a false 
negative, type 2 error). Power is dependent on three factors: alpha level, 
which was set p =0.05; sample size and lastly effect size, which is the 
magnitude of difference between groups. Minimal acceptable power > 
0.8 has been recommended to ensure sufficient confidence in detecting 
a relationship (Stevens 2002; Pallant 2007). It has been proposed that if 
the sample is greater than 100 “power is not an issue” i.e. with a sample 
size of 100, power is 0.94, (Stevens 2002, p6). Utilisation of PICANet 
census data was advantageous in offering the possibility of obtaining 
large sample sizes, promoting generalisability and enhancing the power 
of statistical results (Seals et al. 2000; Marshall 2005).  
 
6.12.3 PICANet Patient Population 
Patient episodes from the PICU patient census (local PICANet database) 
were extracted from a 12 month period before the intervention (P1) and a 
12 month period after the intervention (P2) (see figure 6.12.3). Annual 
admissions to the PICU averaged 950 to 1,050 patients, therefore up to 
1,050 patients in the before and after group were anticipated. Analysis of 
these data would provide valuable insights into the impact of the 
intervention at macro level e.g. duration of mechanical ventilation and 
PICU stay. However details about analgesia and sedation received by 
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patients would not be obtainable from these crude data. 
 
 Figure 6.12.3: Selection of ‘before’ and ‘after’ patient census data from PICANet database 
 
6.12.4 Population and Sampling; PASQ 
Therefore a purposive sampling strategy was used to obtain a cohort of 
PICU patients meeting strict inclusion and exclusion criteria for deeper 
analysis using the specifically developed and validated Patient Analgesia 
and Sedation Questionnaire (PASQ). There is the potential for bias in 
control groups without random allocation. While purposive sampling may 
be used to hand-pick sample members who are directly affected by the 
issue under study; Polit and Beck (2008) warn of the lack of 
representativeness of the general population of non-probability sampling. 
LoBiondo-Wood et al. (2006) further propose that purposive sampling is 
the weakest form of sampling strategy with regard to generalisability. 
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Therefore stratification was considered as a means of ensuring 
comparability of the before and after groups. This strategy requires prior 
knowledge of confounding variables. In a highly complex PICU 
population with a range of diagnoses and co-morbidities, this was not 
feasible. For the same reason paired matching was deemed unsuitable. 
Hence it was decided to use homogenous before/after patient samples 
that were similar in terms of diagnosis, severity of illness, age and 
exposure to surgery. Therefore, only patients aged one month to one 
year who had open cardiothoracic surgery were included in this analysis. 
Purposive sampling was therefore utilised to ensure these groups were 
similar except in relation to the independent variable; the before group 
received usual analgesia and sedation management, while the after 
group were managed according to the analgesia and sedation guidelines 
(see figure 6.12.4 for source of PASQ samples).  
 
In this study, the inclusion and exclusion criteria ensured two comparable 
patient groups were selected who shared a common characteristic; an 
analgesic and sedative need on admission to the PICU. This strategy 
eliminated rival explanation for cause and effect relationships, and 
proved advantageous in its convenience and economy. However, 
according to Bowling (2009) results from these types of studies are not 
generalisable to the wider population unless random sampling from that 
population has been employed. Nevertheless, it was anticipated that 
findings from this study may be of great interest to areas where similar 
patient populations were cared for. 
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Figure 6.12.4: Illustration of method of deriving PASQ ‘before’ and ‘after’ patient 
samples   
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6.12.5 Determining Sample Size; PASQ 
Calculation of sample size was based on the study by Jin et al. (2007) 
evaluating the efficacy of a scale for measuring distress in PICU patients 
in guiding optimal sedation in PICU patients using a before/after 
approach. A sample of 20 patients assessed before the introduction of a 
sedation protocol and 21 patients sampled after the introduction of the 
protocol was sufficient to show a significant decrease in the total usage 
of morphine. Dosages were log transformed before they were studied. 
The dosage of morphine for the intervention group was 204.0mg with an 
interquartile range of 94.8 to 493.2mg. For the control group (pre-
intervention group), the average dosage was 495.5mg with an 
interquartile range of 280.3mg to 835.1mg. This provided 80% power to 
detect a change in dosage with a level of significance (alpha) of 0.05. In 
order to detect similar changes in the before and after populations, and 
to be sufficiently powered to study subpopulations and investigate other 
analgesic and sedative agents, 123 patients were recruited. An 
independent biostatistician provided this analysis. 
 
6.12.6 Population; SASQ 
Information was collected from all nurses and doctors working in the 
PICU. The specifically developed and validated SASQ instrument (Staff 
Analgesia and Sedation Questionnaire) was used for this purpose. It was 
recognised that PICU registrars on 6 monthly rotations would not be 
present to complete both ‘before’ and ‘after’ staff surveys. All PICU 
physicians were nevertheless included; their opinions were highly valued 
as they may have had previous experience working in critical care.   
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6.12.7 Nursing and Medical Staffing Levels 
The PICU staff nurse complement comprised 147 nurses in post 
equating to 116.5 whole time equivalent staff nurses. There were 16 
nurses working at Clinical Nurse Manager (CNM) level, either as a shift 
leader or Clinical Nurse Facilitator (CNM 2) or in a Ward Manager or 
service co-ordinator capacity (CNM 3).  The staffing levels in the unit 
therefore equated to 5.98 staff nurses per PICU bed, just below the PICS 
standard recommendation of 6.04 nurses.  
 
The medical staffing comprised 2 Consultant Paediatric Intensivists, 2 
Consultants in Anaesthesiology, 3 Registrars in Paediatric Medicine and 
12 Registrars in Anaesthesiology. The PICS standard for PICU medical 
staffing advised 24 hour cover from an Intensive care consultant. The 
recommended workload per PICU consultant was 8-10 beds. The 
complement of 18 PICU and 5 HDU beds highlighted the dearth of 
medical cover in the PICU, placing enormous pressure on all existing 
staff. Therefore questionnaires were issued to 163 PICU nurses and 19 
doctors who were not involved in testing the instrument.  
 
6.13 Data Collection 
The research questions often dictate which specific methods of data 
collection are most suitable. Without high quality data collection methods, 
the accuracy and robustness of the conclusions are open to criticism 
(Polit et al. 2008). As two research populations were included; PICU 
patients and staff, a combination of data collection methods was deemed 
most appropriate.  
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6.13.1 Data Collection; Patients 
From a patient data perspective, the PICANet database was available 
providing a ‘ready to analyse’ dataset. The information sources used for 
selection of this patient subgroup are illustrated in Figure 6.13.1. After 
ethical approval for the study had been granted, the PICU data manager 
was approached in March 2009 and requested to design and run a query 
to extract patient episodes from the PICANet database:  
 
P1-The before group; consisted of all patients admitted to the PICU 
between the dates of 1st March 2009 to 28th February 2010. These 
patients were treated according to standard analgesia and sedation 
management practices. 
 
P2-The after group; all patients admitted to the PICU between the dates 
of 1st August 2010 to 31st July 2011. This patient group was managed 
according to the changed approach to analgesia and sedation 
management. 
 
As P1 and P2 each comprised over 900 subjects, a subset of P1 and P2 
was required to facilitate more in-depth analysis. Strict inclusion and 
exclusion criteria were used to obtain 2 comparable groups with minimal 
confounding variables. The daily cardiothoracic surgery patient list was 
used to identify patients meeting inclusion criteria, with permission from 
the Cardiothoracic Surgery Department. Selected patients were cross-
referenced with admissions on the PICANet database and cases that did 
not meet inclusion criteria from the P1 and P2 populations were filtered 
out. Once patient episodes were identified, they were cross-referenced 
with the Hospital Inpatient Enquiry database (HIPE) to determine their 
location. Patient healthcare records of relevant subjects were retrieved 
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from the healthcare record library. Laboratory data for risk of organ 
dysfunction scores (PELOD) were kindly retrieved by the Hospital’s Chief 
Medical Scientist. A validated tool specifically designed for the study was 
used to collect the required information anonymously, and in a structured 
manner, maintaining patient confidentiality at all times. 
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Figure 6.13.1: Data sources for PASQ 
 
Through the process outlined above, a retrospective chart review was 
performed on those patients identified for further analysis. Use of existing 
patient records are an important, well recognised data source for nurse 
researchers (Bowling, 2009). While this data source is advantageous in 
terms of time and economy, and does not require participant co-
operation; in some cases the records were not available. A further 
limitation of using patient records is the two major sources of bias 
inherent in this data source; selective deposit and selective survival. 
While it appeared many patient records were missing at random, the 
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representativeness of existing records was considered. The impact of 
this phenomenon was likely to affect the ‘before’ and ‘after’ group 
equally.  
 
6.13.2 Data Collection; Staff 
A standardised descriptive survey approach was chosen to collect data 
from PICU staff. This was achieved by means of a questionnaire, 
allowing the systematic gathering and measurement of objective 
information from a large group of individuals (Norbeck, 1987 cited in 
Parahoo, 2000 p.54). This strategy is a quick and low cost method of 
reaching a large geographically spread sample which can gather detailed 
information and can maintain anonymity effectively. As all respondents 
are asked the same standardised question, interview bias is avoided 
(Rees, 2003). Furthermore, as opinions and knowledge were being 
assessed, the questionnaire was a less intimidating method of data 
collection than face to face contact, and allowed respondents the 
freedom to answer questions honestly and in their own time (LoBiondo-
Wood et al. 2006).  
 
Limitations of this approach included the labour intensive task of 
developing and validating a questionnaire, which was necessary if 
existing tools or scales could not be used. The length of the 
questionnaire and the burden on respondents was considered. In 
addition, little scope for probing and clarifying respondents’ answers was 
provided, although questionnaires are not designed for this. Parahoo 
(2000) acknowledges that the structure and wording of questions and 
response categories can reflect the researcher’s bias. These issues had 
to be given strong consideration at the questionnaire design phase of the 
study. The instruments used to collect patient and staff data will be 
discussed in turn.  
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6.14 Data Collection Instruments  
 
6.14.1 PICANet Census Data 
The Paediatric Intensive Care Audit Network (PICANet) was established 
in the UK in 2001 to improve patient outcomes by providing information 
on delivery of care to critically ill children and an evidence base for 
clinical governance. The need for involvement of Irish PICUs in this 
clinical audit and activity collection policy was long acknowledged by 
clinicians, and formally identified in the HSE commissioned DNV 
strategic review (DNV Consortium, 2008). The study site was the first 
non-UK PICU to contribute data to PICANet, adding an International 
component to the network. For the first time, benchmarking exercises 
with robust data from an Irish PICU was possible.  At the time of the 
study; 37 centres in UK and Ireland were contributing data to PICANet 
and the study site ranked in the top four in terms of amount of annual 
admissions to the PICU. The high quality prospective patient data 
collected daily was vital for providing a starting point for research studies 
such as this.   
 
6.14.2 PICANet; Validity and Reliability  
The most effective means of enhancing reliability is by thoroughly 
training data gatherers to maintain consistency and high quality (Polit et 
al. 2008). Extensive data personnel training and support was provided by 
PICANet, to ensure no loss in continuity of prospective data collection 
and to ensure maximum data quality. Data entered were cross checked 
with another patient database. In addition the PICANet software 
performed internal logical consistency and range checks as data were 
entered and provided an on-screen summary of outstanding validation 
checks. In addition the UK based PICANet team visited each member 
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site annually to complete a validation visit by comparing 20 sets of 
randomly selected patient notes and comparing the data entered with the 
healthcare record. As well being a source of valuable data regarding 
patient demographics and individual PICU episodes; PICANet 
incorporated a mortality prediction tool (PIM), deriving a score for each 
patient entered onto the database. Inclusion of this variable in patient 
data collection provided a means of determining whether before and after 
groups were comparable in terms of severity of illness.   
 
6.14.3 Severity of Illness and Mortality Prediction Tools 
6.14.3(i) PIM and SMR   
The Paediatric Index of Mortality (PIM) is a logistic regression model that 
predicts the risk of death for children admitted to PICU using patient 
medical history, interventions and physiological measurements taken at 
time of first contact with a PICU doctor up to the first hour after admission 
(Shann et al. 1997). These factors were originally selected as good 
predictors of mortality. A reflection of the performance of individual 
PICUs is calculated from the number of actual deaths in a defined patient 
group divided by number of deaths predicted by the aggregate PIM 
scores. This value is termed the ‘Standardised Mortality Ratio’ (SMR). 
Every year PICANet presented the SMR for all PICUs in the PICANet 
Annual Report. These were presented graphically using funnel plots with 
upper and lower control limits. PICUs falling above the upper control 
limits were deemed to have an excess mortality that may warrant 
investigation. While it is considered normal for SMRs to fall with time due 
to improvements in intensive care (Pearson et al. 2001), clinicians such 
as Tibby et al. (2001) remain sceptical that such improved outcomes can 
be attributed to an increase in the quality of intensive care without 
significant treatment breakthroughs or radical service reconfiguration. 
Despite no such developments; PICU mortality was decreasing annually 
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and was 4.2% in 2011, compared with 5.5% in 2003-2004 (PICANet, 
2011).  
 
6.14.3(ii) PIM Validity 
Over time prediction models lose sensitivity and require calibration 
(Pearson et al. 2001). Such decalibration is also an issue with other 
mortality prediction models such as the PRISM score (Paediatric Risk of 
Mortality) and the APACHE score (Acute Patient and Chronic Health 
Evaluation) (Pollack et al. 1996; Knaus et al. 1991). Recalibrated in 2003 
and renamed PIM2; PIM2 was used only for historical comparisons 
(Personal communication with McShane P, PICANet Statistician 30th Nov 
2011). Further recalibration of PIM2 had generated PIM2r, which was 
developed by entering the PIM2 variables into a logistic regression model 
and combining the resultant coefficients. Standard statistical methods 
were used to assess the performance of the recalibrated model in the 
2008‐2010 PICANet data: the area under the ROC curve was 0.84, 
comparable to that reported for PIM2. PIM2r better reflected mortality, 
and development of PIM3 had commenced (Draper et al. 2011). This 
would allow effective monitoring of acuity of PICU admissions and 
outcomes to improve the quality of paediatric intensive care. 
 
6.14.3 (iii) PIM in the Irish Setting 
Prediction tools must discriminate well between deaths and survivors and 
be well calibrated before being used for meaningful comparisons (Brady 
et al. 2006). Pearson et al. (2001) concede that although PIM was 
originally developed in Australia and tested in 4 UK PICUs before being 
adopted by PICANet as the mortality prediction tool incorporated in their 
database; it had not been externally validated for general use in UK 
PICUs. Furthermore it had not been validated for use in an Irish setting. 
Brady et al. (2006) point out that for risk-adjusted mortality rates to be 
meaningful, epidemiological studies should use a tool derived from native 
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data or use the most recent calibration of the chosen tool. Rigorous data 
collection had only recently commenced in Irish PICUs and the body of 
data gathered thus far was not yet substantial. For a tool to calibrate well 
in a validation sample, all factors that influenced outcome must have the 
same distribution in the validation sample as the sample used to develop 
the model. There was some variation in the structure, staffing and 
organisation between Irish and UK PICUs, but given that standards of 
Paediatric Intensive Care in both countries were guided by the Paediatric 
Intensive Care Society standards of care (PICS Standards 2010), it was 
not anticipated that staffing levels and nurse-patient ratios would vary 
hugely.  
 
6.14.3(iv) Interpretation of Mortality Score Using PIM 
The formula of deriving PIM values is provided in table 6.14.3. The score 
should be interpreted as a percentage predicted probability of death. 
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Table 6.14.3: Formula for Calculating PIM Values 
Deriving PIM Score 
Variables Values (1=Yes, =Other) Beta 
Elective Admission   
Underlying Condition   
Response of Pupils to Bright Light 
(>3mm and both fixed) 
  
Mechanical Ventilation in First Hour   
Systolic Blood Pressure (mmHg)  0.021 
Base Excess (mmHg) Arterial or Capillary 
Blood 
 0.071 
Fi02(%)/PaO2 mmHg  0.415 
Predicted Death Rate: [         ] 
Logit = (-4.873) + (values * Beta) + (0.021 * (absolute(SBP-120))) + (0.071 
* (absolute base excess)) + (0.415 * (FiO2/PaO2)) 
Predicted death rate = eLogit/ (1+eLogit) 
Source:  F. Shann et al. (1997) Paediatric index of mortality (PIM): a mortality 
prediction model for children in intensive care. Intensive Care Medicine (23), 
p201-7. 
 
 
6.14.3(v) Interpretation of SMR 
As mentioned, the standardised mortality ratio (SMR) of the population 
was calculated by dividing the observed by the predicted mortality. The 
SMR was a quantity, expressed as either a ratio or percentage. If the 
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SMR was quoted as a ratio and was equal to 1.0, then this means the 
number of observed deaths equalled that of expected cases. If higher 
than 1.0, then there was a higher number of deaths than is expected. 
 
6.14.3(vi) Ventilator Free Days 
Ventilator-free days are defined as days alive and free from mechanical 
ventilation in a 28 day time period in the PICU (Schoenfeld et al. 2002). 
Ventilator free days were calculated as 28 minus the number of ventilator 
dependent days, assuming survival to 28 days or discharge from the 
hospital. Patients who died before 28 days were assigned a score of zero 
to avoid the confounding effect of mortality. Use of ventilator-free days as 
a trial end point allowed smaller sample sizes if it was assumed that the 
treatment being tested simultaneously reduced the duration of ventilation 
and improved mortality. 
 
6.14.4 PICANet Variables 
The patient information obtained from the PICANet database for 2 patient 
groups; P1 and P2 is illustrated in table 6.14.4. 
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Table 6.14.4: Variables Collected from PICANet Data 
PICANet Variables 
Age 
Gestation 
Duration of ventilator dependence 
Length of PICU stay 
Supportive therapies required 
Status at discharge from PICU 
30 day follow up status 
Patients PIM scores 
Group SMR for P1 and P2  
Ventilator free days 
 
 
6.15 The Patient Analgesia and Sedation Questionnaire (PASQ)  
Census data were not conducive to deeper analysis, such as precise 
duration of ventilator dependence, amounts of analgesics and sedatives 
administered and compliance of staff with analgesia and sedation 
guidelines. Therefore selection of a comparable patient group from each 
of the defined time periods (between (01/03/2009 and 28/02/2010) and 
(01/08/2010 and 31/07/2011) meeting pre-defined inclusion criteria was 
carried out. These subgroups facilitated a more rigorous and detailed 
analysis using a purposefully designed questionnaire called PASQ 
(Patient Analgesia and Sedation Questionnaire, see appendix 18).  
 
The PASQ was designed to gather nominal demographic patient 
information and ratio level data including quantities of analgesia and 
sedation given, length of ventilator dependence and PICU stay. The 
before/after analysis of these subgroups focussed on how the 
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intervention impacted the amounts of analgesia and sedation these 
patients received and whether there was a difference in duration of 
mechanical dependence and PICU stay. Duration of mechanical 
ventilation was a main outcome measure of the study. As 91.9% of 
patients post cardiac surgery were ventilated on return to PICU from the 
operating theatre, focussing on this population for further analysis was 
prudent. It was vital to ensure that as a change in practice was occurring, 
the PICU patient was not exposed to any undesirable effects such as 
pain and distress. Therefore patient distress assessment scores were 
obtained. 
 
A further purpose of the PASQ instrument was to determine whether 
PICU staff were compliant with the analgesia and sedation guidelines 
after the intervention. The early post-operative phase was a critical time 
period for PICU nurses and doctors. Controlling pain and managing the 
sedative requirements of patients while moving towards liberation from 
their dependence on mechanical ventilation was hugely challenging and 
required much skill. The analgesia and sedation guidelines and the 
distress assessment tool were particularly relevant in this time period. 
Therefore data collection focussed on the first 72 hours of each subject’s 
PICU stay where the intervention was most relevant. In addition the 
median length of stay in the PICU for cardiothoracic patients was 2.9 
days (IQR 1.6-3.1). Furthermore, the median duration of mechanical 
ventilation was 0.8 days (IQR 0.4-1.9) making this time frame 
appropriate. These retrospective data were extracted from patient 
medical and nursing notes, PICU flowsheets, drug prescription 
documentation and the hospital haematology and biochemistry 
laboratories. The variables collected by PASQ are listed in table 6.15.  
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Table 6.15: Variables required by PASQ 
PASQ Variables 
Date of Birth. Gestation. Gender. 
Surgery Performed. First Procedure? PIM & RACHS Score. 
Aortic Cross Clamp. CPB Time. PELOD; Epoch 1, 2 & 3. 
Analgesia in OT post CPB. Sedation in OT post CPB. Arrival Time in PICU. 
Analgesia in PICU:  
Epoch 1, 2 & 3. 
Sedation in PICU:  
Epoch1, 2 & 3. 
Extubation date & time. 
Precise duration of 
Mechanical Ventilation. 
Precise duration PICU LOS. Discharge status. 
 
6.15.1 PASQ Power Analysis 
Power analysis can be used to calculate sample size. Its use relies on 
having some estimation of the degree of change expected in the 
dependent variable, and is therefore limited to studies where research on 
the subject already exists (McMahon, 1994). The dependent variable in 
this study was dosage of morphine administered; as this was the primary 
analgesic used in the PICU, also possessing anxiolytic properties. From 
the research conducted by Jin et al. (2007) on the efficacy of the 
COMFORT-B scale in assessing optimal sedation in critically ill children 
requiring mechanical ventilation, morphine dosages before and after 
incorporation of a distress assessment tool into practice in a Korean 
PICU were assessed. The dosage of morphine for the intervention group 
was 204.0 mcg [IQR 94.8:493.2]. For the control group the average 
morphine administered was 495.5 mcg [IQR 280.3:835.1].  
The mean COMFORT-B score for the intervention group was 5.32 (SD 
1.1), the mean score for the control group was 6.21(SD 0.9). Based on a 
change in mean score from 5.32 to 6.21 and a common standard 
deviation of 0.9, it was determined that a sample size of 20 patients per 
group (20 in the ‘before’ group and 20 in the ‘after’ group) would provide 
at least 80% power to detect a similar change in dosage with a level of 
significance of 0.05. 
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6.15.2 PASQ; Pilot Study 
Although Polit et al. (2008) recommend computing new estimates of 
reliability when a tool is used in a new setting; piloting an instrument 
designed to collect physiologic measures that are relatively impervious to 
fluctuations from personal or situational factors, this procedure is not 
necessary. Nevertheless a pilot study using this tool was conducted to 
identify any problems and ensure effectiveness of its use.  
 
For the pilot; 10 sets of patient healthcare records were selected and 
data retrieved using the instrument. Administration time of the instrument 
was unacceptably long; up to two hours per subject. This led to 
refinements of the tool, notably a rationalisation of the number of 
analgesic and sedative drugs included. There were a range of these 
agents available for clinicians to prescribe for PICU patients, however the 
6 most commonly used agents were focussed on. These were primarily 
the agents contained in the PICU analgesia and sedation guidelines, 
except for the non-steroidal anti-inflammatory drugs which were often not 
given in the early post-operative period due to the anti-platelet effect 
increasing the risk of post-operative haemorrhage. The 6 
analgesic/sedative drugs selected are contained in Table 6.15.2.  
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Table 6.15.2: The Analgesic and Sedative Drugs Selected for Inclusion in Study 
Drug Name Indication 
Morphine 
 
The primary analgesic in post-operative patients, possessing 
known respiratory depressant effects. Data concerning the 
infusion rate and bolus doses were collected. Differences in 
amounts of morphine in the before and after period provided the 
focus of the study. 
Midazolam A member of the benzodiazepine family and the primary 
sedative used in PICU. The amount of midazolam administered 
via both the intravenous and enteral route was collected. 
Paracetamol A common analgesic and antipyretic. Noted for its opioid 
sparing and co-analgesic properties. Intravenous paracetamol 
was advocated by the analgesia and sedation guidelines. 
Chloral 
Hydrate 
Utilised as a sedative once viability of the oral route of 
administration re-established, despite its mechanism of action 
remaining unknown, and possessing an unpredictable half life 
and no reversal agent. 
Clonidine Classified as an alpha-adrenergic agonist. Utilised in PICU for 
its sedative and mildly analgesic properties, and acknowledged 
as an opioid weaning adjunct. 
Oramorph The oral preparation of morphine; frequently used for its 
analgesic properties once weaning of intravenous morphine 
infusion instituted, also valued as a morphine weaning adjunct. 
 
In order to reflect the acuity of patient participants; PASQ gathered 
information about the level of cardiac risk, and the daily level of patient 
organ dysfunction using validated organ dysfunction score and a cardiac 
risk stratification tool. 
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6.15.3 (i) PELOD  
Mortality is a very blunt measure of a much more complex scenario and 
unlikely to allow fair comparisons or meaningful information upon which 
to base changes in practice. While the PIM score was useful in 
determining mortality risk in PICU patients; death in PICU was not a 
common occurrence ranging from 4-6% of all admissions (PICANet, 
2011). A more common occurrence was paediatric organ dysfunction, 
ranging from 11-27% (Leteurte et el, 2003) making prediction of organ 
dysfunction a valid surrogate outcome. The paediatric logistic organ 
dysfunction (PELOD) score is a valid outcome measure of the severity of 
multiple organ dysfunction syndrome in PICU. It includes 6 key organ 
dysfunction indicators; respiratory, cardiovascular, haematological, 
neurological, renal and hepatic. PELOD is clinically meaningful, has 
construct and content validity, is externally validated and has good 
discriminatory ability in the first 5 days of PICU stay (Leteurte et al. 
2003). The chief medical scientist of the hospital laboratory assisted with 
retrieving the required variables for the first three consecutive post-
operative days spent in PICU to provide a daily measure of the patient’s 
severity of illness. 
 
6.15.3(ii) Interpretation of Organ Dysfunction using PELOD  
The paediatric logistic organ dysfunction score (PELOD) was designed to 
evaluate the clinical course of multiple organ dysfunction over time in 
critically ill children using selected variables representing organ function. 
The following information to guide interpretation of PELOD scores was 
developed by Leteurte et al. (2010):  
 High PELOD score: ≥ 20 points  
(associated with an odds ratio (OR) for death of 40.7 (95% confidence 
interval [CI] 20.3-81.4)).  
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 Medium score 10-19 points  
(associated with an OR for death of 4.2 (95% CI 2.0-8.7)).  
Mortality was 50% when a high score on day 1 increased on day 2. 
PELOD scores indicating a worsening condition or no improvement over 
time were indicators of a poor prognosis in the PICU. 
 
6.15.3 (iii) RACHS 
Because each congenital cardiac defect was a rare condition, assessing 
the quality of care was problematic. The RACHS (risk adjustment for 
congenital heart surgery) system is a risk stratification tool which was 
developed by consensus to compare outcomes of congenital cardiac 
surgery (Al-Radi et al. 2007). It is valuable in making risk-adjusted 
comparisons between groups. A RACHS score was assigned to each 
subject in this study based on the criteria provided by Jenkins et al. 
(2002). Assigning a RACHS score to each patient participant was 
overseen by a consultant cardiothoracic surgeon.  
 
6.15.3 (iv) Interpretation of Cardiac Risk using RACHS 
The risk adjusted congenital heart surgery score (RACHS) is a model 
developed consensually by an 11 member panel where nearly all cardiac 
surgical procedures are divided under six categories of increasing 
predicted operative risk.  Category 1 relates to lowest risk and category 6 
to highest risk. See appendix 19 for the full list of procedures in each 
category.  
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6.15.3 (v) Cardiopulmonary Bypass Time and Aortic Cross Clamp Time  
Placing patients on cardiopulmonary bypass (CPB) during cardiac 
surgery facilitates a bloodless, non-moving field in which to perform 
surgery. Clamping the aorta separates the systemic circulation from the 
outflow of the heart. Research by Nissinen et al. (2009) showed that 
longer CPB and aortic cross clamp times were predictors of immediate 
postoperative morbidity and mortality (area under the curve, AUC: 0.66), 
CPB time (AUC: 0.73) and CPB with unclamped aorta (AUC: 0.77). CPB 
duration intra-operatively of <240 min (30-day death: 1.9% vs 31.5%, 
adjusted OR 8.78, 95%C.I. 4.64-16.61, accuracy 96.0%) and aortic cross 
clamp time of <150 min (30-day death: 1.8% vs 12.2%, adjusted OR 
3.07, 95% C.I. 1.48-6.39, accuracy 91.5%) were associated with a rather 
low risk of immediate postoperative adverse events independently of the 
complexity of surgery patient’s operative risk. Longer than these 
specified durations of CPB and cross clamp were significantly associated 
also with postoperative morbidity, particularly with postoperative stroke 
(OR 1.47, 95%C.I. 1.27-1.71). CPB and aortic cross clamp times were 
presented in minutes as median values.  
 
6.16 Inclusion and Exclusion Criteria PASQ 
The power and strength of experimental and quasi-experimental 
research is related to control (Walker, 2005). This involves strict 
application of standardised procedures to reduce systematic bias and 
eliminate erroneous conclusions (Hicks 1998; Burns and Grove 2001). 
Examples of the exertion of control include randomisation, blinding 
procedures, the use of a comparison group or the use of strict inclusion 
and exclusion criteria. The dividend of effective control is the 
researchers’ ability to state with confidence that the outcome produced 
can only be attributed to the effects of the experiment (Duffy, 1986). In 
this case the careful establishment of sample inclusion and exclusion 
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criteria was performed to control for extraneous variability or bias that 
would limit the strength of evidence contributed by the sampling plan. 
The risk of compromising construct and external validity was 
acknowledged, therefore deep consideration for each inclusion and 
exclusion criterion was given (See table 6.16 for inclusion and exclusion 
criteria).  
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Table 6.16: Inclusion and Exclusion Criteria; PASQ 
PASQ Inclusion Criteria 
Patients admitted to PICU in the defined time period meeting the 
following criteria: 
Admitted from the operating theatre following cardiothoracic surgery. 
Intubated on arrival to PICU. 
Receiving intravenous morphine analgesia. 
Patients who were placed on cardiopulmonary bypass during their surgery. 
Aged from 44 weeks post-conceptual age to 12 months of age. 
 
PASQ Exclusion Criteria 
Patients admitted to PICU in the defined time period meeting the 
following criteria: 
Patients with cerebral pathology including brain ischaemia (COMFORT B 
distress assessment tool not validated in these patients). 
Patients receiving neuromuscular blockade (NMB) via infusion or regular boli. 
(COMFORT B assessment tool not validated in these patients). 
Confirmed syndrome aside from Trisomy 21. 
Did not receive cardiopulmonary bypass during surgery. 
History of cardiac arrest or significant intra-operative events. 
Non-intubated patients (duration of mechanical ventilation was an outcome 
measure). 
> 3 day stay in PICU or NICU prior to current PICU episode (previous exposure 
to opioid therapy).  
>3 days mechanical ventilation prior to cardiac surgery (may have predisposed 
patient to prolonged dependence on mechanical ventilation).  
Regional anaesthesia used (opioid sparing, amount of opioid used was an 
outcome measure) 
Hypersensitivity to opioids. 
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ECLS and/or CVVH therapy (increased doses of opioids may have been 
required to account for adherence to wall of circuit (Mulla et al. 2000)). 
Patients who were receiving comfort care as the goals of sedation and analgesia 
differ for this group. 
Patients with severe developmental delay or those with a neurodegenerative 
disorder as the distress measurement scale was not validated for these groups.  
Patients diagnosed with Neonatal Abstinence Syndrome 
Patients transferred into PICU from another hospital where sedatives had 
already been administered 
Patients resuscitated from cardiac arrest. 
Patients <28 weeks gestation as the distress measurement tool was not 
validated in these patients. 
 
6.17 Perceptions of PICU Analgesia and Sedation Guidelines 
Surveys have shown positive opinions from PICU staff after sedation 
guideline introduction. Alexander et al. (2002) used a 9 item Likert scale 
to determine whether PICU staff found a newly introduced sedation 
protocol easy to use, safe, effective and efficient in managing patient 
comfort. While the majority of responding nurses (n=53) and staff 
physicians agreed that the protocol was associated with more effective 
and efficient patient management; most of the staff physicians (n=3) 
associated the sedation protocol with over-sedation of patients. It was not 
clear whether this was a concern in the PICU prior to implementation of 
the protocol. Similarly, Ista et al. (2009) used a closed ended post-test 
survey to determine PICU nurses’ and physicians attitude and 
satisfaction regarding the utility of a newly introduced sedation protocol. 
Twenty five (96%) of responding nurses found the protocol 
comprehensible and 23 nurses (89%) considered it clinically useful. 
Acknowledging the general acceptance and openness of PICU staff 
towards analgesia and sedation guidelines or protocols; these studies did 
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not offer a baseline for comparison before the introduction of the change 
in practice.  
 
The staff analgesia and sedation questionnaire (SASQ) was designed to 
assess the satisfaction of PICU nurses and doctors with analgesia and 
sedation practices before and after the intervention. Use of the survey 
method allowed access to a large number of study participants without 
the constraints of rigid control. The information gleaned from this staff 
survey gauged the receptiveness of the staff towards the intervention, 
informed development of the analgesia and sedation guidelines and 
enabled detection of changes in staff perceptions of analgesia and 
sedation guidelines. Proceedings of 6-8 weekly Analgesia Sedation 
Committee meetings and informal staff feedback supplemented these 
data. 
 
6.17.1 SASQ Instrument Development  
The instrument used was the SASQ (Staff Analgesia and Sedation 
Questionnaire, (see appendix 20). Items contained in the questionnaire 
were derived from existing literature and input from a committee 
comprising a consultant anaesthesiologist, a consultant Intensivist, the 
PICU pharmacist, the Acute Pain Clinical Nurse Specialist, 2 nurse 
managers and 2 senior PICU nurses. Six independent PICU staff (four 
senior nurses, one consultant anaesthesiologist and one consultant 
Intensivist) formed a panel to validate the SASQ.  
The questionnaire was divided into 3 sections;  
Section A related to the participants’ demographic data and background 
information including level of seniority and duration of experience in 
PICU. Respondents were asked to specify any previous education in 
relation to pain and sedation in PICU they had received.  
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Section B (a) the ‘Satisfaction Section’ of the questionnaire comprised a 
Likert type scale from 1 (strongly disagree) to 6 (strongly agree) about 
the current approach to managing, assessing and weaning analgesia 
and sedation in the PICU. Respondents were specifically asked whether 
they felt the current approach to analgesia and sedation management 
was effective.  
 
Section B(b) the ‘Items of Concern’ section of the questionnaire 
comprised 22 items relating to current practice in analgesia and sedation 
management. Participants were required to place a tick in the box 
accompanying each statement if they felt it was a significant clinical issue 
in the PICU and to document any suggestions or further issues meriting 
concern.  
 
Section C, the ‘Knowledge Section’ of the questionnaire contained 15 
statements derived from the literature and the expert panel relating to 
areas around pain and sedation where confusion and uncertainty 
appeared to exist. These statements were either true or false and 
respondents were required to indicate their level of agreement with each 
item on a Likert style scale ranging from 1 to 6.  
 
Respondent’s knowledge levels were tested on a variety of important 
issues which emerged in contemporary literature including the ability of a 
neonate to sense and interpret pain. Twycross et al. (2009) confirms that 
despite abundant evidence confirming the ability of neonates to sense 
and interpret pain; the misconception that infants do not feel as much 
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pain as adults remains in clinical practice. Neonates represented up to 
30% of annual admissions to the PICU at the study site (Healy et al. 
2013). There are considerable immediate and long-term consequences 
of poorly managed pain and stress for this population; hence it was 
important to include it in the questionnaire.  
A substantial focus was placed on the intricate relationship between pain 
and anxiety, as well as the overlap between analgesics and sedatives. 
The crossover in the roles of analgesia and sedation are illustrated by 
the classic examples of morphine having sedative properties, clonidine 
providing analgesia and anaesthesia and even muscle relaxants having 
an additive effect on reduction of conscious state through deafferentation 
(Bonhomme et al. 2008). Indeed Tobias et al. (1994) have long 
advocated the use of opioids for the treatment of agitation in those 
situations that do not necessarily require analgesia; these authors further 
contend that opioids may be more effective for sedation than 
benzodiazepines in younger children less than 1 year of age. 
In addition, respondents were posed the statement “a child with an open 
sternum requires additional analgesia,” as it seemed from Analgesia and 
Sedation Committee meetings that there was uncertainty in practice 
regarding this. While it is established that neonates who have delayed 
sternal closure after cardiac surgery have a more complex post operative 
recovery that those who have primary sternal closure (Erek et al. 2012), 
there is no evidence to confirm whether any increased analgesic or 
sedative requirement is related to a greater severity of illness or 
increased pain from the wound. Additionally a statement suggesting 
PICU patients on an external circuit such as ECMO (extra-corporeal 
membrane oxygenation) or CVVH (continuous veno-venous 
haemofiltration) required additional analgesia, was included. It is known 
that significant absorption of drugs occurs in external circuits such as 
ECMO circuits, correlating with increased lipophilicity of the drug 
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(Wildschut et al. 2010). Nevertheless, rather than endorsing a dose 
adjustment to account for this, individual assessment rather than a 
blanket approach is advised (Mulla et al. 2000). The final question tested 
the respondents’ knowledge about the COMFORT B tool. Accurate 
responses were anticipated to this question as all nurses had attended a 
training session on its application and all doctors had been involved in an 
awareness campaign regarding its use in practice. 
 
A further 5 questions were added to the SASQ which was administered 
after the intervention. The statement ‘Optimal sedation is when the 
patient is easily rousable, free from pain and anxiety and can tolerate 
medical and nursing procedures’ was presented to respondents to reflect 
a departure from the previous practice of deep sedation towards light 
sedation. Evidence to support the benefits of light sedation and the 
adverse effects of drug induced coma continues to emerge (Kress et al. 
2000; Girard et al. 2008). Respondents were asked about tolerance and 
weaning as it is now known that opioid tolerance occurs earlier in the 
younger age groups, it develops commonly during critical illness and 
results more frequently from prolonged intravenous infusions of opioids 
(Anand et al. 2010). Hence determining the awareness of this 
phenomenon in the PICU was important.  
 
Regarding the use of guidelines in practice; McCormack et al. (2007) 
propose that the goal of guidelines and protocols is to exemplify best 
practice, to provide guidance and reduce needless variation, thereby 
improving effectiveness and efficiency. However, it has been identified 
that protocols and guidelines may be perceived as removing clinical 
judgement and hindering consideration of all facets of the care of the 
participants involved, thereby creating resentment and frustration among 
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healthcare professionals (Ely, 2001). In light of this; participants were 
asked whether they felt that the use of analgesia and sedation guidelines 
hindered autonomy and individual decision making practice. A 
comparison of these responses with opinions before the intervention 
would not be possible for these items.  
 
6.17.2 Validity and Reliability; SASQ 
Validity is the degree to which an instrument measures what it purports 
to measure (Polit et al. 2008), while reliability is concerned with 
consistency and dependability (McCarthy et al. 2008). Threats to validity 
must be anticipated, and design features introduced to eliminate or 
minimise these threats implemented. This results in stronger validity of 
inferences and the evidence from the study being more persuasive (Polit 
et al. 2008).  
 
Content validity refers to judgements (usually made by a panel) about to 
which the content of the instrument appears logically to examine and 
comprehensively include, in a balanced way, the full scope of the 
characteristic or domain it is intended to measure (Bowling, 2009). Field 
(2009) advocates brainstorming with a sample of individuals to generate 
items for inclusion in the questionnaire. The selected panel of experts 
developed the list of items for inclusion in the questionnaire from items 
observed in clinical practice, items emerging at recent PICU conferences 
and analgesia and sedation meetings and the Paediatric Intensive Care 
Standards for the Care of the Critically Ill Child (PICS, 2010).  
 
Six independent PICU staff reviewed the items for inclusion in the SASQ 
questionnaire. Using a content validity index (CVI); only items which 
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scored an I-CVI of >0.8 were selected for inclusion in the final version of 
SASQ. A scale level CVI average value of 0.91 was obtained suggesting 
a highly valid content within the tool (see appendix 21).  
 
With regards to external validity; this is described by Polit et al. (2008) as 
the validity that inferences about observed relationships will hold over 
variations in persons, setting, time or measures of the outcomes. 
External validity concerns the generalisability of causal inferences; this is 
a critical concern for research that aims to yield evidence for evidence-
based nursing practice. All PICU staff were included in the before and 
after questionnaire survey. A demographic profile of respondents should 
enable comparisons; institutions with similar staff characteristics may 
estimate whether they are likely to obtain similar outcomes in their own 
staff population. As subscribers to the Paediatric Intensive are Society’s 
(PICS) standards, including safe staffing levels for PICU and analgesia 
and sedation practice; it was likely that similar staffing structures and 
practice norms existed elsewhere; suggesting a high degree of 
generalisability of the findings of the SASQ survey.  Conduction of a pilot 
test allowed further testing of the instrument; specifically in terms of 
construct validity and reliability. 
 
6.17.3 Pilot Test; SASQ 
The SASQ underwent pilot testing as it was a newly developed 
instrument. This was carried out in advance of the main study to assure 
comprehension and ease of completion of the questionnaire. 
Undertaking this process acted as a faultfinder, allowing the main study 
to progress more smoothly. A group comprising 10 PICU nurses, a PICU 
consultant anaesthesiologist and a registrar in anaesthesiology who were 
not involved in the main study were used to pilot the instrument over a 
two week period.  Feedback was strongly encouraged regarding any 
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ambiguous or difficult statements. Van Teijlingen and Hundley (2002) 
consider evidence of poorly structured questions to be an excess of 
missing data where respondents are unsure or unwilling to reply. Piloting 
commenced on the 12th January 2010 for a two week period.  
 
For the pilot study, a response rate of 83.3% was achieved. Exploratory 
factor analysis was used to investigate the dimensions underlying SASQ. 
Factor analysis identified multiple traits underlying the overall scores, as 
different dimensions were explored within the questionnaire.  For Section 
B, the six item scale, the internal consistency Cronbach’s alpha was 
0.69, indicating acceptable construct validity.  
 
Reliability refers to the consistency, stability and repeatability of results 
(Twycross et al. 2004).  The test-retest technique was used to explore 
the stability of the instrument. This focussed on the instrument’s 
susceptibility to extraneous influences over time, such as participant 
fatigue (Polit et al. 2008). Five of the volunteers who had helped to pilot 
the instrument were given a second questionnaire 2 weeks after 
completing it for the first time. All questionnaires were returned and a 
correlation coefficient of 0.87 was calculated, demonstrating a stable 
instrument.  
 
Following the pilot study some further amendments were made. Many 
questions were reverse phrased to avoid response bias. Formatting was 
changed to create three distinct sections. It was felt this added to the 
overall clarity of the document. Colour was incorporated to enhance face 
validity. The respondents felt that the completion time of the 
questionnaire was acceptable. 
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6.18 Data Analysis 
A biostatistician was consulted at the design-phase of the research, and 
advised on the appropriate approach to the data analyses. The statistics 
package SPSS version 20 enabled the organisation, summarisation, 
interpretation and communication of numeric information. Legitimate 
conclusions were reached through synthesising characteristics of the 
data. Bowling, (2009) recommends first producing descriptive statistics, 
to describe the findings and visualise any skewness. The distributions 
informed any required recoding of the variables. An appreciation of 
trends in the data emerged from patterns in the numbers.  
 
The level of significance was set at alpha (p=0.05, two tailed) which is an 
acceptable level for social research (Smithson, 2000). Microsoft Access 
software was also used for additional graphic capabilities. The study 
findings are presented in section 3 with accompanying graphs and tables 
to aid clarity. 
 
 6.18.1 Data Verification 
Bowling (2009) recommends the appointment of an independent checker 
to verify the integrity of collected data. For this research project, ten 
percent of completed PASQ questionnaires (n=12) and ten percent of 
returned SASQ questionnaires (n=17) were randomly selected by the 
clinical supervisor of the research and data checked by the PICU data 
manager. The cut-off for complete data re-check was >10% inaccuracies. 
The quality of these data were reported as very good with <5% error 
rate. Identified discrepancies were corrected by revisiting patient notes. 
Missing data were coded appropriately.    
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6.18.2 Data Analysis; PICANet 
Anonymous patient data were obtained from the PICANet Microsoft 
Access database and entered into SPSS v20 after first being cleaned. 
Simple descriptive statistics were then used to present the characteristics 
of both the before and after groups. Pearson’s chi square was used to 
compare before and after PICANet cohort data based on an independent 
samples t-test. Repeated measures were not suitable given the large 
size of the study sample. Correlational analysis enabled relationships to 
be explored and significance was established using Pearson’s r and 
Spearmans rho. A level of significance of <0.05 was considered 
statistically significant for the purposes of this study.  
 
6.18.3 Data Analysis; PASQ 
No identifying patient data were used in the study. Once collected, coded 
and uploaded to the SPSS statistics package version 20; PASQ data 
were cleaned. Histograms were used to plot the duration of mechanical 
ventilation and length of PICU stay for each group. Visual inspection of 
the histograms allowed determination of the distribution of the data and 
identification of outliers. The Shapiro-Wilks test was used to determine 
whether data were normally distributed when this was not obvious from a 
visual inspection. Standard deviation analysis determined the 
homogeneity of the two samples. Dosages of drugs were log transformed 
where appropriate to assist with analysis. 
 
Nominal data were compared using the Chi-square test (or Fisher’s exact 
test in the case of low predicted cell counts). The t-test was also used to 
test differences in group means for parametric data (Pallant, 2007). 
These data were presented as mean values with standard deviations. 
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Non-parametric data were presented as median values with interquartile 
ranges. The Mann-Whitney-U test was applied to compare groups. Other 
tests used to compare the groups included Spearman’s rho (or Kandall’s 
tau) where the relationship strength in ordinal data was explored, and 
pearson’s r correlation coefficient was computed to examine 
relationships in this study. Analysis of PICU patients’ level of distress 
scores revealed whether patients’ comfort levels were maintained within 
acceptable limits. Illustrations including contingency tables and scatter 
plots were used to present the data and support the text. All p values 
were two-sided and a value of <0.05 considered statistically significant. 
Accordingly, the main outcomes that were focussed on in terms of PICU 
patients were:  
 Was there a change in the mean dosage of morphine administered to 
patients after the introduction of the analgesia and sedation guidelines? 
 Was there a difference in selected analgesics and sedatives 
administered to PICU patients after the intervention? 
 Was there a difference in the median length of patient ventilator days 
after the introduction of the analgesia and sedation guidelines? 
 Was there a difference in the median length of patient PICU stay after 
the introduction of the analgesia and sedation guidelines? 
 
6.18.4 Data Analysis SASQ 
All returned questionnaires were analysed, consistent with an ‘all case 
analysis’. Likert type responses for the ‘Satisfaction Section’, alluding to 
‘level of satisfaction with analgesia and sedation practices’ were re-
coded and treated as scale variables. A sum of scores was calculated to 
allow comparison of means between groups. The ‘Items of Concern’ 
section comprising a list of 22 items was rescaled to ‘total score’ for each 
response in SASQ 1 and SASQ 2. For Section C; the ‘Knowledge 
Section’, responses to the true or false statements were transformed, 
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allowing the respondent to achieve a total score for this section which 
was rescaled to a percentage and handled as a scale variable.  
 
Comparisons were made between groups. For all respondents the 
independent t -test was used to analyse differences in group means. For 
respondents who answered both SASQ 1 and SASQ 2, their responses 
were treated as matched pairs and analysed using paired samples t- 
test. In these cases each respondent acted as their own control. Chi 
square analysis and Pearson product-moment correlation and Spearman 
correlation were used to explore the strength of relationships between 
two continuous variables. The main outcomes that were focussed on in 
terms of PICU staff were: 
 Were staff satisfied with methods of assessing distress in PICU? 
 What were the main areas of concern regarding analgesia and 
sedation in PICU before and after the intervention? 
 Were there any knowledge weaknesses or areas of uncertainty 
that required an education focus? 
 Did staff feel the analgesia and sedation guidelines and distress 
assessment tool were clinically valuable in managing patients in PICU? 
 
Level of compliance with guidelines reflected the extent of adoption into 
practice and gave an indication as to their clinical utility. The following 
readily measurable criteria were used to explore the extent of compliance 
with the guidelines: 
 
 Was the morphine running at an appropriate rate on the patient‘s 
return from theatre (≤40mcg/kg/hr)? 
 Was a distress assessment score recorded within the first 2 hours 
post-operatively? 
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 Was IV paracetamol administered in the first 24 hours post-
operatively? 
 Were morphine boluses prescribed? 
 Was non-opioid analgesia prescribed? 
 
6.18.5 Extraneous Variables 
It is well acknowledged that in before/after studies the degree to which 
any changes can be attributed to the independent variable may be 
uncertain as other factors may be responsible for these changes 
(Watson et al. 2008). It is crucial to observe for such extraneous or 
confounding variables. A change in medical staffing occurred during the 
course of this study with two full time anaesthesiologists leaving the 
department and two full time equivalent intensivists commencing in the 
PICU. This may have impacted patient length of mechanical ventilation 
and PICU stay. To control for this, the post-intervention patient group 
were divided into before medical staffing change (MSC) and after 
medical staffing change. The mean duration of mechanical ventilation 
and PICU stay was measured for each period and compared using chi 
square analysis to detect any significant difference. 
 
6.19 Negotiation of Access 
Access to the study populations was sought from the Clinical Director of 
PICU and the Clinical Nurse Manager level 3 of PICU. These individuals 
had demonstrated a strong commitment to the changed approach to 
analgesia and sedation management in the PICU and were instrumental 
in their support towards implementation of the guidelines in practice. 
Access to patient census data and patient healthcare records was 
granted.  
 
 165 
 
In addition, permission to recruit nurses and doctors working in the unit 
was sought from the Clinical Director of PICU and the Clinical Nursing 
Manager level 3 in order to administer SASQ at two time points. 
Assurance that a reasonable questionnaire completion time of on 
average 20 minutes was given. The support of both individuals was 
obtained (See appendices 22 and 23 for letters of permission). Staff 
nurse meetings and medical handovers were suggested as opportune 
moments for highlighting the study, administering the questionnaires and 
encouraging their completion and return. A letter of invitation to 
participate accompanied each questionnaire, providing the potential 
respondent with information about the study (see appendix 24) Due to 
the nature of the shifts worked by nurses, and on-call patterns of doctors; 
access to some staff was difficult. Therefore handover proved to be an 
ideal opportunity to update staff, pass on important information and 
remind staff to return completed questionnaires. CNMs and CNFs 
approached agreed to reiterate the importance of the study and 
encourage staff participation. Permission was given to place data 
collection boxes at nurses’ stations and staff coffee rooms with written 
notices placed on notice boards to provide information and encourage 
participation.  
 
Having gained permission to address each participant individually with 
named envelopes, regular visits to the clinical areas to pick up completed 
questionnaires were carried out. This approach allowed the respondents 
to fill in the questionnaires at their own convenience in private but with 
the personal contact of the interviewer. The respondent could thereby 
ask questions about the study and get clarification on what was required. 
According to Trochim (2006) this strategy is likely to increase the number 
of participants who are willing to respond.  
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6.20 Ethical Considerations 
Research in nursing practice must comply with a code of ethics. In 
response to human rights violations various codes of ethics have been 
developed. The first of these to be recognised was the Nuremberg Code, 
created after the Nazi atrocities were made public in the Nuremberg 
trials. Several others including the Declaration of Helsinki have been 
since developed, adopted in 1964 by the World Health Organisation, and 
revised in 2000 (Polit et al. 2008).  
 
The main Irish law dealing with data protection is the Data Protection Act 
1988. The 1988 Act was amended by the Data Protection Amendment 
Act 2003 bringing Irish data protection law into line with the European 
Union Data Protection Directive 95/46/EC (www.dataprotection.ie).  An 
Bord Altranais has an established code of ethics: the Code of Conduct 
for Nurses and Midwives, (ABA, 2000). Hospitals must act in accordance 
with both local and International laws on the protection of human rights. 
Nurse researchers must comply with the following four principles:  
 autonomy or respect for patients 
 the principle of beneficence- to do good for patients; non-
malificence- to do them no harm 
 to act in accordance with justice and fairness  
  to maintain patient confidentiality (Tschudin, 2003).  
 
6.20.1 Ethical Considerations; PICANet 
Inherent in the endeavour to improve patient outcomes by participating in 
International audit is the dilemma of contributing patient data which has 
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meaning and value, while simultaneously not disclosing details which 
may compromise patient confidentiality. 
 
The Irish Data Commissioner was approached in November 2008 to 
advise on the most appropriate means of exporting patient data from the 
study site to the PICANet central server in Leeds, UK, while maintaining 
patient confidentiality. Through negotiation with the Deputy Data 
Commissioner, an acceptable arrangement was arrived at. Patient data 
would be anonymised before data left the study centre, by removing their 
name and the first two lines of the address. The date of birth and number 
of weeks gestation could be retained which are variables which are of 
great significance clinically (Ciara M. O’ Sullivan, Office of the Irish Data 
Commissioner personal communication, November 2008, see appendix 
25). This arrangement was also acceptable to the hospital’s Ethics 
Committee. No data was exported to the PICANet Central Server in 
Leeds until official confirmation was received from the Irish Data 
Commissioner’s office on 9th March 2009. 
 
6.20.2 Ethical Considerations; PASQ and SASQ 
Two initial meetings were held with the Hospital Ethics Committee in 
advance of commencing the study in order to discuss the research and 
ensure it was ethically compliant. A research application document was 
completed which requested in depth information regarding the purpose of 
the study, risks to participants and provisions to ensure safety and 
confidentiality. The Ethics Committee agreed that the research proposal 
had merit and advised a more detailed plan be submitted (see 
appendices 26 and 27).  
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After fulfilling this request, on 24th March 2010 a further meeting with the 
hospital Ethics Committee took place. A lengthy discussion addressed 
issues of ethical concern. The committee were reassured that anonymity 
of patients and staff would be preserved throughout the study. 
Meticulous collection, analysis, reporting and storing of the data would 
ensure veracity of the research. It was confirmed that supervision was 
provided by a lecturer in Nursing in The Royal College of Surgeons in 
Ireland with experience in research. Clinical supervision was to be 
provided by a Consultant Intensivist in PICU. As the researcher would 
distribute questionnaires to PICU staff at two time points, assurance was 
given that participants would be asked to return completed 
questionnaires without any identifiable data. Therefore, the involvement 
of a gatekeeper allowed re-issue of questionnaires to individuals 
according to their study number to ensure before and after responses 
matched. Implied consent was assumed when respondents voluntarily 
returned the completed questionnaire. Once collected, raw data were to 
be stored securely in a locked cabinet until upload onto the researchers’ 
password protected computer which was accessible to the researcher 
and study supervisor only.  
 
The outcome of this meeting was the granting of approval to explore the 
impact of a changed approach to analgesia and sedation management in 
the PICU (REC Reference GEN/128/09, see appendix 28). Full 
compliance with the requirements of the Hospital Ethics Committee as 
well as adherence to the researcher’s professional obligations (An Bord 
Altranais Code of Professional Conduct, 2000) was maintained at all 
times throughout the duration of the study. 
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6.20.3 Amendments to Ethical Approval  
From the outset of the study it had been anticipated that data on study 
patients experiencing withdrawal syndrome would be collected as part of 
the investigation into analgesia and sedation management. However, as 
the study progressed, it became apparent that collection of these data 
was unfeasible. The introduction of a tool to assess patient withdrawal 
syndrome was delayed, therefore there was no validated method of 
determining whether withdrawal syndrome was present or not. As a 
result it was not possible to examine this phenomenon as part of the 
study.  
 
Amendments are changes made to the research after a favourable 
ethical opinion has been given. They can be ‘substantial’ or ‘non-
substantial’. These changes were deemed to be substantial by my 
research supervisor; hence the Ethics Committee were again 
approached on 29th September 2010. It was agreed that withdrawal 
syndrome would not be addressed as part of the research, but would be 
pursued clinically by the PICU Analgesia and Sedation Committee. This 
was acceptable to the Ethics Committee and a favourable response to 
pursuing with the study was granted (see appendix 29). 
  
Once analysis of census data commenced, it emerged that patients with 
Down’s Syndrome or Trisomy 21 (T21) were disproportionally affected by 
the intervention than those without T21 (see results and discussion 
chapters). The Ethics Committee were again approached for permission 
to treat the T21 population as a subgroup for special focus. This approval 
was granted on 22nd May 2012. (See appendix 30).  
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6.21 Conclusion 
This chapter has outlined the research questions and clearly described 
the methodology employed in answering these questions. Applying the 
best evidence to support practice and generate new knowledge are the 
hallmarks of excellence and allow practitioners to deliver safe and quality 
care. The area of analgesia and sedation in PICU affected both patients 
and healthcare staff enormously and had the potential to impact the 
institution, patients’ families as well as the scientific community. The next 
section will present the findings of this study.  
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Section 3: Study Findings 
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Chapter 7: Findings from PICANet Patient 
Census Data 
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7.0 Introduction  
It is customary for research results to be ordered in terms of overall 
importance. The results of this study will first focus on the PICU patient; 
and findings from analysis of the PICANet patient census data will first be 
presented. Working from the general to the specific; findings of 
subgroups of the census data, interrogated by means of the PASQ 
(Patient Analgesia and Sedation Questionnaire) will follow. The focus will 
then shift to the PICU staff, where the results of the before and after 
SASQ (Staff Analgesia and Sedation Questionnaire) surveys will be 
presented. The minutes from regular PICU Analgesia and Sedation 
Committee meetings will be synopsised and presented, and finally an 
evaluation of the change intervention using the CIPP model will then be 
presented.  
 
7.1.1 Patient Census Data; General Comments 
The following data were extracted from the PICANet local database. The 
pre-intervention patient group was termed P1, while the post-intervention 
group was referred to as P2. The time periods under consideration are 
presented in table 7.1.1, and were appropriate as the intervention 
commenced on the 1st March 2010 leading to the rollout of the PICU 
analgesia and sedation guidelines on the 2nd June 2010.  
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Table 7.1.1: Selection Periods for Deriving Patient Samples P1 and P2 
 
As key research questions involved comparing groups before and after 
the intervention, information about the comparability of the groups with 
regard to background and baseline variables is provided in table 6.14.4, 
so it could be clear that selection bias did not occur. The null hypothesis 
was used in this study; accordingly findings of statistical significance 
were those where a p value of ≤0.05 (two-tailed) emerged. Results which 
did not achieve statistical significance may nevertheless be of clinical 
significance in the PICU setting.   
 
7.1.2 Patient Census Data; Demographics 
As can be seen from data presented in Table 7.1.2, there were 920 
patients in the pre-intervention group (P1) and 965 patients in the post-
intervention group (P2). Both groups were well matched in terms of age, 
weight and gestation. However, a statistically significant difference 
emerged between group P1 and P2 regarding sex (p=0.045). There were 
a greater number of males 58% (n=535) than females in P1, and this 
was true to a lesser degree in P2 where males accounted for 54% 
(n=517) of PICU admissions. The number of patients requiring invasive 
ventilation and inotropic drugs for cardiovascular support was similar in 
both groups. Correction for multiple testing using a test such as 
Bonferroni was considered, however this was not performed as it is a 
very conservative correction; nothing was likely to emerge as significant. 
Furthermore using it may have resulted in important differences being 
Patient Group 
Number: 
Time period admitted to PICU during: 
P1 01/03/2009 to 28/02/2010. 
P2 01/08/2010 to 31/07/2011. 
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overlooked. The predominance of male patients particularly in P1 was 
not considered to have implications acknowledging there was no gender 
distinction when administering PICU care to patients, both sexes being 
treated equally.  
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Table 7.I.2: Demographic and Clinical Characteristics of Samples P1 and P2 
*p compares P1 and P2 based chi-square or Mann-Whitney-U  
 
7.1.3 Patient Census Data; Mortality 
There was no statistical difference in the number of non-survivors in 
groups P1 and P2 (P1; 6% n=55, P2; 56% n=54, p=0.73). However, at 
30 days after PICU discharge there were more non-survivors in P1 (P1 
2.1%, n=18; P2 1.4% n=13). There are cases that are untraceable at 30 
days post discharge from PICU, rendering the calculation of percentage 
survivors at this time point somewhat inaccurate. Nevertheless, this 
Field P1 
(n=920) 
P2 
(n=965) 
*p 
Male n (%) 535 (58.2%) 517 (53.6%) 0.045 
Invasive Ventilation n (%) 659 (71.6%) 653 (67.7%) 0.062 
Inotropic Support n (%) 455 (49.5%) 474 (49.1%) 0.884 
Alive on PICU Discharge n (%) 865 (94.0%) 910 (94.4%) 0.731 
Alive at 30 Day Follow Up n (%) 828 (96.4%) 864 (95.5%) 0.053 
Age in Years 
Median [IQR] 
0.62 
[0.09:3] 
0.47 
[0.07:3.22] 
0.945 
Weight in KG 
Median [IQR] 
7.0 
[3.64:14.7] 
5.64 
[3.43:13.8] 
0.723 
Gestation in Weeks 
Median [IQR] 
40  
[37:42] 
40 
[37.48:41] 
0.076 
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difference in survival at 30 days after discharge from PICU did not 
achieve statistical significance (p=0.053).  
 
7.1.4 Patient Census Data; Diagnostic Group 
The diagnostic groupings for P1 and P2, as determined by the PICANet 
administration team are presented in Table 7.1.4. The groupings 
assigned to patients by PICANet were based on primary diagnoses 
which were assigned ICD 10 codes, an internationally recognised clinical 
nomenclature. These classifications have been endorsed by the Clinical 
Advisory Group, a team of PICU consultants charged with informing the 
PICANet management team and providing clinical governance 
(www.picanet.org.uk). The diagnostic groupings for P1 and P2 were 
largely comparable, aside from the infection and musculoskeletal patient 
groupings, where differences approached statistical significance 
(p=0.05). It was arguable whether this imbalance would impact outcome 
and introduce a confounding variable. This was born in mind when 
analysing the clinical data of these groups, including the severity of 
illness of both groups. Ultimately the cardiac group were selected for 
more in-depth analysis in answering the primary and secondary research 
hypotheses; the infection and musculoskeletal patient groupings would 
not influence this analysis. 
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Table 7.1.4: Diagnostic Groups of P1 and P2 Samples  
Diagnostic Group P1 (%) 
n=920 
P2 (%) 
n=965 
Total (%) 
N=1,885 
p Value* 
Neurological 30 (3.3) 23 (2.4) 53 (2.8) 0.25 
Cardiac 418 (45.4) 476 (49.3) 894 (46.7) 0.06 
Respiratory 197 (21.4) 192 (19.9) 389 (20.3) 0.42 
Oncology 40 (4.3) 36 (3.7) 76 (4.0) 0.5 
Infection 28 (3.0) 16 (1.7) 44 (2.3) 0.05 
Musculoskeletal 21 (2.3) 37 (3.8) 58 (3.0) 0.05 
Gastrointestinal 82 (8.9) 82 (8.5) 164 (8.6) 0.75 
Other 38 (4.1) 46 (4.8) 84 (4.4) 0.5 
Blood and Lymph 18 (2.0) 11 (1.1)  29 (1.5) 0.15 
Trauma 11 (1.2) 7 (0.7) 18 (0.9) 0.29 
Endocrine/Metabolic 20 (2.2) 13 (1.3) 33 (1.7) 0.17 
Multisystem 1(0.1) 0 (0) 1 (0.1) 0.31 
Body wall and 
Cavities 
16 (1.7) 26 (2.7) 42 (2.2) 0.16 
*p values based on Pearson Chi-Square test. 
 
7.1.5 Duration of Dependence on Mechanical Ventilation and PICU Stay 
It is not unusual for clinical datasets to have data skewed by the 
presence of outliers. This renders the mean an insensitive measure. 
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Therefore median values and interquartile ranges were used in 
presenting the data below (table 7.1.5). 
 
Table 7.1.5: Duration of Mechanical Ventilation and PICU stay for P1 and P2 
Variable P1 Mean P1 Median 
[IQR] 
P2 Mean P2 Median 
[IQR] 
p 
Ventilator Free days 
(VFD) 
22.55 26 22.9 26 0.46 
Duration of Mechanical 
Ventilation 
6.75 3[2:7] 7.26 3[2:7] 0.44 
Length of PICU Stay 7.53 4[2:8] 7.95 4[2:8] 0.47 
*p value based on Mann-Whitney-U 
As is evident from table 7.1.5, overall there was no statistically significant 
difference in ventilator free days, duration of mechanical ventilation or 
length of PICU stay between the before and after intervention groups P1 
and P2.   
 
7.1.6 Severity of Illness on Admission to PICU; PIM and SMR  
The paediatric index of mortality (PIM) has been recalibrated by the 
PICANet management team, and is termed version 2 recalibrated, or 
PIM2r. The PIM2r scores and the standardised mortality ratio (SMR) 
gave an indication of the acuity of patients on admission to the PICU. 
PIM scores were based on clinical values recorded from the first face to 
face contact between the patient and the PICU doctor until one hour after 
admission to PICU. The SMR was calculated from overall group PIM 
scores. These values enabled a comparison between P1 and P2 based 
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on severity of illness on admission to PICU. These are presented in table 
7.1.6(a). 
 
Table 7.1.6(a): Paediatric Index of Mortality and Standardised Mortality Ratio of 
P1 and P2 
Group n Deaths 
(n) 
Mean 
(PIM2r) 
sd 
(PIM2r) 
SMR SMR 
(CI) 
OR 95% CI p 
P1 920 55 0.373 ±0.073 1.6 1.22-2.07  
0.73 
 
0.47-1.13 
 
0.72 P2 965 54 0.443 ±0.092 1.3 0.94-1.62 
*Paediatric Index of Mortality version 2 Recalibrated. 
 
There was no statistically significant difference in unadjusted mortality 
between the 2 periods when tested both by a chi-square test and logistic 
regression. The odds ratio was calculated at 0.73 (p=0.72, 95% CI 0.47-
1.13) where an odds ratio of <1 favoured group P2.  
 
7.1.7 Recalculation of PIM and SMR 
Because SMR values were elevated, analysis was done to examine the 
quality of underlying data used to determine PIM values. It emerged that 
almost 40% (n=36, 39.2%) of patients in P1 did not have blood gas 
values recorded in the first hour of admission to PICU resulting in an 
overestimation of SMR as a consequence of imputation for missing 
values. Values were automatically imputed into the model which 
predicted a positive outcome; this was effective when a child is admitted 
to PICU for observation and may not have been acutely unwell; thereby 
not warranting the stress of obtaining an arterial blood gas. However, if 
an arterial blood gas was unobtainable because the patient was 
collapsed and peripherally shut down; although the risk of mortality was 
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likely to be high, nevertheless neutral values predicting survival would be 
imputed in the place of missing arterial gas values. This gave rise to an 
underestimation of mortality by the model for the PICU at the study site. 
This was recognised at medical directorate level, and targeted 
awareness and education initiatives were implemented to encourage the 
capture of all variables used for calculating PIM scores within the first 
hour of the patients’ admission. This was effective as an increase in 
patient blood gas analysis in the defined time period occurred (see table 
7.1.7(a)). Subsequently 84.9% (n-819) of P2 patients had blood gas 
analysis performed within one hour of contact with PICU, representing a 
notable improvement in blood gas capture.  
 
Table 7.1.7(a): Percentage of Patient Blood Gases Obtained Within One Hour of 
PICU Admission; Feb 2009 to July 2010 
Months Admissions 
(n) 
Blood Gases Completed 
n(%) 
Feb-Apr ‘09 193 105 (54) 
May-Jul ’09 237 125 (53) 
Aug-Oct ‘09 218 108 (50) 
Nov ’09-Jan ‘10 251 178 (71) 
Feb-Apr ‘10 264 222 (84) 
May-Jul ‘10 233 191 (82) 
 
 
 
The aggregate PIM and SMR scores were recalculated and only those 
patients from P1 and P2 who had blood gas values captured within the 
first hour of PICU admission were included, see table 7.1.7(b). 
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Table 7.1.7(b): PIM and SMR P1 and P2 Only Where Blood Gases Recorded in First 
Hour of PICU Admission  
Group n Deaths 
(n) 
Mean 
(PIM2r) 
Sd 
(PIM2r) 
SMR SMR 
CI 
OR 95% 
CI 
*p 
P1 559 34 0.04 0.08 1.39 0.97-
1.91 
 
0.89 
 
0.53-
1.49 
 
0.66 
P2 819 48 0.05 0.09 1.25 0.93-
1.64 
*p value based on chi square test 
Analysis was performed on the PIM and SMR values derived from P1 
and P2 where only cases with full PIM variable capture were included. As 
can be seen in table 7.1.7(b), although SMR values decreased, the 
difference in SMR between P1 and P2 was not statistically significant 
when the chi-square test was applied (p=0.66). The recalculated risk 
adjusted odds ratio for death was 0.89 (p=0.66; CI 0.53-1.49). The t-test 
for independent groups returned a non-statistically significant result for 
the difference in mean recalibrated PIM2r score (PIM2r difference = - 
0.003 t= 0.63, p= 0.53 CI –0.01-0.01). This suggested that patients in 
group P1 and P2 were well matched in terms of risk of mortality. The 
data were examined to determine whether there were subgroups which 
required a particular focus. Patients with T21 emerged as such a group.  
 
7.1.8 Effect of the Intervention on the T21 Population 
The study site had a higher proportion of patients with T21 than any 
other centre contributing data to the PICANet database with up to 10.2% 
of all admissions having this syndrome (PICANet local database, 
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extracted February 2012). The incidence of T21 in United Kingdom 
PICUs reporting to PICANet in 2011 was 0.3% (498 from 160,000 
admissions, personal communication with PICANet statistician Dr. P 
McShane). It was acknowledged however that this number was highly 
unlikely to be accurate due to under-reporting. The percentage of 
patients in the study groups P1 and P2 with T21 is presented in Table 
7.1.8.  No statistically significant difference in the proportion of T21 
patients in P1 and P2 emerged when the chi-square test was applied 
(p=0.45). 
 
Table 7.1.8(a): The percentage of T21 and Non-T21 Patients in P1 and P2 
 
Trisomy 21 
P1 (n=920) P2 (n=965) p 
 
0.45 84 (9.1%) 98 (10.2%) 
 
 
7.1.9 Duration of Mechanical Ventilation and PICU Stay in T21 vs non-T21  
The T21 group distinguished itself from the study cohort due to their well 
documented medical co-morbidities. In this cohort, it was identified that 
there was a statistically significant baseline difference in the median 
duration of mechanical ventilation (p=0.017) and baseline duration of 
PICU stay (p<0.001) between T21 and non-T21 patients in P1 (See table 
7.1.9(a)).  
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Table 7.1.9(a): Baseline Demographic Data & Median Duration of Mechanical 
Ventilation and PICU stay for P1 Patients; T21 & Non-T21 
Category All P1 
(N=920) 
T21 
(n=84) 
Non T21 
(n=836) 
*p 
Male Sex (%) 535 (58.15%) 55 (65.48%) 480 (57.42%) 0.19 
Age Median 
[IQR] 
0.62 [0.09-3] 0.52 [0.29-1.09] 0.67 [0.08-3.33] 0.61 
Weight Median 
[IQR] 
7 [3.64-14.7] 5.61 [4.65-8.3] 7.31 [3.57-15] 0.179 
Invasive 
Ventilation Days 
Median [IQR] 
3 [2-7] 4 [2-9] 3 [2-7] *0.017 
Length of PICU 
Stay 
Median [IQR] 
4 [2-8] 6 [(3-12] 4 [2-8] ***<0.001 
*p Value based on Chi Square or Mann-Whitney-U test 
 
The statistically significant difference in baseline duration of ventilator 
dependence and length of PICU stay between T21 and non-T21 patients 
justified the decision to analyse this subgroup separately. The impact on 
the intervention on the duration of mechanical ventilation and PICU stay 
of the T21 subgroup in isolation was examined (See Table 7.1.9(b)). 
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Table 7.1.9(b): Median Length of Ventilation and PICU Stay; T21 Patients P1 & P2 
T21 Patients 
 P1 (N=84) P2 (N=98) p 
Mechanical Ventilation Days, Median 
[IQR] 
4 [2:9] 3 [2:6] *0.04 
Length of Stay, Median [IQR] 6 [3:12] 
 
5 [3:9] 0.086 
*p Value based on Mann-Whitney-U test 
 
There was a statistically significant decrease in the duration of 
mechanical ventilation (p=0.04) but this was not accompanied by a 
statistically significant reduction in PICU stay (p=0.79) for the T21 
subgroup after the intervention. The non-T21 subgroup was examined 
separately to determine the effect of the intervention on these variables 
without the influence of the patients with T21 (See table 7.1.9(c)). 
 
Table 7.1.9(c): Median Length of Ventilation and PICU Stay; Non-T21 Patients P1 & 
P2 
*p Value based on Mann-Whitney-U test 
 
Non-T21 Patients 
 P1 (N=836) P2 (N=867) p 
Mechanical Ventilation Days,  Median 
[IQR] 
3 [2:7] 3 [2:7] 0.86 
Length of Stay,  Median [IQR] 4 [2:8] 4 [2:8] 0.79 
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As is evident from table 7.1.9(c), the intervention did not appear to 
impact the duration of mechanical ventilation and PICU stay of non-T21 
patients. Notably there was no statistically significant difference in 
median length of mechanical ventilation after the intervention for T21 and 
non-T21 patients 3[2:7] and 3[2:6] (p=0.36) respectively, and there was 
no statistical difference between median length of PICU stay for T21 and 
non-T21 patients (5 [3:9], 4[2:8] respectively, p=0.28) when the Mann-
Whitney-U test was applied.  
 
7.1.10 Compliance with Analgesia and Sedation Guidelines 
Ideally, quantification of the compliance with the guidelines in P2 would 
have given an estimate of the penetration of the guidelines and 
educational programme. This may have helped to identify the patients in 
P2 that received the guidelines, which could have been factored into a 
post-hoc analysis against P1. This would have allowed comparison of 
patients fully compliant with the guidelines in P2 with P1. The writer 
chose not to do this, for the following reasons. Firstly, because as 
prescribing practice in the P1 group was completely different to that of 
P2, it made direct comparison meaningless. Following this, the tool used 
to measure compliance would be arbitrary and unvalidated. 
 
7.2 Confounding Variables  
Because a change in medical staffing occurred during the course of this 
study; analysis to address any possible effect of this variable was 
performed. Two whole time equivalent consultant intensivists joined the 
PICU staff, and two whole time equivalent anaesthesiologists 
relinquished all PICU duties to work full time in the operating theatre 
department. To determine whether this change in medical staffing may 
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have had an influence on the study variables; the group P2 was divided 
into before and after medical staffing change (MSC) and the Mann-
Whitney-U test applied to explore any effects on median duration of 
mechanical ventilation (Tv) and length of PICU stay (PICU LOS). There 
were no statistically significant differences detected in either duration of 
ventilation or length of PICU stay when this potential confounding 
variable was tested; (before MSC Tv 7.3 (n=86), after MSC Tv 6.89 
(n=552) (p=0.79), before MSC PICU LOS 8.0 (n=86), after MSC PICU 
LOS 7.6 (n=552) (p=0.78).  
 
Table 7.2: The Effect of a Change in Medical Staffing on Study Variables  
 Before 
Mean 
(N=86) 
SD 
After 
Mean 
(N=552) 
SD 
Total 
Mean 
(N=638) 
SD 
p 
*Tv 7.32 10.18 6.89 11.56 7.00 12.09 0.794 
**PICU   
   LOS 
7.97 10.26 7.57 12.23 7.74 12.76 0.779 
*Tv refers to the length of time the patient was ventilator dependent  
**PICU LOS denotes the length of stay in PICU  
 
 
7.3 Summary of Findings from PICANet Patient Census Data 
 P1 and P2 were well matched in terms of demographic, clinical 
and mortality variables, although there was a predominance of 
males in both groups. 
 There were no statistically significant differences in ventilator free 
days, duration of mechanical ventilation or length of PICU stay 
between the before and after intervention groups P1 and P2. 
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 There was a similar amount of patients diagnosed with T21 in P1 
and P2. 
 T21 patients had a longer duration of ventilator dependence than 
non-T21 patients at baseline, and this proved to be statistically 
significant (p=0.017). 
 Patients with T21 also had a longer duration of PICU stay at 
baseline than those without T21, this was highly statistically 
significant (p<0.001). 
  After the intervention, there was no longer a statistically 
significant difference in either duration of mechanical ventilation or 
PICU length of stay between the T21 and non-T21 groups.  
 There was a statistically significant decrease in the median 
duration of mechanical ventilation of one day for patients with T21 
after the intervention (p=0.04).  
 There was no statistically significant difference in the median 
length of PICU stay after the intervention for this patient group.  
 The intervention appeared to have no statistically significant 
impact on the duration of mechanical ventilation and PICU stay of 
non-T21 patients. 
 A change in medical staffing did not appear to have a confounding 
effect on study variables. 
 
7.4 Limitations of PICANet Patient Census Data 
The intervention had a disproportionate effect on the T21 population 
which warranted further investigation. Census data is not conducive to 
deeper analysis, and in this case was not sufficiently precise. More 
specifically, the duration of mechanical ventilation and PICU stay was 
rounded to whole days in the PICANet database. A greater degree of 
precision was required in order to determine the extent of and the 
possible reasons why the T21 population were impacted 
disproportionately by the intervention. This necessitated the analysis of 
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particular information e.g. whether there was a difference in analgesic 
and sedative drugs administered to this patient group leading to a 
decrease in reliance on mechanical ventilation after the intervention and 
shorter PICU stay. To capture this data, the Patient Analgesia and 
Sedation Questionnaire (PASQ) was specifically developed and 
validated. Analysis of the data obtained using this instrument was carried 
out to gain greater insight into the reasons for these disparities. The 
findings of this analysis will be presented in the next chapter.  
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Chapter 8: Findings from PASQ Data   
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8.0 PASQ Introduction 
In order to answer the questions that emerged from analysis of the 
census cohorts P1 and P2; comparable patient samples from before and 
after the intervention were required. Using strict inclusion and exclusion 
criteria to ensure comparability of groups, specific information was 
obtained using the PASQ instrument. All the patients who met the 
eligibility criteria were included in the analysis, consistent with an 
‘intention-to-treat’ strategy.  The findings of this analysis will now be 
presented.   
 
8.1 PASQ Patient Selection 
Patient selection for PASQ 1 (before intervention) and PASQ 2 (after 
intervention) was undertaken in accordance with the CONSORT 
guidelines (see figure 8.1). Using the timelines illustrated in Table 6.12.3, 
a total of 1,067 relevant procedures carried out in these time periods 
were identified from the cardiac list. The patients undergoing these 
procedures who were under the age of one month and over the age of 
one year were filtered out, 490 procedures remained. Only first cases 
were selected, of which 355 remained. A cross reference with the 
PICANet database allowed elimination of cases where cardiopulmonary 
bypass was not used. The remaining 163 patients were assessed for 
eligibility. 4 patients were excluded because of a previous prolonged stay 
in a Neonatal Intensive Care Unit, a further 3 patients had been on IV 
morphine prior to admission for more than 5 days and were excluded. 4 
patients were supported on ECLS (Extra Corporeal Life Support) post-
operatively and thus not included, while one patient had sensitivity to 
morphine and an alternative agent was used for post-operative 
analgesia, and thus was excluded. One patient experienced an intra-
operative haemorrhage and required cardiopulmonary resuscitation 
hence was excluded from analysis. A further 23 cases were excluded 
due to missing data and inability to locate their healthcare records. 
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Missing patient records was an issue which had been identified by 
hospital management as a significant clinical risk and strategies had 
been put in place to address this such as electronic chart tracking and a 
computerised information management system in the PICU. In total 123 
patients were included in the final analysis. 
 
 
 
Figure 8.1: Flowchart Depicting Sample Selection for PASQ 1 and PASQ 2 
 
8.1.1 Time Periods Considered 
It was decided to focus data collection on the first 72 hours post-
operatively. The early post-operative phase was a critical period in the 
management of the post-operative patient, when clinical staff worked to 
stabilise the patient. Analgesic and sedative requirements were likely to 
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be higher in this phase and these agents were gradually weaned as the 
requirement for them decreased. In addition, the median length of PICU 
stay for patients post cardiac surgery was 3 days in this study setting; 
hence focussing on the first 72 hours post-operatively was further 
justified.  In order to facilitate equitable comparisons between group 
PASQ 1 and PASQ 2, each 24 hour period was termed an ‘Epoch’, see 
table 8.1.1. 
   Table 8.1.1: Epoch Number and Corresponding Time Period 
Epoch Number Corresponding Time Period 
Epoch 1 t= 0-24 Hours 
Epoch 2 t=24-48 Hours 
Epoch 3 t=48-72 Hours 
 
 
The variables collected by PASQ such as severity of illness and 
complexity of surgery and their interpretation are now described.  
 
8.1.2(i) Interpretation of Mortality Score Using PIM 
The Paediatric Index of Mortality (PIM) is a logistic regression score used 
to estimate mortality risk from data obtained from patient physiological 
and arterial blood gas variables measured within the period from the time 
of first contact with an intensive care doctor to one hour after arrival in 
the PICU. The score should be interpreted as a percentage predicted 
probability of death (see table 8.1.2). 
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8.1.2(ii) Interpretation of Cardiac Risk Using RACHS 
The risk adjusted congenital heart surgery score (RACHS) is a model 
developed consensually by an 11 member panel where nearly all cardiac 
surgical procedures are divided under six categories of increasing 
predicted operative risk.  Category 1 relates to lowest risk and category 6 
to highest risk. These data are presented as percentage of subjects per 
risk level in table 8.1.2. 
 
8.1.2(iii) Interpretation of Organ Dysfunction Using PELOD  
The paediatric logistic organ dysfunction score (PELOD) was designed to 
evaluate the clinical course of multiple organ dysfunction over time in 
critically ill children using selected variables representing organ function. 
The following information to guide interpretation of PELOD scores was 
developed by Leteurte et al. (2010):  
 High PELOD score: > or = 20 points  
(associated with an odds ratio (OR) for death of 40.7 (95% confidence 
interval [CI] 20.3-81.4)).  
 Medium score 10-19 points  
(associated with an OR for death of 4.2 (95% CI 2.0-8.7)).  
Mortality was 50% when a high score on day 1 increased on day 2. 
PELOD scores indicating a worsening condition or no improvement over 
time were indicators of a poor prognosis in the PICU. 
 Low score < 10 points. 
(associated with a low risk of complications and mortality). 
 
8.1.2(iv) Cardiopulmonary Bypass Time and Aortic Cross Clamp Time  
Placing patients on cardiopulmonary bypass (CPB) during cardiac 
surgery facilitates a bloodless, non-moving field in which to perform 
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surgery. Cross clamping the aorta separates the systemic circulation 
from the outflow of the heart (Nissinen et al. 2009). Duration of CPB and 
cross clamp time (XCT) were predictors of immediate postoperative 
morbidity and mortality. Cardiac procedures with CPB<240 min and 
XCT<150 min were associated with a rather low risk of immediate 
postoperative adverse events independent of the complexity of surgery 
or patient’s operative risk. CPB and XCT durations above these cut-off 
parameters were significantly associated with postoperative morbidity, 
particularly with postoperative stroke. These times are presented in 
minutes as mean values in table 8.1.2.  
 
8.1.2(v) Ventilator Free Days 
Ventilator-free days (VFD) is defined as days alive and free from 
mechanical ventilation in a 28 day time period in the PICU (Schoenfeld et 
al. 2002). Ventilator free days were calculated as 28 minus the number of 
ventilator dependent days, assuming survival to 28 days or discharge 
from the hospital. Patients who died before 28 days were classified as 
‘missing’ to avoid the confounding effect of mortality. Use of ventilator-
free days as a trial end point allowed smaller sample sizes if it was 
assumed that the treatment being tested simultaneously reduced the 
duration of ventilation and improved mortality. 
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Table 8.1.2: Background Characteristics by Group, PASQ 1 and PASQ 2 
Characteristic (Unit) PASQ 1 
N=61 
PASQ 2 
N=64 
*p 
Value 
Male Sex, n(%) 29 (47.5%) 34 (53.1%) 0.59 
Corrected Age in Weeks, Median [IQR] 24 [14.2:30.6] 26 
[19.1:34.9] 
0.59 
Weight at Surgery (KG), Median [IQR] 5.76 [4.8:6.57] 6.38 
[5.17:7.62] 
0.29 
Gestation in Weeks, Median [IQR] 38.3 [37:40] 40 
[37.48:40] 
0.02* 
Cardiopulmonary Bypass Time, in min, 
Median [IQR] 
95 [68.5:135] 97 [81:125] 0.6 
Aortic Cross Clamp Time, in min, Median 
[IQR] 
57 [41.5:93.0] 66 [51:88] 0.33 
PIM Score, Median [IQR] 2.2 [1.75:2.85] 2.2 
[1.73:2.7] 
0.44 
RACHS-1 Score 
2 
3 
4 
5 
   
 
0.06 
36 (59%) 26 (40.6%) 
18 (29.5%) 32 (50%) 
7 (11.5%) 5 (7.8%) 
- 1 (1.6%) 
PELOD Epoch 1, Median [IQR] 
Estimated Mortality Risk Epoch 1, 
Median [IQR] 
12 [2:12] 
1.7 [0.1:1.7] 
12 [2:12] 
1.7 [0.1:1.7] 
0.56 
PELOD Epoch 2, Median [IQR] 
Estimated Mortality Risk Epoch 2, 
Median [IQR] 
11 [2:12] 
1.3 [0.1:1.7] 
11 [2:12] 
1.15 
[0.1:1.7] 
0.57 
 197 
 
PELOD Epoch 3, Median [IQR] 
Estimated Mortality Risk Epoch 3, 
Median [IQR] 
1.5 (0.75:11] 
0.1 [0.08:1.3] 
6.0 [0.0:11] 
0.55 
[0.0:1.3] 
0.8 
*p values are based on Mann-Whitney-U for scale variables and Pearson 
Chi Square Test for continuous data.  
 
8.2 Baseline Demographic & Clinical Characteristics; PASQ 1 & 
PASQ 2 
The baseline demographic and clinical characteristics including mortality 
and cardiac surgery risk and organ dysfunction score are presented in 
table 8.1.2. As is evident from the table, patients in PASQ 1 had slightly 
lower corrected age (actual age in weeks minus weeks premature). No 
other demographic variables that were examined emerged as 
significantly different between the two groups.  
 
8.2.1 Mortality, Cardiac Surgery Risk and Organ Dysfunction Scores 
PIM scores were comparable for both groups indicating equitable risk of 
mortality. Comparable RACHS scores confirmed both groups were 
similar in terms of the degree of predicted operative risk. PELOD scores 
indicated a similar risk of organ dysfunction for each of the 3 Epochs for 
PASQ 1 and 2. The associated mortality risk was consistently lower in 
PASQ 2, but this did not reach statistical significance.  
 
8.2.2 Research Hypotheses 
Data collected using the PASQ instrument were used to address the 
primary and secondary null hypotheses:  
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Primary Hypothesis:  
“Standardised pain and sedation management did not cause a reduction 
in the dosage of morphine administered to patients in PICU” 
and furthermore: 
Secondary Hypothesis:  
“The implementation of standardised pain and sedation was not 
associated with a change in duration of mechanical ventilation and PICU 
stay.” 
as discussed in the methodology chapter, (section 2, chapter 6).  
 
8.2.3 Analgesia & Sedation Administered; PASQ 1 and PASQ 2 
Analgesia and sedation administered to PASQ 1 and PASQ 2 subjects 
was compared. The primary analgesic for PICU patients post cardiac 
surgery was intravenous morphine administered by infusion. Due to 
concerns that the respiratory depressant effects of morphine may have  
prolonged patient’s dependence on mechanical ventilation causing 
extended PICU stay; this agent was focussed on in the study. The 
intervention promoted the astute use of all analgesics and sedatives, 
ensuring that the most appropriate agent was administered, based on 
clinical need as determined by an assessment of patient’s distress and 
pain using a validated instrument; COMFORT-B. The patterns of 
administration of these agents before and after the intervention will be 
discussed in turn, commencing with morphine. 
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8.2.4 Morphine Administered; PASQ 1 and PASQ 2 
Average morphine administered to PASQ 1 and PASQ 2 patients was 
plotted on a histogram (see Figure 8.2.4(a)). Visual inspection revealed a 
right skew. On application of the Shapiro-Wilks test, the resulting p value 
was highly statistically significant (<0.001), prompting the rejection of the 
null hypothesis and concluding that the data did not come from a normal 
distribution.  Average morphine doses were log transformed, and again 
plotted on a histogram (see Figure 8.2.4(b)). These data appeared less 
skewed, nevertheless the Shapiro-Wilks test was employed to assess 
whether the distribution of the data was normal. A significant p value was 
obtained (p=0.01). Morphine doses were thus analysed according to a 
non-parametric model, doses between groups compared primarily using 
the Mann-Whitney-U test. 
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Figure 8.2.4(a): Mean Morphine Administered PASQ 1 & PASQ 2, Epoch 1-3 
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Figure 8.2.4(b): Log Transformed Mean Morphine Administered PASQ 1 & PASQ 2, 
Epoch 1-3 
 
 
As is evident in table 8.2.4, median morphine administered via infusion 
was consistently lower after the intervention for each of the 3 Epochs, but 
this did not reach statistical significance. This is illustrated in a boxplot, 
see figure 8.2.4(c). 
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Table 8.2.4: Median Morphine Administered, PASQ 1 & PASQ 2, Epochs 1 to 3 
Morphine Infusion Rates, PASQ 1 and PASQ 2 in Epochs 1-3 
 PASQ 1 PASQ 2  
*p 
n Mean Median  [IQR] n Mean Median  
[IQR] 
 
Epoch 1 61 36.74 36.0 
[27.65: 43.85] 
64 33.44 29.37 
[29.0-37.1] 
0.127 
Epoch 2 53 17.95 14.75 
[10.23-14.75] 
54 15.87 13.65 
[8.75: 19.25] 
0.404 
Epoch 3 17 11.9 0 
[0:19.13] 
15 8.57 0 
[0:16] 
0.819 
*p values based on Mann-Whitney-U test 
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Figure 8.2.4(c):  Median Morphine Administered, Epoch 1-3, PASQ 1 & 2  
 
The boxplot offers an illustration for comparing the distribution of median 
morphine doses administered in PASQ 1 and PASQ 2 in Epoch 1-3. The 
median for the morphine rate in PASQ 2 is slightly lower than that in 
PASQ 1 in Epochs 1 and 2. In Epoch 3 the median in both PASQ 1 and 
PASQ 2 is zero. The length of the box in PASQ 2 is consistently shorter 
in all 3 Epochs; representing a narrower interquartile range, where 50% 
of cases lie. The greater length of PASQ 1 boxes compared to PASQ 2 
boxes gives an indication of the wider spread of morphine infusion rates 
before the intervention all 3 Epochs. The whiskers mark the highest and 
lowest values that are not outliers, and the whiskers are lower in all 3 
Epochs for PASQ 2. Two outliers- values that are 1.5 times the 
interquartile range and two extreme points (over 3 times the IQR) are 
evident for PASQ 2 in Epoch 1 and one outlier in PASQ 1 in Epoch 1. 
Three outliers and 1 extreme point are evident in Epoch 2 for PASQ 2, 
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and one outlier and one extreme point in the same Epoch in PASQ 1. In 
Epoch 3 there are no extreme points evident, but there is one outlier in 
PASQ 2 and two in PASQ 1.   
 
8.2.5 Analysis of Morphine Administered via Infusion; PASQ 1 vs PASQ 2 
To determine whether the difference in morphine administered via 
infusion was statistically significant; the Mann-Whitney-U test was 
applied as data were not normally distributed, see figures 8.2.4(a) and 
8.2.4(b). Because p was >0.05 (a non-significant result) in all 3 Epochs, it 
could not be concluded that the intervention resulted in a statistically 
significant reduction in the amount of morphine being administered to 
patients.  
 
8.2.6 Morphine Rate on Return from Operating Theatre 
A major element of the intervention involved promoting the judicious use 
of morphine infusions in the immediate post-operative period, avoiding 
excessively high infusion rates as advised by international best practice. 
The morphine rate on return from theatre was not normally distributed 
when inspected on a histogram. A floor effect was evident; as all patients 
had a morphine infusion with a set rate of ≥40mcg/kg/hour on returning 
from the operating theatre to the PICU (see figure 8.2.6(a)).  The 
presence of patients who had extremely high morphine infusion rates on 
return from theatre in PASQ 1 is evident in the histogram; two patients 
returning to PICU with morphine infusions running in excess of 
160mcg/kg/hr. In PASQ 2, there were no such incidences.    
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Figure 8.2.6(a): Morphine Rate on Return from Operating Theatre PASQ 1 & 2 
 
The rate of morphine on return from theatre was compared between 
PASQ 1 and 2 using Mann-Whitney-U (see table 8.2.6(a)). A highly 
statistically significant difference between morphine infusion rates on 
return from surgery emerged between the 2 groups (p=<0.001); PASQ 2 
patients returning from theatre receiving lower morphine infusion rates, 
which proved statistically significant. 
 
 
 
 206 
 
 Table 8.2.6(a): Morphine Rate on Return from Operating Theatre PASQ 1 vs PASQ 2 
Morphine PASQ 
1 or 2 
N Median Mean Mean 
Rank 
Sum of 
Ranks 
Mann-
Whitney
-U 
p  
mcg/kg/hr PASQ 1 61 80 69.51 214.2 39192.0 12780.0 <0.001 
PASQ 2 64 40 55.38 163.1 31308.0 
 
 
Figure 8.2.6(b): Simple Dot Plot Illustrating Morphine Rate on Return from 
Theatre, PASQ 1 vs PASQ 2 
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The rate of morphine infusing on return from the operating theatre in 
PASQ 1 and PASQ 2 is illustrated in a simple dot plot in figure 8.2.6(b). 
The decreased incidence of morphine rates infusing in excess of 80 
mcg/kg/hr in PASQ 2 compared with PASQ 1 are evident in this 
illustration.    
 
8.2.7 Morphine Administered to T21 Patients 
Analysis of the census data suggested that T21 patients were 
disproportionally affected by the intervention, duration of dependence on 
mechanical ventilation and length of PICU stay being reduced after the 
intervention, which proved statistically significant. To determine whether 
the intervention may have resulted in a reduction in morphine 
administered to T21 patients, offering some rationale for this finding; 
separate analysis was done on morphine administered to this group. 
Firstly the T21 and non-T21 groups were compared to detect baseline 
differences on morphine administered. 
 
There were no statistically significant differences between baseline mean 
morphine administered to T21 and non-T21 patients in PASQ 1 and 
PASQ 2 when the Mann- Whitney-U test was applied (see table 
8.2.7(a)). The morphine administered to T21 patients was therefore 
assessed in isolation. 
 
 
 
 
 
 
 208 
 
 
Table 8.2.7(a): Morphine Administered T21 and non-T21, PASQ 1 & 2 
PASQ 1 
 
T21 N Mean 
Rank 
Sum of 
Ranks 
*p 
Average Morphine Via 
Infusion, Epoch 1-3 
No 28 30.63 857.50 0.879 
Yes 33 31.32 1033.50 
PASQ 2 
 
T21 N Mean 
Rank 
Sum of 
Ranks 
*p 
Average Morphine Via 
Infusion, Epoch 1-3 
No 41 35.16 1441.50 0.127 
Yes 23 27.76 638.50 
* p values based on Mann-Whitney-U test. 
 
The log transformed doses of morphine administered to T21 patients in 
Epoch 1 were normally distributed on a histogram and the Shapiro-Wilks 
significance of p=0.442 confirmed these data were normally distributed. 
Comparison of PASQ 1 and PASQ 2 was therefore done using a 
parametric model; the t-test for independent groups (table 8.2.7(b)). 
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Table 8.2.7(b): T-test Comparing Morphine Administered T21 Patients, Epoch 1, 
PASQ 1 vs PASQ 2 
Mean Morphine Administered, T21 Patients PASQ 1 vs PASQ 2 
 
PASQ 
1 or 2 
N Mean Std. 
Deviation 
Std. Error 
Mean 
Log Mean Morphine 
Epoch 1 
PASQ 1 33 3.55 0.31 0.05 
PASQ 2 23 3.4 0.21 0.04 
Independent Samples t-Test 
 Levene’s Test for 
Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df Sig (2-
tailed) 
Mean 
Difference 
STD. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Log 
Morphine 
Epoch 1 
Equal 
Variances 
Assumed 
8.19 0.006 1.83 54.0 0.072 0.14 0.07 -0.01 0.28 
Equal 
Variances 
Not 
Assumed 
  1.96 53.99 0.055 0.14 0.07 -0.003 0.27 
 
To determine whether the difference was attributable to the intervention 
or random fluctuations; the independent samples t-test was applied (see 
table 8.2.7(b)). An assumption underlying the t-test is that the population 
variances for the two groups are equal. Levene’s test for equality of 
variances revealed that the two variances were significantly different for 
Epoch 1 (sig. = 0.006). The value of the t-statistic was 1.96 for Epoch 1, 
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and the two-tailed probability for the differences in group means was 
.055. Because p was >0.05 (a non-significant result), it could not be 
concluded that the intervention resulted in reduced amounts of morphine 
being administered to T21 patients in Epoch 1. This did not infer that the 
intervention was not effective, as failure to reject the null hypothesis did 
not mean that there was evidence that the null was true.  
 
The 95% confidence interval for the population mean difference is also 
provided in table 8.2.7(b). It could be concluded with 95% confidence 
that the mean difference in log transformed morphine administered in 
Epoch 1 for PASQ 1 and PASQ 2 lay between -0.003 and 0.27 
mcg/kg/hour. As zero lay within this interval, there was a possibility that 
there were no group differences in the population. Consistent with this 
finding the null hypothesis of equal means was not rejected on the basis 
of the t-test.  
 
Morphine administration in T21 patients in Epoch 1 to 3 was plotted on a 
histogram (see figure 8.2.7(a)). Visual inspection revealed data were 
skewed to the right, and this was confirmed by the Shapiro-Wilks test (p= 
<0.001), therefore non-parametric methods of analysis were used to 
compare median morphine administered in PASQ 1 vs PASQ 2 for T21 
patients in Epoch 1-3.  
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Figure 8.2.7(a): Morphine Administered T21 Patients, PASQ 1 & PASQ 2, Epoch 1-3 
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Median morphine administered to T21 patients before and after the 
intervention is presented in table 8.2.7(c).  
 
Table 8.2.7(c): Morphine Administered T21, PASQ 1 & PASQ 2 
T21 Patients: Morphine Administered,T21, PASQ 1 and 2 Epochs 1-3 
 PASQ 1 PASQ 2  
*
p 
n Mean Median  
[IQR] 
n Mean Median  
[IQR] 
Epoch 1 33 36.29 33.92 
[26.9-44.15] 
23 30.89 32.0 
[27.0-35.0] 
0
.154 
Epoch 2 25 20.11 16.1 
[11.7-26.9] 
13 12.82 9.7 
[0.0-13.0] 
*
0.015 
Epoch 3 20 29.5 0 
[0.0-30.0] 
8 12.66 0 
[0:10.83] 
0
.636 
*p values based on Mann-Whitney-U test. 
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As is evident from table 8.2.7(c); the median amount of morphine 
administered to T21 patients after the intervention was less in Epoch 2, 
and this reached statistical significance. The average overall morphine 
for Epoch 1-3 is illustrated using a boxplot in figure 8.2.7(b).  
 
 
Figure 8.2.7(b): Median Morphine Administered T21, PASQ 1 & 2 
 
The length of the box is shorter in PASQ 2, where 50% of the rates of 
infusion on return from the operating theatre for T21 patients lie. The 
whisker does not extend as far upwards in PASQ 2, indicating the 
highest rate which is not an outlier was much less in this group. There 
was only 1 extreme case in PASQ 2 (3 times the interquartile range); 
while there were 4 outliers in PASQ 1 (values 1.5 times the interquartile 
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range).  The rate of morphine on return from theatre for the T21 
population was then focussed on.  
 
8.2.8 Rate of Morphine on Return from OT, T21 Patients 
A histogram display of rate of morphine on return from theatre for T21 
patients revealed a skewed distribution (see figure 8.2.8(a)). Again, a 
notable floor effect proved no patient returned from the operating theatre 
without a minimum of 40mcg/kg/hr of morphine infusing.  
 
 
Figure 8.2.8(a): Morphine Rate on Return from Operating Theatre T21, PASQ 1 & 
PASQ 2 
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As the data were not normally distributed; non-parametric analyses were 
used to determine whether there was a statistically significant difference 
in morphine infusion rate on return from theatre after the intervention. A 
reduction in mean morphine rate after the intervention emerged (see 
table 8.2.8) and this proved to be statistically significant when the Mann-
Whitney-U test was applied (p=0.026). This is illustrated in a simple dot 
plot in figure 8.2.8(b). 
Table 8.2.8: Rate of Morphine on Return from Theatre, T21 PASQ 1 & PASQ 2 
T21 
Patients 
PASQ 
1 or 2 
N Mean 
Rank 
Sum of 
Ranks 
Mann-
Whitney-U 
p 
Morphine 
mcg/kg/hr 
PASQ 1 33 32.18 1062.00 258.00 *.026 
PASQ 2 23 23.22 534.00 
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Figure 8.2.8(b) Rate of Morphine on Return from Theatre, T21 PASQ 1 & 2 
 
8.3 Additional Analgesics and Sedative Agents Assessed 
The other analgesic and sedative agents assessed as part of this study 
were midazolam, chloral hydrate, paracetamol, clonidine and oramorph. 
These were the most frequently used agents in the PICU and were 
contained in the analgesia and sedation guidelines. It was of great 
importance to determine whether the pattern of administration of these 
agents changed after the intervention.  
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8.3.1 Midazolam Administered in PASQ 1 and PASQ 2 
Midazolam is a benzodiazepine and was the most commonly used 
sedative in the PICU. The mechanism of action of midazolam is through 
gamma-aminobutyric acid (GABA) inhibitory neurotransmitter. Prolonged 
administration may result in physical dependence, and abstinence 
syndrome may develop after abrupt discontinuation. The intervention 
promoted the use of this agent based on clinical need, by evaluating 
whether undersedation was present through patient assessment using 
COMFORT-B. Due to low numbers of patients receiving midazolam after 
Epoch 1 (P1 n=6, P2 n=1) analysis focussed on midazolam administered 
in the first Epoch (see table 8.3.1).  
 
Table 8.3.1: Midazolam Administered PASQ1 and PASQ 2, Epoch 1 
Midazolam Administered in Epoch 1 via Infusion and Bolus, PASQ 1 
and PASQ 2  
 PASQ 1 
N=61 
PASQ 2 
N=64 
 
*p 
Mean Rank Median  
[IQR] 
Mean Rank Median  
[IQR] 
 
Infusion 
mcg/kg/hr 
 
64.22 
 
0 [0-1.2] 
 
60.83 
 
0 [0-0.5] 
 
0.566 
Bolus 
mcg/kg 
62.66 0 [0-2] 62.34 0 [0-1.0] 0.965 
*p values based on Mann-Whitney-U test 
 
A histogram display of administered midazolam revealed a significant left 
skew, and the Shapiro-Wilks test for normality returned a p value of 
<0.001, confirming data were not normally distributed hence the non-
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parametric model of analysis was used. As is evident from table 8.3.1; 
the median amount of midazolam administered to patients was reduced 
after the intervention. On application of the Mann-Whitney-U test for non-
parametric data, a non-statistically significant reduction emerged for both 
midazolam infusion and intravenous bolus in Epoch 1 after the 
intervention. On this basis it could not be concluded that the intervention 
caused a reduction in amounts of midazolam administered to PICU 
patients.  
 
8.3.2 Chloral Hydrate Administered to Patients in PASQ 1 and PASQ 2 
Chloral hydrate is a paediatric sedative which was used commonly in the 
post-operative period once gastro-intestinal motility had returned. Use of 
this drug in moderation was endorsed due to its prolonged half-life in 
neonates, unpredictable effects and absence of a reversal agent. As a 
significant component of the intervention involved the introduction of a 
validated distress assessment tool, it was anticipated that more judicious 
use of this sedative would occur after the intervention.  
Table 8.3.2: Chloral Hydrate Administered PASQ 1 and PASQ 2, Epoch 1-3  
Chloral Hydrate Administered (mg/kg), PASQ 1 and PASQ 2 in Epochs 1-3 
 PASQ 1 PASQ 2  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 61 102.45 100.25  
[5.02-150.0] 
64 89.46 90.53  
[49.2-131.3] 
0.091 
Epoch 2 44 92.99 98.64 
[49.77-138.37] 
42 83.37 75.17 
[49.07-127.67] 
0.468 
Epoch 3 32 74.07 72.94 
[24.9-102.24] 
27 68.93 54.64 
[25.0-99.47] 
0.755 
*p values based on Mann-Whitney-U test 
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The assumption that distribution of chloral hydrate data were normally 
distributed was violated with a significant Shapiro-Wilks value of 
p=<0.001. The Mann-Whitney-U test was therefore used to determine 
whether the differences in chloral hydrate in PASQ 1 and PASQ 2 were 
statistically significant. Although median doses of chloral hydrate 
administered in all 3 Epochs were lower in PASQ 2 than PASQ 1; this 
was not statistically significant when the Mann-Whitney-U test was 
applied (see table 8.3.2). This is illustrated in Figure 8.3.2.  
 
 
Figure 8.3.2: Chloral Hydrate administered PASQ 1 & PASQ 2, Epoch 1-3 
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8.3.3 Paracetamol Administered PASQ 1 and PASQ 2 
In line with the multidisciplinary developed analgesia and sedation 
guidelines; intravenous paracetamol was indicated in the early post-
operative period due to its co-analgesic and opioid-sparing properties. 
For this reason, it was anticipated that the intervention would have a 
statistically significant impact on the amount of paracetamol administered 
to patients, with the PASQ 2 cohort receiving more paracetamol than 
PASQ 1 patients.  
 
As was anticipated, PASQ 2 patients received more paracetamol in all 3 
Epochs than PASQ 1 patients (see table 8.3.3 for mean values and 
figure 8.3.3 for illustration).  
 
Table 8.3.3: Paracetamol Administered PASQ 1 & PASQ 2, Epoch 1-3 
Paracetamol Administered (mg/kg), PASQ 1 and PASQ 2 in Epochs 1-3 
 PASQ 1 PASQ 2  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 61 48.66 45.0 
[45-60] 
64 56.7 60 
[58.2-60.0] 
**0.001 
Epoch 2 44 48.55 45.0 
[45-60] 
42 52.47 58.83 
[44.84-60] 
0.232 
Epoch 3 32 46.41 45.0 
[45-60] 
27 43.76 45.0 
[41.66-60] 
0.567 
*p values based on Mann-Whitney-U test. 
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Figure 8.3.3: Paracetamol Administered PASQ 1 & PASQ 2, Epoch 1-3 
 
As is evident from table 8.3.3 and in the boxplot illustration in figure 
8.3.3; there was a highly statistically significant difference between the 
paracetamol administered in PASQ 1 and PASQ 2 in Epoch 1 (p=0.001). 
The greater variances in doses of paracetamol administered in Epoch 1 
before the intervention are evident in the longer box, where 50% of the 
cases lie. The whisker which reaches downwards and there are 2 outliers 
reflecting the cases who received low doses of paracetamol. The shorter 
box in PASQ 2 Epoch 1 acutely reflects the narrowing of the dose range 
after the intervention; most of the patients receiving the full dose of 
paracetamol in the first 24 hours after surgery in PASQ 2. 
In Epoch 2 the difference was not statistically significant; however the 
higher median in the PASQ 2 group indicated most of the patients 
continued to receive full doses of the drug. This tapers off in Epoch 3 
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with both PASQ 1 and PASQ 2 receiving a similar median dose of 
paracetamol. 
 
8.3.4 Oramorph Administered to Patients in PASQ 1 and PASQ 2 
Oramorph is the oral form of morphine; a strong analgesic which is 
effective in weaning patients from intravenous morphine. It was 
introduced after the initial post-operative period, and it was advised that 
morphine was changed from the intravenous route to the oral route as 
soon as was viable after surgery to minimise the risk of developing 
physiological dependence to the opiate.  
 
Table 8.3.4: Oramorph Administered PASQ 1 & PASQ 2, Epoch 1-3  
Oramorph Administered (mcg/kg), PASQ 1 and PASQ 2 in Epochs 1-3 
 PASQ 1 PASQ 2  
*p n Mean Median [IQR] n Mean Median [IQR] 
Epoch 1 61 27.22 0 
[0-0] 
64 21.18 0 
[0-0] 
0.96 
Epoch 2 44 153.16 0 
[0-282.24] 
42 183.78 76.57 
[0-387.99] 
0.44 
Epoch 3 32 181.62 0 
[0-414.8] 
27 223.98 139.4 
[0-381.3] 
0.37 
*p values based on Mann-Whitney-U test. 
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Figure 8.3.4: Oramorph Administered PASQ 1 & PASQ 2, Epoch 1-3  
 
In Epoch 1, both before and after the intervention, the median dose of 
oramorph administered was 0. The reason for this was that all patients 
would have had an intravenous morphine infusion running; thereby 
negating the requirement for oral morphine. In Epoch 2 and 3, the 
median oramorph administered was higher in PASQ 2 than PASQ 1; 
however these differences did not emerge as statistically significant on 
application of the Mann-Whitney-U test as evident in table 8.3.4 and 
figure 8.3.4. 
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8.3.5 Clonidine Administered to Patients in PASQ 1 and PASQ 2 
Valued for its sedative and analgesic properties in the post-operative 
period as well as an opioid weaning adjunct; clonidine was advocated in 
the analgesia and sedation guidelines. Determination of clinical need 
based on careful patient assessment was promoted. An increase in the 
use of clonidine was therefore anticipated. 
 
Table 8.3.5: Clonidine Administered PASQ 1 & 2, Epoch 1-3  
Clonidine Administered (mcg/kg), PASQ 1 and PASQ 2, Epochs 1-3 
 PASQ 1 PASQ 2  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 61 0.49 0 
[0-0.23] 
64 1.11 0 
[0-2.01] 
**0.001 
Epoch 2 44 1.08 0 
[0-2.61] 
42 1.64 1.0 
[0-2.98] 
*0.048 
Epoch 3 32 1.18 0 
[0-2.78] 
27 1.56 1.0 
[0-2.94] 
0.148 
*p values based on Mann-Whitney-U test 
 
As evident in table 8.3.5 and illustrated in figure 8.3.5; there was a 
statistically significant increase in doses of clonidine administered in 
Epoch 1 (p=0.001) and Epoch 2 (p=0.048). A statistically significant 
difference in clonidine administered did not emerge in Epoch 3 on 
application of the Mann-Whitney-U test. The median clonidine dose of 
zero for all 3 Epochs in PASQ 1 reflected the pattern of not choosing this 
agent in the management of post-operative cardiac patients before the 
intervention.  
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Figure 8.3.5: Clonidine Administered PASQ 1 & 2, Epoch 1-3  
 
8.4.0 Analgesia and Sedation in the T21 vs Non-T21 Sub-groups 
As part of the analysis of the impact of the intervention on the pattern of 
analgesia and sedative drug administration examined in this research, 
the T21 patients were analysed separately to determine any differences 
that may have explained the statistically significantly longer dependence 
on mechanical ventilation and longer duration of PICU stay in this patient 
group before the intervention. As morphine has already been addressed; 
the agents midazolam, chloral hydrate, paracetamol, clonidine and 
oramorph will be discussed in turn.  
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8.4.1 Midazolam Administered, T21 vs Non-T21  
In determining whether the intervention resulted in a statistically 
significant reduction in the amount of midazolam administered to T21 
patients by continuous intravenous infusion and intermittent intravenous 
bolus; analysis focussed on Epoch one as due to low cell counts for 
Epoch 2 and 3, computation was not possible. The Shapiro-Wilks test 
revealed both the midazolam infusion and midazolam bolus data came 
from a skewed distribution (p<0.001 for both), hence non-parametric 
methods of analysis were used. 
 
Table 8.4.1: Midazolam Administered via Infusion & Bolus, T21 Epoch 1 PASQ 1 & 
2 
T21 Patients: Midazolam Administered in Epoch 1 via Infusion and 
Bolus, PASQ 1 and 2 
 PASQ 1 PASQ 2  
*p n Mean  Median  
[IQR] 
n Mean  Median  
[IQR] 
Infusion 
mcg/kg/min 
 
33 
2.05 0 
[0-1.2] 
 
23 
0.32 0 
[0-0.5] 
0.39 
Bolus 
mcg/kg 
1.21 0 
[0-2.5] 
0.96 0 
[0-1.0] 
0.795 
*p values based on Mann-Whitney-U test 
 
 
Median values for midazolam infusion were zero both before and after 
the intervention, however the interquartile range was less than half after 
the intervention (see table 8.4.1). Although the mean amount of 
midazolam boluses had reduced after the intervention; a low level of use 
of midazolam boluses was reflected in a median value of zero before the 
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intervention. The interquartile range was reduced after the intervention; 
however differences in both midazolam infusion and boluses before and 
after the intervention proved not to be statistically significant when the 
Mann-Whitney-U test was applied. Therefore it could not be concluded 
that the intervention was responsible for the reduction of midazolam 
administered to T21 patients.  
 
8.4.2 Chloral Hydrate Administered T21 vs Non-T21 Patients  
It was noted that T21 patients received less chloral hydrate after the 
intervention in all 3 Epochs (see table 8.4.2(a)). However this reduction 
did not emerge as statistically significant on application of the Mann-
Whitney-U test.  
 
Table 8.4.2(a) Chloral Hydrate Administered, T21, PASQ 1 & 2, Epoch 1-3 
T21 Patients: Chloral Hydrate Administered (mg/kg), PASQ 1 and PASQ 2, 
Epochs 1-3 
 PASQ 1 PASQ 2  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 33 110.39 140.2 
[54.84-150.0] 
23 104.36 105.08 
[71.3-145.02] 
0.473 
Epoch 2 25 106.59 100 
[73.11-147.32] 
13 87.01 73.82 
[49.34-128.9] 
0.286 
Epoch 3 20 95.15 98.08 
[45.38-146.45] 
8 76.02 81.57 
[40.93-105.23] 
0.533 
*p values based on Mann-Whitney-U test 
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However when the amount of chloral hydrate administered to T21 
patients and non-T21 patients was compared; a statistically significant 
disparity emerged. T21 patients received more chloral hydrate than non-
T21 patients before the intervention which approached statistical 
significance in Epoch 2 and reached statistical significance in Epoch 3 
(see table 8.4.2(b)).  
 
Table 8.4.2(b): Chloral Hydrate Administered, T21 vs NonT21, PASQ 1, Epoch 1-3 
T21 vs Non-T21 Patients: Chloral Hydrate Administered (mg/kg),  
PASQ 1, Epochs 1-3 
 T21 Non-T21  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 33 110.39 140.2 
[54.84-150.0] 
28 93.1 89.71 
[50.59-143.89] 
0.234 
Epoch 2 25 106.59 100 
[73.11-147.32] 
19 75.1 71.77 
[47.3-101.69] 
*0.05 
Epoch 3 20 95.15 98.08 
[45.38-146.45] 
12 39.02 39.02 
[0-71.65] 
*0.004 
*p values based on Mann-Whitney-U test. 
 
Analysis was carried out to determine whether the T21 group continued 
to receive more chloral hydrate after the intervention. A non-significant 
Mann-Whitney-U value in each Epoch confirmed that there was no 
statistically significant difference in the amount of chloral hydrate 
administered to T21 and non-T21 patients after the intervention (see 
table 8.4.2(c)).   
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Table 8.4.2(c): Chloral Hydrate Administered, T21 vs NonT21, PASQ 2, Epoch 1-3 
T21 vs Non-T21 Patients: Chloral Hydrate Administered (mg/kg),  
PASQ 2 in Epochs 1-3 
 T21 Non-T21  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 23 104.36 105.08 
[71.3-145.02] 
40 80.90 78.95 
[47.36-110.24] 
0.095 
Epoch 2 13 87.01 73.82 
[49.34-128.9] 
29 81.74 75.33 
[36.95-133.57] 
0.817 
Epoch 3 8 76.02 81.57 
[40.93-105.23] 
19 65.94 50.0 
[24.89-79.94] 
0.288 
*p values based on Mann-Whitney-U test. 
 
A crosstab calculation was run between T21 and Chloral Hydrate 
administered in each Epoch. A statistically significant Spearman 
Correlation emerged for Epoch 1 (p=0.049) and a highly statistically 
significant correlation emerged for Epoch 3 (p=0.003) suggesting that 
before the intervention patients were likely to receive higher amounts of 
chloral hydrate in Epoch 2 and 3 if they had T21. The crosstabulation 
was repeated to determine whether patients with T21 were likely to 
receive higher doses of chloral hydrate after the intervention. The 
resulting spearman coefficient was non- statistically significant confirming 
this was not the case in PASQ 2 (see table 8.4.2(d)). 
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Table 8.4.2(d): Correlation Analysis Chloral Hydrate Administered T21 vs Non-T21 
Patients, PASQ 1 & 2, Epochs 1-3 
Chloral Hydrate Administration to T21 vs Non-T21 Patients, PASQ 1 & 2, 
Epochs 1-3 
 PASQ 1 PASQ 2 
Spearman’s 
Correlation Value 
p Spearman’s 
Correlation Value 
p 
Epoch 1 0.154 0.237 0.212 0.095 
Epoch 2 0.298 *0.049 0.036 0.820 
Epoch 3 0.516 **0.003 0.208 0.297 
 
A boxplot illustration of chloral hydrate received by T21 versus non-T21 
patients before and after the intervention effectively depicts how the 
difference in administration of chloral hydrate to these groups was less 
erratic after the intervention (see figure 8.4.2). 
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Figure 8.4.2: Chloral Hydrate Administration T21 vs Non-T21, PASQ 1 & 2, Epochs 
1-3 
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8.4.3 Paracetamol Administered T21 vs Non-T21 Patients  
An increase in the median paracetamol administered to T21 patients in 
Epoch 1 after the intervention was noted, and this emerged as 
statistically significant on application of the Mann-Whitney-U test (see 
table 8.4.3(a)). There was an increase in median paracetamol 
administered in Epoch 2 after the intervention which was not statistically 
significant (p=0.897), while in Epoch 3 there was no change. 
Table 8.4.3(a) Paracetamol Administered, T21 PASQ 1 & 2, Epochs 1-3 
T21 Patients: Paracetamol Administered (mg/kg), PASQ 1 & 2, Epochs 1-3 
 PASQ 1 PASQ 2  
*p n Mean Median  [IQR] n Mean Median  
[IQR] 
Epoch 1 33 49.09 45.0 
[45.0-60.0] 
23 57.37 60.0 
[60.0-60.0] 
*0.01 
Epoch 2 25 50.4 45.0 
[45.0-60.0] 
13 50.08 59.15 
[44.31-60.0] 
0.897 
Epoch 3 20 47.25 45.0 
[45.0-60.0] 
8 45.19 45.0 
[33.84-59.58] 
0.593 
*p values based on Mann-Whitney-U test 
 
In order to ascertain whether there baseline differences in paracetamol 
administered between T21 and non-T21 patients before the intervention; 
the Mann-Whitney-U test was applied to PASQ 1 data. No statistically 
significant differences emerged as can be seen in table 8.4.3(b).  
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Table 8.4.3(b) Paracetamol Administered, T21 vs Non-T21, PASQ 1, Epochs 1-3  
T21 vs Non-T21 Patients: Paracetamol Administered (mg/kg), PASQ 1, 
Epochs 1-3 
 T21 Non-T21  
*p n Mean Median  [IQR] n Mean Median  
[IQR] 
Epoch 1 33 49.09 45.0 
[45.0-60.0] 
28 48.16 45.0 
[45.0-60.0] 
0.688 
Epoch 2 25 50.4 45.0 
[45.0-60.0] 
19 46.11 45.0 
[45.0-60.0] 
0.231 
Epoch 3 20 47.25 45.0 
[45.0-60.0] 
12 45.0 52.5 
[30.0-60.0] 
0.95 
*p values based on Mann-Whitney-U test 
 
Similarly; to appreciate whether any differences existed in paracetamol 
administered between T21 and non-T21 patients in the post-intervention 
period; the Mann-Whitney-U test was applied to PASQ 2 data. No 
statistically significant differences emerged as can be seen in table 
8.4.3(c).  
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Table 8.4.3(c) Paracetamol Administered, T21 vs Non-T21, PASQ 2, Epochs 1-3  
T21 vs Non-T21 Patients: Paracetamol Administered (mg/kg), PASQ 2, 
Epochs 1-3 
 T21 Non-T21  
*p n Mean Median  [IQR] n Mean Median  
[IQR] 
Epoch 1 23 57.37 60.0 
[60.0-60.0] 
40 56.31 60.0 
[57.03-60.0] 
0.406 
Epoch 2 13 50.08 59.15 
[44.31-60.0] 
29 53.55 58.5 
[44.82-60.0] 
0.805 
Epoch 3 8 45.19 45.0 
[33.84-59.58] 
19 43.15 45.0 
[41.66-60.0] 
0.957 
*p values based on Mann-Whitney-U test 
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The paracetamol administered to T21 and non-T21 patients before and 
after the intervention is depicted in the boxplot illustration below (figure 
8.4.3).  
 
Figure 8.4.3: Paracetamol Administration T21 Vs Non-T21, PASQ 1 & 2, Epochs 1-3 
 
8.4.4 Oramorph Administered in PASQ 1 and PASQ 2: T21 Patients 
In both PASQ 1 and 2; the median dose of oramorph received by 
patients with T21 was zero. In Epochs 2 and 3 patients with patients with 
T21 appeared to receive more oramorph after the intervention. However 
this did not reach statistical significance on application of the Mann-
Whitney-U test (see table 8.4.4(a)).  
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Table 8.4.4(a) Oramorph Administered, T21 Patients, PASQ 1 & PASQ 2 
Oramorph Administered (mcg/kg), T21 Patients PASQ 1 & 2, Epochs 1-3 
 PASQ 1 PASQ 2  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 33 10.99 0 
[0-0] 
23 38.25 0 
[0-0] 
0.494 
Epoch 2 25 188.35 0 
[0-363.01] 
13 261.04 96.3 
[0-461.1] 
0.474 
Epoch 3 20 208.49 94.34 
[0-454.48] 
8 277.12 277.12 
[34.85-
510.83] 
0.427 
*p values based on Mann-Whitney-U test 
 
To determine whether there were any baseline differences between 
oramorph administered to T21 and non-T21 patients before the 
intervention; the Mann-Whitney-U test was used. This returned a non-
statistically significant result for all 3 Epochs before the intervention (see 
table 8.4.4(b)). 
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Table 8.4.4(b) Oramorph Administered, T21 vs Non-T21, PASQ 1 
T21 vs Non-T21 Patients: Oramorph Administered (mcg/kg), PASQ 1, 
Epochs 1-3 
 T21 Non-T21  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 33 10.99 0 
[0-0] 
28 46.33 0 
[0.0] 
0.693 
Epoch 2 25 188.35 0 
[0-363.01] 
19 108.25 0 
[0-101.69] 
0.326 
Epoch 3 20 208.49 94.34 
[0-454.48] 
12 136.84 0 
[0-299.1] 
0.391 
*p values based on Mann-Whitney-U test 
 
To determine whether any statistically significant differences between 
oramorph administered to T21 and non-T21 patients emerged after the 
intervention; the Mann-Whitney-U test was again used. This returned a 
non- statistically significant result for all 3 Epochs after the intervention 
(see table 8.4.4(c)). 
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Table 8.4.4(c) Oramorph Administered, T21 vs Non-T21, PASQ 2  
T21 vs Non-T21 Patients: Oramorph Administered (mcg/kg), PASQ 2, 
Epochs 1-3 
 T21 Non-T21  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 23 38.25 0 
[0-0] 
40 11.37 0 
[0-0] 
0.374 
Epoch 2 13 261.04 96.3 
[0-461.1] 
29 149.15 0 
[0-278.12] 
0.372 
Epoch 3 8 277.12 277.12 
[34.85-510.83] 
19 201.6 29.0 
[0-350.0] 
0.379 
*p values based on Mann-Whitney-U test 
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A visual interpretation of these findings is presented in the boxplot figure 
8.4.4. 
 
 
Figure 8.4.4: Oramorph Administration T21 vs Non-T21, PASQ 1 & 2, Epoch 1-3 
 
8.4.5 Clonidine Administered T21 vs Non-T21 Patients  
Similar to non-T21 patients, the T21 patients received more clonidine 
after the intervention in all 3 Epochs. However the difference in mean 
clonidine administered transpired to be statistically significant only in 
Epoch 1 (p=0.004), see table 8.4.5(a). 
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Table 8.4.5(a) Clonidine Administered, T21 PASQ 1 & PASQ 2 
Clonidine Administered (mcg/kg), T21 Patients: PASQ 1 & 2,  Epochs 1-3 
 PASQ 1 PASQ 2  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 33 0.28 0 
[0-0] 
23 0.98 0.76 
[0-2.01] 
*0.004 
Epoch 2 25 0.80 0 
[0-0.74] 
13 0.58 1.05 
[0-3.28] 
0.122 
Epoch 3 20 1.03 0 
[0-1.64] 
8 1.72 1.84 
[0.2-3.2] 
0.158 
*p values based on Mann-Whitney-U test 
 
The data were analysed to determine whether there was a baseline 
difference in clonidine administered to T21 patients before the 
intervention. As is evident in table 8.4.5(b), the Mann-Whitney-U test 
confirmed that there were no statistically significant differences between 
clonidine administered to T21 and non-T21 patients before the 
intervention.  
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Table 8.4.5(b) Clonidine Administered, T21 vs Non-T21, PASQ 1 
Clonidine Administered (mcg/kg), T21 vs Non-T21 Patients: PASQ 1, 
Epochs 1-3 
 T21 Non-T21  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 33 0.28 0 
[0-0] 
28 0.74 0 
[0-0.99] 
0.165 
Epoch 2 25 0.80 0 
[0-0.74] 
19 1.44 0 
[0-3.82] 
0.229 
Epoch 3 20 1.03 0 
[0-1.64] 
12 1.43 0 
[0-2.96] 
0.759 
*p values based on Mann-Whitney-U test 
 
The Mann-Whitney-U test was repeated in the post-intervention data. No 
statistically significant differences emerged between clonidine 
administered to T21 and non-T21 patients after the intervention (see 
table 8.4.5(c)). 
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Table 8.4.5(c) Clonidine Administered, T21 vs Non-T21, PASQ 2  
Clonidine Administered (mcg/kg), T21 vs Non-T21 Patients: PASQ 2, 
Epochs 1-3 
 T21 Non-T21  
*p n Mean Median  [IQR] n Mean Median  [IQR] 
Epoch 1 23 0.98 0.76 
[0-2.01] 
40 1.18 0.84 
[0-2.35] 
0.875 
Epoch 2 13 0.58 1.05 
[0-3.28] 
29 1.66 1.0 
[0-2.99] 
0.856 
Epoch 3 8 1.72 1.84 
[0.2-3.2] 
19 1.49 0.96 
[0-2.94] 
0.591 
*p values based on Mann-Whitney-U test 
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The increase in clonidine administered to T21 patients in PASQ 2 is 
evident in the boxplot in figure 8.4.5. 
 
Figure 8.4.5: Clonidine Administration T21 vs Non-T21, PASQ 1 & 2 
 
A point summary of findings related to analgesia and sedation derived 
through analysis of data collected using PASQ is presented below. 
 
8.5 Summary of Findings from PASQ Analgesia & Sedation 
Analysis 
  
 There was no statistically significant difference in the average 
amount of morphine administered to study patients in each of the 
3 Epochs after the intervention. 
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 A major element of the intervention involved reinforcing the 
judicious use of morphine infusions and avoiding especially high 
infusion rates. Rates that morphine infusions were set at on return 
to PICU from the operating theatre were lower after the 
intervention, this proved highly statistically significant.  
 PASQ 2 patients received more morphine boluses in Epoch 1 than 
PASQ 1 patients, this proved to be statistically significant.  
 There was no statistically significant difference in midazolam 
administered to patients, either by infusion or intravenous bolus 
after the intervention. 
 Use of intravenous paracetamol was advocated by the guidelines 
in the post-operative period. This drug has co-analgesic and 
opioid-sparing properties making it valuable in the post-operative 
population. An increase in the amount of paracetamol 
administered after the intervention emerged in Epoch 1. This 
proved to be highly statistically significant. 
 Clonidine is an α2 adrenergic-agonist useful for sedation and 
analgesia which can be useful in ameliorating opioid withdrawal 
symptoms.  The amount of clonidine administered was higher in 
Epochs 1 and 2 after the intervention, and this finding reached 
statistical significance. 
 Oramorph is the oral form of the opioid morphine. There was no 
statistically significant difference in the amount of oramorph used 
after the intervention in the population studied. 
 There was a focussed analysis on analgesics and sedatives 
administered to patients with T21. A statistically significant 
reduction in morphine administered to T21 patients after the 
intervention was observed in Epoch 2.  
 Judicious use of chloral hydrate was advocated due to its 
unpredictable effects, prolonged half-life and absence of a 
reversal agent. Patients with T21 received more chloral hydrate in 
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Epochs 2 and 3 than non-T21 patients before the intervention. 
This finding proved to be statistically significant.  
 After the intervention there was no statistically significant 
difference in chloral hydrate administration between T21 and non-
T21 patients.  
 
 
It was clear that there were differences in the pattern of analgesia and 
sedative drug administration after the intervention. Further analysis was 
required to determine whether a change in patients’ length of 
dependence on mechanical ventilation and PICU stay occurred after the 
intervention. 
 
8.6 Duration of Mechanical Ventilation PASQ 1 vs PASQ 2 
Consistent with the research hypothesis, the median duration of 
mechanical ventilation before and after the intervention was compared 
(see table 8.6). Inspection of a histogram revealed skewed distribution of 
duration of dependence on mechanical ventilation; therefore the Mann-
Whitney-U test was applied. A non-statistically significant result emerged 
from application of this test indicating no significant difference in length 
on mechanical ventilation after the intervention (p=0.07). It could not be 
concluded that the intervention led to a decrease in patients’ length of 
dependence on mechanical ventilation. The secondary null hypothesis 
was therefore not rejected.  
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Table 8.6: Duration of Ventilator Dependence PASQ 1 and PASQ 2 
All Patients 
PASQ 
1 or 2 
N Mean 
Rank 
Median IQR Sum of 
Ranks 
Mann- 
Whitney
-U 
* p 
Duration of 
Ventilation 
PASQ 1 61 69.01 1.27 
0.96-
2.16 
4209.5  
1585.5 
 
  
0.07 
PASQ 2 64 57.27 1.07 
0.82-
1.73 
3665.5 
*p value based on Mann-Whitney-U Test 
 
8.6.1 Duration of Mechanical Ventilation; T21 vs non-T21  
The length of dependence on mechanical ventilation for the T21 
population before and after the intervention was assessed to determine 
whether this subgroup was disproportionally affected. Visual inspection 
of histogram for duration of mechanical ventilation before and after the 
intervention for the T21 population revealed data were not normally 
distributed. Therefore a comparison of PASQ 1 and PASQ 2 again using 
Mann-Whitney-U was carried out.  
 
Before intervention, the median difference between length of intubation 
for T1 and non-T21 was not statistically significant when Mann-Whitney-
U applied (p=0.06), nor was it statistically significant after the intervention 
(p=0.36). However when only T21 patients were analysed, there was a 
statistically significant reduction in median length of mechanical 
ventilation after the intervention (p=0.012).The intervention appeared to 
have benefitted the T21 population disproportionately (see table 8.6.1).   
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Table 8.6.1: Duration of Mechanical Ventilation for T21 Subjects PASQ 1 & PASQ 2 
*p Value based on Mann-Whitney-U test 
 
In summary, there was a statistically significant reduction in the duration 
of mechanical ventilation for T21 patients after the intervention, 
confirmed by a p value of 0.012 on application of the Mann-Whitney-U 
test. 
 
8.7 Length of PICU Stay PASQ 1 vs PASQ 2  
The duration of PICU stay for PASQ 1 and PASQ 2 was plotted on a 
histogram. Inspection revealed a skewed distribution. The data were 
therefore treated as non-parametric. Descriptive statistics revealed the 
length of PICU stay was reduced after the intervention from median 3.5 
days (IQR 1.9-6.26) to 2.84 days (IQR 1.9-4.73). The Mann-Whitney-U 
test was applied to determine whether this difference was statistically 
significant. A non-statistically significant two tailed probability emerged 
(p=0.28), see table 8.7 for values. This is illustrated on a bar chart, see 
figure 8.7. 
 
 
T21 
Patients 
PASQ 
1 or 2 
N Mean 
Rank 
Median IQR Sum of 
Ranks 
Mann-
Whitney-U 
p 
Duration of 
Ventilation 
PASQ 1 33 33.09 
1.4 0.97-
3.55 
1092.00 
 
228.00 
 
*0.012 
PASQ 2 23 21.91 
1.05 0.85-
1.25 
504.00 
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Table 8.7: Duration of PICU Stay PASQ 1 vs PASQ 2 
All Patients 
PASQ 
1 or 2 
N Mean 
Rank 
Median IQR Sum of 
Ranks 
Mann-
Whitney
-U 
p 
Duration Of  
PICU Stay 
PASQ 1 61 66.6 
 
3.5 
 
1.9-
6.26 
4061.0  
1734.0 
 
 
 
0.28 
PASQ 2 64 59.6 
 
2.84 
 
1.9-
4.73 
3814.0 
 
 
Figure 8.7: Duration of PICU Stay in Hours PASQ 1 and PASQ 2 
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8.7.1 Length of PICU Stay; T21 Patients 
The duration of PICU stay for T21 patients was reduced after the 
intervention; from median 4 days (IQR 1.95-6.96) to median 3.15 days 
(IQR 1.88-4.92). However this fell short of reaching statistical 
significance when the Mann-Whitney-U test was applied (p=0.09), 
revealing no statistically significant difference in length of PICU stay for 
the T21 population after the intervention (see table 8.7.1). 
 
Table 8.7.1: Duration of PICU Stay T21 Patients, PASQ 1 vs PASQ 2  
T21 
Patients 
PASQ    
1 or 2 
N Mean 
Rank 
Median IQR Sum of 
Ranks 
Mann-
Whitney
-U 
p 
Duration Of 
PICU Stay 
PASQ 
1 
33 31.59 
4.0 1.95-
6.96 1042.5 
 
277.5 
 
 
0.09 
PASQ 
2 
23 24.07 
3.15 1.88-
4.92 
553.5 
 
 
8.8 Compliance with Analgesia and Sedation Guidelines 
Prior to the intervention, no standardised method of assessing pain and 
distress in pre-verbal often intubated post-operative PICU patients 
existed in the study setting. Comparison of pain assessment before and 
after the intervention would therefore be meaningless. In order to 
determine whether there was compliance with the analgesia and 
sedation guidelines; selected elements which were measurable and 
reflected a departure from pre-intervention practice were chosen. These 
comprised the following: 
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 Morphine rate ≤40 mcg/kg/hr on return from operating theatre. 
 Loading dose of Morphine given on starting infusion. 
 Morphine boluses prn (pro re nata) prescribed. 
 COMFORT-B assessment within 2 hours post-operatively.   
 IV paracetamol prescribed. 
 Non-Steroidal Anti Inflammatory Drugs (NSAIDS) prescribed. 
 
8.8(i) Rate of Morphine Infusion on Return from Operating Theatre 
Descriptive statistics revealed in the post-intervention sample, most 
study patients (61%, n=39) returned from the operating theatre with a 
rate of morphine infusing which was in accordance with the analgesia 
and sedation guidelines. However, 39% (n=25) had a rate of morphine 
running that was in excess of the guidelines (see table 8.8(i)). 
 
This was an improvement on pre-intervention practice, where only a third 
(34.4%, n=21) of the study patients had morphine infusion rates which 
were within an acceptable range as outlined by the analgesia and 
sedation guidelines. Over half the pre-intervention sample (34, n=55.7%) 
had morphine infusion rates which were far in excess of the guideline 
rate. 
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Table 8.8(i): Morphine Rate on Return from Theatre PASQ 1 and PASQ 2 
PASQ 1 & PASQ 2 Morphine Rate on Return from Theatre 
Morphine Rate 
mcg/kg/hr 
PASQ 1 N=61 
(n) % 
PASQ 2 N=64 
(n) % 
*p 
40.00 21 (34.4) 39 (60.9) **0.003 
44.00 1 (1.6) - 0.3 
56.00 1 (1.6) - 0.3 
60.00 4 (6.6) 1 (1.6) 0.15 
80.00 27 (44.3) 23 (35.9) 0.34 
84.00 - 1(1.6) 0.33 
100.00 1 (1.6) - 0.3 
120.00 4 (6.6) - *0.04 
160.00 2 (3.3) - 0.14 
Total 61 (100.0) 64 (100.0) 0.14 
*p value based on chi-square test 
 
Chi square analysis revealed more patients returned from the operating 
theatre on 40 mcg/kg/hr in PASQ 2 than in PASQ 1, this proved to be 
statistically significant. More patients returned from the operating theatre 
with a rate of morphine infusing of 120mcg/kg/hr in PASQ 1 than PASQ 
2, and this finding reached statistical significance. A rate of 120mcg/kg/hr 
was considered extremely high and was not endorsed by the analgesia 
and sedation guidelines. Correlation analysis was done to determine the 
strength of the relationship between group (PASQ 1 or 2) and morphine 
rate on return from theatre. This difference proved highly statistically 
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significant when chi square test was applied (p=0.004), with a correlation 
of (Pearson’s r = 0.002).  
 
8.8(ii) Morphine Loading PASQ 1 and PASQ 2 
On starting intravenous morphine infusions, a loading dose of morphine 
was endorsed to ensure the level of morphine was within the therapeutic 
range for analgesia. If the patient did not receive a loading dose of 
morphine in the operating theatre on commencing the morphine infusion, 
the guidelines endorsed administering this loading dose in the PICU. The 
amount of study patients who received morphine loading before and after 
the intervention was compared. 
 
In 4 cases after the intervention morphine loading was administered. In 
three cases this occurred in theatre before PICU admission, and in one 
case it occurred in PICU. There was no evidence of loading doses given 
to patients in PASQ 1; however, extracting data for the time period prior 
to PICU admission was often challenging, due among other reasons to 
the writers’ unfamiliarity with documentation and records in the operating 
theatre department.  
 
8.8(iii) Morphine Boli Prescribed 
If the rate of morphine was insufficient to control the patient’s pain, or if 
there was breakthrough pain, a bolus of morphine was advocated. Pre-
emptive morphine boluses were also endorsed prior to potentially painful 
interventions such as physiotherapy. A histogram display of morphine 
bolus data was skewed to the right, and a test for normality returned a 
significant Shapiro-Wilks value (<0.001). Therefore non-parametric 
methods of analysis were used. PASQ 2 patients received more 
morphine boluses in each of the 3 Epochs than PASQ 1 patients (see 
 253 
 
table 8.8(iii)). This was highly statistically significant in Epoch 1 (p<0.001) 
(see illustration figure 8.8(a)), it also reached statistical significance in 
Epoch 2, but did not reach statistical significance in Epoch 3, perhaps 
because the clinical need for morphine bolus diminishes over time after 
surgery. 
 
Table 8.8(iii): Boluses of Morphine Administered, PASQ 1 & PASQ 2 Epoch 1-3 
Morphine Bolus PASQ 1 & PASQ 2, Epoch 1-3  
 PASQ 1 PASQ 2  
*p n Mean 
(mcg/kg) 
Median  
[IQR] 
n Mean 
(mcg/kg) 
Media
n  
[IQR] 
Epoch 1 61 2.26 0 
[0-0] 
64 26.35 20 
[0-40] 
***<0.001 
Epoch 2 44 0.0 0 
[0-0] 
42 7.38 0 
[0-0] 
*0.019 
Epoch 3 32 0.0 0 
[0-0] 
27 1.85 0 
[0-0] 
0.12 
*p Value based on Mann-Whitney-U test 
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Figure 8.8(a) Morphine Bolus Administered, PASQ 1 & 2, Epoch 1 
 
8.8(iv) Assessment of Pain within the First 2 Hours of Arriving in PICU 
The majority of PASQ 2 patients (70.3%, n=45) had a distress 
assessment score within the first 2 hours after returning from the 
operating theatre. In 29.7% (n=19) cases, this did not occur, see table 
8.8(iv). 
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Table 8.8(iv): COMFORT-B Assessment within 2 Hours Post-Operatively 
Patient Assessment Using COMFORT-B Within 2h of PICU Admission 
 Frequency Percent Valid 
Percent 
Cumulative Percent 
Assessment 
Performed No 
19 29.7 29.7 29.7 
Assessment 
Performed  Yes 
45 70.3 70.3 100.0 
Total 64 100.0 100.0  
 
8.8(v) Intravenous Paracetamol Administered in Epoch 1 
In all but one case (98.4%, n=63), for PASQ 2 patients IV paracetamol 
was administered In Epoch 1 after returning from theatre in accordance 
with analgesia and sedation guidelines. A comparison with PASQ 1 was 
not performed as this was not standard practice prior to the intervention. 
 
8.8(vi) Non-Steroidal Anti-Inflammatory Analgesia Prescribed 
Similarly in 90.6% (n=58) of cases non-opioid analgesia was prescribed 
for PASQ 2 patients. This represented an improvement on the 26.2% 
(n=16) study patients that were prescribed non-opioid analgesia before 
the intervention. See figure 8.8(b) for graph illustrating compliance with 
these 6 selected items.   
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Figure 8.8(b): Compliance with Analgesia and Sedation Guidelines PASQ 2  
 
8.9 Summary of Findings; Duration of Mechanical Ventilation and 
PICU Stay and Guideline Compliance  
 
8.9 (i) Duration of Mechanical Ventilation and PICU Stay 
 Although a reduction in median duration of mechanical ventilation 
emerged after the intervention (PASQ 1= 1.27 days, PASQ 2= 
1.07 days), this was non-statistically significant when the Mann-
Whitney-U test was applied (p=0.07). 
 However when only T21 patients were analysed, there was a 
statistically significant reduction in median duration of ventilation 
after the intervention (p=0.012).  
 There was no statistically significant reduction in the median 
duration of PICU stay after the intervention for either T21 or non-
T21 patients (p=0.28). 
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8.9(ii) Compliance with Guidelines 
Specific elements of the guidelines were selected to assess compliance 
in PASQ 2, including distress assessment and analgesia and sedation 
prescribed. 
 Patients had a COMFORT-B distress assessment carried out 
within 2 hours of returning from theatre in 70.3% (n=45) of cases. 
 98.4%, (n=63), of PASQ 2 patients had IV paracetamol 
administered after returning from theatre in accordance with 
analgesia and sedation guidelines. 
 In 90.6% (n=58) of cases IV morphine boluses were prescribed on 
a PRN basis (pro re nata) as endorsed by the analgesia and 
sedation guidelines. This was in comparison with 8.2 % (n=5) 
before the intervention.  
 In 90.6% (n=58) of cases non-opioid analgesia was prescribed for 
PASQ 2 patients, compared with 26.2% (n=16) before the 
intervention.  
 
 
8.10 Interpretation of COMFORT-B and NRS Scores 
The original eight item COMFORT scale was revised and the 
physiological variables ‘heart rate’ and ‘blood pressure’, which are often 
manipulated by inotropic drugs in PICU were removed by the team of 
Dutch researchers (Ista et al. 2005). The Dutch researchers found that 
remaining 6 items were found to have excellent construct validity 
however scores of between 11 and 22 constituted a ‘grey area’ where 
the nurses’ expert opinion of their patient’s level of comfort was required. 
When the nurses interpretation of sedation or numerical rating scale NRS 
was incorporated into the tool, evaluations in PICU settings using 
exploratory and confirmatory factor analysis resulted in the six item 
COMFORT-B scale which is now used in clinical practice. The optimal 
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clinical cut-off value of the COMFORT-B scale for pain is 17. Distress 
without pain also results in a high COMFORT-B score. On the 0-10 NRS 
(numerical rating scale); pain scores of 4 or higher indicate moderate to 
severe pain (see table 8.10 for cut-off values, refer to Chapter 3 section 4 
for a full account of the development and validation of COMFORT-B).  
The following categories have been described: 
 
Table 8.10: Cut-Off Values for COMFORT-B and NRS Scores 
Cut-Off Values for COMFORT-B and NRS Scores 
COMFORT-B Corresponding 
NRS 
Interpretation 
>22 0-10 Undersedated. 
≥17 ≥4 In Pain. 
<17 ≥4 Unexpressive Pain (where patient may be 
too unwell to display the behavioural 
manifestations of pain which are included in 
COMFORT-B). 
<17 <4 No Pain. 
≥17 <4 Distress not Caused by Pain. 
 
8.10.1 Nature of COMFORT and NRS Scores Recorded 
Descriptive statistics were used to reduce and interpret COMFORT-B 
and NRS assessments using established cut-off scores and 
interpretations. COMFORT-B scores showed normal distribution when 
plotted on a histogram (see figure 8.10.1(a)), while NRS scores had a 
notable floor effect (a score of zero frequently recorded). In many cases 
an NRS score of ‘<4’ to indicate ‘no pain’ was recorded by the nurse. 
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This prevented NRS scores from being analysed as a scale variable; 
instead it was handled as a categorical variable.  
 
 
Figure 8.10.1(a): Histogram displaying COMFORT-B Scores performed PASQ 2 
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For the 64 subjects in P2, a total of 672 distress assessments were 
conducted, one patient did not have any COMFORT-B or NRS scores 
recorded. The median and IQR number of pain and distress 
assessments per subject was 11, IQR [7-13]. Over three quarters of the 
assessments (75.6%, n=405 scores) determined a comfortable non-
distressed state (COMFORT <17, NRS <4). In a quarter of cases 
(24.9%, n=168 scores) a distressed state due to pain was confirmed 
(COMFORT ≥17, NRS ≥4), see table 8.10.1(a). While a COMFORT-B 
score of ≥17 suggested distress in PICU patients. If this score was 
combined with a NRS score<4; the interpretation in practice was that the 
patient was distressed for reasons other than pain (i.e. hunger, 
separation anxiety, undersedation). 
 
Table 8.10.1(a): COMFORT-B and NRS Scores Indicating ‘Pain’ and ‘No Pain’ in 
PASQ 2  
COMFORT-B  & Associated NRS Scores in PASQ 2, N=672  
COMFORT-B NRS Interpretation n(%) Valid 
Percent 
≥17 ≥4 Pain 168 (24.9) 25.0 
<17 NRS <4 No Pain 504 (74.8) 75.0 
 
 
The clinical interpretation of a COMFORT-B score of <11 was of 
oversedation. The majority of patients (n=39, 61.9%) achieved a 
COMFORT-B score of <11 in the study period. While 24 subjects 
(38.1%) never experienced oversedation in the first 72 hours post 
surgery. There was no statistically significant difference in the incidence 
in oversedation between T21 and non-T21 subjects (p=1.0) see table 
8.10.1(b). 
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Table 8.10.1(b) Oversedation in T21 vs NonT21 Patients 
Oversedation (COMFORT-B<11) T21 and non-T21 patients in 
P2 
COMFORT-B Interpretation Non-T21 T21 p 
<11 Never Oversedated 16 8 
1.0 >10 
Oversedated At 
Some Time Point 
25 14 
Total 41 22 
 
 
8.10.2 Analysis of COMFORT-B and NRS Assessments 
As assessments were not independent; with one subject likely to have 
multiple assessments, chi square analysis to compare groups was not 
appropriate. Comparisons were made between T21 and Non-T21 
patients to detect significant differences which may have had implications 
for future clinical practice.  
 
 
 
 
 
 
 
 
 
 262 
 
Table 8.10.2(a): COMFORT-B and NRS Scores for T21 and Non-T21 Patients in P2 
COMFORT-B and NRS Scores for P2 Subjects, T21 and Non-T21 
 T21  
(232 Scores) 
Non-T21  
(442 Scores) 
p value 
COMFORT-B, median [IQR] 14 [12:16] 14 [12:16] 0.29 
NRS, median [IQR] 2 [0-3] 2 [0-3] 0.94 
Distress: COMFORT-B >16, n(%) 44 (19%) 86 (19.6%) 0.92 
Pain, Nurses Judgement: NRS >3, 
n(%) 
39 (20.4%) 70 (21.3%) 0.8 
Comfortable: COMFORT-B <17, NRS 
<4 
174 (75%) 330 (75%) 1.0  
Pain: COMFORT-B>16 & NRS>3, n(%)  46 (10.8%) 25 (10.6%) 0.95 
Oversedation: (COMFORT-B <11), 
n(%) 
30 (12.9%) 62 (14.1%) 0.68 
Pain but not Expressive: COMFORT-B 
<17, NRS >3 
14 (7.3%) 24 (7.1%) 0.94 
Undersedation: COMFORT-B >22 2 (0.86%) 6 (1.36%) 0.57 
 
Median and IQR COMFORT-B scores were the same for T21 and non-
T21 patients, as were NRS scores. There was a good deal of 
consistency in the assessments for T21 and non-T21 patients regarding 
the clinical interpretation of the scores (see table 8.10.2(a)). There was 
no increased likelihood of oversedation between T21 and non-T21 
patients; although T21 patients were more likely to be oversedated in 
Epoch 1 (OR 1.13 CI 0.6-2.1) than in Epoch 2 or 3 (OR 0.65 CI 0.3-1.38). 
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No statistically significant differences emerged regarding the proportion 
of COMFORT-B and NRS scores in each category.  The nature of scores 
per Epoch was therefore assessed to determine how they were 
influenced by time (see table 8.10.2(b)).    
 
Table 8.10.2(b): Nature of COMFORT-B and NRS Scores per Epoch 
COMFORT-B and NRS Scores Epoch 1-3, N=672 Scores 
COMFORT-
B 
NRS Interpretation Epoch 1 
n(%) 
Epoch 2 
n(%) 
Epoch 3 
n(%) 
>22 0-10 Undersedated. 3 (0.45) 4 (0.59) 1 (1.6) 
≥17 ≥4 In Pain. 14 (2.1) 6 (0.89) 2 (0.3) 
<17 ≥4 Unexpressive 
Pain. 
12 (1.78) 8 (1.19) 3 (0.45) 
<17 <4 No Pain. 61 (9.1) 56 (8.31) 29 (4.3) 
≥17 <4 Distress. 23 (3.4) 18 (2.67) 4 (0.59) 
≤10 <4 Oversedated 31(4.6) 16 (2.37) 9 (1.34) 
 
 
As can be seen from table 8.10.2(b), both expressive and unexpressive 
pain as well as distress caused by factors other than pain occurred more 
frequently in the immediate post-operative period (Epoch 1), 49 scores 
meeting these criteria. Oversedation was also recorded more frequently 
in this time period, on 31 occasions. In 61 recorded cases, the patient did 
not exhibit signs suggestive of pain or distress. In Epoch 2, 
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undersedation was recorded more frequently than in Epoch 1, while pain 
and distress were recorded less frequently. 
 
There was no determinable trend regarding the level of recorded 
COMFORT-B score over a 24 hour time period. As can be seen in figure 
8.10.2(b) there was no distinction between daytime assessments versus 
night time assessments.  
 
 
Figure 8.10.2(b) COMFORT –B Scores Performed over 24 Hour Period 
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8.11 Summary of Findings; Assessment of Distress Using 
COMFORT-B 
 For the 64 subjects in P2, a total of 672 distress assessments 
were conducted. The median was 11, and IQR [7-13].  
 Over three quarters of the assessments (75.6%, n=405 scores) 
determined a comfortable non-distressed state (COMFORT < 17, 
NRS < 4). In a quarter of cases (24.9%, n=168 scores) a 
distressed state due to pain was confirmed (COMFORT ≥ 17, 
NRS ≥ 4). 
 There was no statistically significant difference between the T21 
and non-T21 subjects regarding distress (p=0.76), and both T21 
and non-T21patients were more likely to be oversedated in Epoch 
1 than in Epoch 2 or 3.  
 
 
Findings from the analysis of before and after surveys of PICU nurses 
and doctors using the specifically developed and validated SASQ 
instrument will now be presented. The minutes from PICU Analgesia and 
Sedation Committee meetings will be presented, and an evaluation of the 
intervention using the CIPP model undertaken. 
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Chapter 9: Findings from PICU Staff and 
Evaluation  
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9.0 Introduction 
An important aim of the research was to explore the impact of 
implementing guidelines on staff  attitudes and approaches to  analgesia 
and sedation practices.  The SASQ (Staff Analgesia and Sedation 
Questionnaire) was specifically developed to determine the perceptions 
of PICU staff regarding the changed approach to analgesia and sedation 
management in the PICU. The minutes of Analgesia and Sedation 
Committee meetings supplemented the questionnaire data. The CIPP 
model of evaluation offered an appropriate method of appraising the 
intervention. Firstly, the data obtained using the SASQ questionnaire will 
be presented. 
 
9.1 SASQ; Data Collection 
Data were collected for SASQ 1 in February 2010. Training PICU staff on 
using COMFORT-B commenced in March 2010 and the analgesia and 
sedation guidelines were rolled out on Tuesday 1st June 2010. SASQ 2 
(after guideline introduction) was administered in June 2011, 12 months 
after the introduction of the COMFORT-B assessment tool and the 
analgesia and sedation algorithm and guidelines.  
 
9.1.1 SASQ; Data Analysis 
All returned questionnaires were analysed, consistent with an ‘all case 
analysis’. Likert type responses for the ‘Satisfaction Section’ (Section B), 
alluding to ‘level of satisfaction with analgesia and sedation practices’ 
were re-coded and treated as scale variables. A sum of scores was 
calculated to allow comparison of means between groups. The ‘Items of 
Concern’ section (Section C) comprising a list of 22 items was summed 
to ‘total score’ for each response in SASQ 1 and SASQ 2. For Section D; 
the ‘Knowledge Section’, responses to the true or false statements were 
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transformed, allowing the respondent to achieve a total score for this 
section which was rescaled to a percentage.  
 
Comparisons were made between before and after responses. For all 
respondents the independent t-test was used to analyse differences in 
group means. For respondents who answered both SASQ 1 and SASQ 2 
(n=67), their responses were treated as matched pairs and analysed 
using paired samples t-test. In these cases each respondent acted as 
their own control.  
 
9.2 SASQ Findings 
For the main study, there was a 58% (n=105) response to SASQ 1 and a 
51.9% (n=94) response to SASQ 2. There was a 70% response rate 
from nurses targeted and a 37.5% response rate from doctors. Well over 
half responding nurses (58.1%, n=54) had between 6 and 20 years of 
experience, while 14% (n=13) had over 20 years experience. 
Conversely, of the doctors who responded, 41.7%, (n=5) indicated to 
have less than 6 months of PICU experience. The demographic 
information of respondents are presented in Table 9.2. 
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Table 9.2: Demographic Data of SASQ Respondents 
Demographic Data, SASQ Respondents 
SASQ 1 
N=105 
SASQ 2 
N=94 
Nurses n (%) 
n=93 (76.9%) n=84 (90.4%) 
Doctors n (%) 
n=12 (42.9%) n=10 (9.6%) 
Nurse Level n (%) 
Staff Nurse 77 (73.3%)  Staff Nurse 71 (75.5%) 
Clinical Nurse 
Manager 
(CNM) 
16 (15.3)  CNM 14 (14.9%) 
Doctor Level n (%) 
Consultant 4 (3.8%)  Consultant 3 (3.2%) 
Registrar 8 (7.6%)  Registrar 7 (7.4%) 
Length of PICU Experience n (%) 
 Nurses Doctors Nurses Doctors 
0-1yr 9 (9.7%) 7 (58.3%) 10 (11.9%) 5 (50%) 
>1yr-5yrs 18 (19.4%) 4 (33.3%) 22 (26.2%) 4 (40%) 
>5yrs-10yrs 33 (35.1%) - 23 (27.4%) - 
>10yrs 33 (35.1%) 1 (8.3%) 29 (34.5%) 1 (10%) 
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9.2.1 Section B(a) Satisfaction with Analgesia and Sedation Practice in PICU  
The paired t-test was used to explore whether satisfaction with analgesia 
and sedation practice was significantly different after the intervention. 
Respondents who answered both SASQ 1 and SASQ 2 were included in 
this analysis. A statistically significant increase in PICU staff satisfaction 
after the intervention did emerge (t value 4.6 p<0.001, CI of the 
difference 95% 5.6 to14.3), (see table 9.2.1).  
For 4 of the elements, a statistically significant increase in satisfaction 
was noted. 85% of respondents felt that “A standardised tool for 
assessing distress in PICU patients [COMFORT-B] would be [is] valuable 
for patient management in the PICU”, both before and after the 
intervention. However there was a reduction in the number of 
respondents who perceived the tool combined with guidelines to be 
valuable in patient management in PICU. One year after the introduction 
of the guidelines and COMFORT-B, this number had decreased slightly 
from 92.5%, (n=97) to 81% (n=76).  
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Table 9.2.1: Section B(a) Satisfaction with Analgesia & Sedation Management, 
SASQ 1 & 2 
 
 
*p value based on paired samples t-test 
 
9.2.2 Section B(b) Items of Concern Related to Analgesia and Sedation in 
PICU  
Of the list of 22 items presented to respondents, there was a highly 
statistically significant reduction in the number of items respondents felt 
merited concern after the intervention.  The paired samples t-test 
revealed a mean reduction of 2.8 items, (SD 5.0, 95% CI 1.6-4.0, t=4.5, 
p<0.001) (See table 9.2.2 for item list and responses).  The areas where 
the most significant changes occurred  after the intervention were in 
relation to the assessment of pain and sedation, the tools available to do 
this and the prioritisation of sedation (all p-values<0.001). After the 
intervention, the lack of prioritisation of pain, inconsistency in practice at 
Please Indicate your level of 
agreement or satisfaction with the 
following statements: 
SASQ1 
Agree  
n (%) 
SASQ2 
Agree  
n(%) 
t value SD Mean 
Difference 
(95% CI) 
Range of 
Differenc
e 
p 
value 
1.With current approach to managing 
A&S in PICU 
18 
(26.9%) 
40 
(59.7%) 
-6.1 1.1 -0.82 0.6-1.1 <0.001 
2.Current methods for assessing 
distress in PICU 
21 
(31.3%) 
47 
(70.1%) 
-5.5 1.3 -0.9 0.6-1.2 <0.001 
3.Current weaning strategy from A&S 15 
(22.4%) 
28 
(41.8%) 
-3.2 1.4 -0.55 0.2-0.9 0.002 
4.Current methods of evaluating 
over/undersedation 
11 
(16.4%) 
36 
(53.7%) 
-5.9 1.2 -0.84 0.6-1.1 <0.001 
 
5.Standardised distress assessment 
tool would be/is valuable in PICU 
56 
(83.6%) 
55 
(82.1%) 
1.8 1.1 0.24 0.0-0.5 0.09 
6.Assessment tool combined with 
guidelines would be/is valuable in 
PICU 
62 
(92.5%) 
53 
(79.1%) 
3.6 1.1 0.46 0.2-0.7 0.001 
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consultant level, the overuse and underuse of opioid infusions, the lack 
of alternative agents prescribed and over-administration of analgesics 
were less of a concern to respondents (p<0.05).  
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Table 9.2.2: Section B(b) Items of Concern; SASQ 1 & SASQ 2 
* Chi Square test was used to compare groups. 
  
  
Do you feel concern is warranted in the PICU  
regarding the following items:   
  
SASQ 1   
(n=105)   
  
SASQ 2   
(n=94)   
  
* Sig    
(2 tailed)   
Item (abbreviated).   Indicated Concern   
(n)   
Indicated Concern   
(n)   
  
4. Lac k of sedation assessment tools   69 (65.7%)   13 (13.8%)   < 0.00 1   
3. Lack of pain assessment tools   59 (56.2%)   7 (7.4%)   < 0.00 1   
2. Sedation assessment   64 (61%)   19 (20.2%)   <0.001   
1. Pain assessment   60 (57.1%)   20 (21.3%)   <0.001   
6. Lack of prioritisation of sedat ion   40 (38.1%)   15 (16%)   0.003   
5. Lack of prioritisation of pain   46 (43.8%)   27 (28.7%)   0.008   
19.  Inconsistency at consultant level   75 (71.4%)       53   ( 56.4 %)   0.04   
16.  Overuse opioid infusions   21 (20%)   5 (5.3%)   0.03   
15.  Underuse of opiate infusions   13 (12.4%)   2 (2.1%)   0 .02   
21. Lack of alternative agents prescrib ed   51 (48.6%)        34   ( 36.2 %)   0.03   
7. Over - administration analgesics   29 (27.6%)   16 (17%)   0 .19   
8.  Over - administration sedation   31 (29.5%)   22 (23.4%)   0 .47   
10.  Sedation weaned too rapidly   50 (47.6%)   39 (41.5%)   0 .71   
11. Delayed weaning of analgesia   41 (39%)   32 (34%)   0 .23   
9. Analgesia weaned too rapidly   72 (68.6%)   60 (63.8%)   1.0   
22. Non - pharmacological methods not used   53 (50.5%)        44   ( 46.8 %)   0.35   
14.  Overuse continuous sedation infusions   16 (15.2%)   11 (11.7%)   0.41   
13. Underuse continuous sedation infusions   24 (22.9%)   19 (20.2%)   1.0   
17. Not using sedative drug holidays   29 (27.6%)        28   ( 29.8 %)   0 .29   
12.  Delayed weaning of sedation   28 (26.7%)   23 (24.5%)   0 .5   
18.  Nurses unwillingness to wean analgesi a   22 (21%)        18   ( 19.1 %)   0 .8   
20.  Nurses unwillingness to wean sedation   26 (24.8%)        28   ( 29.8 %)   0 .83   
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After the intervention, over half of respondents still felt that analgesia was 
weaned too rapidly SASQ 1 (n=72, 68.6%) and SASQ 2 n=60, (63.8%), 
while rapid weaning of sedation was a notable concern to PICU staff 
before (SASQ 1 n=50, 47.6%) and after (SASQ 1 n=39, 41.5%) the 
intervention. Conversely around a quarter of respondents indicated 
concern regarding nurses unwillingness to wean sedation (n=26, 24.8%) 
and this increased after the intervention by 5% (n=28, 29.8%).  
  
9.2.3 Section C: Specialist Knowledge Regarding Analgesia and Sedation in 
PICU 
In the knowledge section of the questionnaire, the median percentage 
correct scores for SASQ 1 and SASQ 2 were 68% for both doctors and 
nurses (See Figure 9.2.3).  
Figure 9.2.3: Section C; Correct Responses Nurses and Doctors SASQ 1 & 2 
Responses to individual items in Section C are presented in table 9.2.3. 
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Table 9.2.3: Responses to Specialist Knowledge Section C 
 
 SASQ 1 
N=105 
SASQ 2 
N=94 
True/False Statement. 
True or 
False 
Strongly 
Agree 
/Agree 
Neither/ No 
Response 
Strongly 
Disagree 
/Disagree 
Strongly 
Agree 
/Agree 
Neither/ No 
Response 
Strongly 
Disagree 
/Disagree 
2. Patients who are not treated appropriately for 
pain are vulnerable to stressors such ICU 
psychosis. 
T 98 
(93.3%) 
5 
(4.8%) 
2 
(1.9%) 
91 
(96.8
%) 
2 
(2.1%) 
1 
4. In assessing the agitated patient it is important 
to consider physiological aetiologies, e.g. 
hypercapnia and hypoxia. 
T 94 
(89.5%) 
7 
(6.7%) 
4 
(3.8%) 
85 
(90.4
%) 
8 
(8.5%) 
1 
6. A neonate has less ability to sense and interpret 
pain than an adult. 
F 11 
(10.5%) 
6 
(5.7%) 
88 
(83.8%) 
6 
(6.4%
) 
4 
(4.3%) 
84 
7. Morphine infusions should be used with great 
caution in neonates, particularly those under 28 
weeks gestation. 
T 94 
(89.5%) 
4 
(3.8%) 
7 
(6.7%) 
81 
(86.2
%) 
11 
(11.7%) 
2 
(2.1%) 
8. Some sedatives including ketamine have been 
shown to damage the developing brain in animals 
as they are neurotoxic. 
T 47 
(44.8%) 
49 
(46.7%) 
9 
(8.6%) 
41 
(43.6
%) 
50 
(53.2%) 
3 
(3.2%) 
9.  Pain can be effectively assessed using be 
patients facial expression alone. 
F 11 
(10.5%) 
8 
(7.6%) 
86 
(81.9%) 
11 
(11.7%) 
 
7 
(7.4%) 
76 
(80.9%) 
12. It is not necessary to ensure adequate patient 
sedation when administering neuromuscular 
blocking agents such as pancuronium. 
F 11 
(10.5%) 
5 
(4.8%) 
89 
(84.8%) 
11 
(11.7%) 
 
4 
(4.3%) 
79 
(84%) 
13.  A patient with an open sternum requires 
additional analgesia. 
F 68 
(94.8%) 
20 
(19%) 
17 
(16.2%) 
51 
(54.3
%) 
22 
(23.4%) 
21 
(22.3%) 
14. A patient receiving CVVH or ECMO should not 
require additional analgesia and/or sedation to 
compensate for that lost in the circuit. 
F 24 
(22.9%) 
29 
(27.6%) 
52 
(49.5%) 
14 
(14.9%) 
30 
(31.9%) 
50 
(53.2%) 
17. Physiological adaptation or tolerance develops 
more rapidly in children than adults.  
T    46 
(48.9
%) 
29 
(30.1%) 
19 
(20.2%) 
18. Tolerance may develop more rapidly with 
continuous infusions than with bolus 
administration of opiates. 
T    40 
(42.6
%) 
32 
(34%) 
22 
(23.4%) 
19. Rapid weaning or abrupt discontinuation of 
sedation is associated with rebound agitation and 
T    88 
(93.6
%) 
3 
(3.2%) 
3 
(3.2%) 
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Subjects responded similarly to the knowledge items in section C on both 
occasions; despite a 17 month time period between surveys (see table 
9.2.3). A good understanding of the ability of a neonate to sense and 
interpret pain was demonstrated, 84% (n=88) in SASQ 1 and 89.4% 
(n=84) in SASQ 2 correctly responding to this item. Similar clarity was 
shown regarding the sensitivity of premature neonates to morphine; 
71.2% (n=89) of SASQ 1 respondents and 86.2% (n=81) of SASQ 2 
respondents correctly indicating morphine infusions should be used with 
great caution in neonates.  
 
Less clarity was shown regarding the neurotoxic effects of ketamine on 
the developing brain. While only 44.8% (n=47) of SASQ 1 respondents 
and 43.6% (n=41) of SASQ 2 respondents agreed that such a risk 
existed, in both the before and after group over 40% of respondents were 
undecided (42% and 49% respectively). There was no distinction 
between nurses and doctors in terms of understanding regarding this 
item. Uncertainty was also shown regarding the requirement for a patient 
with an open sternum to have additional analgesia 64.8% (n=68) of 
SASQ 1 and 54.3% (n=51) of SASQ 2 respondents agreeing with this 
statement, possibly reflecting a paucity of evidence in the literature. More 
than half of respondents disagreed that patients on CVVH or ECMO 
required additional analgesia and/or sedation (SASQ 1 =51%, SASQ 
2=53.2%). An increased knowledge that COMFORT-B was validated in 
neonates was shown, 51.4% of SASQ 1 and 62% of SASQ 2 
respondents agreeing with this statement. 
 
9.2.4 Additional Items Section C   
The five additional statements which were added to SASQ 2 concerning 
optimal sedation, tolerance, abrupt cessation of sedation and whether 
PICU staff felt that the analgesia and sedation guidelines hindered 
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autonomy and decision making practice were analysed separately as a 
before and after comparison was not possible. 
 
There was a clear consensus regarding optimal sedation, with 86.2% 
(n=81) agreeing that the statement “optimal sedation is when the patient 
is easily rousable, free from pain and anxiety and can tolerate medical 
and nursing procedures”. However, less clarity was shown regarding 
physiological adaptation and tolerance. Just under half of respondents 
(48.9%, n=46) agreed that “physiological adaptation or tolerance 
develops rapidly in children”. Similarly, when posed the statement 
“tolerance may develop more rapidly with continuous infusions than with 
bolus administration”, 42.6% (n=40) of respondents agreed. The majority 
of respondents (93.6%, n=88) agreed that “rapid weaning or abrupt 
discontinuation of sedation is associated with rebound agitation and 
increased incidence of distress”.  
 
The statement “the use of analgesia and sedation guidelines hinders 
autonomy and individual decision-making practice” was put to 
respondents. Only 13% (n=11) of responding nurses and 20% (n=2) of 
responding doctors held this view, while the majority of respondents, 
almost three quarters (73.4%, n=69) disagreed with this statement.  
 
9.3 Limitations of SASQ 
The doctors at Registrar level who completed the SASQ 1 were no 
longer working in the PICU when SASQ 2 was administered. 
Nevertheless, an equally valuable set of responses were obtained from a 
different complement of registrars in SASQ 2. This was not a randomised 
study; therefore other concomitant factors may have influenced the 
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results. However, during the study, no other significant changes in 
practice occurred.  
 
Aside from questionnaires providing a rich source of data regarding staff 
attitude and opinion; regular open access Analgesia and Sedation 
Committee meetings occurred throughout the research study and to the 
present day. Minutes from these meetings were recorded and captured 
further evidence regarding the acceptance or otherwise of the change 
initiative. A synopsis of these meeting minutes is now presented. See 
appendix 15 for full meeting minutes.   
 
9.4 Analysis of Analgesia and Sedation Committee Meeting 
Minutes 
An awareness that some direction regarding analgesia and sedation 
management was verbalised at the inaugural Analgesia and Sedation 
Committee meeting on 6th April 2010. The COMFORT-B distress 
measurement tool was endorsed as the most appropriate instrument for 
use in the PICU population and training began. A decision was made to 
commence development of an analgesia and sedation algorithm 
incorporated into practice guidelines for use at the bedside. The 
multidisciplinary team highlighted the daily clinical challenges of not 
having evidence based guidelines in place; such as patients returning 
from operating theatre with excessively high morphine rates infusing, and 
uncertainty around morphine loading and bolus doses.  
 
At the subsequent meeting on 5th April; feedback from the PICU staff 
revealed support for the guidelines and work on refining the content for 
different analgesic and sedative agents e.g. clonidine and chloral hydrate 
commenced. Commitment was received from the medical staff to 
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undergo training on COMFORT-B and support the adoption of the 
guidelines into clinical practice. Although feedback at subsequent 
meetings continued to indicate the guidelines were useful and valued in 
clinical practice; sufficient buy in at consultant level was questioned (9th 
December 2010 meeting minutes). A strategy to prescribe the 
appropriate analgesics and sedatives pre-operatively was suggested. 
Ward walkarounds were also proposed, and requesting COMFORT-B 
scores at ward rounds and handovers was endorsed. Education for new 
doctors at the start of their 6 monthly rotation was universally approved. 
 
The failure of some nurses to act on low COMFORT-B scores (indicating 
oversedation) was highlighted on 25th Jan 2011. Regular assessment of 
patient distress was found to require reinforcement, and the shift leaders 
agreed to prompt bedside nurses. Failure to deliver morphine loading in 
the operating theatre continued to be an issue, therefore a decision was 
made to allow morphine loading in the PICU if not done in theatre. 
Weaning analgesia and sedation as well as monitoring for signs of 
withdrawal syndrome were highlighted at this meeting.  
 
There was universal consensus on 8th March 2011 that overall 
improvements had been made to analgesia and sedation management, 
with an increased awareness of the dangers of under and oversedation. 
Efforts were still required to ensure good practice continued.  The 
following meeting on 14th April 2011was attended by an International 
Expert on pain and distress in PICU who endorsed the approach 
undertaken in the PICU. Education on withdrawal syndromes and 
paediatric delirium was delivered by the expert and this session was well 
received.  
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The results of an audit of analgesia and sedation practices in the UK and 
Ireland was presented at the meeting on 8th June 2011. This facilitated 
an appreciation of similarities and differences between practice at the 
study site and that of neighbouring PICUs. Case scenarios from the 
PICU were presented to reinforce clinical issues, and the dangers of not 
adhering to the guidelines emphasised. Amendments were made to the 
guidelines based on feedback and consultant input, awareness was 
raised around the amendments and a direct referral pathway to the Acute 
Pain Clinical Nurse Specialist set up, for challenging patients and those 
in withdrawal.  
 
At the meeting on 20th September 2011, laboratory data from 3 patients 
receiving morphine in the PICU postoperatively was presented by a 
researcher doing a pharmacokinetic and pharmacodynamic study. The 
dosing guidelines around morphine loading, bolus doses and infusion 
rates were reinforced by the data presented. Newly published highly 
relevant literature was distributed to staff. Minutes from 16th November 
2011 indicated that morphine loading continued to be a challenge and 
this again had to be addressed with consultant anaesthetist staff. There 
was a request for the development of guidelines for managing the 
sedative and analgesic needs of the PICU patient undergoing a 
procedure such as chest drain removal. Reassurance was given that 
development of these procedural guidelines was already underway at 
this point.  
 
By 6th February 2012 the focus began to shift from the majority of the 
PICU population, to managing the analgesic and sedative needs of the 
more challenging patient; such as the cognitively impaired or those on 
extracorporeal membrane oxygenation (ECMO). This suggested that 
staff were comfortable with the routine use of the guidelines. Specific 
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recommendations were put in place for such patients. Feedback 
regarding use of the analgesia and sedation weaning guidelines was 
predominantly positive. On the 6th November 2012 staff offered their 
feedback on the clinical utility of the procedural analgesia and sedation 
guidelines. Further refinements were required. It was agreed that a 
strong focus and vigilance around withdrawal syndrome should continue, 
particularly for the long-stay patients who were likely to have more 
exposure to analgesic and sedative agents.   
 
9.5 Summary of Findings from PICU Staff Surveys Using SASQ and 
Analgesia and Sedation Committee Minutes  
 PICU staff satisfaction with analgesia and sedation practice 
increased after the intervention. This was statistically significant 
(p<0.001). 
 This increased satisfaction with analgesia and sedation practice 
was reinforced at analgesia and sedation meetings, and the focus 
began to shift to analgesic and sedative of the more complex 
PICU patient, i.e. patients on ECMO or with cognitive impairment.  
 There was a slight reduction in the number of individuals who felt 
the COMFORT-B assessment tool combined with guidelines was 
valuable in patient management in PICU from 92.5%, (n=97) to 
81% (n=76), suggesting the intervention may not have met all 
expectations. 
  Of the list of 22 items related to pain, sedation and analgesia in 
PICU presented to respondents, there was a mean reduction of 
2.8 items which respondents felt merited concern after the 
intervention. 
 The areas where the most significant changes occurred  after the 
intervention were in relation to the assessment of pain and 
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sedation, the tools available to do this and the prioritisation of 
sedation (all p values<0.001).  
 After the intervention, the lack of prioritisation of pain, 
inconsistency in practice at consultant level, the overuse and 
underuse of opioid infusions, the lack of alternative agents 
prescribed and over-administration of analgesics were less of a 
concern to respondents (p<0.05). 
 In the knowledge section of the questionnaire, there was no 
statistically significant change in correct responses to true/false 
statements after the intervention; median correct scores 68% for 
both doctors and nurses.  
 The majority of respondents (73.4%, n=69) disagreed with the 
statement “the use of analgesia and sedation guidelines hinder 
autonomy and individual decision-making practice”.  
 Ensuring that a morphine loading dose was administered to 
patients on starting the morphine infusion in the operating theatre 
was a major challenge and frequently raised at analgesia and 
sedation meetings. 
 An amendment was made to the guidelines permitting morphine 
loading to be administered in the PICU had it not been delivered in 
theatre.  
 Recognising and managing withdrawal syndrome in PICU patients 
proved to be a considerable challenge at the start of this project, 
and vigilance continued to be required for long-stay patients who 
were at increased risk of withdrawal syndrome due to increased 
exposure to analgesic and sedative agents. 
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9.6 Evaluation 
The motivation for this research project centred around the need for 
change in order to bring an evidence based approach to a fundamental 
aspect of PICU care. Effective evaluation was required to assess 
whether change had occurred. The intervention will now be evaluated 
using steps of the CIPP model; context, input, process and product (see 
table 9.6). 
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Table 9.6: Evaluation of Intervention using CIPP Framework 
Context 
What were the 
needs? 
 
 To align analgesia and sedation practice with best 
available evidence. 
 To introduce a validated instrument to assess 
distress in the PICU population. 
What were the 
impediments to 
meeting needs? 
 Buy in from PICU nurses and doctors. 
 Motivation to change practice. 
 Time to dedicate to selecting validated instrument, 
developing analgesia and sedation guidelines, 
raising awareness and training staff. 
What expertise, 
services and 
assets were 
available? 
 PICU staff who were dissatisfied with current 
approach to pain and sedation.  
 The PICU Research Nurse. 
 The PICU education team. 
 The PICU pharmacist. 
 The Acute Pain Clinical Nurse Specialist. 
 Knowledgeable clinicians and nurses. 
 Supportive Clinical Director and Clinical Nurse 
Manager level 3. 
 Links with internationally renowned expert in 
distress assessment in PICU. 
 Access to multidisciplinary team. 
 Library membership to review available literature.  
 Access to teaching facilities. 
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What relevant 
opportunities 
existed? 
 Membership of PICS; networking with other PICUs. 
 Academic link to 3rd level institution. 
 Potential access to research funding. 
 Access to patient notes and medication 
administration records. 
 Access to PICU staff to conduct questionnaire 
surveys. 
 Availability of conference room for conducting 
stakeholder meetings. 
 
 
Input 
What were the 
potential 
approaches to 
meeting the 
identified 
clinical need? 
 
 
 A randomised controlled trial was considered. 
However randomisation was not feasible in a single 
site study while preventing crossover effects. 
 A two-site study was discussed. The only other 
PICU in the city caters for a very select population, 
therefore analgesia and sedation practices at the 
two sites were not comparable at baseline.  
 The cycles of an action research approach proved 
restrictive and overly complex.   
How feasible 
was a 
before/after 
study given the 
specific context 
of the need? 
 The before/after approach allowed for control 
conditions without the need for randomisation. The 
retrospective control group provided a basis for 
comparison of practice and attitudes after the 
intervention. 
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Process 
How was the 
intervention 
implemented? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Key stakeholders were identified. 
 A multidisciplinary analgesia and sedation 
committee was formed and open meetings were 
held 1-2 monthly. 
 2 weekly teaching and quality ward walk arounds 
were carried out. 
 A comprehensive literature review was conducted 
to select the most appropriate distress assessment 
instrument. 
 Staff questionnaires were developed and validated 
to determine attitudes and perceptions around 
analgesia and sedation practice. 
 An expert in distress assessment in PICU visited 
and carried out awareness and teaching sessions 
with staff. 
 Analgesia and sedation guidelines were developed 
by the multidisciplinary committee. 
 All staff; nurses, doctors, physiotherapists and 
dietician received 2 hour instruction on how to 
competently assess distress using COMFORT-B.  
 The inter-rater reliability of all training scores was 
recorded. 
 The guidelines and distress assessment instrument 
were introduced into practice on 1st June 2010. 
 Consultants were prompted to request COMFORT-
B scores during ward rounds. 
 Message reminding staff to assess pain was placed 
on all screensavers.  
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 Pain awareness month held annually in the 
hospital. 
 Compliance with guidelines was reviewed at the 
bedside and through reviewing patient notes. 
 Questionnaires were administered to staff before 
and after the intervention. 
What 
implementation 
problems were 
encountered? 
 Patients were not receiving morphine loading in the 
operating theatre as per the analgesia and sedation 
guidelines. 
 Due to workload issues, the consultant intensivists 
were unable to commit to 2 weekly teaching and 
quality ward walk arounds from October 2010. 
How well were 
the 
implementation 
problems 
addressed? 
 The guidelines were altered to allow morphine 
loading to be given in the PICU if this had not been 
done in the operating theatre. 
 A less rigid approach to teaching and quality ward 
walkarounds was adopted. Walkarounds were 
conducted when time and physician availability 
allowed, or when it was deemed that highlighting 
particular issues related to analgesia and sedation 
was required. 
What did 
participants 
think about the 
quality of the 
process? 
 Informal feedback from participants at analgesia 
and sedation meetings was generally positive. 
 Formal feedback from staff surveys revealed an 
increase in satisfaction after the changed approach 
to analgesia and sedation management.   
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Product 
What positive 
outcomes of the 
intervention can 
be identified? 
 
 
 
 
 
 
 
 
 Raised awareness of appropriate analgesia and 
sedation management in the PICU evident. 
 Validated method of distress assessment in use in 
the PICU.   
 Evidence based analgesia and sedation guidelines 
successfully incorporated into practice. 
 1-2 monthly analgesia and sedation meetings 
established. 
 2 staff surveys carried out. 
 Utilisation of the multimodal approach to analgesia 
and sedation management was evident after the 
intervention with patients receiving significantly 
more paracetamol and clonidine. 
 Analysis of COMFORT-B scores in this study 
revealed effective control of patients’ pain and 
sedation. 
What negative 
outcomes of the 
intervention can 
be identified? 
 Analysis of staff questionnaires revealed no change 
in knowledge levels after the intervention. 
Were the 
intended 
outcomes of the 
intervention 
realised? 
 A change in practice was successfully 
implemented; however, there was no change in 
duration of patients’ duration of mechanical 
ventilation or duration of PICU stay after the 
intervention. 
Were there 
unintended 
outcomes; 
 There was a change in the pattern of morphine 
administration after the intervention, characterised 
by lower infusion rates and an increase in bolus 
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either positive 
or negative? 
administration. 
 Unexpectedly, analysis revealed a disparity 
between T21 and non-T21 patients. There was a 
significant decrease in the duration of mechanical 
ventilation for patients with T21 after the 
intervention. 
 There was no longer a disparity between chloral 
hydrate doses administered to T21 patients 
compared with non-T21 patients after the 
intervention. 
 It was recognised that analgesia and sedation 
weaning guidelines were required. There were 
developed and incorporated into practice. 
What were the 
short-term 
implications of 
outcomes? 
 Patients received analgesia and sedation based on 
clinical need. 
 Use of a validated distress assessment tool 
removed subjectivity and allowed equitable patient 
treatment. 
 Evidence based guidelines at the bedside reduced 
inconsistency and uncertainty from practice. 
 A high level of clinical utility and involvement from 
key stakeholders fostered compliance from staff. 
 A high level of nurse autonomy at the bedside had 
the potential to reduce delays in patients receiving 
required pain and sedative treatment. 
What were the 
longer-term 
implications of 
outcomes? 
 A shorter duration of mechanical ventilation for 
patients with T21 may have decreased their 
exposure to complications associated with 
mechanical ventilation such as ventilator 
associated pneumonia and tracheal stenosis. This 
may also have reduced disruption to the parental 
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bonding process and cognitive and social 
development.  
 More efficient use of PICU resources leads to 
increased turnover and may have had financial 
implications in the longer-term. 
 Improved staff satisfaction through empowerment 
and greater multidisciplinary collaboration may 
have led to reduced attrition and staff turnover. 
 Using the multimodal approach to analgesia and 
sedation may have reduced the incidence of 
tolerance, dependence and withdrawal syndrome. 
 Having a validated distress assessment instrument 
in use in the PICU was a prerequisite for 
conducting much needed analgesia and sedation 
studies. 
What impacts of 
the intervention 
were observed? 
 Analgesia and sedation practice was in compliance 
with best practice. 
 COMFORT-B distress assessment and the 
guidelines were successfully embedded into 
practice. 
 The language of pain and sedation was consistent 
among PICU staff, facilitating open discussion and 
high level dialogue. 
How effective 
was the 
programme? 
 The programme was highly effective due to the 
commitment, support and hard work of the PICU 
team. 
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How 
sustainable is 
the 
programme? 
 Sustainability was ensured by training ‘super-users’ 
to deliver teaching to new staff on how to assess 
PICU patients competently using COMFORT-B. 
Capacity was built by retaining a key group of 
multidisciplinary stakeholders who monitored 
compliance, offered feedback and considered 
emerging evidence. A forum for pain and sedation 
issues was created in the weekly PICU risk 
meeting; ensuring issues were dealt with promptly. 
How easily can 
the intervention 
be adopted in 
other settings 
with similar 
needs? 
 This intervention was not without its challenges. 
However the proven patient and staff benefits could 
not be ignored. This intervention did not require 
considerable financial or material investment. 
However a considerable investment of time, energy 
and multidisciplinary engagement was necessary. 
Therefore it could be adopted in similar settings 
where there is a genuine desire to base patient 
analgesic and sedative management on current 
best evidence. 
    Source: Stufflebeam et al. (2007). 
 
9.7 Conclusion 
The findings from rigorous analysis of questionnaire data as well as 
information from meeting minutes from PICU doctors and nurses who 
continued to be affected by the intervention during every working day has 
been presented. The CIPP model of evaluation has been utilised to 
undertake a thorough appraisal of all facets of the intervention. The 
discussion chapter which follows will address these findings in the 
context of their clinical and statistical significance, relevance for practice 
and how they are novel in the current field of research in this area. The 
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strengths and limitations of the study will be considered, and the next 
steps following on from this study presented. 
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Section 4: Discussion and 
Conclusion 
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Chapter 10: Discussion 
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10.0 Introduction 
Effective analgesia and sedation management is a fundamental 
component of every functioning PICU. However, the approach to 
assessing and managing pain and sedation in the PICU at the study site 
was traditionally based on personal preferences and unit culture. This 
key area of care needed a review in the context of best practice. The 
writers’ research study brought together over 180 staff in order to actively 
change the approach to pain and sedation, aspiring to an evidence 
based practice model of care.  
 
Through applying an appropriate methodological process with academic 
and consultant clinician support; a new approach to assessing and 
managing pain and distress was developed and implemented. This 
chapter will firstly reiterate the study hypotheses and research question. 
The study findings will then be discussed in the context of existing 
knowledge and literature. Firstly, the research hypotheses will be 
revisited to ascertain whether the null hypothesis was accepted or 
rejected.  
 
Primary Hypothesis: 
Standardised pain and sedation management does not cause a 
reduction in the dosage of morphine administered to patients in PICU. 
Ultimately the null hypothesis was not rejected on the basis of this study, 
as the reduction in morphine administered to PICU patients did not reach 
statistical significance (p=0.127). However, the pattern of morphine 
administration changed considerably with patients returning from the 
operating theatre on significantly lower morphine infusion rates (p>0.001) 
and receiving significantly more morphine boluses (p=0.026) as required, 
based on clinical need in line with best practice. 
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Secondary Hypothesis:  
The implementation of standardised pain and sedation is not associated 
with a change in duration of mechanical ventilation and PICU stay.  
The secondary null hypothesis similarly was not rejected, as no 
statistically significant difference in duration of mechanical ventilation or 
PICU stay emerged after the intervention. However, the T21 population 
demonstrated a statistically significant reduction in duration of 
mechanical ventilation after the changed approach to analgesia and 
sedation management (p=0.012).  
Acknowledging the significant role staff play in prescribing and 
administering analgesic and sedative agents; the additional research 
question was also addressed:  
Did PICU staff welcome the standardisation of analgesia and sedation 
management and perceive it as clinically valuable one year after its 
implementation?  
There was a statistically significant increase in PICU staff satisfaction 
after the intervention (P<0.001), good levels of compliance with the new 
guidelines was also demonstrated. 
 
The changed approach to analgesia and sedation management had 
considerable implications for patients, staff, the hospital and the wider 
PICU community as well as for research and education. The writers’ 
study showed a reduced duration of mechanical ventilation after the 
intervention in the T21 population which was statistically significant. Such 
an effect has the potential to reduce exposure to the complications of 
mechanical ventilation and hospital acquired infections.  A change in the 
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pattern of analgesics and sedatives administered to patients emerged, 
characterised by significantly lower starting rates of morphine infusion 
and administration of bolus doses as required based on clinical need in 
line with best practice. This finding was notable in light of existing 
evidence citing the complications of inappropriate analgesia and sedation 
management (Tobias, 2000a). In the writers’ PICU, staff now use 
validated methods to consistently assess patient pain and distress from 
their admission to the PICU right up until they are discharged to the 
ward. The language of communicating patient comfort became 
consistent across all levels and disciplines attending PICU patients in line 
with the new order of practice. Favourable responses from PICU nurses 
and doctors correspond with good levels of compliance with the 
guidelines. The neighbouring PICU adopted the same approach to pain 
and sedation as a result of the success and clinically significant benefits 
of the writers’ study. Valuable research collaborations have also evolved 
from the writers’ study and an important pharmacokinetic and 
pharmacodynamic study has been possible at the study site as a result 
of the implementation of validated pain assessment. High level dialogue 
about pain and sedation now occurs between clinicians and nurses, 
where previously uncertainty and a lack of direction prevented this from 
occurring.  
   
This section of the thesis will discuss the study findings in the context of 
current literature and research in this area. The discussion section is in 5 
distinctive parts; 10.1, 10.2, 10.3, 10.4, and 10.5. Part 10.1 deals with the 
clinical outcomes of the study for PICU patients, as the impact on 
patients must be the primary focus of all our interventions. Part 10.2 
addresses the changed pattern of analgesic and sedative administration 
in line with best research evidence, and the significance of this. Part 10.3 
focuses on the nature and trends of patients’ COMFORT-B and NRS 
scores in the context of similar studies. Part 10.4 looks at how the 
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intervention impacted staff attitudes and approaches to analgesia and 
sedation, a hugely important consideration given the multidisciplinary 
nature of this phenomenon. Finally the importance of clinical significance 
versus statistical significance will be briefly explored in 10.5.  
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10.1: Clinical Outcomes of Study for PICU Patients  
10.1.1 Impact of Intervention on Duration of Mechanical Ventilation and 
PICU Stay 
A notable finding of this study was the fundamental differences between 
T21 and non-T21 patients at baseline. Patients with T21 had a 
statistically significantly longer duration of mechanical ventilation and a 
longer duration of PICU stay than non-T21 patients before the change in 
analgesia and sedation practice. This first emerged on analysis of the 
baseline PICU census data and was also reflected on analysis of PASQ 
data. This statistically significant difference in baseline duration of 
ventilator dependence for the T21 population was notable given that the 
associated severity of illness and risk of mortality was not higher than 
non-T21 patients. 
 
However, in terms of international literature this finding is not new. 
Morray et al. (1986) noted the longer duration of post-operative 
ventilation and intensive care stay for patients with T21. Furthermore, 
these authors proposed that children with T21 undergoing cardiac 
surgery had a higher mortality and morbidity than age matched controls 
having similar surgery. The prolonged dependence of T21 patients on 
mechanical ventilation post-operatively has previously been explained by 
the increased incidence of abnormalities of the respiratory system 
associated with this syndrome, which can complicate the peri-operative 
period (Mitchell et al. 1995). In addition, T21 is associated with more 
frequent episodes of chest infection because of the relative immune 
deficiency which is a feature of the syndrome (Beilin et al. 1981).  
 
Importantly, the writers’ study demonstrated that by standardising pain 
and distress assessment and management; the inequalities between 
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duration of mechanical ventilation in patients with and without T21 were 
reduced.  No alternative explanations such as other changes in treatment 
strategies or service reconfiguration could be offered that explain this 
finding. The reduction in duration of mechanical ventilation for all patients 
approached, but did not reach statistical significance (p=0.07), however 
this reduction was statistically significant in the T21 population (p=0.012). 
Kollef et al. (1998) suggest that reducing the duration of ventilatory 
support can directly improve patient outcomes; primarily by reducing the 
incidence of VAP and systemic complications. 
 
The clinical impact of the statistically significant reduction in duration of 
mechanical ventilation in patients with T21 after standardisation of 
analgesia and sedation practice was notable. In the paediatric population 
complications related to intubation and mechanical ventilation include 
vocal cord paralysis, subglottic stenosis, tracheitis and parenchymal 
complications such as pneumothoraces, ventilator induced lung injury 
and ventilator associated pneumonia (VAP) (Schultz et al. 2005). It is 
well established that patients with ventilator associated pneumonia have 
significantly longer intensive care length of stay and hospital costs 
compared with non-infected patients (Warren et al. 2003). Conversely, 
Dasta et al. (2005) determined that mechanical ventilation was 
associated with higher daily costs for patients receiving treatment in the 
intensive care unit throughout their entire intensive care unit stay. 
Furthermore; according to Schultz et al. (2005) patients requiring 
prolonged mechanical ventilation have a lower survival rate. The 
implications of prolonged PICU stay include a higher incidence of 
mortality and resource utilisation. This is exemplified by evidence from 
Gonzales-Cortes et al. (2011) who confirmed that 3.9% (n=83) of 
patients admitted to a Spanish PICU over a 4 year period stayed for 28 
days or more. Among these patients mortality was significantly higher 
(22.9% vs 2%) than the wider patient group, and long stay patients had a 
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96.3% incidence of nosocomial infection.  Therefore interventions that 
result in a shorter duration of mechanical ventilation and intensive care 
unit length of stay could lead to substantial reductions in morbidity, 
mortality and total inpatient costs.  
 
There was an acute awareness of the need to efficiently care for patients 
in an environment in which there was increasing demand for limited 
healthcare resources. Interventions that may aid in minimising duration of 
PICU stay were thus highly valued. Given the beneficial impact of the 
standardisation of analgesia and sedation practice particularly for the 
T21 population; analgesia and sedation guideline adherence was 
strongly encouraged and refinements were made where necessary to 
ensure maximum clinical utility. There was potential for a more effective 
use of PICU resources resulting in a higher throughput of patients with a 
subsequent reduction in patient waiting lists. This would have a 
considerable impact for children awaiting paediatric cardiac and spinal 
surgery; where the availability of a PICU bed for the recovery period 
determined whether surgery could proceed or not.  
 
The demand for PICU beds was effectively illustrated by the numbers of 
Irish children awaiting full spinal surgery for correction of deformities 
such as scoliosis and kyphosis. In 2012, 58 full corrections were 
performed with all cases recovering in PICU in the early post-operative 
period.  At the time of writing, there were 97 children on the waiting list 
for this surgery, and lack of PICU bed availability had resulted in the 
number of patients on this list rising steadily (Personal communication 
with Michelle Harrington, Orthopaedic Clinical Nurse Specialist 24th 
March 2013). This directly impacted the quality of daily life of these 
children and their families, where the affected child had limited mobility 
and reduced capacity to carry out their activities of living.  
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In addition to the economic consequences and impacts on the service; a 
shorter duration of mechanical ventilation was likely to result in less 
disruption to the child’s cognitive development and parental bonding 
process. The stress associated with a PICU admission on patients and 
their families has been described by Colville and Pierce (2012). The 
consequences of this stress are not insignificant; symptoms of post 
traumatic stress disorder (PTSD) have been described in children who 
had previously been inpatients in PICU. Importantly, Board and Ryan-
Wenger (2002) found that in comparison to parents of children with 
general paediatric admissions and clinic presentations; parents of 
children admitted to PICU had significantly greater stress and disturbed 
family function at 6 months following discharge. Awareness among PICU 
staff of the impact of the PICU admission on the patient and their family 
was a high priority in the PICU, and psychological support during the 
patients’ PICU stay was available. Beyond the PICU stay, follow up 
support after discharge was essential to minimise the psychological 
impact of the experience on the child and their family. 
 
In the context of current literature; the finding of no statistically significant 
reduction in duration of mechanical ventilation or PICU stay in the study 
population in this study was inconsistent with studies in adult critical care 
settings where the introduction of analgesia and sedation guidelines and 
protocols were predominately associated with a reduced duration of 
mechanical ventilation and decreased ICU and hospital length of stay 
(Jackson et al. 2010). In the paediatric setting; a dramatic decrease in 
the duration of mechanical ventilation and PICU stay was observed by 
Jin et al. (2007) after the introduction of protocol directed sedation in a 
Korean PICU. The mean duration of mechanical ventilation decreased 
from 12.5 to 11.0 days (p=0.04) and median PICU length of stay 
decreased from 19.5 days to 15.0 days (p=0.04). Although these findings 
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were noteworthy; they may not be generalisable to the Irish PICU setting 
where practices differ. This was evident in that continuous 
neuromuscular blockade infusions were used in 9 of the Korean study 
patients in the intervention group and eight in the control group. Use of 
neuromuscular blockade infusions rarely occurred in the study setting 
highlighting a fundamental difference in practice between settings. The 
median duration of PICU stay for PASQ patients in the writers’ study was 
3.5 days before and 2.85 days after the intervention. This represented a 
considerably shorter PICU stay than that of the Korean PICU, rendering 
the quality of direct comparisons questionable.  
 
The Korean study highlighted the extent to which drugs used for 
analgesia and sedation impacted the duration of mechanical ventilation 
and subsequently PICU stay of PICU patients. A comparison of the post-
operative analgesia and sedation administered before and after the 
intervention was explored in the writers’ study. Acknowledging the 
significant findings which emerged regarding patients with T21, a 
particular focus was placed on these patients.  
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10.2: Changed Pattern of Analgesic and Sedative Administration 
10.2.1 Changes in the Administration of Primary Analgesics and Sedatives  
The amount of analgesia and sedation administered to patients collected 
by the PASQ instrument for time periods before and after the Intervention 
gave valuable insights into the change in pattern of drug administration. 
This was highly evident with regards to the primary analgesic and 
sedative used in the post-operative period; morphine and midazolam. In 
light of research evidence and differences in baseline clinical data; 
special consideration was given to patients with T21. Until very recently a 
widespread clinical impression existed that children with T21 required 
multiple and higher doses of sedatives in the postoperative period when 
compared to non-T21 patients (Kalyanayaman et al. 2007). This view 
was widely held (Stoetling et al. 1988; Millar 1990; Greenly et al. 1993). 
A retrospective study by Gakhal et al. (1998) determined that children 
with T21 were more likely to receive additional sedatives and muscle 
relaxants post-operatively than controls; and were more likely to still be 
receiving morphine on day 3 after surgery.  
 
This theory has only recently been investigated scientifically with 
Valkenburg et al. (2012a) demonstrating there were no significant 
differences in analgesia and sedation requirements for children with T21 
undergoing surgical repair of duodenal atresia compared with non-T21 
controls. The same researcher has more recently investigated the 
pharmacokinetics and pharmacodynamics of morphine and midazolam in 
T21 versus non-T21 patients at this study site. The presence of T21 was 
found to have no influence on post-operative analgesia and sedation 
requirements or morphine pharmacokinetics (Valkenburg et al. 2012b). In 
addition, the Valkenburg et al. (2012b) study corroborated the findings 
regarding a similar duration mechanical ventilation and PICU stay in T21 
and non-T21 patients after the intervention. These findings reinforced the 
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standardised approach to analgesia and sedation management in the 
PICU, where the cornerstone was assessment of pain and distress using 
an instrument which was validated in the T21 population.  
 
Intravenous morphine administered to PICU patients can be delivered via 
a loading dose, continuous infusion and bolus administration. A loading 
dose was advised at initiation of therapy to ensure the morphine level 
was at the therapeutic range for analgesia. It was advised that the rate of 
morphine infusion which was set in the operating theatre prior to transfer 
back to PICU if the patient has had surgery, should be set at a moderate 
level with the option of administering morphine boluses for breakthrough 
pain and as pre-emptive analgesia. The intervention was synonymous 
with a considerable change in the pattern of morphine administration to 
PICU patients. 
 
After the intervention there was no statistically significant reduction in the 
amount of intravenous morphine delivered by continuous infusion in the 3 
study Epochs. The mean morphine infusion rate after the intervention in 
Epoch 1 was 33.44mcg/kg/hr (median 29.37[29-37]) compared with a 
mean of 36.74 (median 36 [27.65-43.8]) before the intervention 
(p=0.127). Unsurprisingly, Valkenburg et al. (2012b) reported a similar 
mean morphine infusion rate in the first 24 hours post-operatively at the 
same study setting (32 mcg/kg/hr) for post-operative cardiac patients. 
 
In contrast to the current study; Alexander et al. (2002) found that PICU 
patients received significantly more sedation; including the synthetic 
opioid fentanyl, when on a sedation protocol. This study was unusual in 
its design, in that the sedation management of seven purposively 
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selected patients was reviewed. Treatment was reviewed retrospectively, 
and periods when they were managed on and off the protocol analysed.  
 
However, the unchanged amount of median infused opioid after the 
intervention found in the writers’ study was in contrast to findings of 
similar studies in PICU settings. Ista et al. (2009a) studied the effects of 
the introduction of standard sedation assessment and a sedation 
protocol using a pre-test/post-test design in a Dutch PICU. Within the 
new protocol, nurses were permitted to wean or bolus morphine and 
midazolam with the guidance of COMFORT-B assessments. Over the 
first 7 days of their admission analgesic and sedative doses of a 
convenience sample of 27 patients pre-test and 29 patients post-test 
were recorded. Median morphine administration rose significantly from 
6.9 to 11.2 mcg/kg/hr (p=0.004) after the intervention. Additional agents 
such as clonidine and paracetamol were also administered but analysis 
was not done on these agents. 
 
The results of Ista et al.’s (2009a) study raise many questions. A 
statistically significant increase in morphine and midazolam use after the 
intervention was found which is strongly divergent to the findings from 
the writers’ study, where a not dissimilar protocol was introduced. 
Differences in baseline practices may be the reason for this disparity. In 
the Dutch study; bedside nurses were given the freedom to titrate 
morphine and midazolam in accordance with the protocol. This 
represented a change in practice from before the intervention where 
physicians assumed this responsibility. This contrasts considerably with 
practice in the writers’ study setting; where bedside nurses have long 
practiced weaning and augmenting analgesia and sedation infusions as 
their judgement saw fit. The Dutch nurses may have been more liberal 
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with doses than their medical colleagues would have been prior to the 
change in practice. 
 
Conversely, in evaluating the effect of a sedation algorithm on unplanned 
extubation rates; Popernack et al. (2004) reported that an increase in 
patients experiencing oversedation did not occur after sedation algorithm 
introduction in their PICU. This is qualified with the reasoning that the 
PICU length of stay did not increase after the change in practice. No 
sedation assessment measurements were included to verify this finding; 
drawing uncertainty over this assumption. In the current study analgesia 
and sedation administered to patients before and after the change in 
practice were measured to directly ascertain the impact of the 
intervention, and no decrease in morphine received by patients in the 
post-intervention period confirmed. Additionally, pain and distress 
assessments were gathered to investigate incidence of oversedation.  
 
For T21 patients; median morphine administered by infusion in PASQ 2 
was statistically significantly reduced after the intervention in Epoch 2 
compared with the same Epoch prior to the intervention (p=0.015). In the 
24-48 hours post-operative period; the morphine infusion rate had 
reduced from an average of 20 mcg/kg/hr (median 16.1 [11.7-26.9]) 
down to 12.8 mcg/kg/hr (median 9.7 [0-13.0] p=0.015). In contrast, 
Gakhal et al. (1998) reported lower morphine infusion rates in their study 
comparing the analgesia and sedation requirements on 16 children with 
T21 and 16 without T21 after cardiac surgery. The mean infusion rate for 
the first 24 hours after surgery was 26 mcg/kg/hr for the T21 group, and 
24 mcg/kg/hr for the non-T21 group. The use of observational 
pain/distress assessment or analgesia and sedation guidelines was not 
mentioned in the study. The lower morphine infusion rates confirmed by 
Gakhal et al. could be explained by the quite liberal use of muscle 
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relaxants and sedatives reported. The children were also older than in 
the present study (mean age of 4 years for the T21 group and 5 years for 
the non-T21 group), which may be explained by the later correction of 
congenital defects in that era compared with the present day. Not 
unexpectedly a higher rate of morphine infusion of 32mkg/kg/hr was 
reported by Valkenburg et al. (2012b), for both T21 and non-T21 
patients, given that this study took place in the same study site as the 
writers’ study. 
 
Regarding the rate the patients’ morphine infusion was set at prior to 
returning to the PICU from the operating theatre; there was no evidence 
that established the optimal morphine infusion rate after cardiac surgery 
in children. After a loading dose; a starting rate of 40mcg/kg/hr was used, 
after which the dose would be titrated based upon effect and pain scores, 
as endorsed by the analgesia and sedation guidelines. Lynn et al. (1984) 
evaluated the respiratory effects of continuous morphine infusion in 
children following cardiac surgery and found that infusions of 10-30 
mcg/kg/hr resulting in serum concentrations of 10-22 ng/ml provided 
adequate analgesia, and did not impair weaning from mechanical 
ventilation. A higher morphine infusion rate was endorsed by Semsroth 
et al. (1990). In their study Semsroth et al. (1990) determined that 
children post cardiac surgery who were analgesed with morphine 
infusions of 30-60mcg/kg/hr had an improved post-operative course 
demonstrated by lower oxygen consumption than those managed with 
intermittent morphine boluses of 50mcg/kg. 
 
Patients come to PICU post-operatively with a morphine infusion already 
running. The infusion starting rate is at the discretion of the doctor 
providing anaesthesia for the case, and was traditionally subject to wide 
variability based on individual preferences and practice patterns. 
 309 
 
Introduction  of the analgesia and sedation guidelines aimed to 
standardise this practice; acknowledging that patients coming to PICU 
from theatre with morphine infusions running in excess of 100mcg/kg/hr 
was not uncommon and confirmed by PASQ 1 data. Therefore a major 
element of the intervention involved reinforcing the judicious use of 
morphine infusions and avoiding especially high infusion rates. 
Importantly, this study found that morphine infusion rates on return to 
PICU from the operating theatre were lower after the intervention, this 
proved highly statistically significant (p=<0.001). There was no distinction 
between T21 and non-T21 patients either before or after the intervention; 
both groups saw an equitable reduction in morphine rate. This was a 
beneficial patient effect of the standardisation of analgesia and sedation 
practice. 
 
Regarding morphine boluses; conversely it is known that patients 
receiving lower initial doses of opioids are more likely to develop opioid 
tolerance compared to those receiving high doses (Anand et al. 2013); 
therefore initial doses of 40mcg/kg/hr were endorsed, with the option of 
administering a loading dose of 100mcg/kg if loading was not 
administered in theatre. The option provided of giving an additional bolus 
of 50mcg/kg if needed based on assessment of the patient’s pain level 
was also provided. 
 
Use of morphine boluses are well supported in the literature. Tobias et al. 
(1994) propose that a continuous opioid infusion supplemented with 
intermittent bolus doses offer the best level of analgesia and sedation 
and analgesia in PICU. The writers’ study revealed that use of morphine 
boluses significantly increased after the intervention. In fact, over half the 
patients in PASQ 2 (n=38, 59.38%) received boluses of morphine 
compared with only 2 patients (3.28%) in PASQ 1. These boluses were 
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based on clinical need, as determined by standardised pain assessment 
and outlined in the guidelines.  
 
This is in contrast to Alexander et al.’s, (2002) findings. In their review of 
patients managed using a sedation protocol; Alexander et al (2002) 
reported no significant difference between the periods on and off the 
protocol in terms of the number of boluses of the synthetic opioid fentanyl 
received. It may be the case that after the intervention in the writer’s 
study, nurses were more empowered and the existence of the guidelines 
allowed patients who were undersedated to be identified and treated 
more readily.  
 
In summary, it is clear that the intervention was synonymous with an 
altered pattern of morphine administration in the post-operative period. 
Patients returned to PICU with morphine infusion rates set statistically 
significantly lower; and statistically significantly more morphine boluses 
were administered to patients after the intervention based on clinical 
need as determined by standardised assessment of their pain and 
sedation status.  
 
These findings are noteworthy given that Anand et al. (2010) warn that 
opioid therapy may lead to opioid induced hyperalgesia or opioid 
tolerance, dependence and withdrawal syndromes. Significantly these 
effects occur more commonly in children than in adults because of 
developmental changes in metabolism, excretion, drug efficacy, receptor 
subtypes, signal transduction, receptor induction, or cellular regulatory 
pathways (Chahal et al. 1998; Ebert et al. 1998; Rahman et al. 1998; 
Baba et al. 2000; Liu et al. 2001; Anand et al. 2010).  While it has been 
identified that prolonged hospital stays occur more frequently among 
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children with prolonged opioid exposure (Tobias 1990 & 1994; Fonsmark 
et al. 1999); sicker children inadvertently require longer hospital stays, 
undergo more painful procedures and have a greater requirement for 
analgesia. Nevertheless the respiratory depressant effects of opioids 
cannot be ignored. It is not unlikely that the impact of the intervention on 
duration and mechanical ventilation and PICU stay were related to 
changes in opioid use. This brings us to consider the primary sedative 
agent in the study setting; midazolam, a drug which is receiving an 
increased research focus of late. 
 
In this study, post-hoc analysis revealed no statistically significant 
reduction in the amount of midazolam given via infusion or bolus after the 
intervention. Similarly; Alexander et al. (2002) found that there was no 
difference in midazolam boluses received between PICU patients on a 
sedation protocol and off it. This finding is in direct contrast to Ista et al.’s 
(2009a) findings where a doubling of midazolam doses from 54 to 
112.8mcg/kg/hr (p=0.001) was reported after introducing a sedation 
algorithm with targeted COMFORT-B scores.  
 
The median daily midazolam dose for patients after the intervention was 
123.17mcg/kg/day in the writers’ study. This is comparably less than the 
median midazolam infusion rate reported by Johansson et al. (2009) of 
150mcg/kg/day in their analysis of analgesia and sedation practices in a 
Swedish PICU. Jenkins et al. (2007) reported a median daily midazolam 
rate ranging from 260mcg/kg/day in neonates to 160mcg/kg/day in 
adolescents, after investigating sedation practices in UK PICUs. 
However, these rates are not specific to children post surgery as they are 
in the current study. 
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In recent times, midazolam is increasingly being discussed in the 
literature. While it is the most commonly used agent to sedate PICU 
patients (Rhoney and Murray, 2002), possessing sedative, anxiolytic, 
hypnotic, muscle relaxant and anticonvulsant effects; it has no analgesic 
properties. However, combinations of benzodiazepines and opioids are 
synergistic in producing sedation (Brinker, 2004). Although tolerance to 
sedation effects has been reported as a result of benzodiazepine use; 
high doses are also reported as synonymous with moderate to severe 
withdrawal symptoms. There are increasing concerns that midazolam 
and other γ-aminobutyric-acid agonists administered during cerebral 
synaptogenesis may adversely affect cerebral development (Jevtovic-
Todorovic et al. 2000; Ikonomidou et al. 2001; Mellon et al. 2007). 
Therefore the goal of using the lowest dose of midazolam required for 
desired therapeutic effect; and discontinuation when no longer required 
is described by Brinker et al. (2004). The findings of the writers’ study 
reveal a lower rate of midazolam administration compared with other 
centres, now this drug is used based on patient assessment and clinical 
need. 
 
10.2.2 Changed Pattern of Co-analgesia and Adjuvant Agent Administration 
The ideal single agent to provide optimal analgesia and anxiolysis for the 
PICU patient has not yet emerged, therefore a multidrug regimen is 
required to attain optimum outcomes for the ventilated paediatric patient 
(Brinker et al. 2004). The multi-modal approach to pain has been 
endorsed by the International Association for the Study of Pain (IASP) 
(2012). Carbajal et al. (2005) have determined that in neonates, 
morphine alone appears not to provide sufficient analgesia for the acute 
pain caused by invasive procedures. A combination of analgesic and 
sedative approaches are therefore endorsed. Guidance on the use of co-
analgesic agents is provided by the analgesia and sedation guidelines as 
this was sought by staff at the analgesia and sedation committee 
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meetings. The intervention had a considerable impact on the use of 
these drugs, and there are a number of examples of how the pattern of 
specific drugs was altered in line with best available evidence.  
 
The first such example is chloral hydrate. This drug has been used as an 
oral sedative for many years even though the mechanisms of its action 
remain unknown (Boswinkel et al. 2005). It was listed as the 7th most 
frequently used drug for sedation in the U.S by Twite in 2004. Judicious 
use of this drug is advocated due to its unpredictable effects, pro-longed 
half-life in premature neonates and absence of a reversal agent (Mayers 
et al. 1991). Although after the intervention no statistically significant 
reduction in the median amount of chloral hydrate administered to 
patients emerged through post-hoc analysis; importantly a major 
disparity emerged between T21 and non-T21 patients regarding the use 
of this drug. In PASQ 1; patients with T21 received statistically 
significantly more chloral hydrate than non-T21 patients in Epoch 2 and 3 
(p=0.049 and 0.003 respectively). After the intervention there was no 
longer a statistically significant difference between the amount of chloral 
hydrate administered to T21 and non-T21 patients.  
 
This finding raised the question of why this population received more of 
the oral sedative chloral hydrate before standardised pain and distress 
assessment. This has particular relevance at the study site given the 
large percentage of annual admissions to the PICU annually with T21 (9-
10% of all PICU admissions). This is due to the study site’s position as 
the Irish national centre for cardiac surgery. Some 44-58% of children 
with T21 are born with a congenital heart defect and Ireland has a 
relatively high prevalence of T21 due to socio-economic and cultural 
factors (Weijerman et al. 2010). 
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The assessment of pain and distress in patients with T21 prior to 
standardisation of practice may have been challenging for nurses. IQ 
values in individuals with T21 range from 30-70; indicating mild to 
moderate mental impairment (Cunnif et al. 2001). Children with T21 have 
delayed psychomotor development. Mental development shows a 
deceleration between the ages of 6 months and 2 years (Volman et al. 
2007).  Weijerman et al. (2010) confirm children with T21 have more 
pronounced neurobehavioural problems; most frequently reported are 
disruptive behaviour disorders such as attention deficit hyperactivity 
disorder (6.1%), conduct/oppositional disorder (5.4%), or aggressive 
behaviour (6.5%). The intensive care environment is a noisy, unfamiliar 
and frightening environment for any patient; and in the post-operative 
period perhaps even more so due to intubation and restricted mobility. 
For children with T21, with the behavioural characteristics outlined; fear 
and anxiety may manifest in a way that is more challenging for the 
bedside nurse to manage than for a patient who may not have T21. In 
the initial post-operative period the nurse is primarily concerned with 
maintaining the stability of the patient, and the security of the 
endotracheal tube, central venous access and invasive monitoring 
devices. Increased sedative administration to subdue these behavioural 
manifestations may traditionally have occurred, based on subjective 
assessment. 
 
Valkenburg et al. (2011) tested the COMFORT-B instrument in 76 
patients with T21 and 466 without T21, all aged 0-3 years. The 
psychometric properties of the instrument were comparable in both 
groups, and confirmatory factor analysis revealed that a 1-factor model 
was sufficient to represent the 6 items of the COMFORT-B instrument. It 
is therefore argued that higher administration of chloral hydrate to 
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patients with T21 before the change in analgesia and sedation practice 
was based on subjective interpretation of their behavioural 
manifestations. Reducing the subjectivity somewhat by using a mainly 
observational instrument is likely to have moderated the number of 
judgements concluding in undersedation warranting sedation. There is a 
strong association between excessive sedative use and respiratory 
depression (Tobias, 2000b). Therefore the implications of this statistically 
significant reduction in the amount of the sedative chloral hydrate 
received by T21 patients after the intervention may have contributed to 
the statistically significant decrease in their duration of dependence on 
mechanical ventilation.    
 
A further example of the changing trend in drug use in line with current 
evidence is that of paracetamol. Intravenous paracetamol was endorsed 
by the guidelines in the post-operative period, and in compliance with this 
recommendation a highly statistically significant increase in the amount 
of paracetamol administered after the intervention emerged (<0.001), all 
but one patient receiving this analgesic post-operatively. This increase in 
paracetamol administered in the initial post-operative period may have 
had an opioid sparing effect. This proposition is supported by research 
from Ceelie et al. (2013) who conducted an RCT into the effect of 
intravenous paracetamol on post-operative morphine requirements in 
neonates and infants undergoing major non-cardiac surgery. Ceelie et al. 
(2013) showed that in the first 48 hours post-operatively the cumulative 
morphine dose in the paracetamol group (n=33), was significantly lower 
than the morphine group (n=38), (p<0.001). Notably pain scores and 
adverse effects were not statistically different between these groups. 
This finding has great relevance for pain management is post-operative 
PICU patients where the side effects of morphine, particularly respiratory 
depression are a major concern, and reinforces the importance of 
paracetamol in post-operative pain management.     
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Although no statistically significant difference between paracetamol 
administered between T21 and non-T21 patients emerged; 
pharmacokinetic analysis of paracetamol has revealed altered 
metabolism and lower clearance in children and adults with T21 (Greiner 
et al. 1990). This is a factor which must be taken into consideration in the 
post-operative management of patients with T21 receiving paracetamol. 
 
Another drug which appeared to be impacted by the change in practice 
was clonidine. Use of the sedative clonidine was endorsed in the 
analgesia and sedation guidelines, as it decreases the dose 
requirements of other sedatives, and can be useful in ameliorating opioid 
withdrawal symptoms (Lyons et al. 1996). Subsequently, after the 
intervention; post-hoc analysis revealed that the amount of clonidine 
administered was statistically significantly higher in Epoch 1 and 2 
(p=0.001 and p=0.048 respectively). Statistical analysis did not reveal 
any differences in the pattern of clonidine administration between T21 
and non-T21 patients. The use of clonidine in PICU was examined by 
Arenas-Lopez et al. (2004). In contrast to the writers’ study Arenas-
Lopez et al. (2004 found that where clonidine was used in combination 
with intravenous morphine in 24 children (n=24), there was an overall 
decrease in the average hourly requirements for morphine. The clear 
benefit of incorporating clonidine as part of a multimodal approach to 
pain and sedation in the PICU is underlined by this finding. 
 
The results of the writers’ study are therefore unique and noteworthy. 
The current practice of analgesic and sedative administration in the PICU 
is underpinned by the best available research evidence. The effect of the 
implementation of the analgesia and sedation guidelines on the pattern 
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of administration of key drugs, and the underlying differences the 
analgesic and sedative approach to the T21 population offer a unique 
finding in this area. It also makes a strong contribution to the body of 
evidence in this field which currently is inconsistent and lacking.  This 
analysis underscores the importance of being acutely familiar with one’s 
own study population, so that particular sub-groups requiring a special 
focus can be handled appropriately.  Dissemination of these findings may 
encourage other PICUs to consider standardising analgesia and sedation 
practice and incorporate a pain assessment tool which is validated in 
their patient populations.  
 
10.2.3 Compliance with Guidelines 
The wide variations in analgesia and sedation practices in PICUs is well 
acknowledged in the literature (Anand et al. 2013). As a result; large 
variations in the doses, frequency, routes of administration, off-label use 
of drugs and untested combinations of drugs are reported, often driven 
by individual preferences or local culture (Matthews et al. 1993; Jenkins 
et al. 2007; Anand et al. 2010).  The analgesia and sedation guidelines 
introduced into practice in June 2010 were received well by staff, based 
on best available evidence and expert consensus, and designed to offer 
a more consistent evidence based approach to practice. It is well 
acknowledged that practice variation in the use of opioid analgesia may 
lead to a higher prevalance of complications such as oversedation, 
respiratory depression, hypotension and opioid withdrawal (Anand et al. 
2013). While guidelines to reduce practice variability are associated with 
improved patient outcomes, it was vital to ascertain to what extent 
adherence to these guidelines occurred clinically.  
 
Specific elements of the guidelines were selected to assess compliance 
in PASQ 2, including distress assessment and analgesia and sedation 
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prescribed. Overall good compliance with pain and distress assessment, 
as well as administration of analgesic and sedative agents was evident. 
This is testament to the clinical utility of the intervention; as poor 
compliance would be a reflection of a poorly designed intervention.  
 
However, although most study patients returned from the operating 
theatre with a rate of morphine infusing which was in accordance with the 
analgesia and sedation guidelines; 39% had a rate of morphine running 
that was in excess of the guidelines. In addition; there was very poor 
compliance with administering morphine loading to patients in the 
operating theatre when commencing the morphine infusion, to ensure 
morphine levels were in the therapeutic range for analgesia. Failure of 
administration of morphine loading was an issue which emerged at many 
analgesia and sedation meetings, and was a source of considerable 
concern for PICU staff. Analysis of PASQ 2 data revealed morphine 
loading was administered to only 4 cases after the intervention. If 
morphine levels were sub-therapeutic for PASQ 2 patients; it is not 
surprising that these patients required significantly more morphine 
boluses than PASQ 1 patients.  
 
Administering morphine loading and setting infusion rates at 
commencement of therapy was primarily the responsibility of the 
consultant providing anaesthesia for the patient in the operating theatre. 
This fell outside the PICU jurisdiction, although at the study site some 
consultants in anaesthesia provided PICU cover on occasion. 
Communicating the change in practice to anaesthesiologists who had 
limited contact with the PICU was a huge challenge which endures to this 
day. Ista et al. (2009a) echo the reluctance of physicians to follow clinical 
guidelines. These researchers found that physicians prefer to follow their 
clinical impression rather than providing treatment based on guidelines. 
 319 
 
 
Therefore an amendment was made to the guidelines to prompt PICU 
nurses to request the morphine loading dose if it had not been 
administered in theatre. This facilitated improved practice regarding this 
issue. Transferring responsibility for adherence to this item of the 
guidelines to the PICU nurses was rationalised by findings that nurses 
level of compliance with guidelines is generally good. This strategy is 
supported by Brook et al. (1999) who propose that nurse directed 
protocols are successful because it allows rapid clinical decision making 
to occur at the patient’s bedside. Nurses level of compliance with 
guidelines and protocols and influencing factors has been addressed by 
several authors. 
 
Lawrence and Fulbrook (2012) reported good overall nurse compliance 
with six process measures including pain and sedation assessment in a 
before/after study in an adult ICU in Australia. The positive influence of 
feedback to staff as well as practice audit was highlighted in this study. 
Audit and was similarly used to successfully improve nurse compliance 
with ventilator care bundles in adult ICUs by Bird et al. (2010). 
Conversely, Van Neiuwenhoven et al. (2006) attributed non-compliance 
of nurses to staff related factors such as commitment and motivation to 
change. While Sinuff et al. (2008) proposed a multifaceted approach to 
create a sustained behavioural change of guideline compliance, including 
an active education strategy with reminders, audit and feedback. These 
strategies were incorporated into practice and continue to be utilised. 
Teaching rounds and ‘quality ward walk arounds’ afforded a learning 
opportunity for bedside nurses and a chance to clarify uncertainties. A 
direct referral pathway to the Acute Pain Clinical Nurse Specialist 
ensured issues were dealt with promptly and novel strategies utilised 
such as reminders regarding pain assessment on PICU screensavers. 
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Analysis of the recorded distress scores of study patients will now be 
discussed.   
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10.3: Pain and Distress in PICU 
10.3.1 Patient Assessment  
Analysis showed distress assessment using COMFORT-B had become 
part of the PICU culture one year after its introduction into practice. The 
majority of COMFORT-B assessments reflected a comfortable non-
distressed state; suggesting effective control of pain and sedation. The 
scores obtained were comparable with those reported by Ista et al. 
(2009a), who found in their study of the effect of introducing COMFORT-
B on the assessment of sedation levels in the PICU, median scores were 
relatively low reflecting the predominance of optimal sedation in the 
PICU. This study found that there was no pattern regarding the time that 
COMFORT-B and NRS assessments were made. This is in direct 
contrast to Ista et al. (2009a) who reported significantly lower 
COMFORT-B scores during the night time than the day time. This led to 
the conclusion that nurses in the Dutch study were more focussed on the 
comfort of the patient rather than being concerned about prolonging their 
length of PICU stay by administering additional sedatives and 
analgesics.  
 
The nature of the PICU is of great relevance at this point. In the study 
setting; decisions about discharging patients to the ward were usually 
made during the morning ward round. Therefore night nurses were 
unlikely to administer additional sedation if it was not warranted in the 
early morning period, as this may potentially delay the patients’ 
progression out of the PICU. Similarly, there was an acute awareness of 
weaning sedation when it was appropriate to do so. Conversely, 
Alexander et al. (2002) describe using the original 8 item COMFORT 
scale combined with a sedation protocol featuring a specified baseline 
prescription of midazolam and fentanyl to be titrated to achieve a target 
COMFORT score. A retrospective analysis of 7 purposefully selected 
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patients revealed that time periods when patients were on the sedation 
protocol were characterised by a moderate number of incidences of 
under-sedation. However, the most severe episodes of under-sedation 
occurred when the patient was off the sedation protocol. One may 
therefore assume that the protocol had the effect of ameliorating cases of 
under-sedation. Acknowledging that Alexander et al. (2002) found 
significantly more sedation was given to patients while on the sedation 
protocol; less severe episodes of undersedation while on the protocol 
were not unexpected.   
 
Given the significant reduction in the decrease in duration of dependence 
on mechanical ventilation of T21 patients after the intervention, it was 
notable that this study found there was no statistically significant 
difference between the T21 and non-T21 subjects regarding incidence of 
distress (p=0.76). It has been acknowledged that a major challenge for 
effective pain management in children with cognitive impairment is 
difficulty in pain assessment (Malviya et al. 2005). This was reflected in 
the minutes of analgesia and sedation meetings where staff requested 
information about assessing distress in cognitively impaired patients. 
While children with T21 are more likely to experience pain due to the 
conditions associated with the syndrome, such as congenital cardiac 
lesions. However, expressing this pain is more challenging for this group 
due to developmental delay, poor expressive language and speech 
intelligibility skills, and visual and hearing impairment (Roberts et al. 
2007). It is well acknowledged that the ability to accurately measure pain 
represents the key for its successful clinical management (Loggia, 2012). 
Determining whether there was a difference in the assessment of pain 
and distress in the T21 population was therefore of great importance. 
Conversely, it was noted by Valkenburg et al. (2012b) that children with 
T21 were more at risk of oversedation (OR =3.0 95% CI 1.7-5.3) than 
those without T21 during their study of the pharmacokinetics and 
 323 
 
pharmacodynamics of morphine in T21 versus non-T21 patients at the 
study site. A similar finding did not emerge from this study. Although all 
patients were more at risk of oversedation in Epoch 1 than Epoch 2 or 3; 
there was no increased risk in the T21 population compared with the 
non-T21 patients.  
 
In summary; this research identified a distinctive and significant change 
in the pattern of analgesia and sedation use in the PICU in line with 
current research. Nurses’ compliance with certain measurable aspects of 
the guidelines was good and compared favourably with similar studies. 
Strategies were employed to deal with some deficiencies with physicians’ 
engagement with the change in practice.  
 
Overall, the assessment of pain and distress using the COMFORT-B 
instrument was adopted successfully into practice. The incidence of 
distress and pain indicated by the assessments was low; comparable to 
similar research. In contrast to other research; this study did not report 
increased analgesic and sedative dosages to achieve target COMFORT-
B scores. Moreover; no significant difference was determined between 
under and oversedation in patients with T21 versus those without T21, 
which was reported in other studies.  The findings from the PICU staff 
surveys using SASQ (Staff Analgesia and Sedation Questionnaire) 
before and after the intervention will now be discussed. 
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10.4 Impact of the Intervention on PICU Staff Attitudes to 
Analgesia and Sedation Practices 
10.4.1 Findings from PICU Staff Survey Using SASQ 
It is well acknowledged that a major influencing factor in best practice 
guideline implementation is positive staff attitude (Ploeg et al. 2007). 
Without the endorsement of those most closely involved with prescribing 
and administering these agents, a successful change in practice is 
unlikely to occur. The effectiveness of pain and distress management 
strategies could not have been assessed without implementation of a 
validated method of measuring these phenomena- the COMFORT-B. 
Nurses in the PICU were well trained to use this scale, given the high 
inter-rater reliability generated. How adoption of this instrument as well 
as incorporation of the analgesia and sedation guidelines into practice 
was received by the PICU nurses and doctors was vital in determining its 
feasibility clinically.   
 
This study found that there was an overwhelmingly positive 
receptiveness by PICU nurses and doctors to adopting a more consistent 
approach to assessing and managing patient distress in the PICU. One 
year after the intervention a significant increase in satisfaction with 
analgesia and sedation management, assessing pain and distress, 
weaning analgesics and sedatives and evaluating under and over-
sedation was revealed. The COMFORT-B tool remained valued by 85% 
of respondents 12 months after its introduction. This increase in 
satisfaction among PICU staff are supported by findings from Alexander 
et al. (2002) who reported that a sedation treatment algorithm together 
with a delegation of decision-making authority to nurses might increase 
patient comfort and be more satisfying both for physicians and for nurses 
in their daily work. Alexander et al. ’s (2002) findings correlate with 
research by Edgar (1999) where autonomy was found to be strongly 
linked to nurses’ work motivation and job satisfaction.  
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However, it appeared that all expectations may not have been met 
however, as 20% fewer respondents indicated satisfaction with 
COMFORT B combined with the analgesia and sedation guidelines in 
SASQ 2. It is well acknowledged that observational assessment of 
distress in PICU is challenging. Administration of COMFORT B requires 
a 2 minute observation of the patient to avoid under reporting of pain 
(Boerlage et al. 2012). This may prove challenging for the busy PICU 
nurse. COMFORT-B assessment reflects a moment in time, hence there 
is a requirement for additional, objective and validated monitoring tools to 
measure PICU patient distress, such as skin conductance or near infra-
red spectroscopy.  
 
Due to the 6 month duration of PICU registrars’ employment contracts; 
no non-consultant doctors answered both SASQ 1 and SASQ 2, a 
complete change of PICU registrars had occurred between surveys. A 
third of doctors who responded indicated to have had no previous 
education on pain and sedation. The majority of doctors cited 
anaesthesia as their specialty, as the safe delivery of anaesthesia to 
patients is a major role of this specialty; proficiency with agents used for 
analgesia and sedation may be assumed. The implications of this are 
significant. Engagement of the PICU medical staff who were on a six 
months rotation was vital so that they were familiar with the methods of 
assessing pain and distress in PICU patients, and familiar with the 
analgesia and sedation guidelines, so that agents could be prescribed 
accordingly. This was of vital importance at each bedside, and nurses in 
their patient advocacy role had a responsibility to ensure this was 
occurring.  
  
 326 
 
10.4.2 Specific Areas of Concern Regarding Pain and Sedation in PICU 
It appeared that there was less concern regarding the prioritisation and 
assessment of pain and sedation as well as the inappropriate use of 
opioid infusions and inconsistency in practice at consultant level after the 
intervention. It is evident from the literature that consultants practice 
varies considerably not only between institutions, but between individual 
consultants within institutions (Tang et al. 1999). While analgesic and 
sedative agent preferences may strongly influence patient management, 
introduction of the evidence based guidelines and assessment tool 
appeared to have facilitated some consistency.  Conversely some areas 
that required a clinical focus emerged. 
 
While there remained a considerable number of individuals who 
considered analgesia and sedation weaning to be too rapid; a not 
insignificant number indicated concern over delayed analgesia and 
sedation weaning. Indeed failure of some nurses to wean sedation 
appropriately when indicated by low COMFORT-B scores was raised at 
analgesia and sedation meetings. Proportionally more doctors than 
nurses felt that nurses could be more proactive in weaning analgesia. 
Findings from research by Ista et al. (2009a) suggested PICU nurses 
may be more engaged with the comfort of the patient and less focussed 
on length of patient stay, which could explain this anomaly. Consistent 
with this finding, most physicians (n=3) surveyed about a sedation 
protocol in a Canadian PICU associated use of the protocol with over-
sedation of patients (Alexander et al. 2002). The concerns regarding 
delayed weaning of analgesia prompted development of the 
multidisciplinary weaning guidelines. These were introduced into practice 
in November 2012. 
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10.4.3 Knowledge Regarding Pain and Sedation 
Subjects responded similarly to the knowledge items on both occasions; 
despite a 17 month time period between surveys. This is not uncommon 
in before/after surveys (Bowling, 2009).No difference in knowledge was 
demonstrated between assessments. Although similar research by Jam 
Gatell et al. (2012) found an educational intervention produced a 
significant increase in nurses’ scientific knowledge regarding ventilator 
associated pneumonia prevention. In contrast, Twycross (2002) 
ascertained that education regarding pain management does not always 
result in a change in behaviour.  
 
Limited awareness was demonstrated regarding physiological adaptation 
and tolerance. Tobias (2000a) described tolerance as “a decrease in a 
drug’s effect over time or the need to increase the dose to achieve the 
same effect,” while “physiological dependence is the need to continue a 
sedative or analgesic agent to prevent withdrawal” (p 2122-3).  Tolerance 
and dependence are now well acknowledged complications of 
continuous infusions of sedatives as well as analgesics, particularly 
opioids (Cho et al. 2007). Awareness of clinical staff regarding these 
issues is the key to avoiding their occurrence. Similarly, a focus is 
required to emphasise the deleterious effects of some sedative agents 
on developing brains, as recent studies on primates have demonstrated 
that exposure to ketamine resulted in increased neuronal cell death 
(Rappaport et al. 2011). A close watch on emerging evidence must be 
maintained, so that current practices can be adapted if required in line 
with new findings to ensure the safety of PICU patients is safeguarded.  
 
In summary a statistically significant increase in satisfaction was 
demonstrated regarding analgesia and sedation practice after the 
intervention by medical and nursing staff. This endorsed the intervention 
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and supported COMFORT-B as a clinically useful and valuable method 
of assessing distress in PICU. The value of the analgesia and sedation 
guidelines combined with COMFORT-B may not have met all 
expectations; nonetheless 80% of respondents felt they were valuable in 
patient management one year after introduction. To date, ongoing 
feedback from clinicians is sought, analgesia and sedation meetings 
occur bi-monthly and work continues on refining the guidelines to 
enhance their utility.  
 
Concerns regarding inconsistent approaches to weaning analgesia and 
sedation emerged as well as uncertainty regarding tolerance and 
physiological dependency. Weaning guidelines were put in place and 
awareness was raised clinically regarding these issues through unit 
based tutorials and maintaining a focus on them at analgesia and 
sedation meetings. The use of evidence based guidelines to guide 
clinical decisions in practice underpins high quality patient care and 
improved patient outcomes. Although analysis did not reveal the 
anticipated statistically significant patient outcomes; adopting such a 
strategy in relation to analgesia and sedation has shown to be welcomed 
and valued by clinical staff. As a valuable component of this intervention 
involved regular open engagement with the multidisciplinary team; the 
minutes of analgesia and sedation meetings will now be briefly 
discussed. 
 
10.4.4 Analgesia and Sedation Meeting Minutes 
The minutes of the analgesia and sedation committee meetings 
illustrated the multidisciplinary effort involved in bringing an evidence 
base to this area of practice. The receptiveness to changing the 
approach to analgesia and sedation management highlighted at the 
inaugural meeting was reflected in the staff survey. The level of 
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commitment required from staff nurses to consultants to PICU managers 
was evident at every meeting held. Challenges outlined in these 
meetings such as inconsistencies at consultant level were mirrored by 
the findings from the SASQ questionnaires. Certain issues i.e. ensuring 
that patients received a morphine loading dose in the operating theatre 
continued to be a problem 2 years after the intervention and required a 
novel solution; administering the loading dose in the PICU if it had not 
been given in the operating theatre. Awareness of and management of 
withdrawal syndrome proved to be a greater challenge than originally 
anticipated and required a proactive effort from all members of the team. 
To the present day a strong focus is maintained on recognising and 
managing withdrawal syndrome, particularly in long-stay patients.  
 
Overall, a variety of measures were employed at analgesia and sedation 
meetings to maintain the high profile of the project, from the involvement 
of outside experts, to presentation of scientific data, and case scenarios 
to drive and sustain this change in practice. Reinforcement of the merit of 
this change in practice was obtained through assurance from an 
international expert, comparisons of our new practice with that of our 
neighbouring PICUs in the UK through our involvement with PICS and 
PICANet, and through feedback from the bedside PICU staff. Clinical and 
statistical significance will now be discussed. 
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10.5 Clinical vs Statistical Significance 
Ultimately the null hypothesis was not rejected on the basis of this study, 
as the reduction in morphine administered to PICU patients did not reach 
statistical significance (p=0.127). However, the pattern of morphine 
administration changed considerably with patients returning from the 
operating theatre on significantly lower morphine infusion rates and 
receiving more morphine boluses. The secondary null hypothesis 
similarly was not rejected. Although the T21 population demonstrated a 
statistically significant reduction in duration of mechanical ventilation after 
the changed approach to analgesia and sedation management, this did 
not extend to the larger study group. Furthermore, in addressing the 
additional research question into whether PICU staff welcomed the 
standardisation of analgesia and sedation management and perceive it 
as clinically useful one year after its implementation; clearly the 
intervention was welcomed, demonstrated high clinical utility and fulfilled 
the needs and expectations of staff for the most part.  
 
While respected research authors stress the importance of statistical 
conclusion validity in order to prevent distortions of the truth (Cook and 
Campbell 1979; Burns and Grove 2001), it is strongly argued that this 
may not represent the clinical or practical importance of the research 
results (LeFort 1993; Hollis 1994; Hicks 1998). According to Fethney 
(2010), statistical significance is a statement about the likelihood of 
findings being due to chance. Classical significance testing, with its 
reliance on p values, can only provide a dichotomous result – statistically 
significant, or not. Limiting interpretation of research results to p values 
means that researchers may either overestimate or underestimate the 
meaning of their results. Fethney (2010) further contends that very often 
the aim of clinical research is to trial an intervention with the intention that 
results based on a sample will generalise to the wider population. In this 
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instance the p value on its own provides no information about the overall 
importance or meaning of the results to clinical practice, nor does it 
provide information as to what might happen in the future, or in the 
general population. A further inadequacy of statistical significance has 
been identified by Jacobson et al. (1991). While statistical tests provide 
no information on the variability of response to therapy within the sample; 
information regarding within-treatment variability of outcome is of the 
utmost importance to clinicians. Conventional statistical comparisons 
between groups therefore tell us very little about the ability of a 
treatments ability to make a difference in peoples’ lives.  
 
The behavioural sciences have long grappled with the limitations of 
statistical significance to evaluate treatment efficacy. According to 
Jacobson et al. (1991) the value of clinical significance is recognised, but 
the optimal methods for deriving it remains to be determined. 
Furthermore, Richardson (2000) argues that many well designed RCTs 
will produce moderate differences in outcome, but this difference may be 
of clinical importance either to the patient or the degree to which study 
results lead to clinical changes in behaviour.  
 
Indeed Hayat (2010) argues that statistical significance is not an 
objective measure and there is an obligation for the researcher to 
consider and evaluate the clinical and practical importance of a study’s 
results. Naylor and Lewellyn-Thomas (1994) outlined potential 
approaches used to determine the clinical importance of studies. These 
included the opinions of clinical experts; using consensus development, 
while van Walraven et al (1999) proposed the use of physician surveys to 
determine appropriate minimal clinically important differences (MCIDs). 
Others have suggested the perspective of patients is important in 
determining clinical importance (Llewellyn-Thomas et al. 1989; Man-Son-
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Hing et al. 1996). Another strategy developed by Detsky (1985) involved 
using economic analysis to determine sample size MCIDs for clinical 
trials. This strategy was aimed at funding agencies to rationally allocate 
monies to trials prioritising clinically important effects. Despite being 
methodologically attractive; these approaches added additional steps to 
the research design process and have not been widely implemented 
(Chan et al. 2001). 
 
In summary, the lack of statistically significant results in the writers’ study 
does not infer that the changes in clinical practice were insignificant. This 
project involved members of the clinical team working together to 
develop and implement guidelines. The results of this study had 
implications beyond the patient and PICU staff, but for other patients, 
patients’ families, the wider hospital, research, education, clinical practice 
and Irish healthcare. It was therefore suggested that the significance of 
research findings are viewed in the context of both their statistical and 
clinical significance.  
 
10.6 Conclusion 
The pervading objective of this study was to implement lasting and 
evidence based change. The study findings have been discussed in the 
context of current literature and research, and the debate around 
statistical versus clinical significance has been alluded to. The next 
section will provide a conclusion to the study, recommendations for 
practice, education, research and dissemination, and finally a reflection 
on the study. 
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Chapter 11:  Study Conclusions and 
Recommendations 
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11.0 Introduction 
During the last decade, the paediatric critical care community has called 
for more rigorous testing of sedatives and analgesics in critically ill 
children. Assessment of the effects of development and critical illness on 
drug metabolism and dosage requirements is limited. A first step in this 
process was understanding the existing state of sedative and analgesic 
use in the PICU, and how this was impacted by standardising patient 
pain and distress assessment and titrating drug administration 
accordingly. The implementation of standardised pain and sedation 
assessment and management was successful in the PICU. Importantly, 
without the implementation of validated pain and distress assessment 
embedded into practice as part of this study; any research evaluating 
sedatives and analgesics at the study site would be impossible.  
 
As a consequence of the current economic downturn, increased 
challenges are presented to healthcare workers including fewer staff, 
reduced budgets, increased workloads and rationalisation of services 
(Curtis, 2010 p224). The change in practice brought about by the writers’ 
study embodied the creativity and innovation that was required to 
improve the quality of patient care and efficiencies in expenditure that 
were called for in order to deal with existing circumstances. This chapter 
will present the implications for practice of this research, as well as the 
implications on education and research. A plan for the dissemination of 
the research will be provided. The chapter will progress with a 
consideration of the study strengths and limitations and significance at a 
wider level, culminating in personal reflections at the study conclusion. 
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11.1 Recommendations for Practice 
The clinical implications of this study were multifaceted. There has been 
a change in the pattern of analgesic and sedative administration in the 
PICU to comply with current best evidence. Amid recent concerns 
regarding the harmful effects of some anaesthetic agents on the 
developing brain; basing drug administration on clinical need rather than 
on habit or personal preference was crucial. An approach that devolved 
the responsibility of determining each patients analgesic and sedative 
needs based on a robust assessment of their pain and distress status 
has proven to benefit patients and staff in the PICU.  
 
The potential benefits caused by a reduction in duration of mechanical 
ventilation and for the T21 population are significant and far reaching. A 
shorter dependence on mechanical ventilation may result in a reduced 
exposure to the complications associated with ventilation such as 
tracheitis and ventilator associated pneumonia as well as hospital 
acquired infections; which carry an increase in morbidity and mortality. 
The intervention did not result in a statistically significantly altered 
duration of PICU stay. However, endeavours which have the potential to 
reduce patients stay in PICU must be actively pursued as such a 
decrease would result in less disruption to the patient’s cognitive 
development and to the parental bonding process, helping to preserve 
normal development and maintain the integrity of the family. In the long-
term this may benefit patients helping them to develop as independent, 
fully functional individuals.  
 
The cost of caring for a ventilated patient is €2000 to €5000 per day. The 
median reduction of ventilator dependence for PICU stay for T21 patients 
was 0.35 days. In financial terms, this translated to a potential annual 
saving of €30,000 to €175,000 based on current patient turnover of over 
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1,000 annually in the 23 bed PICU with >85% occupancy and incidence 
of patients with T21 of 10%. However this was a notional figure; 
technically a reduction of patients’ PICU stay would make the hospital 
more efficient and increase throughput. Until the system change 
becomes embedded where ‘the money follows the patient’, such a direct 
financial consequence would not be visible (Personal communication 
with S Moores, Director of Finance at study site, 20th March 2013).  
 
Nevertheless, the potential to increase patient turnover as a 
consequence of shorter duration of mechanical ventilation could combat 
lengthening hospital inpatient waiting lists. As well as this lessening the 
burden on individuals and their families of coping daily with disability 
while awaiting surgical correction; early surgical intervention is often 
synonymous with better outcomes, reducing the development of 
irreversible secondary complications.  From an additional fiscal 
perspective, a decrease in exposure to complications such as ventilator 
associated and hospital acquired infections would have a major impact 
on healthcare budgets, as these complications have a major impact on 
overall healthcare costs annually. We are currently being asked to 
provide an efficient service while operating in an environment where the 
2013 budget was reduced by €1 billion. Any initiative with proven patient 
benefits which is amenable to staff and makes better use of valuable 
resources must be embraced. 
 
Importantly, an effective strategy to manage pain and sedation has 
benefits for PICU staff. From a humanitarian perspective, acknowledging 
clinicians’ ethical obligations to their patients, ameliorating or eliminating 
human suffering has the potential to increase job satisfaction. This may 
increase staff morale and reduce staff turnover at a time when retention 
of highly trained specialist PICU nurses is challenging; acknowledging 
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the attractive financial packages available to them in overseas hospitals 
such as those in the Middle East and Canada.  
 
Beyond the PICU, work has commenced throughout the hospital on 
developing ‘Pain Champions’ at ward level to promote awareness and 
improve pain management. A strong collaboration has developed with 
the only other PICU in Ireland who have also adopted COMFORT-B to 
assess distress. The analgesia and sedation guidelines have also been 
shared with this hospital; thus moving towards standardisation of PICU 
practice at a National level. Specific recommendations materialising from 
this research are to: 
 Provide neurodevelopmental follow up for patients who have had 
prolonged exposure to analgesic and sedative agents. 
 Continue to feed back any new high quality research to key 
stakeholders and review practice accordingly, so that practice is 
always in line with best available evidence. 
 Raise the profile of pain hospital wide through the development of 
‘Pain Champions’ at ward level. 
 Ongoing collaboration with PICUs countrywide and internationally. 
 
 
11.2 Recommendations for Education  
The intervention was synonymous with a major educational initiative; 
each staff member receiving a two hour tutorial and workshop on 
assessing pain and distress using COMFORT-B. Excellent inter-rater 
agreement illustrated the effectiveness of this strategy. Every new 
member of staff received this training programme, all training scores 
were recorded and inter-rater agreement measured using Cohens’ 
Kappa. Individuals were deemed competent in COMFORT-B 
assessment once a Cohen’s Kappa score of >0.8 was achieved. This 
 338 
 
approach has proven successful in ensuring consistency among all PICU 
staff in addressing pain and sedation.  
 
The staff surveys revealed there were some areas where uncertainty and 
knowledge deficits existed. These included the deleterious effects of 
some analgesics and sedatives on the developing brain. This was 
addressed so that diligence was exercised when administering these 
drugs. A greater awareness of the issues of tolerance, dependence and 
withdrawal was also required. The regular Analgesia and Sedation 
meetings have proven an ideal forum to provide a focus on these 
particular issues. A result of this has since been the introduction of a 
validated withdrawal scoring tool- the Sophia Observation Scale (Ista et 
al. 2009b) into practice. In addition guidelines to direct the weaning of 
analgesics and sedatives have been developed. These have become 
well established in practice.  Specific recommendations for education 
are: 
 
 Continue to train all new staff members in pain and sedation 
assessment and management in a consistent manner. 
 Provide education where deficiencies have been identified; 
harmful effects of some sedatives on the developing brain, 
tolerance, dependence and withdrawal.  
 Ensure medical personnel on 6 monthly rotations receive tuition 
on current PICU analgesia and sedation practice. 
 
 
11.3 Recommendations for Research  
Despite the widespread use of sedatives in the PICU; high quality 
evidence to guide practice is still lacking. Recent advances have 
 339 
 
improved the feasibility of pharmacokinetic studies in infants and 
children, as the required blood sample volume and number of samples 
required for analysis has decreased substantially. Possible genotype-
phenotype associations related to pain in children with T21 are showing 
promise as six possible candidate genes are located on chromosome 21. 
 
Future paediatric studies are needed to compare alternative analgesic 
strategies and importantly to address optimal doses of post-operative 
morphine through RCTs. To date dosing recommendations are based on 
institutional guidelines only without the support of high quality studies. 
Notably a validated pain and distress assessment tool has been adopted 
into practice which is a prerequisite for any PICU based research; 
particularly where analgesia and sedation are being studied.   
 
Children with T21 currently enjoy an improved life expectancy resulting in 
a predicted substantial growth in this population. Hence there must 
therefore be a focus on projected changes in their long-term morbidity. 
This longer life span also needs to be analysed in terms of quality. The 
non-universal effect of this intervention led to the commencement of a 
study examining the pharmacokinetics and pharmacodynamics of 
morphine and midazolam in T21 patients at this study centre. The 
findings of this study should have major implications for the management 
of analgesia and sedation in patients with T21 in PICU, and will go a long 
way towards providing real evidence where it is currently deficient. These 
specific recommendations for research are advised: 
 
 A DBRCT to determine the optimal dose of morphine infusion 
post-operatively using COMFORT-B scores as an outcome 
measure. 
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 A non-inferiority study comparing the clinical effectiveness of 
similar agents used for post-operative analgesia and sedation, 
commencing with clonidine versus dexmedetomidine.  
 A prospective cohort study assessing the quality of life of patients 
with T21, in particular the significance of extended life expectancy. 
 A cost benefit analysis of introducing guidelines in a PICU. 
 A cluster trial to compare the effectiveness of analgesia and 
sedation guidelines in PICU.  
 
11.4 Dissemination of Research Findings 
This study has raised the profile of an area of practice which urgently 
required a focus in the PICU at the study site. The neighbouring PICU 
has since adopted the COMFORT-B distress assessment instrument, 
and developed analgesia and sedation guidelines appropriate for their 
patient population. Strong links have developed with other PICUs where 
COMFORT-B is also being adopted. This is facilitated by the writers’ 
position as a member of the Paediatric Intensive Care Society (PICS) 
nurses subgroup on pain and sedation, a proactive group charged with 
researching and developing practice in this area so that advances in 
PICU care can be achieved.  
 
This research has been presented to the writers’ peers, and PICU 
consultants, managers and clinical director at the bi-annual Anaesthesia 
and PICU Research Meeting on 8th March 2013. Constructive feedback 
was provided. A regular account of this study and its findings are 
circulated to all PICU staff as part of the monthly departmental bulletin 
letter, and a synopsis of the study was included in the quarterly Regional 
Nurse Practice Development Unit newsletter. The research was also 
presented to the National Children’s Research Centre, who supported 
the study financially, on 16th April 2013, at the hospitals Annual Research 
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Day on the 24th May 2013, at the RCSI Gathering event in September 
2013, and at the Irish Research Nurses Network Annual Meeting, 
University College Cork on the 27th November 2013. From an 
International perspective, an oral presentation of this research was 
delivered at the European Societies for Paediatric and Neonatal 
Intensive Care (ESPNIC) Annual Conference on the 12th to 15th of June 
2013, and was awarded the prize for best oral nursing presentation. Two 
articles are currently being finalised for submission to a leading medical 
journal “Paediatric Critical Care Medicine” and a nursing journal “Nursing 
in Critical Care”. 
  
11.5 Study Strengths 
The use of a baseline group allowed robust comparisons allowing 
inferences about the many effects of the intervention; including how it 
impacted patients’ duration of mechanical ventilation and PICU stay, as 
well as the analgesics and sedatives they received. By using surveys to 
interview nurses and doctors, a valuable dimension of the impact of the 
all encompassing intervention was provided. Nurses can and must be 
involved in defining appropriate sedation and comfort management for 
their children. In addition, the presence of the writers’ academic 
supervisor at some of the PICU based analgesia and sedation meetings 
gave assurance to the writers’ work colleagues that this study had 
academic merit, and was visible evidence of the narrowing theory and 
practice gap. 
 
Another major strength of the study was that an area of clinical practice 
was addressed that urgently required a research focus in the PICU. 
Therefore much interest and support was secured from physicians and 
nurses who were keen to become involved and improve care in this area. 
A major focus of pain and sedation research internationally has led to the 
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refinement of the COMFORT-B instrument and its validation in the T21 
population. This study would not have been feasible without this work, 
and it has opened the door to further research where it is currently 
lacking. 
 
11.6 Study Limitations 
As the study used a retrospective patient group admitted to PICU before 
the intervention for baseline comparison, there is the possibility that other 
factors rather than the intervention were responsible for observed 
differences in the study. Indeed it has been argued that there is a general 
upward trend in the quality of PICU care and patient outcomes. However, 
it is argued that in the short time frame of the study period without 
breakthroughs in treatment or significant reconfiguration of the service; it 
was unlikely that any other rationale could be attributed to such a 
reduction in length of patient ventilation and PICU stay. The findings of 
this study were generalisable to PICU patients post cardiac surgery, 
between 44 weeks post-conceptual age and one year of age.  
 
No randomisation processes were employed as it would have been 
unfeasible to blind PICU nurses and doctors to the study or prevent 
crossover effects. Consequently there may have been unmeasured 
factors which were unknown to the writer and may have impacted on the 
results. To overcome these limitations; a two site RCT could have been 
carried out, where one PICU would act as the control site and the other 
PICU receive the intervention, alternatively a cluster trial may have been 
undertaken. Given that standardised analgesia and sedation 
management has largely proven beneficial in adult ICUs; a step-wedge 
design could be used so that both sites received the intervention, but at 
different time points. Given that the 2 Irish PICUs have significantly 
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different patient populations and outcomes, each site would be 
comparing the impact of the intervention with their own baseline data.  
 
11.7 Confounding Variables 
Without randomisation, the minimisation of confounding variables was 
not assured. Every effort was made to eliminate or control for the effects 
of confounding variables on study results. These efforts included the use 
of strict inclusion and exclusion criteria to obtain two patient groups for 
analysis that were well matched in terms of standard demographic 
variables, severity of illness and complexity of surgery. External effects, 
such as that of a change in medical staffing was analysed for any 
potential influence of the variables under focus. Through examination of 
baseline data; T21 patients emerged as a group where statistically 
significant differences in duration of mechanical ventilation and PICU 
stay existed before the intervention. To control for this, separate analysis 
was done on the T21 patients where appropriate. Accordingly, the 
potential for confounding variables exerting an effect must be considered 
for any researchers who may undertake a similar study using the outlined 
methodology.     
 
11.8 Reflections on the Study 
This research study proved to be an enormously worthwhile exercise; 
however it was not without its difficulties. Reviewing and changing the 
practice of over 150 nurses and 30 doctors required a huge level of 
collaboration, communication, motivation and co-operation. A strong 
group of multidisciplinary stakeholders was crucial in achieving this. 
Ongoing commitment was vital in ensuring that this change in practice 
was sustained. A high level of support at management level was shown 
at an early stage and continues to the present day.  
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Support was also obtained from Monique van Dijk, Associate Professor, 
Quality of Care, Erasmus Medical Centre and Queen Sofia Children’s 
Hospital, who along with her team has undertaken much of the work of 
refining the COMFORT-B instrument and validating it in the patient 
groups in which it is used. Professor van Dijk visited the PICU in 2010 
and delivered a series of lectures on “Pain, Sedation and Delirium in 
PICU” to large audiences. Importantly, she trained a group of nurses to 
expert level, who could then provide the 2 hour training to each PICU 
nurse and doctor on how to perform a patient assessment using 
COMFORT-B. Follow up visits form Professor van Dijk have helped to 
keep the profile of this topic high on everybody’s agenda. A strong 
research collaboration has developed from this connection which has 
benefitted both centres through joint research studies.  
 
11.9 Personal Reflections  
Acknowledging that the study was challenging at times, it proved to be 
an extremely valuable learning experience. The role of researcher 
offered a huge insight into what was involved in a project such as this, 
and gave an appreciation and an insight that will prove invaluable in 
critiquing and conducting further research in the future. Addressing a 
topic that has such relevance for practice was rewarding as the profile of 
this topic has been effectively raised- pain and sedation in PICU is now 
an issue which is discussed and debated at a high level in the clinical 
setting. Each Friday at the weekly PICU ‘Risk Huddle’, incidents which 
occurred during the week are discussed, varying from clinical near 
misses and drug errors, as well as environmental and parental concerns. 
Any issues which relate to pain or sedation are now investigated and 
followed up by the writer and reported back to the Clinical Director as 
well as the Nurse Manager of PICU.  Hence the implications from this 
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study are likely to be far reaching, making it a hugely worthwhile 
endeavour and a very productive use of time. 
 
The study was made feasible by a high level of institutional support, and 
an openness and willingness of both medical and nursing staff to have 
current practices analysed and engage with methods to improve 
practices in this area. In the 1970s and 1980s a realisation emerged that 
it was no longer adequate to base nursing practice on tradition, 
assumptions and precedent (Hicks and Hennessy, 1997). This shift in 
attitude has continued to the present day, this eagerness to change 
practice for the better must be fostered and embraced so that the 
children we have the privilege of helping through the hospital experience 
will benefit from the very best care we can offer them. 
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 Appendix 1: PICU Occupancy Rates January to November 2012 
 
Source: PICU Annual Report (Healy et al. 2011) 
 
 
 
  
 Appendix 2: Demographics and Summary Indicators of PICU Activity 
Category 2011 2010 2009 
Admissions 1020 994 823 
Male : Female 533(52%):487(48%) 563(57%):431(43%) 474(58%):349(42%) 
Age (years) 
 
Mean 2.92 +/- 4.49 Mean 2.55 +/- 3.98 Mean 2.78 +/- 4.28 
Median 0.58 
(0.1-3.89) 
Median 0.58 
(0.08-3.46) 
Median 0.69 
(0.11-3.34) 
Range 0-17.66 Range 0-18.89 Range 0-17.78 
Total Bed 
Occupancy (days) 
7574 7669 6399 
Length of Stay 
(days) 
 
 
Mean 7.43 +/- 15.63 Mean 7.72 +/- 13.28 Mean 7.78 +/- 11.96 
Median 3 (2-7) Median 4 (2-8) Median 4 (2-8) 
Mode 2 Mode 2 Mode 2 
Range 1-304 Range 1-252 Range 1-113 
Admissions 
Requiring 
Ventilation 
675 (66.18%) 680 (68.41%) 571 (69.38%) 
Total Invasive 
Ventilation Days 
4781 4877 4104 
Duration of 
Invasive 
Ventilation (days) 
 
Mean 7.08 +/- 16.09 Mean 7.17 +/- 13.56 Mean 7.19 +/- 11.23 
Median 3 (2-6) Median 3 (2-7) Median 3 (2-8) 
Mode 2 Mode 2 Mode 2 
Range 1-241 Range 1-213 Range 1-101 
Readmission 
(within 24 hrs) 
5 (0.49%) 22 (2.21%) 14 (1.7%) 
Readmission 
(within 48 hrs) 
22 (2.16%) 30 (3.02%) 17 (2.07%) 
PICU Mortality 53 (5.2%) 53 (5.33%) 55 (6.68%) 
30-Day Post 
Discharge 
Mortality 
14 (1.37%) 15 (1.51%) 14 (1.7%) 
Total Mortality 67 (6.57%) 68 (6.84%) 69 (8.38%) 
Source: PICANet Local Database (Accessed 06 June 2012). 
 Appendix 3: Number/Percent of Admissions Receiving PICU-
Specific Interventions 
 
Source PICU Annual Report (Healy et al. 2011). 
 
 
 
 
 
 
 
 
 
 
  
 Appendix 4: Nociception, Basic Process of Normal Pain Transmission 
Transduction: Conversion of one form of energy to another. This process occurs in 
the periphery when a noxious stimulus causes tissue damage. The damaged cells 
release substances that activate or sensitise nociceptors. This activation leads to the 
generation of an action potential.  
Sensitising substances released by damaged cells: 
Prostaglandins (PG) 
Bradykinin (BK) 
Serotonin (5HT) 
Substance P (SP) 
Histamine (H) 
An action potential results from: 
Release of the above sensitising substances (nociceptive pain) 
+ a change in the charge along the neuronal membrane 
The change occurs when Na+ moves into the cell and other ion transfers occur 
Transmission: The action potential continues from the site of damage to the spinal 
cord and ascends to higher centres. Transmission may be considered in three phases: 
 Injury site to spinal cord. Nociceptors terminate in the spinal cord. 
 Spinal cord to brain stem and thalamus. Release of substance P and other 
neurotransmitters continue the impulse across the synaptic cleft between 
the Nociceptors and the dorsal horn neurons. From the dorsal horn of the 
spinal cord, neurons such as the spinothalmic tract ascend to the 
thalamus. Other tracts carry the message to different centres in the brain. 
 Thalamus to cortex. Thalamus acts as a relay station sending the impulse 
to central structures for processing. 
Perception of pain: Conscious experience of pain.  
Modulation: Inhibition of nociceptive impulses. Neurons originating in the brain 
stem descend to the spinal cord and release substances such as endogenous opioids, 
serotonin (5HT) and norepinephrine (NE), that inhibit the transmission of nociceptive 
impulses. 
Source: McCaffery, M; Pasero, C (1999) Pain: Clinical Manual. St Louis, Mosby: p. 20. 
 Appendix 5: Schematic Diagram of the Development of Cutaneous 
Sensory Perception in the Neonate 
 
 
The schematic depicts development of cutaneous sensory  perception, myelination of the pain 
pathways, maturation of the foetal neocortex and electroencephalographic patterns in the human 
foetus and neonate, (Anand et al. 1987 p1322). 
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 Appendix 6: Anxiolytic and Hypnotic Drugs 
 
Benzodiazepines 
Anxiolytics   Hypnotics 
Alprazolam    Quazepam 
Chlordiazepoxide   Midazolam 
Clonazepam    Estazolam 
Clorazepate    Flurazepam 
Diazepam    Temazepam 
Lorazepam   Triazolam 
 
Benzodiazepine Antagonist 
Flumazenil 
Barbiturates       Nonbarbitural Sedatives 
Amobarbital    Antihistamines 
Phenobarbital    Chloral Hydrate 
Pentobarbital     Ethanol 
Secobarbital 
Thiopental 
 
Source: Myceck et al. (2000).  
 Appendix7: COMFORT-B Assessment 
Reference: Koot HM, Boer JB, van Dijk M (2001). 
 Appendix 8:COMFORT-B Cut-Off Values 
 
 
Reference: Analgesia and Sedation Committee PICU June 
2010. 
  
 Appendix 9: PICU Pain and Sedation Management Algorithm 
 
 
  
 
Reference: Analgesia and Sedation Committee PICU June 2010. 
 Appendix 10: Studies Evaluating the Impact of a Changed Approach to Analgesia and Sedation Management in PICU 
Authors 
Date of Publication 
Aim/Objective 
Research Question 
Design Method of data 
collection  
Population 
Size 
 
Results Implications & 
Recommendations 
Significance 
Jin et al. (2007). Efficacy of COMFORT in 
assessing optimal 
sedation in critically ill 
children requiring 
mechanical ventilation. 
Pre-test post-test 
intervention study. 
Prospective 
data=post 
intervention. 
Retrospective 
data for control 
group. 
Control n=20  
Intervention 
n=21 
Decrease in analgesics and sedatives, 
ventilation time 11.0 vs 12.5 days, LOS 
15.0 vs 19.5 days, Withdrawal 1 case vs 7 
cases, & length of sedation 8.0 vs 11.5 
days (all p<0.05) post intervention with 
protocol & COMFORT assessment. 
Optimal comfort score 17-
26.  
Recommend protocol-
based sedation with 
COMFORT scale may 
benefit children requiring 
mechanical ventilation.  
Cont NMB infusion for 9pts 
intervention group and 8 in 
control group. Huge 
differences unit practices. 
Ista et al. (2009). Study effects of sedation 
treatment protocol for 
PICU, and staff 
satisfaction assessed. 
Pre-test post-test 
intervention study 
and staff interview. 
Convenience 
sample of pts Staff 
opinion assessed 
by closed-ended 
survey. 
Pre-test n=27 
Post-test n=29 
More morphine (median 11.2 vs 
6.9mcg/kg p=0.004) & midazolam 
(median 112.8 vs 54mcg/kg p=0.001) used 
post guideline intro, more pts achieved 
adequate COMFORT scores, unable to 
conclude whether protocol improves 
sedation practice. 
Standardising sedation 
management and allowing 
nurses to adjust sedation 
themselves. 
Unable to conclude whether 
protocol improves sedation 
practice. 
AlexanAlexander et al. (2002). Evaluation of a sedation 
protocol for intubated 
critically ill children. 
Retrospective case 
study approach 
using purposive 
patient chart review 
and staff self-report 
survey. 
The time patients 
were on and off 
the sedation 
protocol were 
compared. Pt 
incidents were 
recorded as were 
procedures 
carried out. 
10 cases from 
18 patient 
episodes used 
in an earlier 
study, 
selection 
based on 
diagnosis and 
chart 
availability. 
Significantly higher amounts of fentanyl 
and midazolam given to patients while on 
the sedation protocol (p<0.05).  
Severe incidents (such as problematic 
behaviour) were more likely to occur 
while the patient was off the protocol. 
 
Positive feedback from unit nurses who 
found protocol easy to use and safe. 
Physician responses were mainly 
favourable, yet al.l were undecided 
whether the protocol should be used 
regularly.  
A patient with LOS in PICU 
152 days was excluded 
from data analysis. 
Lack of consistency; lack of 
clarity about when 
patients were ‘on’ or ‘off’ 
the protocol. 
No attempt to control for 
bias evident, data 
contamination highly 
possible.  
Design limited 
generalisability. 
A prospective study using a 
control group and a protocol 
group using a larger more 
representative sample 
would allow a more 
controlled evaluation of the 
study variables and enhance 
the generalisability of its 
findings. 
Popernack et al. 
(2004). 
To determine whether 
use of a standardised 
algorithm of goal 
directed sedation 
impacted the incidence 
of unplanned 
extubations in critically 
ill paediatric patients. 
Prospective 
observational study 
with historical 
controls.  
Post sedation 
algorithm 
introduction, 5 y 
of data were 
compared with 
rates of 
unplanned 
extubations pre-
algorithm. 
 
All ventilated 
patients 
admitted for 5 
years after 
introduction of 
the sedation 
algorithm. 
There was a significant decrease in 
unplanned extubations after the 
introduction of the sedation algorithm 
from 0.44-0.63 to 0-0.19 per 100 
intubated patient days (p<0.05). 
Use of the sedation 
algorithm resulted in a 
decreased number of 
unplanned extubations 
without increasing the 
length of PICU stay 
indicating patients were 
not being over sedated.  
Mandatory sedation 
algorithm for ventilated 
PICU patients safe and 
feasible. 
 Appendix 11: Studies Evaluating the Impact of a Changed Approach to Analgesia and Sedation Management in Adult 
ICU Settings 
Authors 
Date of 
Publication 
Aim/Objective 
Research Question 
Design Methodology  Population Size Results Implications & 
Recommendations 
Relevance to literature 
review  
Devlin et al. 
(1997). 
Evaluate effect of ICU 
sedation guidelines and 
pharmacist interventions 
on clinical outcomes and 
drug cost. 
Pre and post-
intervention study. 
Retrospective 
chart review and 
prospective data 
collection. 
2 groups of 50 
consecutive 
patients. 
No significant difference in ventilator 
weaning time (16h vs 18h, p>0.05). 
Sedation switched to lorazepam from 
midazolam, non-significant reduction in 
drug costs ($4514 vs $1152, p=0.081). 
Aim of patient sedation level; 
sleepy but rousable. 
Intermittent bolus rather than 
continuous benzodiazepine 
infusion. 
Recommend prospective RCT 
APACHE mean scores sign 
higher in post-guideline 
patients, not comparing 
appropriately matched 
groups. 
Brook et al. 
(1999). 
To determine the effect of 
a nursing-implemented 
sedation protocol on the 
duration of mechanical 
ventilation. 
RCT 
Protocol directed vs 
non-protocol 
directed sedation. 
Nursing directed 
protocol 
encouraging use of 
intermittent 
versus continuous 
sedation/analgesia 
infusion. 
Intervention group 
received daily 
interruption of 
sedation.  
Protocol-directed 
sedation group 
n=162 
Non-protocol-
directed-sedation 
group n=159 
The protocol-directed sedation group had 
significantly shorter duration of 
mechanical ventilation (median 55.9h vs. 
117h, p=0.008), shorter ICU LOS (5.7±5.9 
days vs. 7.5±6.5 days, p=0.013) and 
hospital LOS (14.0±17.3 days vs. 19.9±24.2 
days, p<0.001). Of those receiving 
continuous IV sedation (41.1%), those in 
the protocol-directed group had 
significantly shorter duration of 
continuous IV sedation (p=.003). Patients 
in the protocol-directed group also had a 
lower incidence of tracheostomy (6.2% vs. 
13.2%, p=0.038). 
The use of protocol directed 
sedation can reduce the 
duration of mechanical 
ventilation, the intensive care 
unit and hospital lengths of 
stay, and the need for 
tracheostomy among critically 
ill patients with acute 
respiratory failure.  
Single ICU site study, 
generalisability 
compromised.  
Incidence of unplanned 
extubations and VAP not 
assessed which are 
associated with 
inadequate and prolonged 
sedation respectively.  
Nursing compliance with 
protocol not measured.  
Gupta et al. 
(1999). 
Effect of sedation and 
agitation management 
guidelines on drug cost. 
Descriptive account 
of development, 
implementation and 
effect of guidelines.  
Prospective 
pharmacist 
intervention 
programme. 
Number of 
subjects not 
stated. Critically 
ill patients in a 
community 
hospital included.  
The result of guideline introduction is a 
reduction in cost of sedation and agitation 
of >$40,000 per year. 
Significant cost saving after 
sedation and analgesia 
guideline introduction. Focus 
not on patient specific 
outcomes.  
 
Bair et al. 
(2000). 
To determine physician 
and nurse adherence with 
sedation, analgesia and 
NMB guidelines in a 
medical ICU. 
Prospective cohort 
study 
Review of patient 
charts and ICU 
staff interviews 
100 patients 
included. 
29 nurses and 
doctors 
interviewed re 
attitudes and 
perceptions of 
guidelines.  
Majority of treatment regimens reviewed 
partially or fully adhered to guidelines 
Factors such as patient specific 
disease states, learning curve 
of physician as well as 
physician preferences for 
certain medications may have 
influenced adherence. 
Improving adherence to 
analgesia and sedation 
guidelines is essential to 
assess their effectiveness 
in improving clinical 
outcomes.  
 Maclaren et al. 
(2000). 
A prospective evaluation 
of empiric versus 
protocol-based sedation 
and analgesia.  
Prospective two 
phase study: 
empiric before; 
protocol after. 
Evidence-based 
sedation and 
analgesia protocol. 
158 mechanically 
ventilated ICU 
pts. 
Protocol group had less discomfort (11% 
vs 22 0.4% p<0.001); less pain (5.9% vs 
9.6%, p<0.05) lower hourly sedation cost 
($5.68 vs $7.69, p<0.01) trend for longer 
duration of sedation (122.7h vs88.0h, 
p<0.1) and longer duration of mechanical 
ventilation (61.6h vs39.1h, p0.13).  
Patients experienced less pain, 
however savings on drug costs 
may be negated with longer 
duration of ventilator 
dependence. 
Protocol adherence 
=83.7%. 
Mascia et al. 
(2000). 
To examine the 
pharmaco-economic 
impact of rational use 
guidelines on the 
provision of analgesia, 
sedation and 
neuromuscular blockade 
in intensive care.  
Prospective two-
phase study: 
baseline before/ 
guidelines after. 
Guidelines based 
on rational and 
cost-effective use 
of analgesics and 
sedatives. 
158 medical and 
surgical ICU 
patients. 
Guideline group had lower drug costs, 
shorter duration of mechanical ventilation 
(167h vs 317h), shorter ICU LOS (9.2d vs 
19.1d) shorter hospital LOS (19.1d vs 
34.4d)(p<0.05). 
Findings support the use of 
analgesia and sedation 
protocol. 
 
BrattebØ et al. 
(2002). 
To determine effect of a 
scoring system and 
protocol for sedation on 
duration of patient’s need 
for ventilator support in 
surgical ICU. 
Observation Study 
and 
ICU staff Audit. 
Sedation scoring 
and sedation 
protocol 
introduced. 
Baseline data 
from 147 
patients, pre-
intervention 
Post-intervention 
138 patients 
included.  
Mean ventilator time reduced, 7.4 to 5.3 
days after intervention, an 11% reduction 
in mean LOS cited. 
No p values reported. 
Specific and concise aims of 
project served to ensure its 
success. 
Dedicated project group and 
continuous follow up also 
important.  
Interprofessional collaboration 
and regular feedback to staff 
crucial.  
 
De Jonghe et 
al. (2005). 
Determine whether use of 
sedation algorithm 
improved tolerance to ICU 
environment and 
preserved consciousness 
in pts without acute brain 
injury. 
Before/After 
prospective 
controlled study. 
 
Control group; 
conventional 
management 
before 
intervention. 
After group; 
sedation and 
analgesia use 
guided by 
algorithm. 
Control group 
n=54 
Algorithm group 
n=48 
Algorithm resulted in shorter duration of 
mechanical ventilation (median 4.4 days vs 
10.3 days, p=0.014), shorter median PICU 
stay 8.0 days vs 15 days p=0.043, shorter 
median time to arousal; 2 vs 4 days 
p=0.006, reduced incidence of pressure 
sores and ventilator associated pneumonia 
(VAP) p=0.04, reduced mean daily 
cumulative doses of midazolam p=0.015. 
No significant differences in fentanyl usage 
or in rate of unplanned extubation were 
observed. 
Findings support use of 
algorithm based sedation as 
leads to reduced ventilator 
dependence, ICU stay, 
pressure sore and VAP 
incidence, less use of 
midazolam. Large studies using 
post-ICU memories and 
psychological status as primary 
outcomes recommended to 
evaluate sedation algorithms. 
Patient: Nurse ratios= 1:2 
or 3 
Analgesia and sedation 
management, largely 
physician directed. 
Adam et al. 
(2006).  
To evaluate impact of 
sedation management 
guideline on patient 
mortality, length of ICU 
and drug cost. 
Observation 24 
month prospective 
study. 
Control group pre-
guideline period; 
after group post-
guideline period. 
10 bedded 
multidisciplinary 
adult intensive 
care unit over 24 
month period. 
Length of ICU stay or mortality did not 
change significantly, a reduction in drug 
costs from 6285GBP to 3629GBP (p<0.001) 
was noted realising a cost saving of 
63,795GBP in 2y since guideline 
introduction.  
Guideline directed sedation 
significantly reduces sedative 
drug cost per day without 
detrimental effects on 
outcome or length of stay. 
 
Chanques et al. 
(2006).  
Impact of systematic 
evaluation of pain and 
agitation in an ICU. 
Prospective two 
phase study: control 
before/ protocol 
Protocol- 
emphasis on 
systemic 
230 MV medical 
surgical ICU 
patients. 
Protocol group had lower incidence of 
pain (42% vs 63%, p=0.002) lower 
incidence of agitation (12% vs 29%, 
Significant patient benefits 
associated with using validated 
tools to systematically assess 
 
 after. evaluation of pain 
and agitation. 
p=0.002) shorter duration of MV (65h vs 
120h, p<0.05) fewer nosocomial infections 
(8% vs 17%, p<0.05). 
pain and agitation- including 
reduced rate of nosocomial 
infection.  
Afessa et al. 
(2007). 
An evaluation of the 
impact of multiple 
evidence- based clinical 
practice protocols in a 
medical ICU. 
Retrospective 
cohort study. 
Four evidence 
based protocols 
introduced(lung 
protective 
strategy, protein C 
for sepsis, 
hyperglycaemia 
control and 
sedation/analgesia 
protocol). 
8,386 patients 
admitted to a 
medical ICU over 
5 years.  
Reduction in predicted mean mortality 
rates after introduction of protocols: The 
predicted mean mortality rates were 
20.7%, 21.1% and 21.8% with observed 
mortality rates of 19.3%, 18.0% and 16.9% 
during the pre-protocol, transitional and 
protocol periods respectively (p<0.05). The 
28-day ICU free days improved during the 
protocol period although this was limited 
to sicker patients and those who stayed in 
ICU longer.  
The introduction of multiple 
evidence-based protocols is 
associated with improved 
outcome in critically ill medical 
adults. 
Not possible to determine 
effects of each protocol 
individually.  
One study site; limited 
generalisability. 
Arabi et al. 
(2007). 
To examine impact of 
analgesia and sedation 
protocol. 
Before/after 
Prospective 
observational study. 
Patients allocated 
to goal directed 
protocol 
incorporating 
sedation scale, or 
standard practice 
(physician 
directed) on 
admission. 
Protocolised n= 
51,  
unprotocolised 
n=50 
Post 3 months 
Protocolised n= 
53,  
Un-protocolised 
n=53 
 
Significant reduction in the dose of 
fentanyl with protocol use (1964mcg vs 
1344 mcg, p=0.04). Sedation scores 
reflected lighter levels of sedation on days 
3 and 4 (p<0.05). 
Introduction of sedation 
protocol accompanied by 
multifaceted multidisciplinary 
programme effective in 
improving sedation practices. 
Teamwork essential in 
ensuring success of protocol.  
Limitation; Mono-centre 
study. Alternative pt 
allocation to protocol vs 
no protocol, possible 
contamination of data, 
high risk of bias.  
Jakob et al. 
(2007). 
To examine the effect of 
process optimisation  
including use of protocols 
for weaning sedation and 
mechanical ventilation on 
pt outcomes 
Observational study 
and Retrospective 
analysis 
Convenience 
sample of 3 
cohorts of 100 
mechanically 
ventilated pts  
Baseline 
group=pre 
intervention, 
implementation 
I= post change in 
ICU practices, 
Implementation 
II= post sedation 
and ventilation 
weaning protocol 
introduction 
>50% reduction in mortality within 27 
consecutive months (p=0.02). 
Shorter LOS (37 to 25h, p=0.049) and 
reduction in resource use. Shorter 
duration of ventilation for those requiring 
short-term respiratory support (median 
18h to 12h, p=0.046). 
Decrease in use of morphine (p=0.001) 
and midazolam (p=0.05). 
Increase in amount of propofol (p=0.05) 
and fentanyl (p=0.001) used. 
Larger study required to 
enhance generalisability. 
Cannot identify whether 
ventilation or sedation 
weaning protocols contributed 
to reported outcomes. 
Limitations include the 
retrospective design and 
the introduction of many 
simultaneous 
interventions. 
Quenot et al. 
(2007). 
To evaluate the effect of a 
nurse-implemented 
sedation protocol on the 
incidence of ventilator 
associated pneumonia in 
ICU 
Prospective 
before/after study. 
Before 
group=control. 
After group 
sedation managed 
using 
multidisciplinary 
developed 
guidelines. 
423 patients in 
medical ICU.  
 
Protocol group had reduced incidence of 
VAP (6% vs 15%, p=0.005), shorter median 
duration of MV (4.2d vs 8d, p=0.001) and 
reduced likelihood of failed extubation 
(6% vs 13%, p=0.01). 
Nurse-implemented sedation 
protocol demonstrated 
improved outcomes for ICU 
patients- reduced VAP, shorter 
MV duration and more often 
successful extubation. 
 
 Arias-Rivera et 
al. (2008). 
To evaluate the effect of a 
nursing-driven protocol of 
sedation on duration of 
intubation.  
Before-after 
prospective study. 
During the 
observation 
period, sedatives 
and analgesics 
were adjusted as 
per physicians’ 
orders. In the 
intervention phase 
sedatives and 
analgesics were 
adjusted by nurses 
as per sedation 
algorithm 
including a 
sedation scale. 
176 patients in 
the observation 
period and 189 
patients in the 
intervention 
period. 
There were no significant differences in 
the duration of intubation between the 
two periods (median 7 days for both 
groups, p>0.05). The probability of 
successful extubation was higher in the 
intervention period (log-rank 0.02). During 
the intervention period patients were 
more awake without significant difference 
in nursing workload. There was no 
significant decrease in total doses of 
analgesics and sedatives administered.  
The implementation of a 
nursing-driven protocol of 
sedation may improve the 
probability of successful 
extubation in a heterogeneous 
population of mechanically 
ventilated patients.  
Did not match patient 
groups. The observation 
period contained more 
patients with chronic 
obstructive airways 
disease, and fewer 
patients with congestive 
cardiac failure. 
There was a higher 
severity of illness score 
(SAPS) in the observation 
period.  
The baseline practice of 
sedation was inadequate. 
In the observation period 
almost half of the pts were 
oversedated, and only 36% 
in the optimal sedation 
range. Protocol allowed 
for better titration of 
sedation. 
Bennett (2008). To determine if protocol 
directed sedation reduced 
duration of mechanical 
ventilation in ICU. 
Blinded RCT. Usual practice vs 
nurse driven 
protocol directed 
sedation where 
specified 
medications 
administered to 
achieve sedation 
agitation scale 
(SAS) target. 
161 pts in control 
group vs 155 
patients in 
protocol group. 
No differences in duration of mechanical 
ventilation between standard and 
protocolised sedation groups (79h v 58h p 
0.78, <0.05), nor was there a difference in 
mortality or hospital or ICU length of stay.  
Protocol directed sedation was 
neither beneficial nor 
detrimental to ICU patients. 
Randomisation and 
blinding challenging in a 
mono-site study. Data 
contamination cannot be 
out-ruled. 
Bucknall et al. 
(2008). 
 
To compare protocol-
directed sedation 
management with non-
protocolised sedation 
practice in mechanically 
ventilated adults.  
Randomised 
controlled trial. 
Patients randomly 
assigned to 
receive sedation 
directed by formal 
guidelines or usual 
local clinical 
practice.  
Sedation protocol 
group n=153, 
Non-protocolised 
control group 
n=159. 
Median duration of mechanical ventilation 
was 79h in protocol group and 58h in the 
control group (p=0.2). 
Median ICU LOS was 94 in the protocol 
group and 88 in the control group 
(p=0.58).  
Hospital LOS was similar (median 13 days 
for both groups, p=0.97), as were number 
of unplanned self-extubations (p=0.61) 
and patients undergoing tracheostomy 
(p=0.64). 
Protocolised sedation was associated with 
a 22% decrease in the success of weaning 
from mechanical ventilation (p=0.07).   
This study provided no 
evidence of a substantial 
reduction in the duration of 
mechanical ventilation or ICU 
or hospital LOS using protocol 
directed sedation 
management. 
Suggested rationales for this is 
quality high-intensity nurse 
staffing assuming responsibility 
for many aspects of ventilatory 
practice. 
Mono-site study with both 
protocol and control group 
patients in the ICU at the 
same time. Data 
contamination strong 
possibility. Acknowledged 
study limitation that 
noncompliance with 
research protocol in this 
unblinded study was a 
possibility.  
Less use of propofol in the 
protocol group significant 
given that use of this drug 
was found to be 
 synonymous with shorter 
duration off mechanical 
ventilation.  
Marshall et al. 
(2008). 
To evaluate clinical 
pharmacist-enforced ICU 
sedation protocol. 
Before/after study. Before group; 
retrospective 
patients, After 
group ; 
prospective post 
protocol group 
156 mechanically 
ventilated pts 
Control n=78,  
Intervention 
n=78 matched 
groups. 
Duration of mechanical ventilation fell 
from 14 to 7.8days (p<0.001), there was 
also a significant reduction in ICU stay 
(15.8 to 9.9 days, p=0.001) and hospital 
length of stay (22.4 to 15.4 days, p=0.001) 
after the intervention. There were no 
significant differences in mortality, 
tracheostomy rate, incidence of 
unplanned extubation or requirement for 
restraint. 
Pharmacist interventions 
totalled 210, of these 91% 
were accepted. Stronger 
adherence to analgesia and 
sedation protocols resulted in 
shorter duration of mechanical 
ventilation and ICU and 
hospital length of stay. 
Utilising the skills of each 
member of the 
multidisciplinary team 
enhances chances of 
success of intervention. 
Robinson et al. 
(2008). 
The effect of an analgesia-
delirium-sedation 
protocol for critically ill 
trauma pts on ventilator 
days and hospital LOS. 
Retrospective 
review of 
pre=protocol 
(control group) and 
post-intervention 
(protocol) group. 
Intervention 
involved 
introduction of 
pain, agitation and 
delirium scales. 
143 pts included 
Control group 
n=61 
Protocol group 
n=58 
Mean duration of mechanical ventilation 
reduced in protocol group, 1.2 vs 3.2 days 
(p=0.027). The protocol group had more 
ventilator free days 26.4 vs 22.8 days 
(p=0.007). Median ICU LOS was 4.1 in the 
protocol group vs 5.9 days in the control 
(p=0.21), and median hospital LOS was 
reduced in protocol group 12 vs 18 days 
(p=0.036). Opioid equivalent and propofol 
use significantly less in protocol group 
(p<0.01). 
An objective assessment based 
analgesia-delirium-sedation 
protocol without daily 
interruption of medication 
infusion significantly reduced 
ventilator days and hospital 
LOS in critically ill trauma 
patients.  
 
Egerod et al. 
(2010). 
To examine effect of an 
analgo-sedation 
(analgesia based sedation) 
protocol for 
neurointensive care 
patients. 
A before-after 
interventional non-
randomised pilot 
study. 
Intervention 
involved 
introduction of 
analgo-sedation 
approach where 
primary goal is 
addressing pain. 
Observation 
phase n=106, 
intervention 
phase n=109 
Expected drop in use of sedatives, 
including propofol (p<0.001) and 
midazolam (p<0.001) increase in fentanyl 
(p<0.001) and remifentanyl (p=0.003) use. 
Patients selected for daily interruption of 
sedation woke up faster, estimates of pain 
free patients increased from 56.8% to 
82.7% (p<0.001). 
No change in duration of sedation and 
unplanned extubations.  
Protocol partially effective; 
some neuro-intensive patients 
might not benefit from 
protocolised practice. 
Recommend interdisciplinary 
effort to target issues such as 
oversedation and inadequate 
pain management. 
 
Awissi et al. 
(2012). 
To determine whether 
implementing a protocol 
for management of 
analgesia, sedation and 
delirium in the ICU would 
save costs. 
Prospective pre- 
and post protocol 
design used. 
Between 2 
periods; protocols 
for systematic 
management of 
sedation, 
analgesia and 
delirium 
implemented. 
Pre-protocol 
group n=604, 
post-protocol 
group n=610. 
The ICU length of stay shorter among post-
protocol patients (5.43vs6.39 p=0.004) as 
was duration of mechanical ventilation 
(5.95vs7.27 p<0.009). Incidence of 
delirium remained the same. Sedation, 
agitation and pain scores of patients were 
more often within target after protocol. 
Average cost saving of $932.74 per 
hospitalisation. 
Establishing protocols for 
nurse-driven management of 
sedation, analgesia and 
delirium is a cost-effective 
practice and is synonymous 
with savings of nearly $1,000 
per hospitalisation.  
 
 Appendix 12: Studies Evaluating the Impact of Sedation Interruption in Adult ICU Settings 
Authors 
Date of 
Publication 
Aim/Objective 
Research Question 
Design Methodology  Population 
Size 
Results Implications & 
Recommendations 
Significance 
Anifantaki et 
al. (2009) 
Evaluation of nurse led 
daily interruption of 
sedation infusions 
RCT Protocolised patients had 
sedative infusions 
suspended once daily, 
control group received 
standard sedation 
management. 
Intervention 
group n=49  
Control 
group n=48 
No statistically significant differences in 
variables. Median duration of mechanical 
ventilation 8.7 days before vs 7.7 days after 
(p=0.7). Median length of ICU stay 14 vs 12 
days (p=0.5). 
Nursing implemented 
protocol of daily interruption 
of sedation infusions was 
neither beneficial nor harmful 
to patients 
High nurse patient ratio 
1:2 to 1:2.5. 
Also potential for bias 
acknowledged 
 as practice potentially 
influenced by 
awareness of ongoing 
study. 
Kress et al. 
(1996) 
Evaluating midazolam 
versus propofol, all 
patients treated with daily 
interruption of sedation.  
Prospective 
randomised 
blinded 
comparison. 
Midazolam group and daily 
interruption of sedation 
versus propofol group and 
daily interruption of 
sedation 
73 
mechanically 
ventilated 
medical ICU 
patients. 
Median ventilation time in sedation 
interruption group 4.9 days vs 7.3 days for 
control group. No differences in median wake 
up times, high degree of correlation between 
blinded and unblended assessments of level of 
sedation. Faster onset of sedation with 
midazolam. 
First reports of daily 
interruption of sedation, no 
adverse effects reported.  
 
Kress et al. 
(2000). 
An evaluation of daily 
interruption of sedation 
on length of ventilator 
dependence and ICU stay. 
Prospective, 
randomised, 
blinded 
comparison. 
Intervention group: sedation 
infusions suspended once 
daily until pt awake, Control 
group, standard 
management.  
Intervention 
group n=68,   
control 
group n=60. 
Duration of ventilation in intervention group 
2.4 days shorter than control group (p=0.004), 
and ICU LOS 3.5 days shorter in intervention 
group (p=0.02). Hospital LOS did not differ 
(p=0.19). Morphine and midazolam total doses 
lower in intervention group. No difference in 
propofol doses. Intervention group had more 
awake days. Over twice as many pts in control 
group never awakened from sedation. Less 
than half the no. of diagnostic tests to assess 
changes in mental status done in intervention 
group. No Significant differences in no. of 
adverse events. 
Daily interruption of sedation 
infusion is a practical, cost-
effective intervention that can 
readily be performed in the 
ICU. Results show this 
strategy provides acceptable 
sedation, while minimising 
adverse effects.  
Assessment of neurologic 
status possible while sedation 
infusion is stopped. 
A follow up study 
demonstrated daily 
interruption group had 
reduced symptoms of 
post-traumatic stress 
disorder (Kress et al. 
2003). 
Mehta et al. 
(2006). 
To determine the 
feasibility of a study into 
whether adults managed 
with both protocolised 
sedation (PS)and daily 
interruption (DI)of 
sedation have a shorter 
duration of mechanical 
ventilation than those 
managed with 
protocolised sedation.  
Prospective 
randomised 
concealed, 
unblended, 
multi-centre 
pilot trial. 
Patients randomised to PS  
alone or PS with DI. 
Implementation of PS by 
bedside nurses and linked to 
targeted sedation score. The 
PS and DI group had 
sedation infusions 
interrupted daily until they 
awoke.   
PS group n= 
33 
PS with DI 
group n=32. 
Nurse and respiratory therapist workload was 
similar in both groups.  
No differences in duration of mechanical 
ventilation (p=0.79), ICU (p=0.63) and hospital 
LOS (p=0.34) or mortality rates (p=0.8) 
between the two groups. 
The PS and DI group received significantly less 
midazolam (median 375mcg vs 152mcg, 
p=0.03) than the PS group alone.  
The rate of self-extubation was 9% in both 
groups.  
This pilot trial guided the 
design of future multicentre 
trial. Eligibility criteria 
modified to enhance patient 
safety, generalisability and 
accrual. 
One pt in the PS and DI 
group suffered an 
acute coronary 
syndrome during 
sedation interruption. 
This pt subsequently 
died as a result of 
cardiogenic shock. 
 Schweikert et 
al. (2004). 
To determine whether 
daily interruption of 
sedation reduces the 
incidence of complications 
commonly associated with 
critical illness. 
Blinded 
retrospective 
chart review. 
Evaluation of database from 
previous trial of sedation 
interruption to compare 
incidence of complications 
developed in intervention vs 
protocol group. 
 
Intervention 
group n=66, 
Control 
group n=60. 
Patients undergoing daily interruption of 
sedation infusions experienced 13 (2.8%) 
complications vs. 26 (6.2%) in those subjected 
to conventional sedation techniques (p=0.04).  
Daily interruption of sedative 
infusions in mechanically 
ventilated patients reduces 
ICU LOS and decreases the 
incidence of complications 
associated with prolonged 
intubation and mechanical 
ventilation.  
 
Carson et al. 
(2006). 
To determine the efficacy 
of intermittent lorazepam 
vs continuous propofol inf. 
Two site study: University 
of North Carolina and 
University of Chicago, 
Illinois, USA. 
Prospective  RCT  Intermittent lorazepam vs. 
Continuous infusion of 
propofol. Daily interruption 
of sedation was performed 
in both groups. 
132 
mechanically 
ventilated 
medical ICU 
patients. 
Propofol group had shorter duration of 
mechanical ventilation (5.8 vs 8.4days, p=0.04) 
and showed a trend for increased ventilator 
free survival (18.5 vs 10.2 days, p=0.06). 
Evidence supports use of 
propofol infusion for shorter 
duration of MV over 
intermittent lorazepam. 
 
Girard et al. 
(2008). 
Efficacy and safety of a 
paired sedation and 
ventilator weaning 
protocol for pts in ICU. 
Prospective  RCT Patients randomly assigned 
to protocolised 
(spontaneous awakening 
and DIS) group or usual care 
plus daily spontaneous 
breathing trial. 
Four tertiary 
care 
hospitals in 
US, 336 ICU 
patients 
Patients in the protocol group had shorter 
duration of mechanical ventilation (11.6 vs 
14.7days, p=0.02), had shorter duration of stay 
in ICU (9.1 vs 12.9 days, p=0.01), had less 
episodes of self extubation (6 vs 16, p=0.03) 
and had reduced mortality (p=0.01). Re-
intubation rates were the same for both 
groups. 
Daily spontaneous awakening 
trials  (DIS) and combined 
with daily spontaneous 
breathing trials results in 
better outcomes for ICU 
patients than standardised 
care. 
 
 
 
 
 
 
 
 
 
 
 Appendix 13: Intraclass Correlation (ICC) of VAS/NRS Scores 
 Number of Raters Average ICC Single 
1 N=5 0.92 0.69 
2 N=10 0.98 0.84 
3 N=3 0.96 0.90 
4 N=4 0.96 0.86 
5 N=3 0.88 0.71 
6 N=3 0.98 0.94 
7 N=3 0.95 0.86 
8 N=8 0.97 0.83 
9 N=4 0.98 0.93 
10 N=3 0.98 0.94 
11 N=5 0.99 0.93 
12 N=3 0.99 0.97 
13 N=4 0.97 0.90 
14 N=4 0.97 0.87 
15 N=6 0.99 0.96 
16 N=6 0.99 0.94 
17 N=2 0.96 0.92 
18 N=4 0.97 0.88 
19 N=8 0.997 0.98 
20 N=5 0.99 0.95 
21 N=7 0.98 0.88 
22 N=7 0.99 0.94 
23 N=7 0.99 0.97 
24 N=9 0.91 0.54 
25 N=7 0.99 0.96 
26 N=9 0.90 0.50 
27 N=8 0.85 0.42 
28 N=12 0.94 0.56 
29 N=3 0.96 0.88 
30 N=3 0.99 0.96 
31 N=11 0.99 0.88 
32 N=4 0.96 0.87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix 14: Linearly Weighted Kappa of COMFORT Scores from 
Staff Training 
 
N Valid 147  
 Missing 0  
 Mean 0.96  
 Median 0.92  
 Mode 0.96  
 
Std. 
Deviation 0.053  
 Minimum 0.64  
 Maximum 1  
Percentiles 25 0.88  
 50 0.92  
 75 0.96  
 
 
 
* Represents a subject who obtained a Cohen’s Kappa score of 0.64 from COMFORT 
training scores. Training was repeated and a greater level of agreement was achieved. 
 
 Appendix 15: Minutes of Analgesia and Sedation Committee 
Meetings 
6th April 2010 Analgesia and Sedation Committee Meeting . 
Attendees: 
Jacinta McGinley, Tracey Wall, Eileen Butler, Eilis Gilsenan, Linda O’ Donnell, Claire 
Magner. 
TW explained to JMG that we need some direction currently regarding sedation and 
analgesia in PICU, both from a nursing and anaesthetic perspective.  
CM presented information pertaining to pain and sedation assessment tools currently 
available for use clinically. There is some familiarity with FLACC and CRIES; neither are 
validated in the ventilated PICU patient, therefore not suitable for our guidelines. PIPP 
performs well in validation studies, but it is only suitable for neonates. COMFORT with 
incorporated VAS meets the criteria for assessing distress; both pain and sedation are 
therefore addressed. It is suitable for premature neonates from 28 weeks gestation, 
and can be used in children up to 3 years of age. It is the preverbal and ventilated 
patients that pose the greatest challenge for assessment of distress- therefore the 
COMFORT tool was universally endorsed as the tool we should adopt. JMG feels the 
COMFORT scale should form the cornerstone of our analgesia and sedation guidelines. 
It will facilitate a targeted approach to managing analgesia and sedation and improve 
communication as medical staff will be unable to ignore high scores. 
A treatment algorithm is required. LOD used the sickle cell protocol as a good example 
of this. EB and CM will review similar formats for pain and analgesia. 
EG and LOD raised concern regarding patients returning from OT without morphine 
infusions connected. JMG confirmed that this is a critical incident and warrants 
reporting. JMG highlighted the need for loading dose of morphine prior to surgical 
incision in OT. LOD proposed that PICU nurses would be happier to run morphine 
infusion at a reasonably low level once morphine boluses are prescribed.  
The concentration of morphine infusions was discussed. Traditionally 40mck/kg per ml 
was used as it was useful for fluid restricted patients. However, we are now seeing 
cases of 20mcg/kg per ml used. This makes nurses more aware at the bedside of the 
amount of morphine being administered, especially in cases of high infusion rates.  
EB confirmed morphine boluses should be prescribed on the prn section of the drug 
kardex, TW suggested they should be prescribed when the inotropes are being 
prescribed.  
Proposed Sedation Protocol for Post Op Cardiac patients 
Morphine Loading dose in OT. 
 On return to PICU morphine should be infusing at: 
 max 40mcg/kg/hr for non-neonates 
 max 20mcg/kg/hr for neonates 
Morphine bolus prescribed in drug kardex. 
COMFORT Score at 2 hours: 
COMFORT Score <12; Wean morphine infusion by 10% 
COMFORT Score 12-14; Leave morphine rate unchanged. Reassess in 2H 
COMFORT Score >17; Administer a bolus of morphine. Reassess within the hour. If 
ineffective r/v by anaesthetist. 
At time of COMFORT score, assess VAS also. If COMFORT high but VAS low- sedation is 
the issue. PRN chloral Hydrate. Midazolam not always suitable.  
Patients may have regular paracetamol and NSAID if no contraindication. Ensure urea 
and creatinine results are within normal range.  
LOD proposed some patients, e.g. those with chest drains insitu may have a 
requirement for background/regular analgesia. JMG acknowledged some groups e.g. 
Fontans have a significant analgesia requirement. EB suggested transfer to the ward 
on prn oramorph. TW felt that depending on ward activity, patients may not receive 
any oramorph.  
CM proposed staff need to be aware of withdrawal symptoms particularly if patient on 
morphine infusion for ≥5 days. It was agreed that issue of withdrawal should be 
incorporated into protocol, however LOD felt introducing a withdrawal scale at this 
point may not be a good idea.  
EG and LOD acknowledged the existence of a culture of routine chloral administration. 
EB suggested that melatonin could be introduced in order to establish a day/night 
routine for patients. 
TW proposed that we roll out the new PICU sedation protocol in PICU floor 2 initially. 
EB will have a treatment algorithm ready for this date. Staff training on the COMFORT 
Scale must reach all 130 staff. Core group identified who will train other staff 
members. Training DVD to be used as a refresher. 
CM plans to commence staff audit by next week to establish current satisfaction with 
sedation management in PICU and receptiveness to change. Patient charts will be 
audited also to determine how much analgesia and sedation patients are receiving so 
comparisons can be made after protocol introduction.  
DONM: 5th May 2010.   
 5th May 2010 Analgesia and Sedation Committee Meeting.  
Attendees: 
Jacinta McGinley, Tracey Wall, Eileen Butler, Eileen Tiernan, Caroline Kelly, Claire 
Magner. 
Apologies:  
Margo Byrne 
Agenda: 
Review of proposed sedation/analgesia algorithm and guidelines. 
Feedback from staff sedation/analgesia audit. 
Plan for progression. 
Discussion: 
EB circulated pain and sedation guidelines that we have developed. These guidelines 
incorporate an algorithm to facilitate a consistent stepwise approach to analgesia and 
sedation management. The COMFORT scale forms the cornerstone of the guidelines. 
The guidelines were well received by the group and reflect a huge amount of work. CM 
queried whether it should be made explicit that chloral is not necessary for patients 
every 6 hours. JMG advised rewording around this to “CONSIDER” chloral, thereby not 
encouraging its routine use 6 hourly. CK forwarded that IV paracetamol was 
encouraged by Monique Van Dijk on her visit, but similar support for IV paracetamol is 
not reflected in the clinical area. CM confirmed that early results of clinical trials 
comparing IV morphine and IV paracetamol support IV paracetamol’s effectiveness- 
CM to source supporting research results. 
JMG confirmed weaning dosages to be used in new protocol. 
CK expressed concern regarding the inappropriate use of NMB agents. They should be 
used where a patient is difficult to ventilate NOT difficult to sedate. JMG proposed 
NMB’s should be used under the direction of the Consultant Anaesthetist on call.  
Regarding clonidine- JMG feels that this should be used as a rescue and not a routine 
prescription. In terms of weaning morphine; IV morphine tends to be weaned off more 
quickly than oramorph. If pt goes to ward on oramorph, weaning may be prolonged.  
EB raised the issue of withdrawal symptoms. It was universally agreed that there is no 
visible withdrawal scale in PICU. JMG favours the Sophia Observation Scale (SOS). This 
will have to be incorporated into the sedation policy so that those on morphine or 
midazolam infusions ≥ 5 days will be monitored for signs and symptoms of 
benzodiazepine or opiate withdrawal.  
 CM fed back preliminary findings from staff audit. So far there has been a 35% 
response rate. There is overwhelming dissatisfaction with our current pain and 
sedation management strategy amongst nurses and doctors. There is strong support 
for a new sedation protocol that incorporates a pain/sedation assessment tool. Many 
nurses feel that the support and involvement of PICU doctors is crucial to the success 
of this new protocol. Many doctors feel that nurses are not keen to wean infusions of 
analgesia. Almost all of surveyed nurses felt that inconsistency at consultant level is a 
major issue for pain and sedation in the PICU.  
Regarding the COMFORT tool, 50 nurses have been trained on using it. JMG will ensure 
that her medical colleagues are familiar with the tool. ET advised that 75% of staff 
need to be trained to maximise chances of its success. EB proposed a “train the 
trainer” strategy to help with getting staff trained up in time for protocol rollout. CK 
“volunteered” to train staff on night duty if feasible. 
Tasks: 
 Continue with COMFORT training. Almost 100 staff still require training.  CM, 
CK and Education Team. 
 Minor amendments to guidelines to be made, send updated version to Nurse 
Practice Committee for review.      
 EB and CM. 
 Once approval from NPC obtained; incorporate guidelines into the Pain Resource 
Folder. Summary sheets to be laminated and inserted into every bedside folder.
 CM. 
 Continue to raise awareness of change in practice and facilitate COMFORT 
training. All group. 
DONM: 14th September. Venue to be confirmed. 
 
 
 
 
 
 
 
 
 
 14th Sept 2010 Analgesia and Sedation Committee Meeting.  
Attendees: 
Jacinta McGinley, Tracey Wall, Eileen Butler, Eileen Tiernan, Caroline Kelly, Claire 
Magner. 
Apologies:  
Margo Byrne 
Agenda: 
 Review of previous minutes. 
 Update on staff training  
 Plan for progression. 
* This meeting was adjourned due to a cardiac arrest on the unit.  
DONM 9th Dec 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
09th December 2010 Analgesia and Sedation Committee 
Meeting. 
Attendees: Claire Magner, Tracey Wall, Eileen Tiernan, Eileen Butler, Christine Smith, 
Bernie Gallagher, Ellie Brennan, Lorna Redmond, Cormac Breatnach. 
Apologies: Jacinta McGinley 
Minutes: 
Current Position: 
CM welcomed CB to the committee and gave a brief background and rationale for the 
development of the guidelines. Feedback on the compliance with the guidelines was 
given, this remains an issue at all levels.  
TW proposed that if individuals conform with the guidelines from the outset, 
continuance of this practice is more likely. ET confirmed that the guidelines have good 
utility in practice, and have proved useful at the bedspace. BG forwarded that in 
practice, patients returning from OT in pain still occurs, and recounted an example.  
CB queried whether there is consensus among the consultant group regarding the 
guidelines. Long-standing practices exist and changing practice may not be feasible. 
TW forwarded that the patient and what is best for them is our primary concern.  
Suggested Solutions: 
CB proposed the use of “pump sheets” which would have the patient specific doses of 
analgesia and sedation written pre-operatively. EB highlighted the danger of having 
multiple drug kardex’s in circulation. LR suggested that the anaesthetist could 
prescribe post-op analgesia during the pre-op patient visit. CB forwarded that we have 
limited influence of OT practices, if we are compliant with the guidelines within the 
confines of the PICU, there is a good chance of it’s success. CS reinforced the 
importance of educating the new PICU Dr’s in January about the guidelines. This was 
universally endorsed. Instruction on the COMFORT tool and the significance of scores 
must be included also. CM proposed that the profile of pain assessment must be 
maintained at a high level. COMFORT scores must be included during handovers/ward 
rounds.  
CB proposed “Nurse and Dr. signout” where unit Dr’s perform a unit walkaround to 
bedspaces to discuss issues including pain each morning. Each evening the bedside 
nurse would provide a brief presentation of the patient and relevant issues.  This 
suggestion was well received by the group.  
Further Rollout of Guidelines: 
 EB recounted how guidelines for post-op cardiac group less complex than non-surgical 
patients as they are less homogenous group. CB offered advice re analgesic options to 
consider for this population, the key issue is ensuring COMFORT and pain scores are 
effectively and routinely done.  
CM highlighted that even though it is the discretion of individual PICU’s to determine 
cutoff scores for COMFORT, higher scores are tolerated in non-surgical patients. It was 
universally agreed to maintain the cutoff of 17- above which pain or sedation is an 
issue in our PICU’s for all patients.  
Plan: 
 CB to speak to JM re pre-PICU pt experience 
 Access to new PICU Doctors in January to highlight pain assessment and 
guidelines, TW,CM, EB.  
 Adherence to guidelines once patient in PICU, bolus analgesia if required pre 
decrease in dose. 
 Continued endorsement of routine pain assessment.  All group.  
 Titrate analgesia/ sedation to COMFORT score. 
 Communication of poor patient experience regarding pain back to individual 
responsible. 
 Consider nurse & Dr signout/ ward walkaround, CB, TW. 
 
Thank you to all for attendance and input, 
Next meeting 25th Jan 2011, 10.30 am. 
 
 
 
 
 
 
 
 
 
 
 
 
 25th Jan 2011 Analgesia and Sedation Committee Meeting. 
 
In Attendance: 
Kathryn McD, Cormac B, Eileen Butler, Bernie G, Tracey W, Eileen Tiernan, Eilis G, 
Barbara M, Christine S, Stephanie L, Lorraine P, Yvonne G, Claire M, Cathy McM, 
Jacinta M, Elisabeth G, Edna de T, Suni J, Ellie B, Brenda F, Julie K, Gill O’ C. 
Apologies: Caroline Kelly, Catriona Dee, Janice Irwin.  
1. Update given by CM on background to Committee, purpose and progress to date. 
Dangers of excessive morphine highlighted as morphine clearance delayed ventilated 
neonate, also premature neonates particularly sensitive to side effects of opioids.  
Cases presented and discussion of same. One child had open sternum, this is not 
adequate justification for administering elevated doses of morphine as per JMcG. 
Compliance with performing COMFORT scores variable. Prompting from shift leader 
very effective, connection not often being made between acceptable COMFORT score 
and reducing morphine infusion rate. Bedside nurse has huge autonomy with weaning 
morphine infusions, we may be missing a valuable window of opportunity to wean if 
we are not proactive. 
2. GOC asked if morphine boluses are prescribed for post-op patients. The general 
consensus was that no, morphine boluses are not routinely prescribed. Morphine 
loading not being given in OT is still an issue, hence patients are returning to unit on 
high rates. JMG proposed that if COMFORT scores are elevated when child returns 
from OT, a morphine bolus can be given in PICU as a once off. The rate can then be 
reduced to an acceptable level (0-20mcgs for neonate, 0-40 for child) and boluses 
given as indicated by COMFORT score.  
3. There was a general consensus that bolus dosed are inadequate. Morphine loading 
and bolus doses will be reviewed by EB and CMM and guidelines changed accordingly. 
To ensure safety, a maximum of 2 boluses will only be permitted before anaesthetic 
review.  This will be discussed with the Registrars by CMM, the education team and 
CM will outline new changes to bedside nurses. 
4. EG expressed concern that PICU patients were receiving inadequate doses of chloral 
hydrate, and then requiring IV midazolam boluses and subsequently fluid boluses for 
hypotension. EB forwarded that in the past oversedation was occurring with routine 
chloral use. JMG stressed that vigilance with IV midazolam is warranted. It was 
confirmed by CMM that the dose of chloral should be linked to the COMFORT score. If 
25mg/kg is not sufficient to produce a satisfactory score then 50mg/kg may be 
necessary.  
 5. TW outlines how rounding will commence each evening from 4-4.30pm. This will 
give bedside nurse opportunity to provide a brief handover on their patient. The 
COMFORT score and aim of sedation will be included.  
6. GOC stated that if a patient who has had prolonged morphine therapy is leaving the 
unit, she must be informed so that follow-up and weaning occurs. We have a number 
of patients who are at significant risk of withdrawal syndrome. Vigilance is required for 
symptoms. Appropriate withdrawal assessment tool must be decided upon- likely to 
adopt the tool used by GOS as appears to have good clinical utility.  
A structured approach to weaning morphine was endorsed by EB: e.g. reduce by 10% 
of original dose daily if >7 days tx. JMG expressed concern that many cases are going 
to ward on Oramorph. This is unnecessary as morphine can often be weaned 
completely off if short duration of therapy. GOC also pointed out that verbal self 
report is the gold standard of pain assessment if the patient is verbal and not 
intubated.  
 
Summary: 
 Post-Op Morphine loading in PICU if not given in OT in addition to ↑COMFORT 
scores. 
 Adjust loading and bolus doses of morphine on algorithm. CMM & EB. 
 Reinforce morphine loading/bolus with Registrars. CMM  
 Use Comfort scores to guide analgesia and sedation management. To be 
reinforced by ED Team and CM. 
 Approve validated withdrawal assessment tool for PICU use. GOC, CM. 
 COMFORT and aim of sedation at evening rounding. CB 
 F/u with GOC for patients leaving unit who have had prolonged morphine inf.  
 Vigilance with IV midazolam, the dose of chloral should be linked to the 
COMFORT score. 
 
 
 
DONM 8th March 2011.  
 
 
 
 
 
 
 8th March 2011 Analgesia and Sedation Committee meeting.  
Attendees: Tracey Wall, Jacinta McGinley, Elaine O’ Rourke, Joanna Breen, Marie 
Lavelle, Janice Irwin, Yvonne Doyle, Eileen Butler, Eileen Tiernan, Claire Magner, 
Stephanie Lawlor, Barbara McManus, Annie McLoughlin, Gill O’ Callaghan, Dermot 
Doherty, Mary Vinola, Moninne Howlett. 
Apologies: Cormac Breatnach, Cathy McMahon. 
Minutes. 
1. Overall improvements in individual patient pain and sedation assessments are being 
made. The dangers of over and under sedation/analgesia are now more widely 
recognised. However in some cases morphine infusions are not being weaned despite 
COMFORT scores indicating oversedation.  Abrupt cessation of infusions has also 
occurred. Inappropriate morphine boluses have been given on 3 occasions (EB to 
clarify boluses in amended sedation guidelines). A further scenario was presented by 
CM where a 2nd half dose of midaz caused profound hypotension in a post-op pt, and a 
lack of a viable alternative IV sedative posed a significant challenge for the bedside 
nurse. 
2. In considering alternative analgesia, JM and DD endorse hydromorphone, 
particularly if pt not responding to opiates. Rotating agents is practiced in some other 
centres. Acknowledging that we are at times limited when faced with a pt requiring 
sedation rather than analgesia and where midaz is not suitable, DD proposed 
dexmedetomidine as an option. This has been useful in certain scenarios i.e. morphine 
anaphylaxis or when other sedatives are ineffective. It can decrease HR although 
without altering cardiac index, and causes less hypotension than clonidine. It is 
expensive, EB will look into this issue.  
 
3. Regarding pts going to ward, JMG clarified if no chest drains insitu, then oral 
analgesia should suffice. But if chest drains insitu, taking into account the patients age, 
weight and number of drains; oramorph prn is suitable, and should be reviewed after 
24h. AML reported that recently patients are not receiving IV paracetamol as there 
was a misunderstanding regarding concerns about cost which was clarified by JMG. 
There is an increased requirement for Anaesthetic Reg’s to be reminded to prescribe 
morphine boluses, ET proposed that reinforcement of this is required at every level. 
 
4. Regarding assessing withdrawal assessment, we had considered using the same tool 
as GOS, which TSH have adopted, however this has been modified, has ambiguous 
terminology and has no evidence of reliability or validity. The SOS (Sophia Observation 
Scale) was developed specifically for PICU and is promising in terms of its clinical 
utility. It has performed well in testing so far. GOC will incorporate teaching on 
withdrawal in pain sessions. 
 
5. Prof Monique van Dijk from Rotterdam will be in OLCHC from 13th to 15th April. She 
will deliver a teaching session on “Withdrawal Syndromes and Paediatric Delirium” on 
14th April from 2-3pm in Lecture Room 2. All are welcome to attend. Incidentally our 
next sedation committee will be earlier on the same day at 11am.   
DONM: 14th April 2011 
 14th April Analgesia and Sedation Committee Meeting. 
In Attendance: Prof Seamus Cowman, Cathy McMahon, Monique van Dijk, TW, Bram 
Valkenburg, Cormac Breatnach, Yvonne Doyle, Lorraine Percy, Stephanie Lawlor, Julie 
Kenneally, Christine Smith, Barbara McManus, Annie McLoughlin, Gill O’Callaghan, 
Catherine Connolly, Eileen Butler, Caroline Nolan. Apologies; Jacinta McGinley. 
1. Overview of minutes from last meeting. Some practice remains inconsistent. 
Reinforcement of making a link between COMFORT score and opportunity for 
weaning analgesia/sedation at the bedside required.  
2. Use of alternative agents must be approached in a structured manner, i.e. not 
over a weekend with an unfamiliar drug and without appropriate knowledge 
and support. CB proposed that we optimise use of the agents we use on a 
habitual basis, our fall back drug must be an agent that is familiar to staff. 
Agents such as dexmedetomidine although endorsed in many centres and 
research papers, remain without comprehensive studies in to their safety in 
children.  Caution is therefore warranted. 
3. CM presented a case scenario where a post-op neonate received an excessive 
infusion rate of morphine for a prolonged period despite COMFORT Scores 
amenable to weaning. CN proposed that patients continue to return from OT 
on high rates of morphine, due to lack of/inadequate loading and high 
morphine infusion rate to compensate. This is in conflict to guidelines. CB 
forwarded that we cannot control what happens in OT, however morphine 
loading could be included on pink sheets with morphine infusion prescription. 
In addition getting morphine boluses prescribed is often problematic. CB to 
reinforce with Anaes Reg’s. Practice has changed in relation to handing over 
OT patients, it remains to be seen if this impacts communication regarding 
agents given in OT.   
4. A comprehensive approach to weaning analgesia and sedation is required. 
GOC confirmed that practice remains variable. MvD explained how the SOS 
withdrawal assessment tool is used. There has been consensus that this tool is 
suitable for use in our units. Bedside education on using this tool is needed. 
Any patient who has had an infusion of opioid or benzodiazepine for ≥5 days 
must have SOS scores done. This will promote vigilance regarding withdrawal 
syndrome which is currently a significant issue. 
 
DONM: Wed 25th May PICU Floor 1 
Tasks to be Addressed 
 Are we changing practice to prescribing morphine loading on pink sheets 
with infusion? CM to clarify with CB. 
 Adjust morphine bolus doses on stated in guidelines. EB, CB, CB, CMM.  
 Adjust guidelines to state “Wean Analgesia+/-Sedation if COMFORT 12-17. 
CM, EB 
 Reinforce at bedside link between COMFORT score and opportunity to 
wean analgesic/sedative infusion. Shift Leaders/Education Team. 
 Ensure Anaes Reg’s are aware morphine boluses + adjuncts must be 
prescribed. CMM and CB 
 Introduce the SOS. Teaching of staff required. TW, Education team, CM  
 8th June 2011 Analgesia and Sedation Committee Meeting.  
 
In Attendance: Yvonne Doyle, Cathy McMahon, Caroline Nolan, Jacinta McGinley, 
Janice Irwin, Stephanie Lawlor, Lorraine Percy, Eileen Butler, Moninne Howlett, Claire 
Magner. 
Apologies: Tracey Wall, Gill O’ Callaghan, Caroline Kelly, Christine Smith, Anne Rynne. 
Minutes: 
1) Feedback given from PICU meeting in Liverpool, where nursing subgroup 
completed an audit on analgesia and sedation practices in UK and Irish PICUs. 
(See attached document). One quarter of PICUs audited do not routinely 
assess pain, three quarters do not have PICU specific analgesia and sedation 
guidelines and many units do not use an appropriate tool to measure patient 
distress. Getting on top of analgesia, sedation and withdrawal issues in PICU 
OLCHC remains a work in progress, but we are further along than many other 
PICU’s. 
2) Review of previous minutes; it was universally agreed that guideline bolus 
doses of morphine are two low. JMG, EB and CMM agreed a more acceptable 
bolus dose. Guidelines and summary sheets will be amended by EB and 
summary sheets in patient bedside notes changed by CM. These will be placed 
in a highly visible location to aid with prescribing. Please note this change and 
raise awareness among bedside nurses and prescribing doctors.  
3) Case scenarios;  
 
Pt 1 had rapid weaning of IV morphine despite increasing COMFORT scores. In 
addition, no morphine boluses were px for this patient nor morphine loading 
in OT. All acknowledged that once pts arrive in PICU- morphine loading (of 50-
100mcgs morphine child<40k) as per guidelines, if loading has not occurred in 
OT. The morphine inf rate can then be reduced to 40mcgs and boluses given as 
required. 
 
Scenario 2 related to a post CDH rep who had delayed closure of abdomen 
wound on unit. Excessive inf rate of morphine (80mcgs/kg/hr) –prescription 
only for 40mcgs max. No regular COMFORT scores done. Distress scores must 
be done regularly particularly for patients on morphine infusions and who 
have strong analgesic requirements. Guidelines may not work for all patients, 
but infusion rates set must not be beyond prescription limits.  
Patient 3 post-op complex cardiac. Patient on 40mcgs for 19h. Boluses of 
morphine, midaz and vecuronium given. COMFORT scores stable. Unstable 
post-op with blood products+++. No weaning of morphine occurred which was 
universally endorsed. In such an unstable post-op case appropriate action was 
taken. In this case the aim of sedation is to maintain COMFORT 10-12 AND VAS 
<4. 
 4) The issue of withdrawal was discussed. Many long-termers in PICU1- a team 
approach is vital in devising and managing weaning strategy. Weaning can 
sometimes be overly rapid due to bed pressures. Ensure all team aware of 
weaning plan and handed over effectively. GOC, CM and Education Team to 
discuss strategy for teaching use of SOS withdrawal tool at bedside. SL 
proposed adding “Analgo-sedative weaning considered?” to emergency 
checklist as a prompt. This was universally endorsed as a bedside prompt, 
feedback is welcome regarding this. JI highlighted that confidence with 
weaning also comes with experience. JMG highlighted importance of mapping 
history of agents used and weaning record. It is a multidisciplinary role- 
nursing, medical and pharmacy. Having a port of call for the bedside nurse is 
crucial, and a named individual coordinating the process. Acknowledging the 
enormous workload of the Acute Pain CNS; referrals from nurses are accepted, 
if withdrawal is suspected (SOS score>4) this may be a route we can take. CM 
to follow up with GOC. We have much available literature and examples of 
weaning guidelines available to us that we can review. EB and CM to f/u. 
 
5) CMM hopes to start fortnightly rounds addressing analgesia and sedation 
issues, VAP and CVC line bundles at the bedside. There was universal 
endorsement of this proposal. 
 
TASKS:       
Amend bolus doses of morphine     EB 
Re-laminate and insert into bedside notes    CM 
Raise awareness of changed doses     All 
?Add analgo-sedative weaning to emergency checklist  SL 
Rollout strategy for SOS    CM/Education Team/GOC 
Streamlining pt referral who may be in withdrawal  CM/GOC/CMM/JMG 
Review weaning guidelines from other hospitals   CM/EB 
 
 
Dates of future meetings: 
Tues 13th Sept. 
Wed 16th Nov. 
Wed 18th Jan. 
 
 
 20th September 2011 Analgesia and Sedation Committee 
Meeting.  
Attendees: Kathryn McDermott, Cormac Breatnach, Catherine Connolly, Vanessa 
Bradley, Lorraine Percy, Tracey Wall, Roisin Ni Chiarra, Janice Irwin, Barbara McManus, 
Karen Grennon, Ciara Corrigan, Maebh Page, Paula Gleeson. 
Apologies: Cathy McMahon, Jacinta McGinley, Gill O’ Callaghan, Eileen Butler. 
Agenda: 
 Review of previous minutes 
 Case presentation 
 Preliminary feedback from OLCHC PICU analgesia and sedation survey 
 Plans for progression, including withdrawal, weaning sedation, pain 
assessment in the cognitively impaired child.  
 Any Other Business 
1) Review of minutes; The PICS UK & Ireland Analgesia and Sedation survey will 
be presented at the PICS conference in Cambridge this week. We have tools in 
place for formal pain and sedation assessment; however we need to address 
pain assessment in the cognitively impaired child. CM circulated a copy of the 
Non-Communicating Children’s Pain Checklist to the group. CB proposed now 
that COMFORT is validated in T21 patients we should determine whether it is 
being validated in cognitively impaired children. If it is not; perhaps we could 
assist in this process. CM to follow up with Monique van Dijk. 
2) When COMFORT score is between 10 and 22 (Ista calls this the ‘grey area’) an 
additional measure is needed to distinguish between pain and sedation. While 
in OLCHC we use the VAS 0-10, where ‘0’ is no pain and ‘10’ is worst pain, 
some centres including TSH use the Nurses Interpretation of Sedation Scale 
where 1 =undersedated, 2=adequately sedated and 3 =oversedated. As most 
of our patients are post-operative; pain is a more of a priority than sedation.  It 
was universally endorsed that we will continue to use the VAS in conjunction 
with COMFORT. 
3) Case presentation of a 2½ old F T21 who underwent vascular ring repair. 
Problems occurred 10h post-op when child self-extubated, removed art & cvc 
lines, extrapleural catheter and pulled chest drain. CB confirmed this was an 
adverse pt outcome. Analgesia and Sedation guidelines were not adhered to; 
morphine loading was not given, regular COMFORT scores were not done. 
Sedation must be considered early for such a patient. 
4) This case scenario highlighted the recent phenomenon of patients returning 
from OT with regional analgesia catheters insitu, such as extrapleural 
catheters, which are not connected to infusions. TW confirmed that the Head 
of Operating Theatre Dept has agreed it must be determined in OT whether 
the line is to be used for regional anaesthesia. If not it should be removed in 
 theatre; if it is to be used then the infusion must started in OT prior to PICU t/f.    
TW to follow up with theatre. LP proposed there is also a lack of confidence 
and an education need regarding epidurals and blocks. CB confirmed we are 
likely to see more of these in the future as they are synonymous with fast 
track surgery. KMD proposed it would be extremely helpful if the wards were 
willing to accept patients who had them, if they are working well it is not ideal 
practice to remove them before t/f to the ward. Education need must be 
determined –LP & Education Team to follow up.   
5) GOC confirmed there are 2-3 post PICU pts in withdrawal on the wards. Early 
identification and intervention is needed to prevent this occurring. Awareness 
and utilisation of the SOS must be promoted. CM and Education team to f/u. 
Ward walkarounds with consultant Intensivist, TW and CM had some success 
in getting feedback from bedside nurses, raising concerns and could also be an 
opportunity for education. CB is willing to become involved in this on a 
fortnightly basis. GOCs involvement would also be welcome. CM to f/u. 
6) Morphine data from 3 sample patients in PICU 2 were obtained by BV during 
his last visit. Using modelling he was able to calculate and graph plasma levels 
of morphine post operatively. When loading was given a peak plasma 
concentration was achieved and then tapered to a steady therapeutic state 
allowing an acceptable infusion rate of 40mcg/kg/hr for non-neonates and 
20mcg/kg/hr for neonates providing good analgesia post-operatively. When 
morphine loading was not given, levels were erratic and fluctuated leading to 
problems with analgesia and sedation. The review article circulated Wolf, A. & 
Jackman, L. (2011) “Analgesia and sedation after paediatric cardiac surgery” 
reinforces the requirement for morphine loading for good post-operative 
management. 
Tasks   
1. Contact MvD regarding pain assessment in cognitively impaired children: CM 
2. Follow up with theatre, Director of Anaesthesia and Divisional Nurse Manager 
re regional anaesthesia infusions: TW 
3. Determine education need regarding regional anaesthesia-catheters and 
infusions: LP & Education Team 
4. Awareness of withdrawal and utilisation of the SOS to be promoted. CM and 
Education team 
5. Fortnightly ward walkabouts to gain feedback, discuss probs, teaching: TW, CB, 
CM 
6. Discuss involvement from GOC: CM 
Thank you to all who attended. 
DONM: 16th Nov 2011 
 
 
 Wed 16th Nov 11.00h-12.30h PICU1 Conference Room 
16th Nov 2011 Analgesia and Sedation Committee Meeting.  
In Attendance: Yvonne Doyle, Eileen Tiernan, Eileen Butler, Monine Howlett, Libby Joseph, 
Barbara McManus, Stephanie Lawlor, Hugh Murphy, Claire Magner. 
Apologies: Jacinta McGinley, Gill O’Callaghan, Tracey Wall, Cathy McMahon, Cormac 
Breatnach, Catriona Dee, Catherine Connolly. 
 Patients experiencing withdrawal syndromes seem not to be a significant problem at 
present, EB suggests this could be as a result of our current patient profile. Use of Sophia 
Observation Scale to determine withdrawal needs to be further endorsed at bedsides; ET to 
f/u. Pharmacists EB and MH as well as GOC are available to help with weaning regimens. 
 Pain assessment tools for the cognitively impaired child reviewed. Overall consensus 
that FLACC will continue to be tool of choice as nurses are familiar with it. 
 Directive from Director of Anaesthesia- if regional analgesia catheter inserted in O/T; 
the infusion must be started there. All pumps removed from PICU2 and O/T Facilitator 
aware. Despite GOC organising education sessions re- regional analgesia; these have been 
poorly attended. ET to put list for staff names who require education on same in kitchen in 
each PICU. Ad hoc sessions at bedside were offered by ET. 
 Both case scenarios presented highlighted a number of issues. Remifentanyl and 
fentanyl are short acting opioids, frequently given intra-operatively - they do not provide 
adequate analgesic cover once the pt is in PICU. It is vital that the patient receives adequate 
morphine loading so they have therapeutic plasma levels in the immediate post-op period. 
Both patients that were highlighted went on to receive midazolam boluses for distress 
(followed by fluid boluses) when in reality they did not get adequate analgesia on return 
from OT. 
 There was a concern raised that morphine boluses are not being routinely prescribed, 
in addition there is reluctance to prescribe morphine loading. Incorrect rates are being 
prescribed e.g 0-80mcg/kg/hr for a neonate. Also, when collecting a pt from O/T, staff may 
receive a verbal report from O/T that morphine loading was given- but no written evidence 
of this exists. This makes initial management difficult. CM to f/u with CB and CMM.  
COMFORT/VAS scores must be done regularly and recorded on flow sheet. Weaning 
guidelines will be presented at next A&S meeting, as no consultants present today.  
Tasks: 
1. Encourage use of SOS when opioids/benzodiazepines used for ≥5 days or when 
withdrawal suspected. Impromptu bedside teaching if required: ET 
2. List in each PICU kitchen for staff who require teaching on regional analgesia, bedside 
teaching on same: ET 
3. Re-iterate importance of morphine loading and boli to medical staff, ensure prescriptions 
have correct dose ranges for morphine. CM to F/u with CB & CMM. 
 DONM: Wed 18th Jan 11.00h-12.30h. PICU1 Conference Room. 
6th Feb 2012 Analgesia and Sedation Committee Meeting. 
In attendance: Emer, Helen, Sarah, Niamh, Jacinta McGinley, Cormac Breatnach, Eileen 
Tiernan, Eileen Butler, Bram Valkenburg, Barbara McManus, Monine Howlett, Lorraine 
Percy, Linda O’Donnell, Julie Edwards-Power, Paula Gleeson, Monique van Dijk, Gill 
O’Callaghan, Cathy McMahon, Claire Magner. 
Apologies: Tracey Wall, Yvonne Doyle. 
Minutes: 
 New Weaning Guidelines Complete: The proposed guidelines for weaning 
analgesia and sedation in children were presented and feedback invited. These 
guidelines are broadly based on the guidelines used in PICU at the Brompton 
and are divided into 4 categories- 
-Category 1: Analgesia +/- sedation for < 5 days. 
-Category 2: Analgesia +/- sedation for 5-10 days. 
-Category 3: Analgesia +/- sedation for >10 days. 
-Long-term patients are addressed separately, an individualised approach was 
universally endorsed. GOC encourages notification of such patients to her.  
Routinely used analgesic and sedative agents in PICU are addressed individually to 
enhance clarity on the approach that should be adopted when weaning them.  
 ECMO patients are unique as they are often on high doses of A&S. JMG 
proposed SOS withdrawal scores should be commenced earlier as they are 
vulnerable to withdrawal symptoms. CB advocated vigilance with these pts as 
when transitioning off ECLS; volume of distribution will decrease once 
separated from circuit. Doses must be reduced appropriately.  
 As clonidine facilitates weaning from opiates CMM advocates progressive 
weaning of the other agents first. EB reinforced when calculating the 
percentage to be weaned- this must be a percentage of the original dose. 
Administration of PRN agents must be linked to a valid pain/distress score, 
PRN Chloral Hydrate is of particular concern.  
 SOS scores. Some inconsistency with scores highlighted with case scenarios. 
MvD stressed that scores must be done in the context of the child’s general 
condition. A common sense approach in also looking for other signs of distress 
is vital. 
Plans for progression: 
1. Simplify SOS ranges as these cutoff points are not validated. 
2. Everyone >10 days in unit should have a weaning plan. 
3. Commence work on Draft 2 of guidelines. JEP proposed April might be 
an appropriate time for rollout of SOS and weaning guidelines after ‘go 
live’ with the Clinical Information Management System is over. 
The group unanimously agreed to meet 3 monthly in future unless deemed otherwise: 
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MvD stressed that scores must be done in the context of the child’s general 
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Plans for progression: 
1. Simplify SOS ranges as these cutoff points are not validated. 
2. Everyone >10 days in unit should have a weaning plan. 
3. Commence work on Draft 2 of guidelines. JEP proposed April might be 
an appropriate time for rollout of SOS and weaning guidelines once 
CIMS Go Live over. 
 
DONM 6th Nov 2012 
 PICU Floor 1 & 2 
Main hospital: + 353 XXXXXXXXX 
      Analgesia and SedationMeeting Minutes  
Date:   Tues 6th Nov 2012   
Venue:   PICU1 Conference Room  
Present:  Claire Magner (CM), Martina Healy (MH) Tracey Wall (TW), Rosie 
Sheehan (RS), Christine Smith (CS), Cathy Mc Mahon (CMM), Julie Mc 
Dermott (JMD), Lorraine Percy (LP), Mong Hoi Tan (MHT) Deirdre 
O’Hara (DOH), Jothy Korathu (JK) Anne Marie, Gill O’Callaghan 
(GOC), Paula Weakliam (PW), Rubi Abraham (RA) Barbara McManus 
B. 
Apologies:  Yvonne Doyle 
 Item Action 
1. Feedback from PICU staff audit into perceptions of analgesia and 
sedation practice by CM. Aim to feedback these findings to PICU 
staff. 
Inconsistency in analgesia and sedation practice remains a 
challenge, both at nursing and at doctor level. 
Delayed weaning continues to be an issue for opioids and sedation. 
-Feedback sessions for staff 
to be organised with 
support of Education Team 
as per TW. 
2. Feedback from Analgesia and Sedation Procedural Guidelines 
given. 12 audit forms returned. Some inconsistency in results, 
opinion divided equally in terms of support for guidelines.  
 
Plan is to laminate, distribute and adopt into practice. We will 
continue to audit these guidelines, feedback and review at next 
A&S meeting. 
-Laminate and distribute 
A&S procedural guidelines 
to each bedspace. CM 
-DRAFT watermark 
removed. 
-Encourage completion of 
pink audit sheet when using 
procedural guidelines. All 
Staff. 
3. 
 
Case scenario presented by CMM regarding patient who presented 
with profound withdrawal symptoms in the ward after 
consistently receiving chloral hydrate 6 hourly in PICU.  
GOC feels many patients are experiencing withdrawal syndrome 
post PICU. 
-Assess the need for chloral 
hydrate regularly. All Staff. 
-Awareness of signs and 
symptoms of withdrawal vital. 
All Staff. 
4. First draft of weaning from Sedation and Opioid Analgesia 
presented by CM. 
This is in draft form at present, feedback from all staff is welcome. 
-Weaning guidelines 
circulated- marked as 
DRAFT at present. 
 
 Appendix 16: Count of Admissions by Category of Primary 
Diagnosis 
 
 
Source: PICANet Local Database (Accessed 06 June 2012). 
 
 
 
 
 
 
 
 
 
 
 
 Appendix 17: PICANet Data Collection Document 
 
 
 
  
 
 
 Appendix 18: PASQ, Patient Analgesia and Sedation 
Questionnaire 
 
  
 
 
  
 
 
  
 
 
 Appendix 19: RACHS Score Categories 
Risk Adjusted Congenital Heart Surgery (RACHS) Score Categories  
RACHS category 1: 
1. Secundum ASD 
2. Aortopexy 
3. PDA (> 30 days of age) 
4. Coarctation (> 30 days of age) 
5. PAPVR repair 
RACHS category 2: 
1. Aortic valvuloplasty (> 30 days of age) 
2. SubAS resection 
3. Pulmonary valvuloplasty or replacement 
4. RV infundibulectomy 
5. RVOT augmentation 
6. Coronary fistula repair 
7. ASD & VSD repair 
8. Primum ASD repair 
9. VSD repair 
10. Tetralogy repair 
11. VSD closure with PA band removal 
12. Repair of unspecified septal defect 
13. TAPVR repair (> 30 days of age) 
14. Glenn shunt 
15. Vascular ring surgery 
16. A-P window repair 
17. Coarctation repair (≤ 30 days of age) 
18. PA stenosis repair 
19. Common atrium closure 
20. LV-RA shunt repair 
RACHS category 3: 
1. AVR 
2. Ross procedure 
3. LVOT patch 
4. Ventriculomyotomy 
5. Aortoplasty 
6. Mitral valvuloplasty or replacement 
7. Tricuspid valvuloplasty or valvectomy or replacement 
8. Tricuspid valve repositioning (Ebstein’s) (> 30 days of age) 
9. Anomalous coronary artery repair with or without intrapulmonary tunnel 
(Takeuchi) 
10. Closure of semilunar valve (aortic or pulmonary valve) 
11. RV-PA conduit 
12. LV-PA conduit 
13. DORV repair with or without RV obstruction 
 Source: Jenkins et al. (2002), p110-8. 
 
14. Fontan 
15. AVSD (complete or transitional) repair with or without valve replacement 
16. PA banding 
17. Tetralogy with Pulm. Atresia repair 
18. Cor triatriatum repair 
19. Systemic-Pulmonary artery shunt 
20. Atrial switch operation 
21. Arterial switch operation 
22. Pulmonary artery reimplantation 
23. Annuloplasty 
24. Coarctation & VSD repair 
25. Cardiac tumor excision 
RACHS category 4: 
1. Aortic valvuloplasty (≤ 30 days of age) 
2. Konno procedure 
3. Complex defect (Single ventricle) repair with VSD enlargement 
4. TAPVR repair (≤ 30 days of age) 
5. Rastelli procedure 
6. Atrial switch with VSD closure 
7. Atrial switch with subpulmonary stenosis repair 
8. Arterial switch with PA band removal 
9. Arterial switch with VSD closure 
10. Arterial switch with subpulmonary stenosis repair 
11. Truncus repair 
12. Repair of … or interrupted aortic arch with or without VSD repair 
13. Unifocalization … Tetralogy-PA 
RACHS category 5: 
1. Tricuspid valve repositioning for neonatal Ebstein’s (≤ 30 days of age) 
2. Truncus with Interrupted aortic arch repair 
RACHS category 6: 
1. Norwood operation 
 Appendix 20: SASQ; Staff Analgesia and Sedation Questionnaire 
 
 
  
 
  
 
 
 Appendix 21: Calculation of Scale-Level Content Validity Index for SASQ  
Item No. J Co Cl B Y G Total S-CVI/Ave 
 
B(a)1 4 4 4 4 4 4 24 1  
2 4 4 4 4 4 4 24 1  
3 4 4 4 4 4 4 24 1  
4 4 3 4 3 4 4 22 0.916  
5 3 3 4 4 4 4 22 0.916  
6 4 4 4 3 4 4 23 0.958  
B(b)1 4 4 4 4 4 4 24 1  
2 4 4 4 4 4 4 24 1  
3 3 3 4 4 3 4 21 0.875  
4 4 4 4 4 4 4 24 1  
5 4 4 4 4 4 4 24 1  
6 4 4 3 3 4 4 22 0.916  
7 4 3 3 3 3 4 20 0.833  
8 4 3 3 3 3 4 20 0.833  
9 4 4 4 4 4 4 24 1  
10 4 4 4 4 4 4 24 1  
11 4 4 3 3 4 4 22 0.916  
12 4 4 3 3 4 4 22 0.916  
13 3 2 3 3 3 3 17 0.708  
14 3 4 4 4 3 3 21 0.875  
15 3 3 2 3 3 3 17 0.708  
16 4 3 4 4 4 4 23 0.958  
17 1 3 3 3 4 3 17 0.708  
18 4 4 3 2 4 3 20 0.833  
19 1 3 4 4 4 4 20 0.833  
20 4 3 1 3 3 4 18 0.75  
21 3 3 4 4 4 4 22 0.916  
22 4 4 2 3 4 4 21 0.875  
Other 4 4 4 4 4 4 24 1  
C1 4 4 4 4 4 4 24 1  
2 4 4 4 4 4 4 24 1  
3 2 4 3 3 3 3 18 0.75  
4 4 4 4 4 4 4 24 1  
5 4 2 3 4 4 4 21 0.875  
6 4 4 4 4 4 4 24 1  
7 4 4 3 4 4 4 23 0.958  
8 4 4 4 4 3 4 23 0.958  
9 2 4 4 4 4 4 22 0.916  
 10 3 3 3 4 4 3 20 0.833  
11 2 3 3 4 3 3 18 0.75  
12 4 4 4 4 4 4 24 1  
13 2 4 3 4 4 4 21 0.875  
14 3 2 4 3 4 3 19 0.792  
15 4 4 4 4 4 4 24 1  
Total 154 157 155 160 166 167 
959 
39.95 39.95/44i
tems=0.9
07954 
 
 
 
 
 
 
 
 Appendix 22: Letter of Permission to Undertake Study from 
Clinical Director of PICU 
 
 
 
 
 
 
 
 
 
 
 Appendix 23: Letter of Permission to Undertake Study from 
Clinical Nurse Manager Level 3 in PICU 
 
 
  
 Appendix 24: Letter of Invitation to Participate in Study for PICU Staff 
Dear PICU colleague,                                                                                        
1ST February 2010                                                                                                                                            
Managing the comfort of children in the Paediatric Intensive Care Unit (PICU) is one of 
the most challenging roles of PICU staff (Playfor, 2000). Critically ill children are cared 
for in an unpredictable and unfamiliar environment where auditory and visual stimuli 
are excessive, painful stimuli are frequent and sleep disturbances are common (Polaner 
et al. 2001, Bavdekar et al. 1999). Therefore one of the key factors in good patient care is 
appropriate analgesia and sedation to ensure comfort during their stay in the PICU.  
Traditionally sedative and analgesic agents have been prescribed by physicians and 
administered by nurses in the PICU, often with a wide margin of discretion and without 
explicit understanding of the target level of sedation or analgesia, (Mehta et al. 2006). 
The satisfaction of nurses and doctors in the PICU regarding current prescribing and 
administration practices is not clear. Providing a more evidence based approach to this 
area of practice is advised, however it is important that the views of all PICU staff into 
consideration. It is therefore my intention to investigate this issue.  
At present I am undertaking a PhD in Nursing in The Royal College of Surgeons in 
Dublin. Part of this course involves the completion of a unique piece of research; this 
project will be supervised from a clinical perspective by a Consultant Anaesthetist and 
by Professor Seamus Cowman in the RCSI. I have obtained approval from the Ethics 
Committee in OLCHC, the Medical Director of PICU and the Director of Nursing in 
OLCHC. It is hoped the study will be completed by May 2013.  
I assure you that your anonymity and confidentiality will be protected throughout the 
study. No personally identifiable details will be revealed when the study is being 
reported. All study data collected will be stored in a locked container and not shared 
with anyone, with the exception of my research supervisor. 
I am available to answer any queries you may have regarding the study at 01 4096744 
or on bleep 845. The completed questionnaire can be put in the sealed envelope 
provided and deposited in the red box in each PICU kitchen I will collect the box after 2 
weeks. Having read the enclosed questionnaire, please respond as honestly as you can 
to each question. Your participation in this research is voluntary and consent to 
participate will be implied on completing the questionnaire.  
Thank you for your time, 
Claire Magner. 
Clinical Audit and Research Nurse.  
Ext 6744, Blp 845 
  
 Appendix 25: Summary of Advice Issued by the Office of the Data 
Protection Commissioner in Relation to Supply of Data to 
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 Appendix 28: Letter of Approval for the Study from the Hospital Ethics 
Committee 
 
 
 
 
 
 
 
 
 Appendix 29: Letter of Approval of Amendments to the Study 
from the Hospital Ethics Committee 
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